original_sentence	e1	e2	relation_type	metadata	preprocessed_sentence
The intestinal absorption of arsenate(As(V)) has been investigated in the chick by means of the in situ ligated duodenal loop technique. 	arsenate	As(V)	none	{'e1': {'word': 'arsenate', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d82.s1.e0'}, 'e2': {'word': 'As(V)', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d82.s1.e1'}, 'sentence_id': 'DDI-MedLine.d82.s1'}	The intestinal absorption of arsenate As V has been investigated in the chick by means of the in situ ligated duodenal loop technique
By this procedure, it was observed that arsenate is rapidly and essentially completely absorbed (80-95%) from the lumen at As(V) concentrations up to 5 mM, declining to about 50% absorption at 50 mM. 	arsenate	As(V)	none	{'e1': {'word': 'arsenate', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d82.s2.e0'}, 'e2': {'word': 'As(V)', 'word_index': [(22, 23)], 'id': 'DDI-MedLine.d82.s2.e1'}, 'sentence_id': 'DDI-MedLine.d82.s2'}	By this procedure it was observed that arsenate is rapidly and essentially completely absorbed NUMBER - NUMBER % from the lumen at As NUMBER concentrations up to NUMBER mM declining to about NUMBER % absorption at NUMBER mM
At stable As(V) concentrations greater than 1 mM, fractional mucosal cell accumulation of As(V) remains constant, while fractional transfer to the body declines. 	As(V)	As(V)	none	{'e1': {'word': 'As(V)', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d82.s4.e0'}, 'e2': {'word': 'As(V)', 'word_index': [(14, 15)], 'id': 'DDI-MedLine.d82.s4.e1'}, 'sentence_id': 'DDI-MedLine.d82.s4'}	At stable As V concentrations greater than NUMBER mM fractional mucosal cell accumulation of As V remains constant while fractional transfer to the body declines
However, total mucosal accumulation of As(V) and that transferred to the body increase in a linear logarithmic fashion from 0.05 to 5 mm As(V). 	As(V)	As(V)	none	{'e1': {'word': 'As(V)', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d82.s5.e0'}, 'e2': {'word': 'As(V)', 'word_index': [(24, 25)], 'id': 'DDI-MedLine.d82.s5.e1'}, 'sentence_id': 'DDI-MedLine.d82.s5'}	However total mucosal accumulation of As V and that transferred to the body increase in a linear logarithmic fashion from NUMBER to NUMBER mm As V
Furthermore, arsenate and phosphate do not appear to share a common transport pathway in the duodenum and no evidence was obtained for any interaction between the two at this level. 	arsenate	phosphate	none	{'e1': {'word': 'arsenate', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d82.s7.e0'}, 'e2': {'word': 'phosphate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d82.s7.e1'}, 'sentence_id': 'DDI-MedLine.d82.s7'}	Furthermore arsenate and phosphate do not appear to share a common transport pathway in the duodenum and no evidence was obtained for any interaction between the NUMBER at this level
Vitamin D3 administration to rachitic chicks was effective in significantly elevating duodenal arsenate absorption, acting primarily to enhance serosal transport.	Vitamin D3	arsenate	mechanism	{'e1': {'word': 'Vitamin D3', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d82.s8.e0'}, 'e2': {'word': 'arsenate', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d82.s8.e1'}, 'sentence_id': 'DDI-MedLine.d82.s8'}	Vitamin D3 administration to rachitic chicks was effective in significantly elevating duodenal arsenate absorption acting primarily to enhance serosal transport
The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.	non-nucleoside reverse transcriptase inhibitors	antiretroviral	none	{'e1': {'word': 'non-nucleoside reverse transcriptase inhibitors', 'word_index': [(4, 7)], 'id': 'DDI-MedLine.d132.s0.e0'}, 'e2': {'word': 'antiretroviral', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d132.s0.e1'}, 'sentence_id': 'DDI-MedLine.d132.s0'}	The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	non-nucleoside reverse transcriptase inhibitor	NNRTI	none	{'e1': {'word': 'non-nucleoside reverse transcriptase inhibitor', 'word_index': [(4, 7)], 'id': 'DDI-MedLine.d132.s1.e0'}, 'e2': {'word': 'NNRTI', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d132.s1.e1'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	The availability of potent non-nucleoside reverse transcriptase inhibitor NNRTI based regimens for antiretroviral therapy and concerns regarding protease inhibitor PI related metabolic disturbances have led to significant shifts in treatment practices in HIV infection
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	non-nucleoside reverse transcriptase inhibitor	antiretroviral	none	{'e1': {'word': 'non-nucleoside reverse transcriptase inhibitor', 'word_index': [(4, 7)], 'id': 'DDI-MedLine.d132.s1.e0'}, 'e2': {'word': 'antiretroviral', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d132.s1.e2'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	The availability of potent non-nucleoside reverse transcriptase inhibitor NNRTI based regimens for antiretroviral therapy and concerns regarding protease inhibitor PI related metabolic disturbances have led to significant shifts in treatment practices in HIV infection
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	non-nucleoside reverse transcriptase inhibitor	protease inhibitor	none	{'e1': {'word': 'non-nucleoside reverse transcriptase inhibitor', 'word_index': [(4, 7)], 'id': 'DDI-MedLine.d132.s1.e0'}, 'e2': {'word': 'protease inhibitor', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d132.s1.e3'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	The availability of potent non-nucleoside reverse transcriptase inhibitor NNRTI based regimens for antiretroviral therapy and concerns regarding protease inhibitor PI related metabolic disturbances have led to significant shifts in treatment practices in HIV infection
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	non-nucleoside reverse transcriptase inhibitor	PI	none	{'e1': {'word': 'non-nucleoside reverse transcriptase inhibitor', 'word_index': [(4, 7)], 'id': 'DDI-MedLine.d132.s1.e0'}, 'e2': {'word': 'PI', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d132.s1.e4'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	The availability of potent non-nucleoside reverse transcriptase inhibitor NNRTI based regimens for antiretroviral therapy and concerns regarding protease inhibitor PI related metabolic disturbances have led to significant shifts in treatment practices in HIV infection
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	NNRTI	antiretroviral	none	{'e1': {'word': 'NNRTI', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d132.s1.e1'}, 'e2': {'word': 'antiretroviral', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d132.s1.e2'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	The availability of potent non-nucleoside reverse transcriptase inhibitor NNRTI based regimens for antiretroviral therapy and concerns regarding protease inhibitor PI related metabolic disturbances have led to significant shifts in treatment practices in HIV infection
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	NNRTI	protease inhibitor	none	{'e1': {'word': 'NNRTI', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d132.s1.e1'}, 'e2': {'word': 'protease inhibitor', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d132.s1.e3'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	The availability of potent non-nucleoside reverse transcriptase inhibitor NNRTI based regimens for antiretroviral therapy and concerns regarding protease inhibitor PI related metabolic disturbances have led to significant shifts in treatment practices in HIV infection
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	NNRTI	PI	none	{'e1': {'word': 'NNRTI', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d132.s1.e1'}, 'e2': {'word': 'PI', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d132.s1.e4'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	The availability of potent non-nucleoside reverse transcriptase inhibitor NNRTI based regimens for antiretroviral therapy and concerns regarding protease inhibitor PI related metabolic disturbances have led to significant shifts in treatment practices in HIV infection
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	antiretroviral	protease inhibitor	none	{'e1': {'word': 'antiretroviral', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d132.s1.e2'}, 'e2': {'word': 'protease inhibitor', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d132.s1.e3'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	The availability of potent non-nucleoside reverse transcriptase inhibitor NNRTI based regimens for antiretroviral therapy and concerns regarding protease inhibitor PI related metabolic disturbances have led to significant shifts in treatment practices in HIV infection
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	antiretroviral	PI	none	{'e1': {'word': 'antiretroviral', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d132.s1.e2'}, 'e2': {'word': 'PI', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d132.s1.e4'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	The availability of potent non-nucleoside reverse transcriptase inhibitor NNRTI based regimens for antiretroviral therapy and concerns regarding protease inhibitor PI related metabolic disturbances have led to significant shifts in treatment practices in HIV infection
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 	protease inhibitor	PI	none	{'e1': {'word': 'protease inhibitor', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d132.s1.e3'}, 'e2': {'word': 'PI', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d132.s1.e4'}, 'sentence_id': 'DDI-MedLine.d132.s1'}	The availability of potent non-nucleoside reverse transcriptase inhibitor NNRTI based regimens for antiretroviral therapy and concerns regarding protease inhibitor PI related metabolic disturbances have led to significant shifts in treatment practices in HIV infection
NNRTI-based regimens may have several advantages over PI-based therapy for initial or prolonged therapy, including more convenient administration regimens, lower tablet volume, fewer drug interactions, and central nervous system penetration. 	NNRTI	PI	none	{'e1': {'word': 'NNRTI', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d132.s2.e0'}, 'e2': {'word': 'PI', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d132.s2.e1'}, 'sentence_id': 'DDI-MedLine.d132.s2'}	NNRTI based regimens may have several advantages over PI based therapy for initial or prolonged therapy including more convenient administration regimens lower tablet volume fewer drug interactions and central nervous system penetration
No data from prospective clinical trials currently exist comparing the 3 approved agents (efavirenz, nevirapine or delavirdine). 	efavirenz	nevirapine	none	{'e1': {'word': 'efavirenz', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d132.s3.e0'}, 'e2': {'word': 'nevirapine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d132.s3.e1'}, 'sentence_id': 'DDI-MedLine.d132.s3'}	No data from prospective clinical trials currently exist comparing the NUMBER approved agents efavirenz nevirapine or delavirdine
No data from prospective clinical trials currently exist comparing the 3 approved agents (efavirenz, nevirapine or delavirdine). 	efavirenz	delavirdine	none	{'e1': {'word': 'efavirenz', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d132.s3.e0'}, 'e2': {'word': 'delavirdine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d132.s3.e2'}, 'sentence_id': 'DDI-MedLine.d132.s3'}	No data from prospective clinical trials currently exist comparing the NUMBER approved agents efavirenz nevirapine or delavirdine
No data from prospective clinical trials currently exist comparing the 3 approved agents (efavirenz, nevirapine or delavirdine). 	nevirapine	delavirdine	none	{'e1': {'word': 'nevirapine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d132.s3.e1'}, 'e2': {'word': 'delavirdine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d132.s3.e2'}, 'sentence_id': 'DDI-MedLine.d132.s3'}	No data from prospective clinical trials currently exist comparing the NUMBER approved agents efavirenz nevirapine or delavirdine
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	efavirenz	nevirapine	none	{'e1': {'word': 'efavirenz', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d132.s4.e0'}, 'e2': {'word': 'nevirapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s4.e1'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over NUMBER weeks as initial therapy with similar responses being observed with nevirapine regimens and superiority observed with efavirenz
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	efavirenz	PI	none	{'e1': {'word': 'efavirenz', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d132.s4.e0'}, 'e2': {'word': 'PI', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d132.s4.e2'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over NUMBER weeks as initial therapy with similar responses being observed with nevirapine regimens and superiority observed with efavirenz
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	efavirenz	indinavir	none	{'e1': {'word': 'efavirenz', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d132.s4.e0'}, 'e2': {'word': 'indinavir', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d132.s4.e3'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over NUMBER weeks as initial therapy with similar responses being observed with nevirapine regimens and superiority observed with efavirenz
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	efavirenz	nevirapine	none	{'e1': {'word': 'efavirenz', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d132.s4.e0'}, 'e2': {'word': 'nevirapine', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d132.s4.e4'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over NUMBER weeks as initial therapy with similar responses being observed with nevirapine regimens and superiority observed with efavirenz
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	efavirenz	efavirenz	none	{'e1': {'word': 'efavirenz', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d132.s4.e0'}, 'e2': {'word': 'efavirenz', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d132.s4.e5'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over NUMBER weeks as initial therapy with similar responses being observed with nevirapine regimens and superiority observed with efavirenz
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	nevirapine	PI	none	{'e1': {'word': 'nevirapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s4.e1'}, 'e2': {'word': 'PI', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d132.s4.e2'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over NUMBER weeks as initial therapy with similar responses being observed with nevirapine regimens and superiority observed with efavirenz
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	nevirapine	indinavir	none	{'e1': {'word': 'nevirapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s4.e1'}, 'e2': {'word': 'indinavir', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d132.s4.e3'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over NUMBER weeks as initial therapy with similar responses being observed with nevirapine regimens and superiority observed with efavirenz
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	nevirapine	nevirapine	none	{'e1': {'word': 'nevirapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s4.e1'}, 'e2': {'word': 'nevirapine', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d132.s4.e4'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over NUMBER weeks as initial therapy with similar responses being observed with nevirapine regimens and superiority observed with efavirenz
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	nevirapine	efavirenz	none	{'e1': {'word': 'nevirapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s4.e1'}, 'e2': {'word': 'efavirenz', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d132.s4.e5'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over NUMBER weeks as initial therapy with similar responses being observed with nevirapine regimens and superiority observed with efavirenz
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	PI	indinavir	none	{'e1': {'word': 'PI', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d132.s4.e2'}, 'e2': {'word': 'indinavir', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d132.s4.e3'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over NUMBER weeks as initial therapy with similar responses being observed with nevirapine regimens and superiority observed with efavirenz
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	PI	nevirapine	none	{'e1': {'word': 'PI', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d132.s4.e2'}, 'e2': {'word': 'nevirapine', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d132.s4.e4'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over NUMBER weeks as initial therapy with similar responses being observed with nevirapine regimens and superiority observed with efavirenz
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	PI	efavirenz	none	{'e1': {'word': 'PI', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d132.s4.e2'}, 'e2': {'word': 'efavirenz', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d132.s4.e5'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over NUMBER weeks as initial therapy with similar responses being observed with nevirapine regimens and superiority observed with efavirenz
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	indinavir	nevirapine	none	{'e1': {'word': 'indinavir', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d132.s4.e3'}, 'e2': {'word': 'nevirapine', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d132.s4.e4'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over NUMBER weeks as initial therapy with similar responses being observed with nevirapine regimens and superiority observed with efavirenz
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	indinavir	efavirenz	none	{'e1': {'word': 'indinavir', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d132.s4.e3'}, 'e2': {'word': 'efavirenz', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d132.s4.e5'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over NUMBER weeks as initial therapy with similar responses being observed with nevirapine regimens and superiority observed with efavirenz
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 	nevirapine	efavirenz	none	{'e1': {'word': 'nevirapine', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d132.s4.e4'}, 'e2': {'word': 'efavirenz', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d132.s4.e5'}, 'sentence_id': 'DDI-MedLine.d132.s4'}	Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over NUMBER weeks as initial therapy with similar responses being observed with nevirapine regimens and superiority observed with efavirenz
A smaller 24-week study has suggested nevirapine may be superior to the PI nelfinavir. 	nevirapine	PI	none	{'e1': {'word': 'nevirapine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d132.s5.e0'}, 'e2': {'word': 'PI', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d132.s5.e1'}, 'sentence_id': 'DDI-MedLine.d132.s5'}	A smaller NUMBER week study has suggested nevirapine may be superior to the PI nelfinavir
A smaller 24-week study has suggested nevirapine may be superior to the PI nelfinavir. 	nevirapine	nelfinavir	none	{'e1': {'word': 'nevirapine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d132.s5.e0'}, 'e2': {'word': 'nelfinavir', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d132.s5.e2'}, 'sentence_id': 'DDI-MedLine.d132.s5'}	A smaller NUMBER week study has suggested nevirapine may be superior to the PI nelfinavir
A smaller 24-week study has suggested nevirapine may be superior to the PI nelfinavir. 	PI	nelfinavir	none	{'e1': {'word': 'PI', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d132.s5.e1'}, 'e2': {'word': 'nelfinavir', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d132.s5.e2'}, 'sentence_id': 'DDI-MedLine.d132.s5'}	A smaller NUMBER week study has suggested nevirapine may be superior to the PI nelfinavir
Limited comparative data in patients with high viral loads treated with nevirapine- or delavirdine-based regimens currently exist. 	nevirapine	delavirdine	none	{'e1': {'word': 'nevirapine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d132.s6.e0'}, 'e2': {'word': 'delavirdine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d132.s6.e1'}, 'sentence_id': 'DDI-MedLine.d132.s6'}	Limited comparative data in patients with high viral loads treated with nevirapine or delavirdine based regimens currently exist
The superiority of efavirenz over indinavir-based regimens has been observed in comparative data in a subset of patients with high viral loads. 	efavirenz	indinavir	none	{'e1': {'word': 'efavirenz', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d132.s8.e0'}, 'e2': {'word': 'indinavir', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d132.s8.e1'}, 'sentence_id': 'DDI-MedLine.d132.s8'}	The superiority of efavirenz over indinavir based regimens has been observed in comparative data in a subset of patients with high viral loads
Efavirenz has demonstrated superiority over nelfinavir in nucleoside-experienced patients, although combining these 2 agents may represent the best approach in these circumstances. 	Efavirenz	nelfinavir	none	{'e1': {'word': 'Efavirenz', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d132.s10.e0'}, 'e2': {'word': 'nelfinavir', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d132.s10.e1'}, 'sentence_id': 'DDI-MedLine.d132.s10'}	Efavirenz has demonstrated superiority over nelfinavir in nucleoside experienced patients although combining these NUMBER agents may represent the best approach in these circumstances
"Enhanced theophylline clearance secondary to phenytoin therapy.
"	theophylline	phenytoin	mechanism	{'e1': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d7.s0.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d7.s0.e1'}, 'sentence_id': 'DDI-MedLine.d7.s0'}	Enhanced theophylline clearance secondary to phenytoin therapy
This report describes two cases in which theophylline clearance accelerated markedly with concomitant phenytoin administration. 	theophylline	phenytoin	mechanism	{'e1': {'word': 'theophylline', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d7.s1.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d7.s1.e1'}, 'sentence_id': 'DDI-MedLine.d7.s1'}	This report describes NUMBER cases in which theophylline clearance accelerated markedly with concomitant phenytoin administration
With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.	phenytoin	theophylline	effect	{'e1': {'word': 'phenytoin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d7.s4.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d7.s4.e1'}, 'sentence_id': 'DDI-MedLine.d7.s4'}	With combined use clinicians should be aware when phenytoin is added of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations
"Selective survival in pentazocine and tripelennamine of Pseudomonas aeruginosa serotype O11 from drug addicts.
"	pentazocine	tripelennamine	none	{'e1': {'word': 'pentazocine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d45.s0.e0'}, 'e2': {'word': 'tripelennamine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d45.s0.e1'}, 'sentence_id': 'DDI-MedLine.d45.s0'}	Selective survival in pentazocine and tripelennamine of Pseudomonas aeruginosa serotype O11 from drug addicts
The growth of Pseudomonas aeruginosa, particularly serotype O11, in pentazocine and tripelennamine 	pentazocine	tripelennamine	none	{'e1': {'word': 'pentazocine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d45.s1.e0'}, 'e2': {'word': 'tripelennamine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d45.s1.e1'}, 'sentence_id': 'DDI-MedLine.d45.s1'}	The growth of Pseudomonas aeruginosa particularly serotype O11 in pentazocine and tripelennamine
Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination. 	heroin	pentazocine	none	{'e1': {'word': 'heroin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d45.s5.e0'}, 'e2': {'word': 'pentazocine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d45.s5.e1'}, 'sentence_id': 'DDI-MedLine.d45.s5'}	NUMBER strains of Staphylococcus aureus a frequent cause of infection in heroin but not in pentazocine and tripelennamine addicts were completely inhibited by the drug combination
Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination. 	heroin	tripelennamine	none	{'e1': {'word': 'heroin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d45.s5.e0'}, 'e2': {'word': 'tripelennamine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d45.s5.e2'}, 'sentence_id': 'DDI-MedLine.d45.s5'}	NUMBER strains of Staphylococcus aureus a frequent cause of infection in heroin but not in pentazocine and tripelennamine addicts were completely inhibited by the drug combination
Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination. 	pentazocine	tripelennamine	effect	{'e1': {'word': 'pentazocine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d45.s5.e1'}, 'e2': {'word': 'tripelennamine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d45.s5.e2'}, 'sentence_id': 'DDI-MedLine.d45.s5'}	NUMBER strains of Staphylococcus aureus a frequent cause of infection in heroin but not in pentazocine and tripelennamine addicts were completely inhibited by the drug combination
Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine. 	tripelennamine	pentazocine	effect	{'e1': {'word': 'tripelennamine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d45.s6.e0'}, 'e2': {'word': 'pentazocine', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d45.s6.e1'}, 'sentence_id': 'DDI-MedLine.d45.s6'}	Dose response curves derived from the results of using the tablets as well as pure powders showed that tripelennamine was responsible for the inhibitory activity which was partially antagonized by pentazocine
aureus, to survive in pentazocine and tripelennamine may explain in part a shift from S. 	pentazocine	tripelennamine	none	{'e1': {'word': 'pentazocine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d45.s9.e0'}, 'e2': {'word': 'tripelennamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d45.s9.e1'}, 'sentence_id': 'DDI-MedLine.d45.s9'}	aureus to survive in pentazocine and tripelennamine may explain in part a shift from S.
Since the arrival of oral erection-supporting medication, patients want to know how safe sexual activity is in cardiovascular disease in general and during use of erection-supporting medication in particular. 	erection-supporting medication	erection-supporting medication	none	{'e1': {'word': 'erection-supporting medication', 'word_index': [(5, 7)], 'id': 'DDI-MedLine.d1.s1.e0'}, 'e2': {'word': 'erection-supporting medication', 'word_index': [(26, 28)], 'id': 'DDI-MedLine.d1.s1.e1'}, 'sentence_id': 'DDI-MedLine.d1.s1'}	Since the arrival of oral erection supporting medication patients want to know how safe sexual activity is in cardiovascular disease in general and during use of erection supporting medication in particular
Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure. 	Sildenafil	long-acting nitrates	advise	{'e1': {'word': 'Sildenafil', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d1.s5.e0'}, 'e2': {'word': 'long-acting nitrates', 'word_index': [(6, 8)], 'id': 'DDI-MedLine.d1.s5.e1'}, 'sentence_id': 'DDI-MedLine.d1.s5'}	Sildenafil is contraindicated in patients using long acting nitrates or who may need to use short acting nitrates because the combination may cause a sharp fall of the blood pressure
Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure. 	Sildenafil	short-acting nitrates	advise	{'e1': {'word': 'Sildenafil', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d1.s5.e0'}, 'e2': {'word': 'short-acting nitrates', 'word_index': [(15, 17)], 'id': 'DDI-MedLine.d1.s5.e2'}, 'sentence_id': 'DDI-MedLine.d1.s5'}	Sildenafil is contraindicated in patients using long acting nitrates or who may need to use short acting nitrates because the combination may cause a sharp fall of the blood pressure
Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure. 	long-acting nitrates	short-acting nitrates	none	{'e1': {'word': 'long-acting nitrates', 'word_index': [(6, 8)], 'id': 'DDI-MedLine.d1.s5.e1'}, 'e2': {'word': 'short-acting nitrates', 'word_index': [(15, 17)], 'id': 'DDI-MedLine.d1.s5.e2'}, 'sentence_id': 'DDI-MedLine.d1.s5'}	Sildenafil is contraindicated in patients using long acting nitrates or who may need to use short acting nitrates because the combination may cause a sharp fall of the blood pressure
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	beta-receptor blockers	calcium antagonists	none	{'e1': {'word': 'beta-receptor blockers', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d1.s6.e0'}, 'e2': {'word': 'calcium antagonists', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d1.s6.e1'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	No interactions have been observed with beta-receptor blockers calcium antagonists thiazide and loop diuretics diuretics and ACE inhibitors
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	beta-receptor blockers	thiazide diuretics	none	{'e1': {'word': 'beta-receptor blockers', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d1.s6.e0'}, 'e2': {'word': 'thiazide diuretics', 'word_index': [(10, 10), (14, 14)], 'id': 'DDI-MedLine.d1.s6.e2'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	No interactions have been observed with beta-receptor blockers calcium antagonists thiazide and loop diuretics diuretics and ACE inhibitors
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	beta-receptor blockers	loop diuretics	none	{'e1': {'word': 'beta-receptor blockers', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d1.s6.e0'}, 'e2': {'word': 'loop diuretics', 'word_index': [(12, 13)], 'id': 'DDI-MedLine.d1.s6.e3'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	No interactions have been observed with beta-receptor blockers calcium antagonists thiazide and loop diuretics diuretics and ACE inhibitors
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	beta-receptor blockers	ACE inhibitors	none	{'e1': {'word': 'beta-receptor blockers', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d1.s6.e0'}, 'e2': {'word': 'ACE inhibitors', 'word_index': [(16, 17)], 'id': 'DDI-MedLine.d1.s6.e4'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	No interactions have been observed with beta-receptor blockers calcium antagonists thiazide and loop diuretics diuretics and ACE inhibitors
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	calcium antagonists	thiazide diuretics	none	{'e1': {'word': 'calcium antagonists', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d1.s6.e1'}, 'e2': {'word': 'thiazide diuretics', 'word_index': [(10, 9), (13, 13)], 'id': 'DDI-MedLine.d1.s6.e2'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	No interactions have been observed with beta-receptor , antagonists , and loop diuretics diuretics and ACE inhibitors .
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	calcium antagonists	loop diuretics	none	{'e1': {'word': 'calcium antagonists', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d1.s6.e1'}, 'e2': {'word': 'loop diuretics', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d1.s6.e3'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	No interactions have been observed with beta-receptor , antagonists , thiazide loop diuretics diuretics and ACE inhibitors .
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	calcium antagonists	ACE inhibitors	none	{'e1': {'word': 'calcium antagonists', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d1.s6.e1'}, 'e2': {'word': 'ACE inhibitors', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d1.s6.e4'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	No interactions have been observed with beta-receptor , antagonists , thiazide loop diuretics diuretics and ACE inhibitors .
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	thiazide diuretics	loop diuretics	none	{'e1': {'word': 'thiazide diuretics', 'word_index': [(10, 9), (13, 13)], 'id': 'DDI-MedLine.d1.s6.e2'}, 'e2': {'word': 'loop diuretics', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d1.s6.e3'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	No interactions have been observed with beta-receptor , calcium , and loop diuretics diuretics and ACE inhibitors .
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	thiazide diuretics	ACE inhibitors	none	{'e1': {'word': 'thiazide diuretics', 'word_index': [(10, 9), (13, 13)], 'id': 'DDI-MedLine.d1.s6.e2'}, 'e2': {'word': 'ACE inhibitors', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d1.s6.e4'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	No interactions have been observed with beta-receptor , calcium , and loop diuretics diuretics and ACE inhibitors .
No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors. 	loop diuretics	ACE inhibitors	none	{'e1': {'word': 'loop diuretics', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d1.s6.e3'}, 'e2': {'word': 'ACE inhibitors', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d1.s6.e4'}, 'sentence_id': 'DDI-MedLine.d1.s6'}	No interactions have been observed with beta-receptor , calcium , thiazide loop diuretics diuretics and ACE inhibitors .
"Interaction of gentamycin and atracurium in anaesthetised horses.
"	gentamycin	atracurium	int	{'e1': {'word': 'gentamycin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d90.s0.e0'}, 'e2': {'word': 'atracurium', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d90.s0.e1'}, 'sentence_id': 'DDI-MedLine.d90.s0'}	Interaction of gentamycin and atracurium in anaesthetised horses
Evoked hind limb digital extensor tension (hoof twitch) was maintained at 40% of baseline for 1 h by atracurium infusion in 7 horses anaesthetised with halothane. 	atracurium	halothane	none	{'e1': {'word': 'atracurium', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d90.s1.e0'}, 'e2': {'word': 'halothane', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d90.s1.e1'}, 'sentence_id': 'DDI-MedLine.d90.s1'}	Evoked hind limb digital extensor tension hoof twitch was maintained at NUMBER % of baseline for NUMBER h by atracurium infusion in NUMBER horses anaesthetised with halothane
Atracurium was again given by infusion to maintain 40% twitch for a second hour, then 2 mg gentamycin/kg bwt were given i.v. 	Atracurium	gentamycin	none	{'e1': {'word': 'Atracurium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d90.s3.e0'}, 'e2': {'word': 'gentamycin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d90.s3.e1'}, 'sentence_id': 'DDI-MedLine.d90.s3'}	Atracurium was again given by infusion to maintain NUMBER % twitch for a second hour then NUMBER mg gentamycin / kg bwt were given i.v.
Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for atracurium plus gentamycin (P = 0.03). 	atracurium	atracurium	none	{'e1': {'word': 'atracurium', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d90.s7.e0'}, 'e2': {'word': 'atracurium', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d90.s7.e1'}, 'sentence_id': 'DDI-MedLine.d90.s7'}	Recovery of hoof twitch from NUMBER % to NUMBER % took NUMBER + - NUMBER min for atracurium alone and NUMBER + - NUMBER min for atracurium plus gentamycin P = NUMBER
Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for atracurium plus gentamycin (P = 0.03). 	atracurium	gentamycin	none	{'e1': {'word': 'atracurium', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d90.s7.e0'}, 'e2': {'word': 'gentamycin', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d90.s7.e2'}, 'sentence_id': 'DDI-MedLine.d90.s7'}	Recovery of hoof twitch from NUMBER % to NUMBER % took NUMBER + - NUMBER min for atracurium alone and NUMBER + - NUMBER min for atracurium plus gentamycin P = NUMBER
Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for atracurium plus gentamycin (P = 0.03). 	atracurium	gentamycin	effect	{'e1': {'word': 'atracurium', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d90.s7.e1'}, 'e2': {'word': 'gentamycin', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d90.s7.e2'}, 'sentence_id': 'DDI-MedLine.d90.s7'}	Recovery of hoof twitch from NUMBER % to NUMBER % took NUMBER + - NUMBER min for atracurium alone and NUMBER + - NUMBER min for atracurium plus gentamycin P = NUMBER
Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for atracurium alone and 13.7 +/- 1.2 min for atracurium plus gentamycin. 	atracurium	atracurium	none	{'e1': {'word': 'atracurium', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d90.s8.e0'}, 'e2': {'word': 'atracurium', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d90.s8.e1'}, 'sentence_id': 'DDI-MedLine.d90.s8'}	Recovery from NUMBER % twitch to NUMBER % fade recovery took NUMBER + - NUMBER min for atracurium alone and NUMBER + - NUMBER min for atracurium plus gentamycin
Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for atracurium alone and 13.7 +/- 1.2 min for atracurium plus gentamycin. 	atracurium	gentamycin	none	{'e1': {'word': 'atracurium', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d90.s8.e0'}, 'e2': {'word': 'gentamycin', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d90.s8.e2'}, 'sentence_id': 'DDI-MedLine.d90.s8'}	Recovery from NUMBER % twitch to NUMBER % fade recovery took NUMBER + - NUMBER min for atracurium alone and NUMBER + - NUMBER min for atracurium plus gentamycin
Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for atracurium alone and 13.7 +/- 1.2 min for atracurium plus gentamycin. 	atracurium	gentamycin	effect	{'e1': {'word': 'atracurium', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d90.s8.e1'}, 'e2': {'word': 'gentamycin', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d90.s8.e2'}, 'sentence_id': 'DDI-MedLine.d90.s8'}	Recovery from NUMBER % twitch to NUMBER % fade recovery took NUMBER + - NUMBER min for atracurium alone and NUMBER + - NUMBER min for atracurium plus gentamycin
At 75% recovery of fade, hoof twitch was 87 +/- 3% for atracurium alone and 82 +/- 4% for atracurium plus gentamycin. 	atracurium	atracurium	none	{'e1': {'word': 'atracurium', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d90.s9.e0'}, 'e2': {'word': 'atracurium', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d90.s9.e1'}, 'sentence_id': 'DDI-MedLine.d90.s9'}	At NUMBER % recovery of fade hoof twitch was NUMBER + - NUMBER % for atracurium alone and NUMBER + - NUMBER % for atracurium plus gentamycin
At 75% recovery of fade, hoof twitch was 87 +/- 3% for atracurium alone and 82 +/- 4% for atracurium plus gentamycin. 	atracurium	gentamycin	none	{'e1': {'word': 'atracurium', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d90.s9.e0'}, 'e2': {'word': 'gentamycin', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d90.s9.e2'}, 'sentence_id': 'DDI-MedLine.d90.s9'}	At NUMBER % recovery of fade hoof twitch was NUMBER + - NUMBER % for atracurium alone and NUMBER + - NUMBER % for atracurium plus gentamycin
At 75% recovery of fade, hoof twitch was 87 +/- 3% for atracurium alone and 82 +/- 4% for atracurium plus gentamycin. 	atracurium	gentamycin	effect	{'e1': {'word': 'atracurium', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d90.s9.e1'}, 'e2': {'word': 'gentamycin', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d90.s9.e2'}, 'sentence_id': 'DDI-MedLine.d90.s9'}	At NUMBER % recovery of fade hoof twitch was NUMBER + - NUMBER % for atracurium alone and NUMBER + - NUMBER % for atracurium plus gentamycin
It was concluded that, although gentamycin did augment the neuromuscular blockade of atracurium, the effect was minimal.	gentamycin	atracurium	effect	{'e1': {'word': 'gentamycin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d90.s11.e0'}, 'e2': {'word': 'atracurium', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d90.s11.e1'}, 'sentence_id': 'DDI-MedLine.d90.s11'}	It was concluded that although gentamycin did augment the neuromuscular blockade of atracurium the effect was minimal
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	immunosuppressive drugs	corticosteroids	none	{'e1': {'word': 'immunosuppressive drugs', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d11.s4.e0'}, 'e2': {'word': 'corticosteroids', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d11.s4.e1'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at NUMBER commonly used immunosuppressive drugs in turn corticosteroids cyclosporin azathioprine methotrexate cyclophosphamide discussing the main non-infection unwanted effects ways to avoid them and what to do if problems arise
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	immunosuppressive drugs	cyclosporin	none	{'e1': {'word': 'immunosuppressive drugs', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d11.s4.e0'}, 'e2': {'word': 'cyclosporin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d11.s4.e2'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at NUMBER commonly used immunosuppressive drugs in turn corticosteroids cyclosporin azathioprine methotrexate cyclophosphamide discussing the main non-infection unwanted effects ways to avoid them and what to do if problems arise
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	immunosuppressive drugs	azathioprine	none	{'e1': {'word': 'immunosuppressive drugs', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d11.s4.e0'}, 'e2': {'word': 'azathioprine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d11.s4.e3'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at NUMBER commonly used immunosuppressive drugs in turn corticosteroids cyclosporin azathioprine methotrexate cyclophosphamide discussing the main non-infection unwanted effects ways to avoid them and what to do if problems arise
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	immunosuppressive drugs	methotrexate	none	{'e1': {'word': 'immunosuppressive drugs', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d11.s4.e0'}, 'e2': {'word': 'methotrexate', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d11.s4.e4'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at NUMBER commonly used immunosuppressive drugs in turn corticosteroids cyclosporin azathioprine methotrexate cyclophosphamide discussing the main non-infection unwanted effects ways to avoid them and what to do if problems arise
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	immunosuppressive drugs	cyclophosphamide	none	{'e1': {'word': 'immunosuppressive drugs', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d11.s4.e0'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d11.s4.e5'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at NUMBER commonly used immunosuppressive drugs in turn corticosteroids cyclosporin azathioprine methotrexate cyclophosphamide discussing the main non-infection unwanted effects ways to avoid them and what to do if problems arise
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	corticosteroids	cyclosporin	none	{'e1': {'word': 'corticosteroids', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d11.s4.e1'}, 'e2': {'word': 'cyclosporin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d11.s4.e2'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at NUMBER commonly used immunosuppressive drugs in turn corticosteroids cyclosporin azathioprine methotrexate cyclophosphamide discussing the main non-infection unwanted effects ways to avoid them and what to do if problems arise
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	corticosteroids	azathioprine	none	{'e1': {'word': 'corticosteroids', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d11.s4.e1'}, 'e2': {'word': 'azathioprine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d11.s4.e3'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at NUMBER commonly used immunosuppressive drugs in turn corticosteroids cyclosporin azathioprine methotrexate cyclophosphamide discussing the main non-infection unwanted effects ways to avoid them and what to do if problems arise
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	corticosteroids	methotrexate	none	{'e1': {'word': 'corticosteroids', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d11.s4.e1'}, 'e2': {'word': 'methotrexate', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d11.s4.e4'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at NUMBER commonly used immunosuppressive drugs in turn corticosteroids cyclosporin azathioprine methotrexate cyclophosphamide discussing the main non-infection unwanted effects ways to avoid them and what to do if problems arise
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	corticosteroids	cyclophosphamide	none	{'e1': {'word': 'corticosteroids', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d11.s4.e1'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d11.s4.e5'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at NUMBER commonly used immunosuppressive drugs in turn corticosteroids cyclosporin azathioprine methotrexate cyclophosphamide discussing the main non-infection unwanted effects ways to avoid them and what to do if problems arise
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	cyclosporin	azathioprine	none	{'e1': {'word': 'cyclosporin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d11.s4.e2'}, 'e2': {'word': 'azathioprine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d11.s4.e3'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at NUMBER commonly used immunosuppressive drugs in turn corticosteroids cyclosporin azathioprine methotrexate cyclophosphamide discussing the main non-infection unwanted effects ways to avoid them and what to do if problems arise
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	cyclosporin	methotrexate	none	{'e1': {'word': 'cyclosporin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d11.s4.e2'}, 'e2': {'word': 'methotrexate', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d11.s4.e4'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at NUMBER commonly used immunosuppressive drugs in turn corticosteroids cyclosporin azathioprine methotrexate cyclophosphamide discussing the main non-infection unwanted effects ways to avoid them and what to do if problems arise
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	cyclosporin	cyclophosphamide	none	{'e1': {'word': 'cyclosporin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d11.s4.e2'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d11.s4.e5'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at NUMBER commonly used immunosuppressive drugs in turn corticosteroids cyclosporin azathioprine methotrexate cyclophosphamide discussing the main non-infection unwanted effects ways to avoid them and what to do if problems arise
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	azathioprine	methotrexate	none	{'e1': {'word': 'azathioprine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d11.s4.e3'}, 'e2': {'word': 'methotrexate', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d11.s4.e4'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at NUMBER commonly used immunosuppressive drugs in turn corticosteroids cyclosporin azathioprine methotrexate cyclophosphamide discussing the main non-infection unwanted effects ways to avoid them and what to do if problems arise
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	azathioprine	cyclophosphamide	none	{'e1': {'word': 'azathioprine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d11.s4.e3'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d11.s4.e5'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at NUMBER commonly used immunosuppressive drugs in turn corticosteroids cyclosporin azathioprine methotrexate cyclophosphamide discussing the main non-infection unwanted effects ways to avoid them and what to do if problems arise
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 	methotrexate	cyclophosphamide	none	{'e1': {'word': 'methotrexate', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d11.s4.e4'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d11.s4.e5'}, 'sentence_id': 'DDI-MedLine.d11.s4'}	This article looks at NUMBER commonly used immunosuppressive drugs in turn corticosteroids cyclosporin azathioprine methotrexate cyclophosphamide discussing the main non-infection unwanted effects ways to avoid them and what to do if problems arise
Thirty male rats of the Fischer-344 strain were divided into three equal groups and were given injections of trimethyl lead (TML) (8.0 or 17.0 mg/kg/ml SC) or the saline vehicle. 	trimethyl lead	TML	none	{'e1': {'word': 'trimethyl lead', 'word_index': [(19, 20)], 'id': 'DDI-MedLine.d93.s4.e0'}, 'e2': {'word': 'TML', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d93.s4.e1'}, 'sentence_id': 'DDI-MedLine.d93.s4'}	NUMBER male rats of the Fischer NUMBER strain were divided into NUMBER equal groups and were given injections of trimethyl lead TML NUMBER or NUMBER mg / kg / ml SC or the saline vehicle
The 20% v/v solution of alcohol was prepared in water from a stock solution of 95% ethanol. 	alcohol	ethanol	none	{'e1': {'word': 'alcohol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d93.s6.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d93.s6.e1'}, 'sentence_id': 'DDI-MedLine.d93.s6'}	The NUMBER % v / v solution of alcohol was prepared in water from a stock solution of NUMBER % ethanol
These results suggest that exposure to environmental lead may alter the biological and behavioral responsiveness of an animal to alcohol.	lead	alcohol	effect	{'e1': {'word': 'lead', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d93.s9.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d93.s9.e1'}, 'sentence_id': 'DDI-MedLine.d93.s9'}	These results suggest that exposure to environmental lead may alter the biological and behavioral responsiveness of an animal to alcohol
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	diazepam	midazolam	none	{'e1': {'word': 'diazepam', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d67.s0.e0'}, 'e2': {'word': 'midazolam', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d67.s0.e1'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	Effect of diazepam and midazolam on the antinociceptive effect of morphine metamizol and indomethacin in mice
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	diazepam	morphine	none	{'e1': {'word': 'diazepam', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d67.s0.e0'}, 'e2': {'word': 'morphine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d67.s0.e2'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	Effect of diazepam and midazolam on the antinociceptive effect of morphine metamizol and indomethacin in mice
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	diazepam	metamizol	none	{'e1': {'word': 'diazepam', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d67.s0.e0'}, 'e2': {'word': 'metamizol', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d67.s0.e3'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	Effect of diazepam and midazolam on the antinociceptive effect of morphine metamizol and indomethacin in mice
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	diazepam	indomethacin	none	{'e1': {'word': 'diazepam', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d67.s0.e0'}, 'e2': {'word': 'indomethacin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d67.s0.e4'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	Effect of diazepam and midazolam on the antinociceptive effect of morphine metamizol and indomethacin in mice
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	midazolam	morphine	none	{'e1': {'word': 'midazolam', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d67.s0.e1'}, 'e2': {'word': 'morphine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d67.s0.e2'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	Effect of diazepam and midazolam on the antinociceptive effect of morphine metamizol and indomethacin in mice
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	midazolam	metamizol	none	{'e1': {'word': 'midazolam', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d67.s0.e1'}, 'e2': {'word': 'metamizol', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d67.s0.e3'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	Effect of diazepam and midazolam on the antinociceptive effect of morphine metamizol and indomethacin in mice
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	midazolam	indomethacin	none	{'e1': {'word': 'midazolam', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d67.s0.e1'}, 'e2': {'word': 'indomethacin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d67.s0.e4'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	Effect of diazepam and midazolam on the antinociceptive effect of morphine metamizol and indomethacin in mice
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	morphine	metamizol	none	{'e1': {'word': 'morphine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d67.s0.e2'}, 'e2': {'word': 'metamizol', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d67.s0.e3'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	Effect of diazepam and midazolam on the antinociceptive effect of morphine metamizol and indomethacin in mice
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	morphine	indomethacin	none	{'e1': {'word': 'morphine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d67.s0.e2'}, 'e2': {'word': 'indomethacin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d67.s0.e4'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	Effect of diazepam and midazolam on the antinociceptive effect of morphine metamizol and indomethacin in mice
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	metamizol	indomethacin	none	{'e1': {'word': 'metamizol', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d67.s0.e3'}, 'e2': {'word': 'indomethacin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d67.s0.e4'}, 'sentence_id': 'DDI-MedLine.d67.s0'}	Effect of diazepam and midazolam on the antinociceptive effect of morphine metamizol and indomethacin in mice
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	midazolam	diazepam	none	{'e1': {'word': 'midazolam', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d67.s1.e0'}, 'e2': {'word': 'diazepam', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d67.s1.e1'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	The influence of midazolam and diazepam on antinociceptive effect of morphine NUMBER mg / kg metamizol NUMBER mg / kg and indomethacin NUMBER mg / kg was investigated in a mouse model using the tail flick and hot-plate tests
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	midazolam	morphine	none	{'e1': {'word': 'midazolam', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d67.s1.e0'}, 'e2': {'word': 'morphine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d67.s1.e2'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	The influence of midazolam and diazepam on antinociceptive effect of morphine NUMBER mg / kg metamizol NUMBER mg / kg and indomethacin NUMBER mg / kg was investigated in a mouse model using the tail flick and hot-plate tests
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	midazolam	metamizol	none	{'e1': {'word': 'midazolam', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d67.s1.e0'}, 'e2': {'word': 'metamizol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d67.s1.e3'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	The influence of midazolam and diazepam on antinociceptive effect of morphine NUMBER mg / kg metamizol NUMBER mg / kg and indomethacin NUMBER mg / kg was investigated in a mouse model using the tail flick and hot-plate tests
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	midazolam	indomethacin	none	{'e1': {'word': 'midazolam', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d67.s1.e0'}, 'e2': {'word': 'indomethacin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d67.s1.e4'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	The influence of midazolam and diazepam on antinociceptive effect of morphine NUMBER mg / kg metamizol NUMBER mg / kg and indomethacin NUMBER mg / kg was investigated in a mouse model using the tail flick and hot-plate tests
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	diazepam	morphine	none	{'e1': {'word': 'diazepam', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d67.s1.e1'}, 'e2': {'word': 'morphine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d67.s1.e2'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	The influence of midazolam and diazepam on antinociceptive effect of morphine NUMBER mg / kg metamizol NUMBER mg / kg and indomethacin NUMBER mg / kg was investigated in a mouse model using the tail flick and hot-plate tests
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	diazepam	metamizol	none	{'e1': {'word': 'diazepam', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d67.s1.e1'}, 'e2': {'word': 'metamizol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d67.s1.e3'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	The influence of midazolam and diazepam on antinociceptive effect of morphine NUMBER mg / kg metamizol NUMBER mg / kg and indomethacin NUMBER mg / kg was investigated in a mouse model using the tail flick and hot-plate tests
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	diazepam	indomethacin	none	{'e1': {'word': 'diazepam', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d67.s1.e1'}, 'e2': {'word': 'indomethacin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d67.s1.e4'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	The influence of midazolam and diazepam on antinociceptive effect of morphine NUMBER mg / kg metamizol NUMBER mg / kg and indomethacin NUMBER mg / kg was investigated in a mouse model using the tail flick and hot-plate tests
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	morphine	metamizol	none	{'e1': {'word': 'morphine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d67.s1.e2'}, 'e2': {'word': 'metamizol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d67.s1.e3'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	The influence of midazolam and diazepam on antinociceptive effect of morphine NUMBER mg / kg metamizol NUMBER mg / kg and indomethacin NUMBER mg / kg was investigated in a mouse model using the tail flick and hot-plate tests
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	morphine	indomethacin	none	{'e1': {'word': 'morphine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d67.s1.e2'}, 'e2': {'word': 'indomethacin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d67.s1.e4'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	The influence of midazolam and diazepam on antinociceptive effect of morphine NUMBER mg / kg metamizol NUMBER mg / kg and indomethacin NUMBER mg / kg was investigated in a mouse model using the tail flick and hot-plate tests
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	metamizol	indomethacin	none	{'e1': {'word': 'metamizol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d67.s1.e3'}, 'e2': {'word': 'indomethacin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d67.s1.e4'}, 'sentence_id': 'DDI-MedLine.d67.s1'}	The influence of midazolam and diazepam on antinociceptive effect of morphine NUMBER mg / kg metamizol NUMBER mg / kg and indomethacin NUMBER mg / kg was investigated in a mouse model using the tail flick and hot-plate tests
Benzodiazepines were administered to mice 30 min before applying the analgesic drugs. 	Benzodiazepines	analgesic drugs	none	{'e1': {'word': 'Benzodiazepines', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s3.e0'}, 'e2': {'word': 'analgesic drugs', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d67.s3.e1'}, 'sentence_id': 'DDI-MedLine.d67.s3'}	Benzodiazepines were administered to mice NUMBER min before applying the analgesic drugs
Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine. 	Diazepam	morphine	effect	{'e1': {'word': 'Diazepam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s5.e0'}, 'e2': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d67.s5.e1'}, 'sentence_id': 'DDI-MedLine.d67.s5'}	Diazepam at doses of NUMBER mg / kg and NUMBER mg / kg injected with morphine was found to decrease the antinociceptive effect of morphine
Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine. 	Diazepam	morphine	none	{'e1': {'word': 'Diazepam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s5.e0'}, 'e2': {'word': 'morphine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d67.s5.e2'}, 'sentence_id': 'DDI-MedLine.d67.s5'}	Diazepam at doses of NUMBER mg / kg and NUMBER mg / kg injected with morphine was found to decrease the antinociceptive effect of morphine
Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine. 	morphine	morphine	none	{'e1': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d67.s5.e1'}, 'e2': {'word': 'morphine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d67.s5.e2'}, 'sentence_id': 'DDI-MedLine.d67.s5'}	Diazepam at doses of NUMBER mg / kg and NUMBER mg / kg injected with morphine was found to decrease the antinociceptive effect of morphine
Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin. 	diazepam	metamizol	effect	{'e1': {'word': 'diazepam', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d67.s6.e0'}, 'e2': {'word': 'metamizol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d67.s6.e1'}, 'sentence_id': 'DDI-MedLine.d67.s6'}	Similarly diazepam decreased the antinociceptive effect of metamizol only in the tail flick test and indomethacin
Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin. 	diazepam	indomethacin	effect	{'e1': {'word': 'diazepam', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d67.s6.e0'}, 'e2': {'word': 'indomethacin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d67.s6.e2'}, 'sentence_id': 'DDI-MedLine.d67.s6'}	Similarly diazepam decreased the antinociceptive effect of metamizol only in the tail flick test and indomethacin
Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin. 	metamizol	indomethacin	none	{'e1': {'word': 'metamizol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d67.s6.e1'}, 'e2': {'word': 'indomethacin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d67.s6.e2'}, 'sentence_id': 'DDI-MedLine.d67.s6'}	Similarly diazepam decreased the antinociceptive effect of metamizol only in the tail flick test and indomethacin
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.	Midazolam	morphine	effect	{'e1': {'word': 'Midazolam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s7.e0'}, 'e2': {'word': 'morphine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d67.s7.e1'}, 'sentence_id': 'DDI-MedLine.d67.s7'}	Midazolam used at doses of NUMBER mg / kg and NUMBER mg / kg decreased the antinociceptive effect of morphine metamizol only in the tail flick test and indomethacin
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.	Midazolam	metamizol	effect	{'e1': {'word': 'Midazolam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s7.e0'}, 'e2': {'word': 'metamizol', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d67.s7.e2'}, 'sentence_id': 'DDI-MedLine.d67.s7'}	Midazolam used at doses of NUMBER mg / kg and NUMBER mg / kg decreased the antinociceptive effect of morphine metamizol only in the tail flick test and indomethacin
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.	Midazolam	indomethacin	effect	{'e1': {'word': 'Midazolam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d67.s7.e0'}, 'e2': {'word': 'indomethacin', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d67.s7.e3'}, 'sentence_id': 'DDI-MedLine.d67.s7'}	Midazolam used at doses of NUMBER mg / kg and NUMBER mg / kg decreased the antinociceptive effect of morphine metamizol only in the tail flick test and indomethacin
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.	morphine	metamizol	none	{'e1': {'word': 'morphine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d67.s7.e1'}, 'e2': {'word': 'metamizol', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d67.s7.e2'}, 'sentence_id': 'DDI-MedLine.d67.s7'}	Midazolam used at doses of NUMBER mg / kg and NUMBER mg / kg decreased the antinociceptive effect of morphine metamizol only in the tail flick test and indomethacin
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.	morphine	indomethacin	none	{'e1': {'word': 'morphine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d67.s7.e1'}, 'e2': {'word': 'indomethacin', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d67.s7.e3'}, 'sentence_id': 'DDI-MedLine.d67.s7'}	Midazolam used at doses of NUMBER mg / kg and NUMBER mg / kg decreased the antinociceptive effect of morphine metamizol only in the tail flick test and indomethacin
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.	metamizol	indomethacin	none	{'e1': {'word': 'metamizol', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d67.s7.e2'}, 'e2': {'word': 'indomethacin', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d67.s7.e3'}, 'sentence_id': 'DDI-MedLine.d67.s7'}	Midazolam used at doses of NUMBER mg / kg and NUMBER mg / kg decreased the antinociceptive effect of morphine metamizol only in the tail flick test and indomethacin
"Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
"	simvastatin	clarithromycin	effect	{'e1': {'word': 'simvastatin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d25.s0.e0'}, 'e2': {'word': 'clarithromycin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d25.s0.e1'}, 'sentence_id': 'DDI-MedLine.d25.s0'}	Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin
OBJECTIVE: To report a case of rhabdomyolysis resulting from concomitant use of clarithromycin and simvastatin. 	clarithromycin	simvastatin	none	{'e1': {'word': 'clarithromycin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d25.s1.e0'}, 'e2': {'word': 'simvastatin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d25.s1.e1'}, 'sentence_id': 'DDI-MedLine.d25.s1'}	OBJECTIVE To report a case of rhabdomyolysis resulting from concomitant use of clarithromycin and simvastatin
DISCUSSION: Clarithromycin is a potent inhibitor of CYP3A4, the major enzyme responsible for simvastatin metabolism. 	Clarithromycin	simvastatin	mechanism	{'e1': {'word': 'Clarithromycin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d25.s9.e0'}, 'e2': {'word': 'simvastatin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d25.s9.e1'}, 'sentence_id': 'DDI-MedLine.d25.s9'}	DISCUSSION Clarithromycin is a potent inhibitor of CYP3A4 the major enzyme responsible for simvastatin metabolism
The concomitant administration of macrolide antibiotics and other hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have resulted in previous reports of rhabdomyolysis. 	macrolide antibiotics	hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors	effect	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d25.s10.e0'}, 'e2': {'word': 'hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors', 'word_index': [(8, 14)], 'id': 'DDI-MedLine.d25.s10.e1'}, 'sentence_id': 'DDI-MedLine.d25.s10'}	The concomitant administration of macrolide antibiotics and other hydroxymethylglutaryl coenzyme A HMG CoA reductase inhibitors have resulted in previous reports of rhabdomyolysis
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	Macrolide antibiotics	HMG-CoA reductase inhibitors	none	{'e1': {'word': 'Macrolide antibiotics', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d25.s12.e0'}, 'e2': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(7, 10)], 'id': 'DDI-MedLine.d25.s12.e1'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS Macrolide antibiotics inhibit the metabolism of HMG CoA reductase inhibitors that are metabolized by CYP3A4 i.e. atorvastatin cerivastatin lovastatin simvastatin
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	Macrolide antibiotics	atorvastatin	mechanism	{'e1': {'word': 'Macrolide antibiotics', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d25.s12.e0'}, 'e2': {'word': 'atorvastatin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d25.s12.e2'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS Macrolide antibiotics inhibit the metabolism of HMG CoA reductase inhibitors that are metabolized by CYP3A4 i.e. atorvastatin cerivastatin lovastatin simvastatin
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	Macrolide antibiotics	cerivastatin	mechanism	{'e1': {'word': 'Macrolide antibiotics', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d25.s12.e0'}, 'e2': {'word': 'cerivastatin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d25.s12.e3'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS Macrolide antibiotics inhibit the metabolism of HMG CoA reductase inhibitors that are metabolized by CYP3A4 i.e. atorvastatin cerivastatin lovastatin simvastatin
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	Macrolide antibiotics	lovastatin	mechanism	{'e1': {'word': 'Macrolide antibiotics', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d25.s12.e0'}, 'e2': {'word': 'lovastatin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d25.s12.e4'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS Macrolide antibiotics inhibit the metabolism of HMG CoA reductase inhibitors that are metabolized by CYP3A4 i.e. atorvastatin cerivastatin lovastatin simvastatin
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	Macrolide antibiotics	simvastatin	mechanism	{'e1': {'word': 'Macrolide antibiotics', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d25.s12.e0'}, 'e2': {'word': 'simvastatin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d25.s12.e5'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS Macrolide antibiotics inhibit the metabolism of HMG CoA reductase inhibitors that are metabolized by CYP3A4 i.e. atorvastatin cerivastatin lovastatin simvastatin
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	HMG-CoA reductase inhibitors	atorvastatin	none	{'e1': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(7, 10)], 'id': 'DDI-MedLine.d25.s12.e1'}, 'e2': {'word': 'atorvastatin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d25.s12.e2'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS Macrolide antibiotics inhibit the metabolism of HMG CoA reductase inhibitors that are metabolized by CYP3A4 i.e. atorvastatin cerivastatin lovastatin simvastatin
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	HMG-CoA reductase inhibitors	cerivastatin	none	{'e1': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(7, 10)], 'id': 'DDI-MedLine.d25.s12.e1'}, 'e2': {'word': 'cerivastatin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d25.s12.e3'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS Macrolide antibiotics inhibit the metabolism of HMG CoA reductase inhibitors that are metabolized by CYP3A4 i.e. atorvastatin cerivastatin lovastatin simvastatin
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	HMG-CoA reductase inhibitors	lovastatin	none	{'e1': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(7, 10)], 'id': 'DDI-MedLine.d25.s12.e1'}, 'e2': {'word': 'lovastatin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d25.s12.e4'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS Macrolide antibiotics inhibit the metabolism of HMG CoA reductase inhibitors that are metabolized by CYP3A4 i.e. atorvastatin cerivastatin lovastatin simvastatin
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	HMG-CoA reductase inhibitors	simvastatin	none	{'e1': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(7, 10)], 'id': 'DDI-MedLine.d25.s12.e1'}, 'e2': {'word': 'simvastatin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d25.s12.e5'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS Macrolide antibiotics inhibit the metabolism of HMG CoA reductase inhibitors that are metabolized by CYP3A4 i.e. atorvastatin cerivastatin lovastatin simvastatin
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	atorvastatin	cerivastatin	none	{'e1': {'word': 'atorvastatin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d25.s12.e2'}, 'e2': {'word': 'cerivastatin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d25.s12.e3'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS Macrolide antibiotics inhibit the metabolism of HMG CoA reductase inhibitors that are metabolized by CYP3A4 i.e. atorvastatin cerivastatin lovastatin simvastatin
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	atorvastatin	lovastatin	none	{'e1': {'word': 'atorvastatin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d25.s12.e2'}, 'e2': {'word': 'lovastatin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d25.s12.e4'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS Macrolide antibiotics inhibit the metabolism of HMG CoA reductase inhibitors that are metabolized by CYP3A4 i.e. atorvastatin cerivastatin lovastatin simvastatin
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	atorvastatin	simvastatin	none	{'e1': {'word': 'atorvastatin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d25.s12.e2'}, 'e2': {'word': 'simvastatin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d25.s12.e5'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS Macrolide antibiotics inhibit the metabolism of HMG CoA reductase inhibitors that are metabolized by CYP3A4 i.e. atorvastatin cerivastatin lovastatin simvastatin
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	cerivastatin	lovastatin	none	{'e1': {'word': 'cerivastatin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d25.s12.e3'}, 'e2': {'word': 'lovastatin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d25.s12.e4'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS Macrolide antibiotics inhibit the metabolism of HMG CoA reductase inhibitors that are metabolized by CYP3A4 i.e. atorvastatin cerivastatin lovastatin simvastatin
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	cerivastatin	simvastatin	none	{'e1': {'word': 'cerivastatin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d25.s12.e3'}, 'e2': {'word': 'simvastatin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d25.s12.e5'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS Macrolide antibiotics inhibit the metabolism of HMG CoA reductase inhibitors that are metabolized by CYP3A4 i.e. atorvastatin cerivastatin lovastatin simvastatin
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 	lovastatin	simvastatin	none	{'e1': {'word': 'lovastatin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d25.s12.e4'}, 'e2': {'word': 'simvastatin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d25.s12.e5'}, 'sentence_id': 'DDI-MedLine.d25.s12'}	CONCLUSIONS Macrolide antibiotics inhibit the metabolism of HMG CoA reductase inhibitors that are metabolized by CYP3A4 i.e. atorvastatin cerivastatin lovastatin simvastatin
To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM), glucose (100 or 150 mg. per 100 ml.), and theophylline (10 mM). 	arginine	glucose	none	{'e1': {'word': 'arginine', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d74.s2.e0'}, 'e2': {'word': 'glucose', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d74.s2.e1'}, 'sentence_id': 'DDI-MedLine.d74.s2'}	To study the pancreatic effects of other agents dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine NUMBER mM glucose NUMBER or NUMBER mg. 100 NUMBER ) theophylline ( NUMBER )
To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM), glucose (100 or 150 mg. per 100 ml.), and theophylline (10 mM). 	arginine	theophylline	none	{'e1': {'word': 'arginine', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d74.s2.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d74.s2.e2'}, 'sentence_id': 'DDI-MedLine.d74.s2'}	To study the pancreatic effects of other agents dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine NUMBER mM glucose NUMBER or NUMBER mg. 100 NUMBER ) theophylline ( NUMBER )
To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM), glucose (100 or 150 mg. per 100 ml.), and theophylline (10 mM). 	glucose	theophylline	none	{'e1': {'word': 'glucose', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d74.s2.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d74.s2.e2'}, 'sentence_id': 'DDI-MedLine.d74.s2'}	To study the pancreatic effects of other agents dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine NUMBER mM glucose NUMBER or NUMBER mg. 100 NUMBER ) theophylline ( NUMBER )
Glucose, alone and in the presence of theophylline, caused subnormal insulin release and less suppression of glucagon release in the diabectics than in the normals. 	Glucose	theophylline	none	{'e1': {'word': 'Glucose', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d74.s4.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d74.s4.e1'}, 'sentence_id': 'DDI-MedLine.d74.s4'}	Glucose alone and in the presence of theophylline caused subnormal insulin release and less suppression of glucagon release in the diabectics than in the normals
Arginine, in the presence of glucose and theophylline, caused excessive glucagon release but nearly normal insulin release in the diabetics. 	Arginine	glucose	none	{'e1': {'word': 'Arginine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d74.s5.e0'}, 'e2': {'word': 'glucose', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d74.s5.e1'}, 'sentence_id': 'DDI-MedLine.d74.s5'}	Arginine in the presence of glucose and theophylline caused excessive glucagon release but nearly normal insulin release in the diabetics
Arginine, in the presence of glucose and theophylline, caused excessive glucagon release but nearly normal insulin release in the diabetics. 	Arginine	theophylline	none	{'e1': {'word': 'Arginine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d74.s5.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d74.s5.e2'}, 'sentence_id': 'DDI-MedLine.d74.s5'}	Arginine in the presence of glucose and theophylline caused excessive glucagon release but nearly normal insulin release in the diabetics
Arginine, in the presence of glucose and theophylline, caused excessive glucagon release but nearly normal insulin release in the diabetics. 	glucose	theophylline	none	{'e1': {'word': 'glucose', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d74.s5.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d74.s5.e2'}, 'sentence_id': 'DDI-MedLine.d74.s5'}	Arginine in the presence of glucose and theophylline caused excessive glucagon release but nearly normal insulin release in the diabetics
Arginine, in the absence of glucose or theophylline, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals. 	Arginine	glucose	none	{'e1': {'word': 'Arginine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d74.s6.e0'}, 'e2': {'word': 'glucose', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d74.s6.e1'}, 'sentence_id': 'DDI-MedLine.d74.s6'}	Arginine in the absence of glucose or theophylline caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals
Arginine, in the absence of glucose or theophylline, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals. 	Arginine	theophylline	none	{'e1': {'word': 'Arginine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d74.s6.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d74.s6.e2'}, 'sentence_id': 'DDI-MedLine.d74.s6'}	Arginine in the absence of glucose or theophylline caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals
Arginine, in the absence of glucose or theophylline, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals. 	glucose	theophylline	none	{'e1': {'word': 'glucose', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d74.s6.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d74.s6.e2'}, 'sentence_id': 'DDI-MedLine.d74.s6'}	Arginine in the absence of glucose or theophylline caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals
Further, these results confirm that the diabetic Chinese hamster's alpha and beta cells respond normally to theophylline, but are relatively insensitive to glucose.	theophylline	glucose	none	{'e1': {'word': 'theophylline', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d74.s11.e0'}, 'e2': {'word': 'glucose', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d74.s11.e1'}, 'sentence_id': 'DDI-MedLine.d74.s11'}	Further these results confirm that the diabetic Chinese hamster 's alpha and beta cells respond normally to theophylline but are relatively insensitive to glucose
"Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats.
"	naloxone	beta-endorphin	none	{'e1': {'word': 'naloxone', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d63.s0.e0'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d63.s0.e1'}, 'sentence_id': 'DDI-MedLine.d63.s0'}	Differential actions of intrathecal naloxone on blocking the tail flick inhibition induced by intraventricular beta-endorphin and morphine in rats
"Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats.
"	naloxone	morphine	none	{'e1': {'word': 'naloxone', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d63.s0.e0'}, 'e2': {'word': 'morphine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d63.s0.e2'}, 'sentence_id': 'DDI-MedLine.d63.s0'}	Differential actions of intrathecal naloxone on blocking the tail flick inhibition induced by intraventricular beta-endorphin and morphine in rats .
"Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats.
"	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d63.s0.e1'}, 'e2': {'word': 'morphine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d63.s0.e2'}, 'sentence_id': 'DDI-MedLine.d63.s0'}	Differential actions of intrathecal naloxone on blocking the tail flick inhibition induced by intraventricular beta-endorphin and morphine in rats
The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied. 	naloxone	beta-endorphin	none	{'e1': {'word': 'naloxone', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d63.s2.e0'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d63.s2.e1'}, 'sentence_id': 'DDI-MedLine.d63.s2'}	The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail flick inhibition induced by intraventricular beta-endorphin and morphine was then studied
The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied. 	naloxone	morphine	none	{'e1': {'word': 'naloxone', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d63.s2.e0'}, 'e2': {'word': 'morphine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d63.s2.e2'}, 'sentence_id': 'DDI-MedLine.d63.s2'}	The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail flick inhibition induced by intraventricular beta-endorphin and morphine was then studied .
The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied. 	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d63.s2.e1'}, 'e2': {'word': 'morphine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d63.s2.e2'}, 'sentence_id': 'DDI-MedLine.d63.s2'}	The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail flick inhibition induced by intraventricular beta-endorphin and morphine was then studied
Intraventricular injection of beta-endorphin and morphine produced an inhibition of the tail-flick response to the heat stimulus in rats. 	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d63.s3.e0'}, 'e2': {'word': 'morphine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d63.s3.e1'}, 'sentence_id': 'DDI-MedLine.d63.s3'}	Intraventricular injection of beta-endorphin and morphine produced an inhibition of the tail flick response to the heat stimulus in rats
Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). 	naloxone	beta-endorphin	effect	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d63.s4.e0'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d63.s4.e1'}, 'sentence_id': 'DDI-MedLine.d63.s4'}	Intrathecal injection of naloxone at doses of NUMBER to NUMBER micrograms caused a dose related blockade of the inhibition of the tail flick response induced by intraventricular injection of beta-endorphin and a high dose of naloxone NUMBER micrograms completely blocked the tail flick inhibition induced by intraventricular beta-endorphin ( NUMBER )
Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). 	naloxone	naloxone	none	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d63.s4.e0'}, 'e2': {'word': 'naloxone', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d63.s4.e2'}, 'sentence_id': 'DDI-MedLine.d63.s4'}	Intrathecal injection of naloxone at doses of NUMBER to NUMBER micrograms caused a dose related blockade of the inhibition of the tail flick response induced by intraventricular injection of beta-endorphin and high dose of naloxone ( 40 NUMBER completely the tail - flick induced by intraventricular beta-endorphin ( 16 micrograms NUMBER
Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). 	naloxone	beta-endorphin	none	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d63.s4.e0'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(46, 46)], 'id': 'DDI-MedLine.d63.s4.e3'}, 'sentence_id': 'DDI-MedLine.d63.s4'}	Intrathecal injection of naloxone at doses of NUMBER to NUMBER micrograms caused a dose related blockade of the inhibition of the tail flick response induced by intraventricular injection of beta-endorphin and high dose of naloxone ( 40 NUMBER completely the tail - flick induced by intraventricular beta-endorphin ( 16 NUMBER .
Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). 	beta-endorphin	naloxone	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d63.s4.e1'}, 'e2': {'word': 'naloxone', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d63.s4.e2'}, 'sentence_id': 'DDI-MedLine.d63.s4'}	Intrathecal injection of naloxone at doses of NUMBER to NUMBER micrograms caused a dose related blockade of the inhibition of the tail flick response induced by intraventricular injection of beta-endorphin and a high dose of naloxone NUMBER micrograms completely blocked the tail flick inhibition induced by intraventricular beta-endorphin ( NUMBER )
Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). 	beta-endorphin	beta-endorphin	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d63.s4.e1'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d63.s4.e3'}, 'sentence_id': 'DDI-MedLine.d63.s4'}	Intrathecal injection of naloxone at doses of NUMBER to NUMBER micrograms caused a dose related blockade of the inhibition of the tail flick response induced by intraventricular injection of beta-endorphin and a high dose of naloxone NUMBER micrograms completely blocked the tail flick inhibition induced by intraventricular beta-endorphin NUMBER micrograms
Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). 	naloxone	beta-endorphin	effect	{'e1': {'word': 'naloxone', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d63.s4.e2'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(46, 46)], 'id': 'DDI-MedLine.d63.s4.e3'}, 'sentence_id': 'DDI-MedLine.d63.s4'}	Intrathecal injection of naloxone at doses of NUMBER to NUMBER micrograms caused a dose related blockade of the inhibition of the tail flick response induced by intraventricular injection of beta-endorphin and high dose of naloxone ( 40 NUMBER completely the tail - flick induced by intraventricular beta-endorphin ( 16 NUMBER .
On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms). 	naloxone	morphine	effect	{'e1': {'word': 'naloxone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d63.s5.e0'}, 'e2': {'word': 'morphine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d63.s5.e1'}, 'sentence_id': 'DDI-MedLine.d63.s5'}	On the other hand intrathecal naloxone NUMBER - NUMBER micrograms had only a very weak effect on the tail flick inhibition induced by intraventricular morphine NUMBER micrograms
Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. 	naloxone	beta-endorphin	effect	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d63.s6.e0'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d63.s6.e1'}, 'sentence_id': 'DDI-MedLine.d63.s6'}	Intraventricular injection of naloxone at doses of NUMBER to NUMBER micrograms equally antagonized in a dose dependent manner the tail flick inhibition induced by intraventricular beta-endorphin and morphine
Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. 	naloxone	morphine	effect	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d63.s6.e0'}, 'e2': {'word': 'morphine', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d63.s6.e2'}, 'sentence_id': 'DDI-MedLine.d63.s6'}	Intraventricular injection of naloxone at doses of NUMBER to NUMBER micrograms equally antagonized in a dose dependent manner the tail flick inhibition induced by intraventricular beta-endorphin and morphine .
Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. 	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d63.s6.e1'}, 'e2': {'word': 'morphine', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d63.s6.e2'}, 'sentence_id': 'DDI-MedLine.d63.s6'}	Intraventricular injection of naloxone at doses of NUMBER to NUMBER micrograms equally antagonized in a dose dependent manner the tail flick inhibition induced by intraventricular beta-endorphin and morphine
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	naloxone	beta-endorphin	none	{'e1': {'word': 'naloxone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d63.s7.e0'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d63.s7.e1'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	The results indicate that a spinal naloxone sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine induced tail flick inhibition and suggest that intraventricular beta-endorphin morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	naloxone	morphine	none	{'e1': {'word': 'naloxone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d63.s7.e0'}, 'e2': {'word': 'morphine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d63.s7.e2'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	The results indicate that a spinal naloxone sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine - tail - inhibition , suggest that intraventricular beta-endorphin and elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	naloxone	beta-endorphin	none	{'e1': {'word': 'naloxone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d63.s7.e0'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d63.s7.e3'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	The results indicate that a spinal naloxone sensitive endorphinergic system is involved in the production of beta-endorphin not morphine - induced - flick , and that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	naloxone	morphine	none	{'e1': {'word': 'naloxone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d63.s7.e0'}, 'e2': {'word': 'morphine', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d63.s7.e4'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	The results indicate that a spinal naloxone sensitive endorphinergic system is involved in the production of beta-endorphin not morphine - induced - flick , and that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d63.s7.e1'}, 'e2': {'word': 'morphine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d63.s7.e2'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	The results indicate that a spinal naloxone sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine induced tail flick inhibition and suggest that intraventricular beta-endorphin morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	beta-endorphin	beta-endorphin	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d63.s7.e1'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d63.s7.e3'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	The results indicate that a spinal naloxone sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine induced tail flick inhibition and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d63.s7.e1'}, 'e2': {'word': 'morphine', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d63.s7.e4'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	The results indicate that a spinal naloxone sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine induced tail flick inhibition and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	morphine	beta-endorphin	none	{'e1': {'word': 'morphine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d63.s7.e2'}, 'e2': {'word': 'beta-endorphin', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d63.s7.e3'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	The results indicate that a spinal naloxone sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine - tail - inhibition , suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	morphine	morphine	none	{'e1': {'word': 'morphine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d63.s7.e2'}, 'e2': {'word': 'morphine', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d63.s7.e4'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	The results indicate that a spinal naloxone sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine - tail - inhibition , suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d63.s7.e3'}, 'e2': {'word': 'morphine', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d63.s7.e4'}, 'sentence_id': 'DDI-MedLine.d63.s7'}	The results indicate that a spinal naloxone sensitive endorphinergic system is involved in the production of beta-endorphin not morphine - induced - flick , and that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;
descending epsilon and mu systems for beta-endorphin and morphine, respectively, are proposed.	beta-endorphin	morphine	none	{'e1': {'word': 'beta-endorphin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d63.s8.e0'}, 'e2': {'word': 'morphine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d63.s8.e1'}, 'sentence_id': 'DDI-MedLine.d63.s8'}	descending epsilon and mu systems for beta-endorphin and morphine respectively are proposed
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	picrotoxin	diazepam	effect	{'e1': {'word': 'picrotoxin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d27.s0.e0'}, 'e2': {'word': 'diazepam', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d27.s0.e1'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	The GABA ergic system and brain edema It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin NUMBER mg / kg removes the antiedematous action of diazepam phenazepam phenibut and amizyl and reduces the action of phentolamine
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	picrotoxin	phenazepam	effect	{'e1': {'word': 'picrotoxin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d27.s0.e0'}, 'e2': {'word': 'phenazepam', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d27.s0.e2'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	The GABA ergic system and brain edema It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin NUMBER mg / kg removes the antiedematous action of diazepam phenazepam phenibut and amizyl and reduces the action of phentolamine
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	picrotoxin	phenibut	effect	{'e1': {'word': 'picrotoxin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d27.s0.e0'}, 'e2': {'word': 'phenibut', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d27.s0.e3'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	The GABA ergic system and brain edema It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin NUMBER mg / kg removes the antiedematous action of diazepam phenazepam phenibut and amizyl and reduces the action of phentolamine
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	picrotoxin	amizyl	effect	{'e1': {'word': 'picrotoxin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d27.s0.e0'}, 'e2': {'word': 'amizyl', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d27.s0.e4'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	The GABA ergic system and brain edema It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin NUMBER mg / kg removes the antiedematous action of diazepam phenazepam phenibut and amizyl and reduces the action of phentolamine
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	picrotoxin	phentolamine	effect	{'e1': {'word': 'picrotoxin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d27.s0.e0'}, 'e2': {'word': 'phentolamine', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d27.s0.e5'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	The GABA ergic system and brain edema It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin NUMBER mg / kg removes the antiedematous action of diazepam phenazepam phenibut and amizyl and reduces the action of phentolamine
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	diazepam	phenazepam	none	{'e1': {'word': 'diazepam', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d27.s0.e1'}, 'e2': {'word': 'phenazepam', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d27.s0.e2'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	The GABA ergic system and brain edema It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin NUMBER mg / kg removes the antiedematous action of diazepam phenazepam phenibut and amizyl and reduces the action of phentolamine
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	diazepam	phenibut	none	{'e1': {'word': 'diazepam', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d27.s0.e1'}, 'e2': {'word': 'phenibut', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d27.s0.e3'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	The GABA ergic system and brain edema It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin NUMBER mg / kg removes the antiedematous action of diazepam phenazepam phenibut and amizyl and reduces the action of phentolamine
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	diazepam	amizyl	none	{'e1': {'word': 'diazepam', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d27.s0.e1'}, 'e2': {'word': 'amizyl', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d27.s0.e4'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	The GABA ergic system and brain edema It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin NUMBER mg / kg removes the antiedematous action of diazepam phenazepam phenibut and amizyl and reduces the action of phentolamine
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	diazepam	phentolamine	none	{'e1': {'word': 'diazepam', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d27.s0.e1'}, 'e2': {'word': 'phentolamine', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d27.s0.e5'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	The GABA ergic system and brain edema It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin NUMBER mg / kg removes the antiedematous action of diazepam phenazepam phenibut and amizyl and reduces the action of phentolamine
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	phenazepam	phenibut	none	{'e1': {'word': 'phenazepam', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d27.s0.e2'}, 'e2': {'word': 'phenibut', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d27.s0.e3'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	The GABA ergic system and brain edema It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin NUMBER mg / kg removes the antiedematous action of diazepam phenazepam phenibut and amizyl and reduces the action of phentolamine
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	phenazepam	amizyl	none	{'e1': {'word': 'phenazepam', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d27.s0.e2'}, 'e2': {'word': 'amizyl', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d27.s0.e4'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	The GABA ergic system and brain edema It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin NUMBER mg / kg removes the antiedematous action of diazepam phenazepam phenibut and amizyl and reduces the action of phentolamine
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	phenazepam	phentolamine	none	{'e1': {'word': 'phenazepam', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d27.s0.e2'}, 'e2': {'word': 'phentolamine', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d27.s0.e5'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	The GABA ergic system and brain edema It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin NUMBER mg / kg removes the antiedematous action of diazepam phenazepam phenibut and amizyl and reduces the action of phentolamine
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	phenibut	amizyl	none	{'e1': {'word': 'phenibut', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d27.s0.e3'}, 'e2': {'word': 'amizyl', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d27.s0.e4'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	The GABA ergic system and brain edema It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin NUMBER mg / kg removes the antiedematous action of diazepam phenazepam phenibut and amizyl and reduces the action of phentolamine
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	phenibut	phentolamine	none	{'e1': {'word': 'phenibut', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d27.s0.e3'}, 'e2': {'word': 'phentolamine', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d27.s0.e5'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	The GABA ergic system and brain edema It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin NUMBER mg / kg removes the antiedematous action of diazepam phenazepam phenibut and amizyl and reduces the action of phentolamine
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. 	amizyl	phentolamine	none	{'e1': {'word': 'amizyl', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d27.s0.e4'}, 'e2': {'word': 'phentolamine', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d27.s0.e5'}, 'sentence_id': 'DDI-MedLine.d27.s0'}	The GABA ergic system and brain edema It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin NUMBER mg / kg removes the antiedematous action of diazepam phenazepam phenibut and amizyl and reduces the action of phentolamine
"Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens.
"	vitamin D	antiestrogens	none	{'e1': {'word': 'vitamin D', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d53.s0.e0'}, 'e2': {'word': 'antiestrogens', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d53.s0.e1'}, 'sentence_id': 'DDI-MedLine.d53.s0'}	Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens
1,25-Dihydroxycholecalciferol D3 (1,25(OH)2D3), the active metabolite of vitamin D, is a potent inhibitor of breast cancer cell growth both in vivo and in vitro. 	25-Dihydroxycholecalciferol D3	1,25(OH)2D3	none	{'e1': {'word': '25-Dihydroxycholecalciferol D3', 'word_index': [(1, 3)], 'id': 'DDI-MedLine.d53.s1.e0'}, 'e2': {'word': '1,25(OH)2D3', 'word_index': [(4, 7)], 'id': 'DDI-MedLine.d53.s1.e1'}, 'sentence_id': 'DDI-MedLine.d53.s1'}	1 NUMBER Dihydroxycholecalciferol D3 NUMBER NUMBER OH 2D3 the active metabolite of vitamin D is a potent inhibitor of breast cancer cell growth both in vivo and in vitro
1,25-Dihydroxycholecalciferol D3 (1,25(OH)2D3), the active metabolite of vitamin D, is a potent inhibitor of breast cancer cell growth both in vivo and in vitro. 	25-Dihydroxycholecalciferol D3	vitamin D	none	{'e1': {'word': '25-Dihydroxycholecalciferol D3', 'word_index': [(1, 3)], 'id': 'DDI-MedLine.d53.s1.e0'}, 'e2': {'word': 'vitamin D', 'word_index': [(12, 13)], 'id': 'DDI-MedLine.d53.s1.e2'}, 'sentence_id': 'DDI-MedLine.d53.s1'}	1 NUMBER Dihydroxycholecalciferol D3 NUMBER NUMBER OH 2D3 the active metabolite of vitamin D is a potent inhibitor of breast cancer cell growth both in vivo and in vitro
1,25-Dihydroxycholecalciferol D3 (1,25(OH)2D3), the active metabolite of vitamin D, is a potent inhibitor of breast cancer cell growth both in vivo and in vitro. 	1,25(OH)2D3	vitamin D	none	{'e1': {'word': '1,25(OH)2D3', 'word_index': [(4, 7)], 'id': 'DDI-MedLine.d53.s1.e1'}, 'e2': {'word': 'vitamin D', 'word_index': [(12, 13)], 'id': 'DDI-MedLine.d53.s1.e2'}, 'sentence_id': 'DDI-MedLine.d53.s1'}	1 NUMBER Dihydroxycholecalciferol D3 NUMBER NUMBER OH 2D3 the active metabolite of vitamin D is a potent inhibitor of breast cancer cell growth both in vivo and in vitro
In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. 	1,25(OH)2D3	antiestrogen	none	{'e1': {'word': '1,25(OH)2D3', 'word_index': [(10, 13)], 'id': 'DDI-MedLine.d53.s3.e0'}, 'e2': {'word': 'antiestrogen', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d53.s3.e1'}, 'sentence_id': 'DDI-MedLine.d53.s3'}	In the experiments reported here we examined the interactions between NUMBER NUMBER OH 2D3 and the antiestrogen NUMBER hydroxytamoxifen TAM which also induces apoptosis in MCF NUMBER cells
In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. 	1,25(OH)2D3	4-hydroxytamoxifen	none	{'e1': {'word': '1,25(OH)2D3', 'word_index': [(10, 13)], 'id': 'DDI-MedLine.d53.s3.e0'}, 'e2': {'word': '4-hydroxytamoxifen', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d53.s3.e2'}, 'sentence_id': 'DDI-MedLine.d53.s3'}	In the experiments reported here we examined the interactions between NUMBER NUMBER OH 2D3 and the antiestrogen NUMBER hydroxytamoxifen TAM which also induces apoptosis in MCF NUMBER cells
In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. 	1,25(OH)2D3	TAM	none	{'e1': {'word': '1,25(OH)2D3', 'word_index': [(10, 13)], 'id': 'DDI-MedLine.d53.s3.e0'}, 'e2': {'word': 'TAM', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d53.s3.e3'}, 'sentence_id': 'DDI-MedLine.d53.s3'}	In the experiments reported here we examined the interactions between NUMBER NUMBER OH 2D3 and the antiestrogen NUMBER hydroxytamoxifen TAM which also induces apoptosis in MCF NUMBER cells
In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. 	antiestrogen	4-hydroxytamoxifen	none	{'e1': {'word': 'antiestrogen', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d53.s3.e1'}, 'e2': {'word': '4-hydroxytamoxifen', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d53.s3.e2'}, 'sentence_id': 'DDI-MedLine.d53.s3'}	In the experiments reported here we examined the interactions between NUMBER NUMBER OH 2D3 and the antiestrogen NUMBER hydroxytamoxifen TAM which also induces apoptosis in MCF NUMBER cells
In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. 	antiestrogen	TAM	none	{'e1': {'word': 'antiestrogen', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d53.s3.e1'}, 'e2': {'word': 'TAM', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d53.s3.e3'}, 'sentence_id': 'DDI-MedLine.d53.s3'}	In the experiments reported here we examined the interactions between NUMBER NUMBER OH 2D3 and the antiestrogen NUMBER hydroxytamoxifen TAM which also induces apoptosis in MCF NUMBER cells
In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. 	4-hydroxytamoxifen	TAM	none	{'e1': {'word': '4-hydroxytamoxifen', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d53.s3.e2'}, 'e2': {'word': 'TAM', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d53.s3.e3'}, 'sentence_id': 'DDI-MedLine.d53.s3'}	In the experiments reported here we examined the interactions between NUMBER NUMBER OH 2D3 and the antiestrogen NUMBER hydroxytamoxifen TAM which also induces apoptosis in MCF NUMBER cells
Our data suggest that TAM significantly potentiates the reduction in cell number induced by 1,25(OH)2D3 alone. 	TAM	1,25(OH)2D3	effect	{'e1': {'word': 'TAM', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d53.s4.e0'}, 'e2': {'word': '1,25(OH)2D3', 'word_index': [(14, 17)], 'id': 'DDI-MedLine.d53.s4.e1'}, 'sentence_id': 'DDI-MedLine.d53.s4'}	Our data suggest that TAM significantly potentiates the reduction in cell number induced by NUMBER NUMBER OH 2D3 alone
Combined treatment with 1,25(OH)2D3 and TAM enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation. 	1,25(OH)2D3	TAM	effect	{'e1': {'word': '1,25(OH)2D3', 'word_index': [(3, 6)], 'id': 'DDI-MedLine.d53.s5.e0'}, 'e2': {'word': 'TAM', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d53.s5.e1'}, 'sentence_id': 'DDI-MedLine.d53.s5'}	Combined treatment with NUMBER NUMBER OH 2D3 and TAM enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation
These data emphasize that apoptosis can be induced in MCF-7 cells either by activation of vitamin-D-mediated signalling or disruption of estrogen-dependent signalling.	vitamin-D	estrogen	none	{'e1': {'word': 'vitamin-D', 'word_index': [(16, 17)], 'id': 'DDI-MedLine.d53.s9.e0'}, 'e2': {'word': 'estrogen', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d53.s9.e1'}, 'sentence_id': 'DDI-MedLine.d53.s9'}	These data emphasize that apoptosis can be induced in MCF NUMBER cells either by activation of vitamin D mediated signalling or disruption of estrogen dependent signalling
The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. 	phenytoin	fluvoxamine	none	{'e1': {'word': 'phenytoin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d60.s2.e0'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d60.s2.e1'}, 'sentence_id': 'DDI-MedLine.d60.s2'}	The serum concentration of phenytoin increased dramatically from NUMBER to NUMBER microg / mL when fluvoxamine was coadministered although the daily dosage of phenytoin and other drugs had not changed
The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. 	phenytoin	phenytoin	none	{'e1': {'word': 'phenytoin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d60.s2.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d60.s2.e2'}, 'sentence_id': 'DDI-MedLine.d60.s2'}	The serum concentration of phenytoin increased dramatically from NUMBER to NUMBER microg / mL when fluvoxamine was coadministered although the daily dosage of phenytoin and other drugs had not changed
The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. 	phenytoin	drugs	none	{'e1': {'word': 'phenytoin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d60.s2.e0'}, 'e2': {'word': 'drugs', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d60.s2.e3'}, 'sentence_id': 'DDI-MedLine.d60.s2'}	The serum concentration of phenytoin increased dramatically from NUMBER to NUMBER microg / mL when fluvoxamine was coadministered although the daily dosage of phenytoin and other drugs had not changed
The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. 	fluvoxamine	phenytoin	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d60.s2.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d60.s2.e2'}, 'sentence_id': 'DDI-MedLine.d60.s2'}	The serum concentration of phenytoin increased dramatically from NUMBER to NUMBER microg / mL when fluvoxamine was coadministered although the daily dosage of phenytoin and other drugs had not changed
The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. 	fluvoxamine	drugs	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d60.s2.e1'}, 'e2': {'word': 'drugs', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d60.s2.e3'}, 'sentence_id': 'DDI-MedLine.d60.s2'}	The serum concentration of phenytoin increased dramatically from NUMBER to NUMBER microg / mL when fluvoxamine was coadministered although the daily dosage of phenytoin and other drugs had not changed
The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. 	phenytoin	drugs	none	{'e1': {'word': 'phenytoin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d60.s2.e2'}, 'e2': {'word': 'drugs', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d60.s2.e3'}, 'sentence_id': 'DDI-MedLine.d60.s2'}	The serum concentration of phenytoin increased dramatically from NUMBER to NUMBER microg / mL when fluvoxamine was coadministered although the daily dosage of phenytoin and other drugs had not changed
During phenytoin and fluvoxamine treatment, ataxia, a typical side effect of phenytoin, was observed. 	phenytoin	phenytoin	none	{'e1': {'word': 'phenytoin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d60.s3.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d60.s3.e1'}, 'sentence_id': 'DDI-MedLine.d60.s3'}	During phenytoin and fluvoxamine treatment ataxia a typical side effect of phenytoin was observed
The genotypes of CYP2C9 and 2C19, the enzymes responsible for phenytoin metabolism, were homozygous for the wild-type alleles (CYP2C9*1/*1 and 2C19*1/ *1). 	CYP2C9	CYP2C9	none	{'e1': {'word': 'CYP2C9', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d60.s4.e0'}, 'e2': {'word': 'CYP2C9', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d60.s4.e1'}, 'sentence_id': 'DDI-MedLine.d60.s4'}	The genotypes of CYP2C9 and 2C19 the enzymes responsible for phenytoin metabolism were homozygous for the wild type alleles CYP2C9 * NUMBER * NUMBER and 2C19 * NUMBER * NUMBER
The interaction may be a result of inhibition of both CYP2C9 and 2C19 by fluvoxamine.	CYP2C9	fluvoxamine	none	{'e1': {'word': 'CYP2C9', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d60.s5.e0'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d60.s5.e1'}, 'sentence_id': 'DDI-MedLine.d60.s5'}	The interaction may be a result of inhibition of both CYP2C9 and 2C19 by fluvoxamine
"High-dose cisplatin with sodium thiosulfate protection.
"	cisplatin	sodium thiosulfate	effect	{'e1': {'word': 'cisplatin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d130.s0.e0'}, 'e2': {'word': 'sodium thiosulfate', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d130.s0.e1'}, 'sentence_id': 'DDI-MedLine.d130.s0'}	High dose cisplatin with sodium thiosulfate protection
Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage. 	Sodium thiosulfate	cisplatin	effect	{'e1': {'word': 'Sodium thiosulfate', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d130.s2.e0'}, 'e2': {'word': 'cisplatin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d130.s2.e1'}, 'sentence_id': 'DDI-MedLine.d130.s2'}	Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin. 	thiosulfate	cisplatin	none	{'e1': {'word': 'thiosulfate', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d130.s3.e0'}, 'e2': {'word': 'cisplatin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d130.s3.e1'}, 'sentence_id': 'DDI-MedLine.d130.s3'}	To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered a fixed NUMBER g / m2 dose of thiosulfate was given intravenously over NUMBER hours concurrently with escalating doses of cisplatin
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin. 	thiosulfate	thiosulfate	none	{'e1': {'word': 'thiosulfate', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d130.s3.e0'}, 'e2': {'word': 'thiosulfate', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d130.s3.e2'}, 'sentence_id': 'DDI-MedLine.d130.s3'}	To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered a fixed NUMBER g / m2 dose of thiosulfate was given intravenously over NUMBER hours concurrently with escalating doses of cisplatin
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin. 	thiosulfate	cisplatin	none	{'e1': {'word': 'thiosulfate', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d130.s3.e0'}, 'e2': {'word': 'cisplatin', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d130.s3.e3'}, 'sentence_id': 'DDI-MedLine.d130.s3'}	To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered a fixed NUMBER g / m2 dose of thiosulfate was given intravenously over NUMBER hours concurrently with escalating doses of cisplatin
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin. 	cisplatin	thiosulfate	none	{'e1': {'word': 'cisplatin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d130.s3.e1'}, 'e2': {'word': 'thiosulfate', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d130.s3.e2'}, 'sentence_id': 'DDI-MedLine.d130.s3'}	To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered a fixed NUMBER g / m2 dose of thiosulfate was given intravenously over NUMBER hours concurrently with escalating doses of cisplatin
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin. 	cisplatin	cisplatin	none	{'e1': {'word': 'cisplatin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d130.s3.e1'}, 'e2': {'word': 'cisplatin', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d130.s3.e3'}, 'sentence_id': 'DDI-MedLine.d130.s3'}	To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered a fixed NUMBER g / m2 dose of thiosulfate was given intravenously over NUMBER hours concurrently with escalating doses of cisplatin
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin. 	thiosulfate	cisplatin	none	{'e1': {'word': 'thiosulfate', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d130.s3.e2'}, 'e2': {'word': 'cisplatin', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d130.s3.e3'}, 'sentence_id': 'DDI-MedLine.d130.s3'}	To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered a fixed NUMBER g / m2 dose of thiosulfate was given intravenously over NUMBER hours concurrently with escalating doses of cisplatin
Cisplatin was administered over the last two hours of the thiosulfate infusion. 	Cisplatin	thiosulfate	none	{'e1': {'word': 'Cisplatin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d130.s4.e0'}, 'e2': {'word': 'thiosulfate', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d130.s4.e1'}, 'sentence_id': 'DDI-MedLine.d130.s4'}	Cisplatin was administered over the last NUMBER hours of the thiosulfate infusion
Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. 	cisplatin	thiosulfate	none	{'e1': {'word': 'cisplatin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d130.s6.e0'}, 'e2': {'word': 'thiosulfate', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d130.s6.e1'}, 'sentence_id': 'DDI-MedLine.d130.s6'}	Comparison of cisplatin pharmacokinetics in patients treated with NUMBER mg / m2 plus thiosulfate to those in patients treated with NUMBER mg / m2 without thiosulfate indicated that there were no changes in the elimination rate constant volume of distribution or total body clearance of cisplatin
Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. 	cisplatin	thiosulfate	none	{'e1': {'word': 'cisplatin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d130.s6.e0'}, 'e2': {'word': 'thiosulfate', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d130.s6.e2'}, 'sentence_id': 'DDI-MedLine.d130.s6'}	Comparison of cisplatin pharmacokinetics in patients treated with NUMBER mg / m2 plus thiosulfate to those in patients treated with NUMBER mg / m2 without thiosulfate indicated that there were no changes in the elimination rate constant volume of distribution or total body clearance of cisplatin
Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. 	cisplatin	cisplatin	none	{'e1': {'word': 'cisplatin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d130.s6.e0'}, 'e2': {'word': 'cisplatin', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d130.s6.e3'}, 'sentence_id': 'DDI-MedLine.d130.s6'}	Comparison of cisplatin pharmacokinetics in patients treated with NUMBER mg / m2 plus thiosulfate to those in patients treated with NUMBER mg / m2 without thiosulfate indicated that there were no changes in the elimination rate constant volume of distribution or total body clearance of cisplatin
Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. 	thiosulfate	thiosulfate	none	{'e1': {'word': 'thiosulfate', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d130.s6.e1'}, 'e2': {'word': 'thiosulfate', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d130.s6.e2'}, 'sentence_id': 'DDI-MedLine.d130.s6'}	Comparison of cisplatin pharmacokinetics in patients treated with NUMBER mg / m2 plus thiosulfate to those in patients treated with NUMBER mg / m2 without thiosulfate indicated that there were no changes in the elimination rate constant volume of distribution or total body clearance of cisplatin
Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. 	thiosulfate	cisplatin	none	{'e1': {'word': 'thiosulfate', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d130.s6.e1'}, 'e2': {'word': 'cisplatin', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d130.s6.e3'}, 'sentence_id': 'DDI-MedLine.d130.s6'}	Comparison of cisplatin pharmacokinetics in patients treated with NUMBER mg / m2 plus thiosulfate to those in patients treated with NUMBER mg / m2 without thiosulfate indicated that there were no changes in the elimination rate constant volume of distribution or total body clearance of cisplatin
Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. 	thiosulfate	cisplatin	none	{'e1': {'word': 'thiosulfate', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d130.s6.e2'}, 'e2': {'word': 'cisplatin', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d130.s6.e3'}, 'sentence_id': 'DDI-MedLine.d130.s6'}	Comparison of cisplatin pharmacokinetics in patients treated with NUMBER mg / m2 plus thiosulfate to those in patients treated with NUMBER mg / m2 without thiosulfate indicated that there were no changes in the elimination rate constant volume of distribution or total body clearance of cisplatin
This study demonstrates that concurrent administration of thiosulfate permits at least a twofold increase in dose and total exposure to cisplatin.	thiosulfate	cisplatin	mechanism	{'e1': {'word': 'thiosulfate', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d130.s8.e0'}, 'e2': {'word': 'cisplatin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d130.s8.e1'}, 'sentence_id': 'DDI-MedLine.d130.s8'}	This study demonstrates that concurrent administration of thiosulfate permits at least a NUMBER fold increase in dose and total exposure to cisplatin
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d103.s1.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d103.s1.e1'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	NUMBER different types of therapy with magnesium are used physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d103.s1.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d103.s1.e2'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	NUMBER different types of therapy with magnesium are used physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d103.s1.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d103.s1.e3'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	NUMBER different types of therapy with magnesium are used physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d103.s1.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d103.s1.e4'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	NUMBER different types of therapy with magnesium are used physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d103.s1.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d103.s1.e5'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	NUMBER different types of therapy with magnesium are used physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d103.s1.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d103.s1.e2'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	NUMBER different types of therapy with magnesium are used physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d103.s1.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d103.s1.e3'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	NUMBER different types of therapy with magnesium are used physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d103.s1.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d103.s1.e4'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	NUMBER different types of therapy with magnesium are used physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d103.s1.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d103.s1.e5'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	NUMBER different types of therapy with magnesium are used physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d103.s1.e2'}, 'e2': {'word': 'magnesium', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d103.s1.e3'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	NUMBER different types of therapy with magnesium are used physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d103.s1.e2'}, 'e2': {'word': 'magnesium', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d103.s1.e4'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	NUMBER different types of therapy with magnesium are used physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d103.s1.e2'}, 'e2': {'word': 'magnesium', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d103.s1.e5'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	NUMBER different types of therapy with magnesium are used physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d103.s1.e3'}, 'e2': {'word': 'magnesium', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d103.s1.e4'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	NUMBER different types of therapy with magnesium are used physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d103.s1.e3'}, 'e2': {'word': 'magnesium', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d103.s1.e5'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	NUMBER different types of therapy with magnesium are used physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d103.s1.e4'}, 'e2': {'word': 'magnesium', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d103.s1.e5'}, 'sentence_id': 'DDI-MedLine.d103.s1'}	NUMBER different types of therapy with magnesium are used physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload
Primary and secondary magnesium deficiencies constitute the sole indication of physiological oral magnesium therapy. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d103.s2.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d103.s2.e1'}, 'sentence_id': 'DDI-MedLine.d103.s2'}	Primary and secondary magnesium deficiencies constitute the sole indication of physiological oral magnesium therapy
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d103.s3.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d103.s3.e1'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d103.s3.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d103.s3.e2'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d103.s3.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d103.s3.e3'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d103.s3.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d103.s3.e4'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d103.s3.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d103.s3.e2'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d103.s3.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d103.s3.e3'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d103.s3.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d103.s3.e4'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d103.s3.e2'}, 'e2': {'word': 'magnesium', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d103.s3.e3'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d103.s3.e2'}, 'e2': {'word': 'magnesium', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d103.s3.e4'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d103.s3.e3'}, 'e2': {'word': 'magnesium', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d103.s3.e4'}, 'sentence_id': 'DDI-MedLine.d103.s3'}	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation
Physiological oral magnesium load constitutes the best tool for diagnosis of magnesium deficiency and the first step of its treatment. 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d103.s4.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d103.s4.e1'}, 'sentence_id': 'DDI-MedLine.d103.s4'}	Physiological oral magnesium load constitutes the best tool for diagnosis of magnesium deficiency and the first step of its treatment
Physiological oral magnesium supplementation (5 mg/kg/day) is easy and can be carried out in the diet or with magnesium salts, with practically only one contra-indication: overt renal failure. 	magnesium	magnesium salt	none	{'e1': {'word': 'magnesium', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d103.s5.e0'}, 'e2': {'word': 'magnesium salt', 'word_index': [(22, 23)], 'id': 'DDI-MedLine.d103.s5.e1'}, 'sentence_id': 'DDI-MedLine.d103.s5'}	Physiological oral magnesium supplementation NUMBER mg / kg / day is easy and can be carried out in the diet or with magnesium salt s with practically only NUMBER contra-indication overt renal failure
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	magnesium	magnesium sparing diuretics	none	{'e1': {'word': 'magnesium', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d103.s6.e0'}, 'e2': {'word': 'magnesium sparing diuretics', 'word_index': [(12, 14)], 'id': 'DDI-MedLine.d103.s6.e1'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics pharmacological doses of vitamin B6 physiological doses of vitamin D and of selenium
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	magnesium	vitamin B6	none	{'e1': {'word': 'magnesium', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d103.s6.e0'}, 'e2': {'word': 'vitamin B6', 'word_index': [(18, 19)], 'id': 'DDI-MedLine.d103.s6.e2'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics pharmacological doses of vitamin B6 physiological doses of vitamin D and of selenium
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	magnesium	vitamin D	none	{'e1': {'word': 'magnesium', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d103.s6.e0'}, 'e2': {'word': 'vitamin D', 'word_index': [(23, 24)], 'id': 'DDI-MedLine.d103.s6.e3'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics pharmacological doses of vitamin B6 physiological doses of vitamin D and of selenium
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	magnesium	selenium	none	{'e1': {'word': 'magnesium', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d103.s6.e0'}, 'e2': {'word': 'selenium', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d103.s6.e4'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics pharmacological doses of vitamin B6 physiological doses of vitamin D and of selenium
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	magnesium sparing diuretics	vitamin B6	none	{'e1': {'word': 'magnesium sparing diuretics', 'word_index': [(12, 14)], 'id': 'DDI-MedLine.d103.s6.e1'}, 'e2': {'word': 'vitamin B6', 'word_index': [(18, 19)], 'id': 'DDI-MedLine.d103.s6.e2'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics pharmacological doses of vitamin B6 physiological doses of vitamin D and of selenium
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	magnesium sparing diuretics	vitamin D	none	{'e1': {'word': 'magnesium sparing diuretics', 'word_index': [(12, 14)], 'id': 'DDI-MedLine.d103.s6.e1'}, 'e2': {'word': 'vitamin D', 'word_index': [(23, 24)], 'id': 'DDI-MedLine.d103.s6.e3'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics pharmacological doses of vitamin B6 physiological doses of vitamin D and of selenium
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	magnesium sparing diuretics	selenium	none	{'e1': {'word': 'magnesium sparing diuretics', 'word_index': [(12, 14)], 'id': 'DDI-MedLine.d103.s6.e1'}, 'e2': {'word': 'selenium', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d103.s6.e4'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics pharmacological doses of vitamin B6 physiological doses of vitamin D and of selenium
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	vitamin B6	vitamin D	none	{'e1': {'word': 'vitamin B6', 'word_index': [(18, 19)], 'id': 'DDI-MedLine.d103.s6.e2'}, 'e2': {'word': 'vitamin D', 'word_index': [(23, 24)], 'id': 'DDI-MedLine.d103.s6.e3'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics pharmacological doses of vitamin B6 physiological doses of vitamin D and of selenium
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	vitamin B6	selenium	none	{'e1': {'word': 'vitamin B6', 'word_index': [(18, 19)], 'id': 'DDI-MedLine.d103.s6.e2'}, 'e2': {'word': 'selenium', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d103.s6.e4'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics pharmacological doses of vitamin B6 physiological doses of vitamin D and of selenium
Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 	vitamin D	selenium	none	{'e1': {'word': 'vitamin D', 'word_index': [(23, 24)], 'id': 'DDI-MedLine.d103.s6.e3'}, 'e2': {'word': 'selenium', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d103.s6.e4'}, 'sentence_id': 'DDI-MedLine.d103.s6'}	Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics pharmacological doses of vitamin B6 physiological doses of vitamin D and of selenium
There are 3 types of indications: specific (for the treatment of some forms of magnesium deficit i.e. acute), pharmacological (i.e. without alterations of magnesium status) and mixed--pharmacological and aetiopathogenic--(for example complications of chronic alcoholism). 	magnesium	magnesium	none	{'e1': {'word': 'magnesium', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d103.s8.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d103.s8.e1'}, 'sentence_id': 'DDI-MedLine.d103.s8'}	There are NUMBER types of indications specific for the treatment of some forms of magnesium deficit i.e. acute pharmacological i.e. without alterations of magnesium status and mixed pharmacological and aetiopathogenic for example complications of chronic alcoholism
Lastly local use of the mucocutaneous and cytoprotective properties of magnesium is still valid, in cardioplegic solutions and for preservation of transplants particularly.	magnesium	cardioplegic solutions	none	{'e1': {'word': 'magnesium', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d103.s15.e0'}, 'e2': {'word': 'cardioplegic solutions', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d103.s15.e1'}, 'sentence_id': 'DDI-MedLine.d103.s15'}	Lastly local use of the mucocutaneous and cytoprotective properties of magnesium is still valid in cardioplegic solutions and for preservation of transplants particularly
"Hypothermia as an index of the disulfiram-ethanol reaction in the rat.
"	disulfiram	ethanol	none	{'e1': {'word': 'disulfiram', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d81.s0.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d81.s0.e1'}, 'sentence_id': 'DDI-MedLine.d81.s0'}	Hypothermia as an index of the disulfiram ethanol reaction in the rat
Decreased core temperature in female rats was investigated as one possible index of the disulfiram-ethanol reaction (DER). 	disulfiram	ethanol	none	{'e1': {'word': 'disulfiram', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d81.s1.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d81.s1.e1'}, 'sentence_id': 'DDI-MedLine.d81.s1'}	Decreased core temperature in female rats was investigated as NUMBER possible index of the disulfiram ethanol reaction DER
Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge. 	ethanol	disulfiram	effect	{'e1': {'word': 'ethanol', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d81.s2.e0'}, 'e2': {'word': 'disulfiram', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d81.s2.e1'}, 'sentence_id': 'DDI-MedLine.d81.s2'}	Core temperature was decreased in rats in a dose dependent manner when ethanol was administered to rats treated with disulfiram NUMBER hours before the ethanol challenge
Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge. 	ethanol	ethanol	none	{'e1': {'word': 'ethanol', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d81.s2.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d81.s2.e2'}, 'sentence_id': 'DDI-MedLine.d81.s2'}	Core temperature was decreased in rats in a dose dependent manner when ethanol was administered to rats treated with disulfiram NUMBER hours before the ethanol challenge
Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge. 	disulfiram	ethanol	none	{'e1': {'word': 'disulfiram', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d81.s2.e1'}, 'e2': {'word': 'ethanol', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d81.s2.e2'}, 'sentence_id': 'DDI-MedLine.d81.s2'}	Core temperature was decreased in rats in a dose dependent manner when ethanol was administered to rats treated with disulfiram NUMBER hours before the ethanol challenge
The decrease in temperature began within 20 minutes after ethanol administration, reaching a maximal decrease between 60 and 120 minutes post ethanol. 	ethanol	ethanol	none	{'e1': {'word': 'ethanol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d81.s3.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d81.s3.e1'}, 'sentence_id': 'DDI-MedLine.d81.s3'}	The decrease in temperature began within NUMBER minutes after ethanol administration reaching a maximal decrease between NUMBER and NUMBER minutes post ethanol
Maximal hypotension was found 120 minutes post ethanol, and returned to normal 300 minutes after ethanol. 	ethanol	ethanol	none	{'e1': {'word': 'ethanol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d81.s6.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d81.s6.e1'}, 'sentence_id': 'DDI-MedLine.d81.s6'}	Maximal hypotension was found NUMBER minutes post ethanol and returned to normal NUMBER minutes after ethanol
"In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans.
"	KRM-1648	ofloxacin	none	{'e1': {'word': 'KRM-1648', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d8.s0.e0'}, 'e2': {'word': 'ofloxacin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d8.s0.e1'}, 'sentence_id': 'DDI-MedLine.d8.s0'}	In vitro activity of KRM NUMBER either singly or in combination with ofloxacin against Mycobacterium ulcerans
The antimicrobial effect of a benzoxazinorifamycin, KRM-1648, either alone or in combination with ofloxacin, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans. 	benzoxazinorifamycin	KRM-1648	none	{'e1': {'word': 'benzoxazinorifamycin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d8.s1.e0'}, 'e2': {'word': 'KRM-1648', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d8.s1.e1'}, 'sentence_id': 'DDI-MedLine.d8.s1'}	The antimicrobial effect of a benzoxazinorifamycin KRM NUMBER either alone or in combination with ofloxacin was evaluated in vitro against NUMBER type strains and NUMBER clinical isolates of Mycobacterium ulcerans
The antimicrobial effect of a benzoxazinorifamycin, KRM-1648, either alone or in combination with ofloxacin, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans. 	benzoxazinorifamycin	ofloxacin	none	{'e1': {'word': 'benzoxazinorifamycin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d8.s1.e0'}, 'e2': {'word': 'ofloxacin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d8.s1.e2'}, 'sentence_id': 'DDI-MedLine.d8.s1'}	The antimicrobial effect of a benzoxazinorifamycin KRM NUMBER either alone or in combination with ofloxacin was evaluated in vitro against NUMBER type strains and NUMBER clinical isolates of Mycobacterium ulcerans
The antimicrobial effect of a benzoxazinorifamycin, KRM-1648, either alone or in combination with ofloxacin, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans. 	KRM-1648	ofloxacin	none	{'e1': {'word': 'KRM-1648', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d8.s1.e1'}, 'e2': {'word': 'ofloxacin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d8.s1.e2'}, 'sentence_id': 'DDI-MedLine.d8.s1'}	The antimicrobial effect of a benzoxazinorifamycin KRM NUMBER either alone or in combination with ofloxacin was evaluated in vitro against NUMBER type strains and NUMBER clinical isolates of Mycobacterium ulcerans
ulcerans was between 0.012 and 0.025 mg/l, while corresponding values for rifampicin and rifabutin were in the range of 0.1-0.8 mg/l and 0.1-0.4 mg/l respectively. 	rifampicin	rifabutin	none	{'e1': {'word': 'rifampicin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d8.s5.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d8.s5.e1'}, 'sentence_id': 'DDI-MedLine.d8.s5'}	ulcerans was between NUMBER and NUMBER mg / l while corresponding values for rifampicin and rifabutin were in the range of NUMBER - NUMBER mg / l and NUMBER - NUMBER mg / l respectively
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	ofloxacin	KRM-1648	effect	{'e1': {'word': 'ofloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d8.s6.e0'}, 'e2': {'word': 'KRM-1648', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d8.s6.e1'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	When combined with ofloxacin KRM NUMBER exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin or rifabutin and ofloxacin
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	ofloxacin	rifampicin	none	{'e1': {'word': 'ofloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d8.s6.e0'}, 'e2': {'word': 'rifampicin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d8.s6.e2'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	When combined with ofloxacin KRM NUMBER exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin or rifabutin and ofloxacin
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	ofloxacin	rifabutin	none	{'e1': {'word': 'ofloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d8.s6.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d8.s6.e3'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	When combined with ofloxacin KRM NUMBER exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin or rifabutin and ofloxacin
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	ofloxacin	ofloxacin	none	{'e1': {'word': 'ofloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d8.s6.e0'}, 'e2': {'word': 'ofloxacin', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d8.s6.e4'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	When combined with ofloxacin KRM NUMBER exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin or rifabutin and ofloxacin
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	KRM-1648	rifampicin	none	{'e1': {'word': 'KRM-1648', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d8.s6.e1'}, 'e2': {'word': 'rifampicin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d8.s6.e2'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	When combined with ofloxacin KRM NUMBER exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin or rifabutin and ofloxacin
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	KRM-1648	rifabutin	none	{'e1': {'word': 'KRM-1648', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d8.s6.e1'}, 'e2': {'word': 'rifabutin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d8.s6.e3'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	When combined with ofloxacin KRM NUMBER exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin or rifabutin and ofloxacin
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	KRM-1648	ofloxacin	none	{'e1': {'word': 'KRM-1648', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d8.s6.e1'}, 'e2': {'word': 'ofloxacin', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d8.s6.e4'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	When combined with ofloxacin KRM NUMBER exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin or rifabutin and ofloxacin
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	rifampicin	rifabutin	none	{'e1': {'word': 'rifampicin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d8.s6.e2'}, 'e2': {'word': 'rifabutin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d8.s6.e3'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	When combined with ofloxacin KRM NUMBER exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin or rifabutin and ofloxacin
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	rifampicin	ofloxacin	effect	{'e1': {'word': 'rifampicin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d8.s6.e2'}, 'e2': {'word': 'ofloxacin', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d8.s6.e4'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	When combined with ofloxacin KRM NUMBER exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin or rifabutin and ofloxacin
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 	rifabutin	ofloxacin	effect	{'e1': {'word': 'rifabutin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d8.s6.e3'}, 'e2': {'word': 'ofloxacin', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d8.s6.e4'}, 'sentence_id': 'DDI-MedLine.d8.s6'}	When combined with ofloxacin KRM NUMBER exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin or rifabutin and ofloxacin
"Interaction between glycine and glutamate in the development of spontaneous motility in chick embryos.
"	glycine	glutamate	effect	{'e1': {'word': 'glycine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d20.s0.e0'}, 'e2': {'word': 'glutamate', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d20.s0.e1'}, 'sentence_id': 'DDI-MedLine.d20.s0'}	Interaction between glycine and glutamate in the development of spontaneous motility in chick embryos
The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone. 	glycine	glutamate	effect	{'e1': {'word': 'glycine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d20.s4.e0'}, 'e2': {'word': 'glutamate', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d20.s4.e1'}, 'sentence_id': 'DDI-MedLine.d20.s4'}	The successive application of glycine NUMBER or NUMBER mg / kg egg weight e.w. and glutamate NUMBER mg / kg e.w. in a NUMBER min interval significantly increased the activation of spontaneous motility of NUMBER day old chick embryos in comparison with the effect of glutamate alone
The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone. 	glycine	glutamate	none	{'e1': {'word': 'glycine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d20.s4.e0'}, 'e2': {'word': 'glutamate', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d20.s4.e2'}, 'sentence_id': 'DDI-MedLine.d20.s4'}	The successive application of glycine NUMBER or NUMBER mg / kg egg weight e.w. and glutamate NUMBER mg / kg e.w. in a NUMBER min interval significantly increased the activation of spontaneous motility of NUMBER day old chick embryos in comparison with the effect of glutamate alone
The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone. 	glutamate	glutamate	none	{'e1': {'word': 'glutamate', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d20.s4.e1'}, 'e2': {'word': 'glutamate', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d20.s4.e2'}, 'sentence_id': 'DDI-MedLine.d20.s4'}	The successive application of glycine NUMBER or NUMBER mg / kg egg weight e.w. and glutamate NUMBER mg / kg e.w. in a NUMBER min interval significantly increased the activation of spontaneous motility of NUMBER day old chick embryos in comparison with the effect of glutamate alone
"Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
"	verapamil	bombesin	effect	{'e1': {'word': 'verapamil', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d133.s0.e0'}, 'e2': {'word': 'bombesin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d133.s0.e1'}, 'sentence_id': 'DDI-MedLine.d133.s0'}	Suppression by verapamil of bombesin enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats
"Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
"	verapamil	azoxymethane	none	{'e1': {'word': 'verapamil', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d133.s0.e0'}, 'e2': {'word': 'azoxymethane', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d133.s0.e2'}, 'sentence_id': 'DDI-MedLine.d133.s0'}	Suppression by verapamil of bombesin enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats
"Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
"	bombesin	azoxymethane	none	{'e1': {'word': 'bombesin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d133.s0.e1'}, 'e2': {'word': 'azoxymethane', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d133.s0.e2'}, 'sentence_id': 'DDI-MedLine.d133.s0'}	Suppression by verapamil of bombesin enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	bombesin	verapamil hydrochloride	none	{'e1': {'word': 'bombesin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d133.s1.e0'}, 'e2': {'word': 'verapamil hydrochloride', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d133.s1.e1'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND The effects of combined administration of bombesin and verapamil hydrochloride verapamil a calcium channel blocker on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane AOM and the labeling index of intestinal cancers were investigated in male Wistar rats
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	bombesin	verapamil	none	{'e1': {'word': 'bombesin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d133.s1.e0'}, 'e2': {'word': 'verapamil', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d133.s1.e2'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND The effects of combined administration of bombesin and verapamil hydrochloride verapamil a calcium channel blocker on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane AOM and the labeling index of intestinal cancers were investigated in male Wistar rats
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	bombesin	calcium channel blocker	none	{'e1': {'word': 'bombesin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d133.s1.e0'}, 'e2': {'word': 'calcium channel blocker', 'word_index': [(13, 15)], 'id': 'DDI-MedLine.d133.s1.e3'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND The effects of combined administration of bombesin and verapamil hydrochloride verapamil a calcium channel blocker on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane AOM and the labeling index of intestinal cancers were investigated in male Wistar rats
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	bombesin	azoxymethane	none	{'e1': {'word': 'bombesin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d133.s1.e0'}, 'e2': {'word': 'azoxymethane', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d133.s1.e4'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND The effects of combined administration of bombesin and verapamil hydrochloride verapamil a calcium channel blocker on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane AOM and the labeling index of intestinal cancers were investigated in male Wistar rats
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	bombesin	AOM	none	{'e1': {'word': 'bombesin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d133.s1.e0'}, 'e2': {'word': 'AOM', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d133.s1.e5'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND The effects of combined administration of bombesin and verapamil hydrochloride verapamil a calcium channel blocker on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane AOM and the labeling index of intestinal cancers were investigated in male Wistar rats
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	verapamil hydrochloride	verapamil	none	{'e1': {'word': 'verapamil hydrochloride', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d133.s1.e1'}, 'e2': {'word': 'verapamil', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d133.s1.e2'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND The effects of combined administration of bombesin and verapamil hydrochloride verapamil a calcium channel blocker on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane AOM and the labeling index of intestinal cancers were investigated in male Wistar rats
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	verapamil hydrochloride	calcium channel blocker	none	{'e1': {'word': 'verapamil hydrochloride', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d133.s1.e1'}, 'e2': {'word': 'calcium channel blocker', 'word_index': [(13, 15)], 'id': 'DDI-MedLine.d133.s1.e3'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND The effects of combined administration of bombesin and verapamil hydrochloride verapamil a calcium channel blocker on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane AOM and the labeling index of intestinal cancers were investigated in male Wistar rats
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	verapamil hydrochloride	azoxymethane	none	{'e1': {'word': 'verapamil hydrochloride', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d133.s1.e1'}, 'e2': {'word': 'azoxymethane', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d133.s1.e4'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND The effects of combined administration of bombesin and verapamil hydrochloride verapamil a calcium channel blocker on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane AOM and the labeling index of intestinal cancers were investigated in male Wistar rats
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	verapamil hydrochloride	AOM	none	{'e1': {'word': 'verapamil hydrochloride', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d133.s1.e1'}, 'e2': {'word': 'AOM', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d133.s1.e5'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND The effects of combined administration of bombesin and verapamil hydrochloride verapamil a calcium channel blocker on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane AOM and the labeling index of intestinal cancers were investigated in male Wistar rats
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	verapamil	calcium channel blocker	none	{'e1': {'word': 'verapamil', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d133.s1.e2'}, 'e2': {'word': 'calcium channel blocker', 'word_index': [(13, 15)], 'id': 'DDI-MedLine.d133.s1.e3'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND The effects of combined administration of bombesin and verapamil hydrochloride verapamil a calcium channel blocker on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane AOM and the labeling index of intestinal cancers were investigated in male Wistar rats
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	verapamil	azoxymethane	none	{'e1': {'word': 'verapamil', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d133.s1.e2'}, 'e2': {'word': 'azoxymethane', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d133.s1.e4'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND The effects of combined administration of bombesin and verapamil hydrochloride verapamil a calcium channel blocker on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane AOM and the labeling index of intestinal cancers were investigated in male Wistar rats
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	verapamil	AOM	none	{'e1': {'word': 'verapamil', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d133.s1.e2'}, 'e2': {'word': 'AOM', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d133.s1.e5'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND The effects of combined administration of bombesin and verapamil hydrochloride verapamil a calcium channel blocker on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane AOM and the labeling index of intestinal cancers were investigated in male Wistar rats
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	calcium channel blocker	azoxymethane	none	{'e1': {'word': 'calcium channel blocker', 'word_index': [(13, 15)], 'id': 'DDI-MedLine.d133.s1.e3'}, 'e2': {'word': 'azoxymethane', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d133.s1.e4'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND The effects of combined administration of bombesin and verapamil hydrochloride verapamil a calcium channel blocker on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane AOM and the labeling index of intestinal cancers were investigated in male Wistar rats
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	calcium channel blocker	AOM	none	{'e1': {'word': 'calcium channel blocker', 'word_index': [(13, 15)], 'id': 'DDI-MedLine.d133.s1.e3'}, 'e2': {'word': 'AOM', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d133.s1.e5'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND The effects of combined administration of bombesin and verapamil hydrochloride verapamil a calcium channel blocker on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane AOM and the labeling index of intestinal cancers were investigated in male Wistar rats
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 	azoxymethane	AOM	none	{'e1': {'word': 'azoxymethane', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d133.s1.e4'}, 'e2': {'word': 'AOM', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d133.s1.e5'}, 'sentence_id': 'DDI-MedLine.d133.s1'}	BACKGROUND The effects of combined administration of bombesin and verapamil hydrochloride verapamil a calcium channel blocker on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane AOM and the labeling index of intestinal cancers were investigated in male Wistar rats
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45. 	AOM	bombesin	none	{'e1': {'word': 'AOM', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d133.s2.e0'}, 'e2': {'word': 'bombesin', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d133.s2.e1'}, 'sentence_id': 'DDI-MedLine.d133.s2'}	METHODS From the beginning of the experiment rats were given NUMBER weekly subcutaneous injections of AOM NUMBER mg / kg body weight and subcutaneous injections of bombesin NUMBER microg / kg body weight every other day and from week NUMBER intraperitoneal injections of verapamil NUMBER or NUMBER mg / kg body weight every other day until the end fo the experiment in week NUMBER
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45. 	AOM	verapamil	none	{'e1': {'word': 'AOM', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d133.s2.e0'}, 'e2': {'word': 'verapamil', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d133.s2.e2'}, 'sentence_id': 'DDI-MedLine.d133.s2'}	METHODS From the beginning of the experiment rats were given NUMBER weekly subcutaneous injections of AOM NUMBER mg / kg body weight and subcutaneous injections of bombesin NUMBER microg / kg body weight every other day and from week NUMBER intraperitoneal injections of verapamil NUMBER or NUMBER mg / kg body weight every other day until the end fo the experiment in week NUMBER
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45. 	bombesin	verapamil	none	{'e1': {'word': 'bombesin', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d133.s2.e1'}, 'e2': {'word': 'verapamil', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d133.s2.e2'}, 'sentence_id': 'DDI-MedLine.d133.s2'}	METHODS From the beginning of the experiment rats were given NUMBER weekly subcutaneous injections of AOM NUMBER mg / kg body weight and subcutaneous injections of bombesin NUMBER microg / kg body weight every other day and from week NUMBER intraperitoneal injections of verapamil NUMBER or NUMBER mg / kg body weight every other day until the end fo the experiment in week NUMBER
Although verapamil administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by bombesin or on the location, histologic type, depth of involvement, labeling index, apoptotic index or tumor vascularity of intestinal cancers, it significantly decreased the incidence of cancer metastasis. 	verapamil	bombesin	none	{'e1': {'word': 'verapamil', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d133.s4.e0'}, 'e2': {'word': 'bombesin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d133.s4.e1'}, 'sentence_id': 'DDI-MedLine.d133.s4'}	Although verapamil administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by bombesin or on the location histologic type depth of involvement labeling index apoptotic index or tumor vascularity of intestinal cancers it significantly decreased the incidence of cancer metastasis
Verapamil also significantly decreased the incidence of lymphatic invasion of adenocarcinomas, which was enhanced by bombesin. 	Verapamil	bombesin	effect	{'e1': {'word': 'Verapamil', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d133.s5.e0'}, 'e2': {'word': 'bombesin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d133.s5.e1'}, 'sentence_id': 'DDI-MedLine.d133.s5'}	Verapamil also significantly decreased the incidence of lymphatic invasion of adenocarcinomas which was enhanced by bombesin
The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 	ruthenium red	RR	none	{'e1': {'word': 'ruthenium red', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d114.s1.e0'}, 'e2': {'word': 'RR', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d114.s1.e1'}, 'sentence_id': 'DDI-MedLine.d114.s1'}	The effects of ruthenium red RR on inositol NUMBER NUMBER NUMBER trisphosphate InsP NUMBER induced responses were studied in rat bone marrow megakaryocytes with the patch clamp whole cell recording technique in combination with fura NUMBER microfluorometry
The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 	ruthenium red	inositol 1,4,5-trisphosphate	none	{'e1': {'word': 'ruthenium red', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d114.s1.e0'}, 'e2': {'word': 'inositol 1,4,5-trisphosphate', 'word_index': [(7, 11)], 'id': 'DDI-MedLine.d114.s1.e2'}, 'sentence_id': 'DDI-MedLine.d114.s1'}	The effects of ruthenium red RR on inositol NUMBER NUMBER NUMBER trisphosphate InsP NUMBER induced responses were studied in rat bone marrow megakaryocytes with the patch clamp whole cell recording technique in combination with fura NUMBER microfluorometry
The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 	ruthenium red	InsP(3)	none	{'e1': {'word': 'ruthenium red', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d114.s1.e0'}, 'e2': {'word': 'InsP(3)', 'word_index': [(12, 13)], 'id': 'DDI-MedLine.d114.s1.e3'}, 'sentence_id': 'DDI-MedLine.d114.s1'}	The effects of ruthenium red RR on inositol NUMBER NUMBER NUMBER trisphosphate InsP NUMBER induced responses were studied in rat bone marrow megakaryocytes with the patch clamp whole cell recording technique in combination with fura NUMBER microfluorometry
The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 	RR	inositol 1,4,5-trisphosphate	none	{'e1': {'word': 'RR', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d114.s1.e1'}, 'e2': {'word': 'inositol 1,4,5-trisphosphate', 'word_index': [(7, 11)], 'id': 'DDI-MedLine.d114.s1.e2'}, 'sentence_id': 'DDI-MedLine.d114.s1'}	The effects of ruthenium red RR on inositol NUMBER NUMBER NUMBER trisphosphate InsP NUMBER induced responses were studied in rat bone marrow megakaryocytes with the patch clamp whole cell recording technique in combination with fura NUMBER microfluorometry
The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 	RR	InsP(3)	none	{'e1': {'word': 'RR', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d114.s1.e1'}, 'e2': {'word': 'InsP(3)', 'word_index': [(12, 13)], 'id': 'DDI-MedLine.d114.s1.e3'}, 'sentence_id': 'DDI-MedLine.d114.s1'}	The effects of ruthenium red RR on inositol NUMBER NUMBER NUMBER trisphosphate InsP NUMBER induced responses were studied in rat bone marrow megakaryocytes with the patch clamp whole cell recording technique in combination with fura NUMBER microfluorometry
The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 	inositol 1,4,5-trisphosphate	InsP(3)	none	{'e1': {'word': 'inositol 1,4,5-trisphosphate', 'word_index': [(7, 11)], 'id': 'DDI-MedLine.d114.s1.e2'}, 'e2': {'word': 'InsP(3)', 'word_index': [(12, 13)], 'id': 'DDI-MedLine.d114.s1.e3'}, 'sentence_id': 'DDI-MedLine.d114.s1'}	The effects of ruthenium red RR on inositol NUMBER NUMBER NUMBER trisphosphate InsP NUMBER induced responses were studied in rat bone marrow megakaryocytes with the patch clamp whole cell recording technique in combination with fura NUMBER microfluorometry
Administering InsP(3) together with RR (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion. 	InsP(3)	RR	effect	{'e1': {'word': 'InsP(3)', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d114.s3.e0'}, 'e2': {'word': 'RR', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d114.s3.e1'}, 'sentence_id': 'DDI-MedLine.d114.s3'}	Administering InsP 3 together with RR NUMBER - NUMBER microM inhibited InsP NUMBER induced responses both Ca NUMBER + and current responses in a dose dependent fashion
Pretreatment of megakaryocytes with extracellular RR (50 microM) also inhibited InsP(3)-induced responses. 	RR	InsP(3)	effect	{'e1': {'word': 'RR', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d114.s4.e0'}, 'e2': {'word': 'InsP(3)', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d114.s4.e1'}, 'sentence_id': 'DDI-MedLine.d114.s4'}	Pretreatment of megakaryocytes with extracellular RR NUMBER microM also inhibited InsP NUMBER induced responses
In contrast, in isolated single pancreatic acinar cells, RR had no effect on InsP(3)-induced responses. 	RR	InsP(3)	none	{'e1': {'word': 'RR', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d114.s6.e0'}, 'e2': {'word': 'InsP(3)', 'word_index': [(13, 14)], 'id': 'DDI-MedLine.d114.s6.e1'}, 'sentence_id': 'DDI-MedLine.d114.s6'}	In contrast in isolated single pancreatic acinar cells RR had no effect on InsP NUMBER induced responses
In addition, we have shown that RR is a useful pharmacological tool with which to examine the InsP(3)-mediated responses of megakaryocytes.	RR	InsP(3)	none	{'e1': {'word': 'RR', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d114.s8.e0'}, 'e2': {'word': 'InsP(3)', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d114.s8.e1'}, 'sentence_id': 'DDI-MedLine.d114.s8'}	In addition we have shown that RR is a useful pharmacological tool with which to examine the InsP NUMBER mediated responses of megakaryocytes
Dual effect of ouabain on the palytoxin-induced contraction and norepinephrine release in the guinea-pig vas deferens.	ouabain	palytoxin	none	{'e1': {'word': 'ouabain', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d56.s0.e0'}, 'e2': {'word': 'palytoxin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d56.s0.e1'}, 'sentence_id': 'DDI-MedLine.d56.s0'}	Dual effect of ouabain on the palytoxin induced contraction and norepinephrine release in the guinea pig vas deferens
Palytoxin (PTX), C129H223N3O54, isolated from marine coelenterates of Palythoa tuberculosa, caused a first rapid contraction followed by the slow phasic contraction of guinea-pig vas deferens. 	Palytoxin	PTX	none	{'e1': {'word': 'Palytoxin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d56.s1.e0'}, 'e2': {'word': 'PTX', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d56.s1.e1'}, 'sentence_id': 'DDI-MedLine.d56.s1'}	Palytoxin PTX C129H223N3O54 isolated from marine coelenterates of Palythoa tuberculosa caused a first rapid contraction followed by the slow phasic contraction of guinea pig vas deferens
In the presence of ouabain (10(-5) M), PTX (10(-8) M) failed to cause the first contraction; 	ouabain	PTX	effect	{'e1': {'word': 'ouabain', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d56.s2.e0'}, 'e2': {'word': 'PTX', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d56.s2.e1'}, 'sentence_id': 'DDI-MedLine.d56.s2'}	In the presence of ouabain NUMBER NUMBER M PTX NUMBER NUMBER M failed to cause the first contraction
When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished. 	ouabain	phentolamine	effect	{'e1': {'word': 'ouabain', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d56.s5.e0'}, 'e2': {'word': 'phentolamine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d56.s5.e1'}, 'sentence_id': 'DDI-MedLine.d56.s5'}	When ouabain was applied to the muscle in the presence of phentolamine both first and second contractile responses to PTX were abolished
When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished. 	ouabain	PTX	none	{'e1': {'word': 'ouabain', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d56.s5.e0'}, 'e2': {'word': 'PTX', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d56.s5.e2'}, 'sentence_id': 'DDI-MedLine.d56.s5'}	When ouabain was applied to the muscle in the presence of phentolamine both first and second contractile responses to PTX were abolished
When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished. 	phentolamine	PTX	none	{'e1': {'word': 'phentolamine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d56.s5.e1'}, 'e2': {'word': 'PTX', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d56.s5.e2'}, 'sentence_id': 'DDI-MedLine.d56.s5'}	When ouabain was applied to the muscle in the presence of phentolamine both first and second contractile responses to PTX were abolished
Exposure of the muscle to ouabain (10(-5) M) markedly increased the PTX-induced release. 	ouabain	PTX	effect	{'e1': {'word': 'ouabain', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d56.s8.e0'}, 'e2': {'word': 'PTX', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d56.s8.e1'}, 'sentence_id': 'DDI-MedLine.d56.s8'}	Exposure of the muscle to ouabain NUMBER NUMBER M markedly increased the PTX induced release
The second response is due to a release of norepinephrine from nerves and was potentiated by ouabain through the increase in the norepinephrine release, whereas the first response was not due to the norepinephrine release but presumably to a direct action on smooth muscle cell and was inhibited by ouabain. 	ouabain	ouabain	none	{'e1': {'word': 'ouabain', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d56.s10.e0'}, 'e2': {'word': 'ouabain', 'word_index': [(49, 49)], 'id': 'DDI-MedLine.d56.s10.e1'}, 'sentence_id': 'DDI-MedLine.d56.s10'}	The second response is due to a release of norepinephrine from nerves and was potentiated by ouabain through the increase in the norepinephrine release whereas the first response was not due to the norepinephrine release but presumably to a direct action on smooth muscle cell and was inhibited by ouabain
Diethyl pyrocarbonate, at pH 7.0, was used to chemically modify exposed histidine residues on toxin A. 	Diethyl pyrocarbonate	toxin A	none	{'e1': {'word': 'Diethyl pyrocarbonate', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d48.s3.e0'}, 'e2': {'word': 'toxin A', 'word_index': [(14, 15)], 'id': 'DDI-MedLine.d48.s3.e1'}, 'sentence_id': 'DDI-MedLine.d48.s3'}	Diethyl pyrocarbonate at pH NUMBER was used to chemically modify exposed histidine residues on toxin A
Modification of toxin A with diethyl pyrocarbonate abolished both its cytotoxic activity and the ability of the toxin to bind Zn-Sepharose gel. 	toxin A	diethyl pyrocarbonate	none	{'e1': {'word': 'toxin A', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d48.s4.e0'}, 'e2': {'word': 'diethyl pyrocarbonate', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d48.s4.e1'}, 'sentence_id': 'DDI-MedLine.d48.s4'}	Modification of toxin A with diethyl pyrocarbonate abolished both its cytotoxic activity and the ability of the toxin to bind Zn Sepharose gel
Treatment of toxin A with [(14)C]-diethyl pyrocarbonate revealed concentration dependent labelling of histidine residues on the toxin molecules. 	toxin A	diethyl pyrocarbonate	none	{'e1': {'word': 'toxin A', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d48.s5.e0'}, 'e2': {'word': 'diethyl pyrocarbonate', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d48.s5.e1'}, 'sentence_id': 'DDI-MedLine.d48.s5'}	Treatment of toxin A with NUMBER C diethyl pyrocarbonate revealed concentration dependent labelling of histidine residues on the toxin molecules
The effects of diethyl pyrocarbonate could be reversed by hydroxylamine treatment. 	diethyl pyrocarbonate	hydroxylamine	none	{'e1': {'word': 'diethyl pyrocarbonate', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d48.s6.e0'}, 'e2': {'word': 'hydroxylamine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d48.s6.e1'}, 'sentence_id': 'DDI-MedLine.d48.s6'}	The effects of diethyl pyrocarbonate could be reversed by hydroxylamine treatment
Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.	toxin A	zinc	none	{'e1': {'word': 'toxin A', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d48.s11.e0'}, 'e2': {'word': 'zinc', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d48.s11.e1'}, 'sentence_id': 'DDI-MedLine.d48.s11'}	Exposed histidines on toxin A are available for zinc chelation and these have been exploited in the development of a novel purification protocol for toxin A using zinc chelating chromatography
Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.	toxin A	toxin A	none	{'e1': {'word': 'toxin A', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d48.s11.e0'}, 'e2': {'word': 'toxin A', 'word_index': [(24, 25)], 'id': 'DDI-MedLine.d48.s11.e2'}, 'sentence_id': 'DDI-MedLine.d48.s11'}	Exposed histidines on toxin A are available for zinc chelation and these have been exploited in the development of a novel purification protocol for toxin A using zinc chelating chromatography
Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.	toxin A	zinc	none	{'e1': {'word': 'toxin A', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d48.s11.e0'}, 'e2': {'word': 'zinc', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d48.s11.e3'}, 'sentence_id': 'DDI-MedLine.d48.s11'}	Exposed histidines on toxin A are available for zinc chelation and these have been exploited in the development of a novel purification protocol for toxin A using zinc chelating chromatography
Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.	zinc	toxin A	none	{'e1': {'word': 'zinc', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d48.s11.e1'}, 'e2': {'word': 'toxin A', 'word_index': [(24, 25)], 'id': 'DDI-MedLine.d48.s11.e2'}, 'sentence_id': 'DDI-MedLine.d48.s11'}	Exposed histidines on toxin A are available for zinc chelation and these have been exploited in the development of a novel purification protocol for toxin A using zinc chelating chromatography
Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.	zinc	zinc	none	{'e1': {'word': 'zinc', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d48.s11.e1'}, 'e2': {'word': 'zinc', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d48.s11.e3'}, 'sentence_id': 'DDI-MedLine.d48.s11'}	Exposed histidines on toxin A are available for zinc chelation and these have been exploited in the development of a novel purification protocol for toxin A using zinc chelating chromatography
Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.	toxin A	zinc	none	{'e1': {'word': 'toxin A', 'word_index': [(24, 25)], 'id': 'DDI-MedLine.d48.s11.e2'}, 'e2': {'word': 'zinc', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d48.s11.e3'}, 'sentence_id': 'DDI-MedLine.d48.s11'}	Exposed histidines on toxin A are available for zinc chelation and these have been exploited in the development of a novel purification protocol for toxin A using zinc chelating chromatography
Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 	Slow-channel calcium blockers	verapamil	none	{'e1': {'word': 'Slow-channel calcium blockers', 'word_index': [(0, 3)], 'id': 'DDI-MedLine.d100.s5.e0'}, 'e2': {'word': 'verapamil', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d100.s5.e1'}, 'sentence_id': 'DDI-MedLine.d100.s5'}	Slow channel calcium blockers such as verapamil diltiazem and nifedipine inhibit platelet activation in vitro and decrease platelet adhesion intravascularly
Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 	Slow-channel calcium blockers	diltiazem	none	{'e1': {'word': 'Slow-channel calcium blockers', 'word_index': [(0, 3)], 'id': 'DDI-MedLine.d100.s5.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d100.s5.e2'}, 'sentence_id': 'DDI-MedLine.d100.s5'}	Slow channel calcium blockers such as verapamil diltiazem and nifedipine inhibit platelet activation in vitro and decrease platelet adhesion intravascularly
Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 	Slow-channel calcium blockers	nifedipine	none	{'e1': {'word': 'Slow-channel calcium blockers', 'word_index': [(0, 3)], 'id': 'DDI-MedLine.d100.s5.e0'}, 'e2': {'word': 'nifedipine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d100.s5.e3'}, 'sentence_id': 'DDI-MedLine.d100.s5'}	Slow channel calcium blockers such as verapamil diltiazem and nifedipine inhibit platelet activation in vitro and decrease platelet adhesion intravascularly
Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 	verapamil	diltiazem	none	{'e1': {'word': 'verapamil', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d100.s5.e1'}, 'e2': {'word': 'diltiazem', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d100.s5.e2'}, 'sentence_id': 'DDI-MedLine.d100.s5'}	Slow channel calcium blockers such as verapamil diltiazem and nifedipine inhibit platelet activation in vitro and decrease platelet adhesion intravascularly
Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 	verapamil	nifedipine	none	{'e1': {'word': 'verapamil', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d100.s5.e1'}, 'e2': {'word': 'nifedipine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d100.s5.e3'}, 'sentence_id': 'DDI-MedLine.d100.s5'}	Slow channel calcium blockers such as verapamil diltiazem and nifedipine inhibit platelet activation in vitro and decrease platelet adhesion intravascularly
Slow-channel calcium blockers, such as verapamil, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 	diltiazem	nifedipine	none	{'e1': {'word': 'diltiazem', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d100.s5.e2'}, 'e2': {'word': 'nifedipine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d100.s5.e3'}, 'sentence_id': 'DDI-MedLine.d100.s5'}	Slow channel calcium blockers such as verapamil diltiazem and nifedipine inhibit platelet activation in vitro and decrease platelet adhesion intravascularly
"Cypermethrin-induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol.
"	Cypermethrin	vitamin E	effect	{'e1': {'word': 'Cypermethrin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d126.s0.e0'}, 'e2': {'word': 'vitamin E', 'word_index': [(12, 13)], 'id': 'DDI-MedLine.d126.s0.e1'}, 'sentence_id': 'DDI-MedLine.d126.s0'}	Cypermethrin induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol
"Cypermethrin-induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol.
"	Cypermethrin	allopurinol	effect	{'e1': {'word': 'Cypermethrin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d126.s0.e0'}, 'e2': {'word': 'allopurinol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d126.s0.e2'}, 'sentence_id': 'DDI-MedLine.d126.s0'}	Cypermethrin induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol
"Cypermethrin-induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol.
"	vitamin E	allopurinol	none	{'e1': {'word': 'vitamin E', 'word_index': [(12, 13)], 'id': 'DDI-MedLine.d126.s0.e1'}, 'e2': {'word': 'allopurinol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d126.s0.e2'}, 'sentence_id': 'DDI-MedLine.d126.s0'}	Cypermethrin induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol
Considering that the involvement of reactive oxygen species (ROS) has been implicated in the toxicity of various pesticides, this study was designed to investigate the possibility of oxidative stress induction by cypermethrin, a Type II pyrethroid. 	cypermethrin	Type II pyrethroid	none	{'e1': {'word': 'cypermethrin', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d126.s1.e0'}, 'e2': {'word': 'Type II pyrethroid', 'word_index': [(33, 35)], 'id': 'DDI-MedLine.d126.s1.e1'}, 'sentence_id': 'DDI-MedLine.d126.s1'}	Considering that the involvement of reactive oxygen species ROS has been implicated in the toxicity of various pesticides this study was designed to investigate the possibility of oxidative stress induction by cypermethrin a Type NUMBER pyrethroid
Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h. 	allopurinol	Vitamin E	none	{'e1': {'word': 'allopurinol', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d126.s6.e0'}, 'e2': {'word': 'Vitamin E', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d126.s6.e1'}, 'sentence_id': 'DDI-MedLine.d126.s6'}	Pretreatment of rats with allopurinol NUMBER mg / kg ip or Vitamin E NUMBER mg / kg per day ig for NUMBER days and a dose of NUMBER mg / kg on the 4th day provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues induced by single high dose of oral cypermethrin administration within NUMBER h
Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h. 	allopurinol	cypermethrin	effect	{'e1': {'word': 'allopurinol', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d126.s6.e0'}, 'e2': {'word': 'cypermethrin', 'word_index': [(56, 56)], 'id': 'DDI-MedLine.d126.s6.e2'}, 'sentence_id': 'DDI-MedLine.d126.s6'}	Pretreatment of rats with allopurinol NUMBER mg / kg ip or Vitamin E NUMBER mg / kg per day ig for NUMBER days and a dose of NUMBER mg / kg on the 4th day provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues induced by single high dose of oral cypermethrin administration within NUMBER h
Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h. 	Vitamin E	cypermethrin	effect	{'e1': {'word': 'Vitamin E', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d126.s6.e1'}, 'e2': {'word': 'cypermethrin', 'word_index': [(56, 56)], 'id': 'DDI-MedLine.d126.s6.e2'}, 'sentence_id': 'DDI-MedLine.d126.s6'}	Pretreatment of rats with allopurinol NUMBER mg / kg ip or Vitamin E NUMBER mg / kg per day ig for NUMBER days and a dose of NUMBER mg / kg on the 4th day provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues induced by single high dose of oral cypermethrin administration within NUMBER h
Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin E.	cypermethrin	allopurinol	effect	{'e1': {'word': 'cypermethrin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d126.s7.e0'}, 'e2': {'word': 'allopurinol', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d126.s7.e1'}, 'sentence_id': 'DDI-MedLine.d126.s7'}	Thus the results suggest that cypermethrin exposure of rats results in free radical mediated tissue damage as indicated by elevated cerebral and hepatic lipid peroxidation which was prevented by allopurinol and Vitamin E
Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin E.	cypermethrin	Vitamin E	effect	{'e1': {'word': 'cypermethrin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d126.s7.e0'}, 'e2': {'word': 'Vitamin E', 'word_index': [(31, 32)], 'id': 'DDI-MedLine.d126.s7.e2'}, 'sentence_id': 'DDI-MedLine.d126.s7'}	Thus the results suggest that cypermethrin exposure of rats results in free radical mediated tissue damage as indicated by elevated cerebral and hepatic lipid peroxidation which was prevented by allopurinol and Vitamin E
Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin E.	allopurinol	Vitamin E	none	{'e1': {'word': 'allopurinol', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d126.s7.e1'}, 'e2': {'word': 'Vitamin E', 'word_index': [(31, 32)], 'id': 'DDI-MedLine.d126.s7.e2'}, 'sentence_id': 'DDI-MedLine.d126.s7'}	Thus the results suggest that cypermethrin exposure of rats results in free radical mediated tissue damage as indicated by elevated cerebral and hepatic lipid peroxidation which was prevented by allopurinol and Vitamin E
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	3H-spiroperidol	none	{'e1': {'word': 'cerulein', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	neuroleptics	none	{'e1': {'word': 'cerulein', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': 'neuroleptics', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	haloperidol	none	{'e1': {'word': 'cerulein', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	pyreneperone	none	{'e1': {'word': 'cerulein', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': 'pyreneperone', 'word_index': [(46, 46)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	3H-spiroperidol	none	{'e1': {'word': 'cerulein', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(57, 58)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	apomorphine	none	{'e1': {'word': 'cerulein', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': 'apomorphine', 'word_index': [(65, 65)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	3H-spiroperidol	none	{'e1': {'word': 'cerulein', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(70, 71)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	cerulein	apomorphine	none	{'e1': {'word': 'cerulein', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d15.s0.e0'}, 'e2': {'word': 'apomorphine', 'word_index': [(79, 79)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	neuroleptics	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'e2': {'word': 'neuroleptics', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	haloperidol	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'e2': {'word': 'haloperidol', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	pyreneperone	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'e2': {'word': 'pyreneperone', 'word_index': [(46, 46)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	3H-spiroperidol	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(57, 58)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	apomorphine	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'e2': {'word': 'apomorphine', 'word_index': [(65, 65)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	3H-spiroperidol	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(70, 71)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	apomorphine	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d15.s0.e1'}, 'e2': {'word': 'apomorphine', 'word_index': [(79, 79)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	neuroleptics	haloperidol	none	{'e1': {'word': 'neuroleptics', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'e2': {'word': 'haloperidol', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	neuroleptics	pyreneperone	none	{'e1': {'word': 'neuroleptics', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'e2': {'word': 'pyreneperone', 'word_index': [(46, 46)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	neuroleptics	3H-spiroperidol	none	{'e1': {'word': 'neuroleptics', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(57, 58)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	neuroleptics	apomorphine	none	{'e1': {'word': 'neuroleptics', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'e2': {'word': 'apomorphine', 'word_index': [(65, 65)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	neuroleptics	3H-spiroperidol	none	{'e1': {'word': 'neuroleptics', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(70, 71)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	neuroleptics	apomorphine	none	{'e1': {'word': 'neuroleptics', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d15.s0.e2'}, 'e2': {'word': 'apomorphine', 'word_index': [(79, 79)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	haloperidol	pyreneperone	none	{'e1': {'word': 'haloperidol', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'e2': {'word': 'pyreneperone', 'word_index': [(46, 46)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	haloperidol	3H-spiroperidol	none	{'e1': {'word': 'haloperidol', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(57, 58)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	haloperidol	apomorphine	none	{'e1': {'word': 'haloperidol', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'e2': {'word': 'apomorphine', 'word_index': [(65, 65)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	haloperidol	3H-spiroperidol	none	{'e1': {'word': 'haloperidol', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(70, 71)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	haloperidol	apomorphine	none	{'e1': {'word': 'haloperidol', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d15.s0.e3'}, 'e2': {'word': 'apomorphine', 'word_index': [(79, 79)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	pyreneperone	3H-spiroperidol	none	{'e1': {'word': 'pyreneperone', 'word_index': [(46, 46)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(57, 58)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	pyreneperone	apomorphine	none	{'e1': {'word': 'pyreneperone', 'word_index': [(46, 46)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'e2': {'word': 'apomorphine', 'word_index': [(65, 65)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	pyreneperone	3H-spiroperidol	none	{'e1': {'word': 'pyreneperone', 'word_index': [(46, 46)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(70, 71)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	pyreneperone	apomorphine	none	{'e1': {'word': 'pyreneperone', 'word_index': [(46, 46)], 'id': 'DDI-MedLine.d15.s0.e4'}, 'e2': {'word': 'apomorphine', 'word_index': [(79, 79)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	apomorphine	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(57, 58)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'e2': {'word': 'apomorphine', 'word_index': [(65, 65)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	3H-spiroperidol	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(57, 58)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(70, 71)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	apomorphine	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(57, 58)], 'id': 'DDI-MedLine.d15.s0.e5'}, 'e2': {'word': 'apomorphine', 'word_index': [(79, 79)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	apomorphine	3H-spiroperidol	none	{'e1': {'word': 'apomorphine', 'word_index': [(65, 65)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(70, 71)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	apomorphine	apomorphine	none	{'e1': {'word': 'apomorphine', 'word_index': [(65, 65)], 'id': 'DDI-MedLine.d15.s0.e6'}, 'e2': {'word': 'apomorphine', 'word_index': [(79, 79)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 	3H-spiroperidol	apomorphine	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(70, 71)], 'id': 'DDI-MedLine.d15.s0.e7'}, 'e2': {'word': 'apomorphine', 'word_index': [(79, 79)], 'id': 'DDI-MedLine.d15.s0.e8'}, 'sentence_id': 'DDI-MedLine.d15.s0'}	Stimulation by cerulein an analog of the octapeptide cholecystokinin of 3H spiroperidol binding after the long term administration of neuroleptics It has been established in experiments on white male rats that prolonged administration twice a day for NUMBER days of haloperidol NUMBER mg / kg and pyreneperone NUMBER mg / kg resulted in the reduced interaction between 3H spiroperidol and low affinity binding sites for apomorphine in subcortical structures whereas 3H spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain
After prolonged administration of neuroleptics the displacing effect of cerulein, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on 3H-spiroperidol binding. 	neuroleptics	cerulein	none	{'e1': {'word': 'neuroleptics', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d15.s1.e0'}, 'e2': {'word': 'cerulein', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d15.s1.e1'}, 'sentence_id': 'DDI-MedLine.d15.s1'}	After prolonged administration of neuroleptics the displacing effect of cerulein an analog of cholecystokinin octapeptide was replaced by the stimulant action on 3H spiroperidol binding
After prolonged administration of neuroleptics the displacing effect of cerulein, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on 3H-spiroperidol binding. 	neuroleptics	3H-spiroperidol	none	{'e1': {'word': 'neuroleptics', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d15.s1.e0'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(22, 23)], 'id': 'DDI-MedLine.d15.s1.e2'}, 'sentence_id': 'DDI-MedLine.d15.s1'}	After prolonged administration of neuroleptics the displacing effect of cerulein an analog of cholecystokinin octapeptide was replaced by the stimulant action on 3H spiroperidol binding
After prolonged administration of neuroleptics the displacing effect of cerulein, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on 3H-spiroperidol binding. 	cerulein	3H-spiroperidol	none	{'e1': {'word': 'cerulein', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d15.s1.e1'}, 'e2': {'word': '3H-spiroperidol', 'word_index': [(22, 23)], 'id': 'DDI-MedLine.d15.s1.e2'}, 'sentence_id': 'DDI-MedLine.d15.s1'}	After prolonged administration of neuroleptics the displacing effect of cerulein an analog of cholecystokinin octapeptide was replaced by the stimulant action on 3H spiroperidol binding
It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration. 	3H-spiroperidol	apomorphine	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d15.s2.e0'}, 'e2': {'word': 'apomorphine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d15.s2.e1'}, 'sentence_id': 'DDI-MedLine.d15.s2'}	It is assumed that increased interaction between 3H spiroperidol and high affinity binding sites for apomorphine on dopamine2 and serotonin2 receptors underlies the antipsychotic action of neuroleptics after their prolonged administration
It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration. 	3H-spiroperidol	neuroleptics	none	{'e1': {'word': '3H-spiroperidol', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d15.s2.e0'}, 'e2': {'word': 'neuroleptics', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d15.s2.e2'}, 'sentence_id': 'DDI-MedLine.d15.s2'}	It is assumed that increased interaction between 3H spiroperidol and high affinity binding sites for apomorphine on dopamine2 and serotonin2 receptors underlies the antipsychotic action of neuroleptics after their prolonged administration
It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration. 	apomorphine	neuroleptics	none	{'e1': {'word': 'apomorphine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d15.s2.e1'}, 'e2': {'word': 'neuroleptics', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d15.s2.e2'}, 'sentence_id': 'DDI-MedLine.d15.s2'}	It is assumed that increased interaction between 3H spiroperidol and high affinity binding sites for apomorphine on dopamine2 and serotonin2 receptors underlies the antipsychotic action of neuroleptics after their prolonged administration
"Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.
"	1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine	MPTP	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine', 'word_index': [(5, 13)], 'id': 'DDI-MedLine.d73.s0.e0'}, 'e2': {'word': 'MPTP', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d73.s0.e1'}, 'sentence_id': 'DDI-MedLine.d73.s0'}	Neurochemical and functional consequences following NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine MPTP and methamphetamine
"Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.
"	1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine	methamphetamine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine', 'word_index': [(5, 13)], 'id': 'DDI-MedLine.d73.s0.e0'}, 'e2': {'word': 'methamphetamine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d73.s0.e2'}, 'sentence_id': 'DDI-MedLine.d73.s0'}	Neurochemical and functional consequences following NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine MPTP and methamphetamine
"Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.
"	MPTP	methamphetamine	none	{'e1': {'word': 'MPTP', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d73.s0.e1'}, 'e2': {'word': 'methamphetamine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d73.s0.e2'}, 'sentence_id': 'DDI-MedLine.d73.s0'}	Neurochemical and functional consequences following NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine MPTP and methamphetamine
The neurochemical and functional consequences following MPTP administration to the rat were evaluated and compared to similar effects following methamphetamine administration. 	MPTP	methamphetamine	none	{'e1': {'word': 'MPTP', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d73.s1.e0'}, 'e2': {'word': 'methamphetamine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d73.s1.e1'}, 'sentence_id': 'DDI-MedLine.d73.s1'}	The neurochemical and functional consequences following MPTP administration to the rat were evaluated and compared to similar effects following methamphetamine administration
It was observed that MPTP induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by pargyline pretreatment. 	MPTP	pargyline	effect	{'e1': {'word': 'MPTP', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d73.s2.e0'}, 'e2': {'word': 'pargyline', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d73.s2.e1'}, 'sentence_id': 'DDI-MedLine.d73.s2'}	It was observed that MPTP induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by pargyline pretreatment
The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm. 	MPTP	amphetamine	effect	{'e1': {'word': 'MPTP', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d73.s3.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d73.s3.e1'}, 'sentence_id': 'DDI-MedLine.d73.s3'}	The MPTP induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm
The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm. 	MPTP	apomorphine	effect	{'e1': {'word': 'MPTP', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d73.s3.e0'}, 'e2': {'word': 'apomorphine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d73.s3.e2'}, 'sentence_id': 'DDI-MedLine.d73.s3'}	The MPTP induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm
The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm. 	amphetamine	apomorphine	none	{'e1': {'word': 'amphetamine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d73.s3.e1'}, 'e2': {'word': 'apomorphine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d73.s3.e2'}, 'sentence_id': 'DDI-MedLine.d73.s3'}	The MPTP induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm
Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment. 	Methamphetamine	MPTP	none	{'e1': {'word': 'Methamphetamine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d73.s4.e0'}, 'e2': {'word': 'MPTP', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d73.s4.e1'}, 'sentence_id': 'DDI-MedLine.d73.s4'}	Methamphetamine like MPTP produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment
Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment. 	Methamphetamine	pargyline	effect	{'e1': {'word': 'Methamphetamine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d73.s4.e0'}, 'e2': {'word': 'pargyline', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d73.s4.e2'}, 'sentence_id': 'DDI-MedLine.d73.s4'}	Methamphetamine like MPTP produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment
Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment. 	MPTP	pargyline	none	{'e1': {'word': 'MPTP', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d73.s4.e1'}, 'e2': {'word': 'pargyline', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d73.s4.e2'}, 'sentence_id': 'DDI-MedLine.d73.s4'}	Methamphetamine like MPTP produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment
"Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition.
"	levofloxacin	oxycodone	none	{'e1': {'word': 'levofloxacin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d124.s0.e0'}, 'e2': {'word': 'oxycodone', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d124.s0.e1'}, 'sentence_id': 'DDI-MedLine.d124.s0'}	Lack of interaction between levofloxacin and oxycodone pharmacokinetics and drug disposition
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. 	trovafloxacin	ciprofloxacin	none	{'e1': {'word': 'trovafloxacin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d124.s1.e0'}, 'e2': {'word': 'ciprofloxacin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d124.s1.e1'}, 'sentence_id': 'DDI-MedLine.d124.s1'}	Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. 	trovafloxacin	opiate	mechanism	{'e1': {'word': 'trovafloxacin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d124.s1.e0'}, 'e2': {'word': 'opiate', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d124.s1.e2'}, 'sentence_id': 'DDI-MedLine.d124.s1'}	Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. 	trovafloxacin	morphine	mechanism	{'e1': {'word': 'trovafloxacin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d124.s1.e0'}, 'e2': {'word': 'morphine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d124.s1.e3'}, 'sentence_id': 'DDI-MedLine.d124.s1'}	Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. 	ciprofloxacin	opiate	mechanism	{'e1': {'word': 'ciprofloxacin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d124.s1.e1'}, 'e2': {'word': 'opiate', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d124.s1.e2'}, 'sentence_id': 'DDI-MedLine.d124.s1'}	Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. 	ciprofloxacin	morphine	mechanism	{'e1': {'word': 'ciprofloxacin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d124.s1.e1'}, 'e2': {'word': 'morphine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d124.s1.e3'}, 'sentence_id': 'DDI-MedLine.d124.s1'}	Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. 	opiate	morphine	none	{'e1': {'word': 'opiate', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d124.s1.e2'}, 'e2': {'word': 'morphine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d124.s1.e3'}, 'sentence_id': 'DDI-MedLine.d124.s1'}	Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine
This decrease in absorption results in a 36% and 50% lower AUC for trovafloxacin and ciprofloxacin, respectively, which could cause clinical failures. 	trovafloxacin	ciprofloxacin	none	{'e1': {'word': 'trovafloxacin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d124.s2.e0'}, 'e2': {'word': 'ciprofloxacin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d124.s2.e1'}, 'sentence_id': 'DDI-MedLine.d124.s2'}	This decrease in absorption results in a NUMBER % and NUMBER % lower AUC for trovafloxacin and ciprofloxacin respectively which could cause clinical failures
The authors investigated the possibility of a similar interaction between oxycodone and levofloxacin. 	oxycodone	levofloxacin	none	{'e1': {'word': 'oxycodone', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d124.s3.e0'}, 'e2': {'word': 'levofloxacin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d124.s3.e1'}, 'sentence_id': 'DDI-MedLine.d124.s3'}	The authors investigated the possibility of a similar interaction between oxycodone and levofloxacin
1 hour after starting the oxycodone or levofloxacin 500 mg p.o. 	oxycodone	levofloxacin	none	{'e1': {'word': 'oxycodone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d124.s6.e0'}, 'e2': {'word': 'levofloxacin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d124.s6.e1'}, 'sentence_id': 'DDI-MedLine.d124.s6'}	NUMBER hour after starting the oxycodone or levofloxacin NUMBER mg p.o.
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens. 	levofloxacin	levofloxacin	none	{'e1': {'word': 'levofloxacin', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d124.s9.e0'}, 'e2': {'word': 'levofloxacin', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d124.s9.e1'}, 'sentence_id': 'DDI-MedLine.d124.s9'}	There was not a significant difference p > NUMBER in AUC NUMBER + - NUMBER vs NUMBER + - NUMBER Cmax NUMBER + - NUMBER vs NUMBER + - NUMBER and tmax NUMBER + - NUMBER vs NUMBER + - NUMBER for levofloxacin versus levofloxacin oxycodone regimens
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens. 	levofloxacin	oxycodone	none	{'e1': {'word': 'levofloxacin', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d124.s9.e0'}, 'e2': {'word': 'oxycodone', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d124.s9.e2'}, 'sentence_id': 'DDI-MedLine.d124.s9'}	There was not a significant difference p > NUMBER in AUC NUMBER + - NUMBER vs NUMBER + - NUMBER Cmax NUMBER + - NUMBER vs NUMBER + - NUMBER and tmax NUMBER + - NUMBER vs NUMBER + - NUMBER for levofloxacin versus levofloxacin oxycodone regimens
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens. 	levofloxacin	oxycodone	none	{'e1': {'word': 'levofloxacin', 'word_index': [(44, 44)], 'id': 'DDI-MedLine.d124.s9.e1'}, 'e2': {'word': 'oxycodone', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d124.s9.e2'}, 'sentence_id': 'DDI-MedLine.d124.s9'}	There was not a significant difference p > NUMBER in AUC NUMBER + - NUMBER vs NUMBER + - NUMBER Cmax NUMBER + - NUMBER vs NUMBER + - NUMBER and tmax NUMBER + - NUMBER vs NUMBER + - NUMBER for levofloxacin versus levofloxacin oxycodone regimens
It was concluded that oral oxycodone and levofloxacin can be administered concomitantly without a significant decrease in AUC, Cmax, or tmax.	oxycodone	levofloxacin	none	{'e1': {'word': 'oxycodone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d124.s10.e0'}, 'e2': {'word': 'levofloxacin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d124.s10.e1'}, 'sentence_id': 'DDI-MedLine.d124.s10'}	It was concluded that oral oxycodone and levofloxacin can be administered concomitantly without a significant decrease in AUC Cmax or tmax
"Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.
"	Sirolimus	rapamycin	none	{'e1': {'word': 'Sirolimus', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d118.s0.e0'}, 'e2': {'word': 'rapamycin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d118.s0.e1'}, 'sentence_id': 'DDI-MedLine.d118.s0'}	Sirolimus mammalian target of rapamycin inhibitor to prevent kidney rejection
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	Sirolimus	immunosuppressants	none	{'e1': {'word': 'Sirolimus', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d118.s2.e0'}, 'e2': {'word': 'immunosuppressants', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d118.s2.e1'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	Sirolimus works differently from the immunosuppressants currently available and except for increased lipid levels the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	Sirolimus	sirolimus	none	{'e1': {'word': 'Sirolimus', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d118.s2.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d118.s2.e2'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	Sirolimus works differently from the immunosuppressants currently available and except for increased lipid levels the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	Sirolimus	cyclosporine	none	{'e1': {'word': 'Sirolimus', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d118.s2.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d118.s2.e3'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	Sirolimus works differently from the immunosuppressants currently available and except for increased lipid levels the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	Sirolimus	tacrolimus	none	{'e1': {'word': 'Sirolimus', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d118.s2.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d118.s2.e4'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	Sirolimus works differently from the immunosuppressants currently available and except for increased lipid levels the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	immunosuppressants	sirolimus	none	{'e1': {'word': 'immunosuppressants', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d118.s2.e1'}, 'e2': {'word': 'sirolimus', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d118.s2.e2'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	Sirolimus works differently from the immunosuppressants currently available and except for increased lipid levels the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	immunosuppressants	cyclosporine	none	{'e1': {'word': 'immunosuppressants', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d118.s2.e1'}, 'e2': {'word': 'cyclosporine', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d118.s2.e3'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	Sirolimus works differently from the immunosuppressants currently available and except for increased lipid levels the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	immunosuppressants	tacrolimus	none	{'e1': {'word': 'immunosuppressants', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d118.s2.e1'}, 'e2': {'word': 'tacrolimus', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d118.s2.e4'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	Sirolimus works differently from the immunosuppressants currently available and except for increased lipid levels the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	sirolimus	cyclosporine	none	{'e1': {'word': 'sirolimus', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d118.s2.e2'}, 'e2': {'word': 'cyclosporine', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d118.s2.e3'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	Sirolimus works differently from the immunosuppressants currently available and except for increased lipid levels the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	sirolimus	tacrolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d118.s2.e2'}, 'e2': {'word': 'tacrolimus', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d118.s2.e4'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	Sirolimus works differently from the immunosuppressants currently available and except for increased lipid levels the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus
Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d118.s2.e3'}, 'e2': {'word': 'tacrolimus', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d118.s2.e4'}, 'sentence_id': 'DDI-MedLine.d118.s2'}	Sirolimus works differently from the immunosuppressants currently available and except for increased lipid levels the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	sirolimus	cyclosporine	none	{'e1': {'word': 'sirolimus', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d118.s3.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d118.s3.e1'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	While additional research is needed the initial clinical data in kidney recipients suggest that sirolimus in combination with cyclosporine or tacrolimus might have the potential to reduce the frequency of rejection episodes permit reductions in cyclosporine or tacrolimus dosage and permit steroid withdrawal Kelly NUMBER
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	sirolimus	tacrolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d118.s3.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d118.s3.e2'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	While additional research is needed the initial clinical data in kidney recipients suggest that sirolimus in combination with cyclosporine or tacrolimus might have the potential to reduce the frequency of rejection episodes permit reductions in cyclosporine or tacrolimus dosage and permit steroid withdrawal Kelly NUMBER
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	sirolimus	cyclosporine	none	{'e1': {'word': 'sirolimus', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d118.s3.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d118.s3.e3'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	While additional research is needed the initial clinical data in kidney recipients suggest that sirolimus in combination with cyclosporine or tacrolimus might have the potential to reduce the frequency of rejection episodes permit reductions in cyclosporine or tacrolimus dosage and permit steroid withdrawal Kelly NUMBER
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	sirolimus	tacrolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d118.s3.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d118.s3.e4'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	While additional research is needed the initial clinical data in kidney recipients suggest that sirolimus in combination with cyclosporine or tacrolimus might have the potential to reduce the frequency of rejection episodes permit reductions in cyclosporine or tacrolimus dosage and permit steroid withdrawal Kelly NUMBER
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d118.s3.e1'}, 'e2': {'word': 'tacrolimus', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d118.s3.e2'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	While additional research is needed the initial clinical data in kidney recipients suggest that sirolimus in combination with cyclosporine or tacrolimus might have the potential to reduce the frequency of rejection episodes permit reductions in cyclosporine or tacrolimus dosage and permit steroid withdrawal Kelly NUMBER
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	cyclosporine	cyclosporine	none	{'e1': {'word': 'cyclosporine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d118.s3.e1'}, 'e2': {'word': 'cyclosporine', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d118.s3.e3'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	While additional research is needed the initial clinical data in kidney recipients suggest that sirolimus in combination with cyclosporine or tacrolimus might have the potential to reduce the frequency of rejection episodes permit reductions in cyclosporine or tacrolimus dosage and permit steroid withdrawal Kelly NUMBER
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d118.s3.e1'}, 'e2': {'word': 'tacrolimus', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d118.s3.e4'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	While additional research is needed the initial clinical data in kidney recipients suggest that sirolimus in combination with cyclosporine or tacrolimus might have the potential to reduce the frequency of rejection episodes permit reductions in cyclosporine or tacrolimus dosage and permit steroid withdrawal Kelly NUMBER
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	tacrolimus	cyclosporine	none	{'e1': {'word': 'tacrolimus', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d118.s3.e2'}, 'e2': {'word': 'cyclosporine', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d118.s3.e3'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	While additional research is needed the initial clinical data in kidney recipients suggest that sirolimus in combination with cyclosporine or tacrolimus might have the potential to reduce the frequency of rejection episodes permit reductions in cyclosporine or tacrolimus dosage and permit steroid withdrawal Kelly NUMBER
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	tacrolimus	tacrolimus	none	{'e1': {'word': 'tacrolimus', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d118.s3.e2'}, 'e2': {'word': 'tacrolimus', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d118.s3.e4'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	While additional research is needed the initial clinical data in kidney recipients suggest that sirolimus in combination with cyclosporine or tacrolimus might have the potential to reduce the frequency of rejection episodes permit reductions in cyclosporine or tacrolimus dosage and permit steroid withdrawal Kelly NUMBER
While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d118.s3.e3'}, 'e2': {'word': 'tacrolimus', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d118.s3.e4'}, 'sentence_id': 'DDI-MedLine.d118.s3'}	While additional research is needed the initial clinical data in kidney recipients suggest that sirolimus in combination with cyclosporine or tacrolimus might have the potential to reduce the frequency of rejection episodes permit reductions in cyclosporine or tacrolimus dosage and permit steroid withdrawal Kelly NUMBER
The EC50 values for isoproterenol, which is not a substrate for norepinephrine uptake-1, were reduced in myocardium in functional classes II to III and IV compared with those in nonfailing myocardium. 	isoproterenol	norepinephrine	none	{'e1': {'word': 'isoproterenol', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d94.s11.e0'}, 'e2': {'word': 'norepinephrine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d94.s11.e1'}, 'sentence_id': 'DDI-MedLine.d94.s11'}	The EC50 values for isoproterenol which is not a substrate for norepinephrine uptake NUMBER were reduced in myocardium in functional classes NUMBER to NUMBER and NUMBER compared with those in nonfailing myocardium
The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. 	cocaine	desipramine	none	{'e1': {'word': 'cocaine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d94.s12.e0'}, 'e2': {'word': 'desipramine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d94.s12.e1'}, 'sentence_id': 'DDI-MedLine.d94.s12'}	The uptake inhibitors cocaine and desipramine NUMBER mumol / liter potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium p < NUMBER but not in functional class NUMBER myocardium
The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. 	cocaine	norepinephrine	effect	{'e1': {'word': 'cocaine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d94.s12.e0'}, 'e2': {'word': 'norepinephrine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d94.s12.e2'}, 'sentence_id': 'DDI-MedLine.d94.s12'}	The uptake inhibitors cocaine and desipramine NUMBER mumol / liter potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium p < NUMBER but not in functional class NUMBER myocardium
The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. 	desipramine	norepinephrine	effect	{'e1': {'word': 'desipramine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d94.s12.e1'}, 'e2': {'word': 'norepinephrine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d94.s12.e2'}, 'sentence_id': 'DDI-MedLine.d94.s12'}	The uptake inhibitors cocaine and desipramine NUMBER mumol / liter potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium p < NUMBER but not in functional class NUMBER myocardium
Radioligand binding experiments using the uptake inhibitor hydrogen-3 mazindol revealed a significant decrease by approximately 30% in norepinephrine uptake-1 carrier density in functional classes II to III and IV myocardium versus nonfailing myocardium (p < 0.05). 	mazindol	norepinephrine	none	{'e1': {'word': 'mazindol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d94.s13.e0'}, 'e2': {'word': 'norepinephrine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d94.s13.e1'}, 'sentence_id': 'DDI-MedLine.d94.s13'}	Radioligand binding experiments using the uptake inhibitor hydrogen NUMBER mazindol revealed a significant decrease by approximately NUMBER % in norepinephrine uptake NUMBER carrier density in functional classes NUMBER to NUMBER and NUMBER myocardium versus nonfailing myocardium p < NUMBER
This defect in the failing heart can be mimicked by the effects of uptake blocking agents, such as cocaine and desipramine, in the nonfailing heart only. 	cocaine	desipramine	none	{'e1': {'word': 'cocaine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d94.s16.e0'}, 'e2': {'word': 'desipramine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d94.s16.e1'}, 'sentence_id': 'DDI-MedLine.d94.s16'}	This defect in the failing heart can be mimicked by the effects of uptake blocking agents such as cocaine and desipramine in the nonfailing heart only
Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine. 	norepinephrine	cocaine	none	{'e1': {'word': 'norepinephrine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d94.s17.e0'}, 'e2': {'word': 'cocaine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d94.s17.e1'}, 'sentence_id': 'DDI-MedLine.d94.s17'}	Compromised norepinephrine uptake NUMBER in functional class NUMBER can not be further increased by cocaine and desipramine
Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine. 	norepinephrine	desipramine	none	{'e1': {'word': 'norepinephrine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d94.s17.e0'}, 'e2': {'word': 'desipramine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d94.s17.e2'}, 'sentence_id': 'DDI-MedLine.d94.s17'}	Compromised norepinephrine uptake NUMBER in functional class NUMBER can not be further increased by cocaine and desipramine
Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine. 	cocaine	desipramine	none	{'e1': {'word': 'cocaine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d94.s17.e1'}, 'e2': {'word': 'desipramine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d94.s17.e2'}, 'sentence_id': 'DDI-MedLine.d94.s17'}	Compromised norepinephrine uptake NUMBER in functional class NUMBER can not be further increased by cocaine and desipramine
Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia. 	Olanzapine	thienobenzodiazepine derivative	none	{'e1': {'word': 'Olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s1.e0'}, 'e2': {'word': 'thienobenzodiazepine derivative', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d83.s1.e1'}, 'sentence_id': 'DDI-MedLine.d83.s1'}	Olanzapine a thienobenzodiazepine derivative is a second generation atypical antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia
Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia. 	Olanzapine	second generation (atypical) antipsychotic agent	none	{'e1': {'word': 'Olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s1.e0'}, 'e2': {'word': 'second generation (atypical) antipsychotic agent', 'word_index': [(6, 10)], 'id': 'DDI-MedLine.d83.s1.e2'}, 'sentence_id': 'DDI-MedLine.d83.s1'}	Olanzapine a thienobenzodiazepine derivative is a second generation atypical antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia
Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia. 	thienobenzodiazepine derivative	second generation (atypical) antipsychotic agent	none	{'e1': {'word': 'thienobenzodiazepine derivative', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d83.s1.e1'}, 'e2': {'word': 'second generation (atypical) antipsychotic agent', 'word_index': [(6, 10)], 'id': 'DDI-MedLine.d83.s1.e2'}, 'sentence_id': 'DDI-MedLine.d83.s1'}	Olanzapine a thienobenzodiazepine derivative is a second generation atypical antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia
In large, well controlled trials in patients with schizophrenia or related psychoses, olanzapine 5 to 20 mg/day was significantly superior to haloperidol 5 to 20 mg/day in overall improvements in psychopathology rating scales and in the treatment of depressive and negative symptoms, and was comparable in effects on positive psychotic symptoms. 	olanzapine	haloperidol	none	{'e1': {'word': 'olanzapine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d83.s3.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d83.s3.e1'}, 'sentence_id': 'DDI-MedLine.d83.s3'}	In large well controlled trials in patients with schizophrenia or related psychoses olanzapine NUMBER to NUMBER mg / day was significantly superior to haloperidol NUMBER to NUMBER mg / day in overall improvements in psychopathology rating scales and in the treatment of depressive and negative symptoms and was comparable in effects on positive psychotic symptoms
The 1-year risk of relapse (rehospitalisation) was significantly lower with olanzapine than with haloperidol treatment. 	olanzapine	haloperidol	none	{'e1': {'word': 'olanzapine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d83.s4.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d83.s4.e1'}, 'sentence_id': 'DDI-MedLine.d83.s4'}	The NUMBER year risk of relapse rehospitalisation was significantly lower with olanzapine than with haloperidol treatment
In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 	olanzapine	risperidone	none	{'e1': {'word': 'olanzapine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d83.s5.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d83.s5.e1'}, 'sentence_id': 'DDI-MedLine.d83.s5'}	In the first double blind comparative study NUMBER week of olanzapine and risperidone olanzapine NUMBER to NUMBER mg / day proved to be significantly more effective than risperidone NUMBER to NUMBER mg / day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms
In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 	olanzapine	olanzapine	none	{'e1': {'word': 'olanzapine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d83.s5.e0'}, 'e2': {'word': 'olanzapine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d83.s5.e2'}, 'sentence_id': 'DDI-MedLine.d83.s5'}	In the first double blind comparative study NUMBER week of olanzapine and risperidone olanzapine NUMBER to NUMBER mg / day proved to be significantly more effective than risperidone NUMBER to NUMBER mg / day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms
In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 	olanzapine	risperidone	none	{'e1': {'word': 'olanzapine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d83.s5.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d83.s5.e3'}, 'sentence_id': 'DDI-MedLine.d83.s5'}	In the first double blind comparative study NUMBER week of olanzapine and risperidone olanzapine NUMBER to NUMBER mg / day proved to be significantly more effective than risperidone NUMBER to NUMBER mg / day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms
In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 	risperidone	olanzapine	none	{'e1': {'word': 'risperidone', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d83.s5.e1'}, 'e2': {'word': 'olanzapine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d83.s5.e2'}, 'sentence_id': 'DDI-MedLine.d83.s5'}	In the first double blind comparative study NUMBER week of olanzapine and risperidone olanzapine NUMBER to NUMBER mg / day proved to be significantly more effective than risperidone NUMBER to NUMBER mg / day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms
In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 	risperidone	risperidone	none	{'e1': {'word': 'risperidone', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d83.s5.e1'}, 'e2': {'word': 'risperidone', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d83.s5.e3'}, 'sentence_id': 'DDI-MedLine.d83.s5'}	In the first double blind comparative study NUMBER week of olanzapine and risperidone olanzapine NUMBER to NUMBER mg / day proved to be significantly more effective than risperidone NUMBER to NUMBER mg / day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms
In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 	olanzapine	risperidone	none	{'e1': {'word': 'olanzapine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d83.s5.e2'}, 'e2': {'word': 'risperidone', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d83.s5.e3'}, 'sentence_id': 'DDI-MedLine.d83.s5'}	In the first double blind comparative study NUMBER week of olanzapine and risperidone olanzapine NUMBER to NUMBER mg / day proved to be significantly more effective than risperidone NUMBER to NUMBER mg / day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms
In contrast, preliminary results from an 8-week controlled study suggested risperidone 2 to 6 mg/day was superior to olanzapine 5 to 20 mg/day against positive and anxiety/depressive symptoms (p < 0.05), although consistent with the first study, both agents demonstrated similar efficacy on measures of overall psychopathology. 	risperidone	olanzapine	none	{'e1': {'word': 'risperidone', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d83.s6.e0'}, 'e2': {'word': 'olanzapine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d83.s6.e1'}, 'sentence_id': 'DDI-MedLine.d83.s6'}	In contrast preliminary results from an NUMBER week controlled study suggested risperidone NUMBER to NUMBER mg / day was superior to olanzapine NUMBER to NUMBER mg / day against positive and anxiety depressive symptoms p < NUMBER although consistent with the first study both agents demonstrated similar efficacy on measures of overall psychopathology
Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol. 	olanzapine	risperidone	none	{'e1': {'word': 'olanzapine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d83.s7.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d83.s7.e1'}, 'sentence_id': 'DDI-MedLine.d83.s7'}	Improvements in general cognitive function seen with olanzapine treatment in a NUMBER year controlled study of patients with early phase schizophrenia were significantly greater than changes seen with either risperidone or haloperidol
Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol. 	olanzapine	haloperidol	none	{'e1': {'word': 'olanzapine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d83.s7.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d83.s7.e2'}, 'sentence_id': 'DDI-MedLine.d83.s7'}	Improvements in general cognitive function seen with olanzapine treatment in a NUMBER year controlled study of patients with early phase schizophrenia were significantly greater than changes seen with either risperidone or haloperidol
Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol. 	risperidone	haloperidol	none	{'e1': {'word': 'risperidone', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d83.s7.e1'}, 'e2': {'word': 'haloperidol', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d83.s7.e2'}, 'sentence_id': 'DDI-MedLine.d83.s7'}	Improvements in general cognitive function seen with olanzapine treatment in a NUMBER year controlled study of patients with early phase schizophrenia were significantly greater than changes seen with either risperidone or haloperidol
However, preliminary results from an 8-week trial showed comparable cognitive enhancing effects of olanzapine and risperidone treatment in patients with schizophrenia or schizoaffective disorder. 	olanzapine	risperidone	none	{'e1': {'word': 'olanzapine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d83.s8.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d83.s8.e1'}, 'sentence_id': 'DDI-MedLine.d83.s8'}	However preliminary results from an NUMBER week trial showed comparable cognitive enhancing effects of olanzapine and risperidone treatment in patients with schizophrenia or schizoaffective disorder
Several studies indicate that olanzapine has benefits against symptoms of aggression and agitation, while other studies strongly support the effectiveness of olanzapine in the treatment of depressive symptomatology. 	olanzapine	olanzapine	none	{'e1': {'word': 'olanzapine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d83.s9.e0'}, 'e2': {'word': 'olanzapine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d83.s9.e1'}, 'sentence_id': 'DDI-MedLine.d83.s9'}	Several studies indicate that olanzapine has benefits against symptoms of aggression and agitation while other studies strongly support the effectiveness of olanzapine in the treatment of depressive symptomatology
Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone. 	Olanzapine	haloperidol	none	{'e1': {'word': 'Olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s10.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d83.s10.e1'}, 'sentence_id': 'DDI-MedLine.d83.s10'}	Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone
Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone. 	Olanzapine	risperidone	none	{'e1': {'word': 'Olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s10.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d83.s10.e2'}, 'sentence_id': 'DDI-MedLine.d83.s10'}	Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone
Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone. 	haloperidol	risperidone	none	{'e1': {'word': 'haloperidol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d83.s10.e1'}, 'e2': {'word': 'risperidone', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d83.s10.e2'}, 'sentence_id': 'DDI-MedLine.d83.s10'}	Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone
In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval. 	olanzapine	clozapine	none	{'e1': {'word': 'olanzapine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d83.s11.e0'}, 'e2': {'word': 'clozapine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d83.s11.e1'}, 'sentence_id': 'DDI-MedLine.d83.s11'}	In addition olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval
In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval. 	olanzapine	risperidone	none	{'e1': {'word': 'olanzapine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d83.s11.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d83.s11.e2'}, 'sentence_id': 'DDI-MedLine.d83.s11'}	In addition olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval
In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval. 	clozapine	risperidone	none	{'e1': {'word': 'clozapine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d83.s11.e1'}, 'e2': {'word': 'risperidone', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d83.s11.e2'}, 'sentence_id': 'DDI-MedLine.d83.s11'}	In addition olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval
In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. 	haloperidol	olanzapine	none	{'e1': {'word': 'haloperidol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d83.s13.e0'}, 'e2': {'word': 'olanzapine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d83.s13.e1'}, 'sentence_id': 'DDI-MedLine.d83.s13'}	In comparison with haloperidol the adverse events reported significantly more frequently with olanzapine in > or = NUMBER % of patients were dry mouth bodyweight gain and increased appetite and compared with risperidone only bodyweight gain occurred significantly more frequently with olanzapine
In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. 	haloperidol	risperidone	none	{'e1': {'word': 'haloperidol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d83.s13.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d83.s13.e2'}, 'sentence_id': 'DDI-MedLine.d83.s13'}	In comparison with haloperidol the adverse events reported significantly more frequently with olanzapine in > or = NUMBER % of patients were dry mouth bodyweight gain and increased appetite and compared with risperidone only bodyweight gain occurred significantly more frequently with olanzapine
In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. 	haloperidol	olanzapine	none	{'e1': {'word': 'haloperidol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d83.s13.e0'}, 'e2': {'word': 'olanzapine', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d83.s13.e3'}, 'sentence_id': 'DDI-MedLine.d83.s13'}	In comparison with haloperidol the adverse events reported significantly more frequently with olanzapine in > or = NUMBER % of patients were dry mouth bodyweight gain and increased appetite and compared with risperidone only bodyweight gain occurred significantly more frequently with olanzapine
In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. 	olanzapine	risperidone	none	{'e1': {'word': 'olanzapine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d83.s13.e1'}, 'e2': {'word': 'risperidone', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d83.s13.e2'}, 'sentence_id': 'DDI-MedLine.d83.s13'}	In comparison with haloperidol the adverse events reported significantly more frequently with olanzapine in > or = NUMBER % of patients were dry mouth bodyweight gain and increased appetite and compared with risperidone only bodyweight gain occurred significantly more frequently with olanzapine
In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. 	olanzapine	olanzapine	none	{'e1': {'word': 'olanzapine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d83.s13.e1'}, 'e2': {'word': 'olanzapine', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d83.s13.e3'}, 'sentence_id': 'DDI-MedLine.d83.s13'}	In comparison with haloperidol the adverse events reported significantly more frequently with olanzapine in > or = NUMBER % of patients were dry mouth bodyweight gain and increased appetite and compared with risperidone only bodyweight gain occurred significantly more frequently with olanzapine
In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. 	risperidone	olanzapine	none	{'e1': {'word': 'risperidone', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d83.s13.e2'}, 'e2': {'word': 'olanzapine', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d83.s13.e3'}, 'sentence_id': 'DDI-MedLine.d83.s13'}	In comparison with haloperidol the adverse events reported significantly more frequently with olanzapine in > or = NUMBER % of patients were dry mouth bodyweight gain and increased appetite and compared with risperidone only bodyweight gain occurred significantly more frequently with olanzapine
Pharmacoeconomic analyses indicate that olanzapine does not significantly increase, and may even decrease, the overall direct treatment costs of schizophrenia, compared with haloperidol. 	olanzapine	haloperidol	none	{'e1': {'word': 'olanzapine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d83.s15.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d83.s15.e1'}, 'sentence_id': 'DDI-MedLine.d83.s15'}	Pharmacoeconomic analyses indicate that olanzapine does not significantly increase and may even decrease the overall direct treatment costs of schizophrenia compared with haloperidol
Compared with risperidone, olanzapine has also been reported to decrease overall treatment costs, despite the several-fold higher daily acquisition cost of the drug. 	risperidone	olanzapine	none	{'e1': {'word': 'risperidone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d83.s16.e0'}, 'e2': {'word': 'olanzapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d83.s16.e1'}, 'sentence_id': 'DDI-MedLine.d83.s16'}	Compared with risperidone olanzapine has also been reported to decrease overall treatment costs despite the several fold higher daily acquisition cost of the drug
Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol, and to broadly the same extent as risperidone. 	Olanzapine	haloperidol	none	{'e1': {'word': 'Olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s17.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d83.s17.e1'}, 'sentence_id': 'DDI-MedLine.d83.s17'}	Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol and to broadly the same extent as risperidone
Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol, and to broadly the same extent as risperidone. 	Olanzapine	risperidone	none	{'e1': {'word': 'Olanzapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d83.s17.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d83.s17.e2'}, 'sentence_id': 'DDI-MedLine.d83.s17'}	Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol and to broadly the same extent as risperidone
Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol, and to broadly the same extent as risperidone. 	haloperidol	risperidone	none	{'e1': {'word': 'haloperidol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d83.s17.e1'}, 'e2': {'word': 'risperidone', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d83.s17.e2'}, 'sentence_id': 'DDI-MedLine.d83.s17'}	Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol and to broadly the same extent as risperidone
CONCLUSIONS: Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia. 	Olanzapine	haloperidol	none	{'e1': {'word': 'Olanzapine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d83.s18.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d83.s18.e1'}, 'sentence_id': 'DDI-MedLine.d83.s18'}	CONCLUSIONS Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia and in the treatment of some patients with first episode or treatment resistant schizophrenia
The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.	haloperidol	risperidone	none	{'e1': {'word': 'haloperidol', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d83.s19.e0'}, 'e2': {'word': 'risperidone', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d83.s19.e1'}, 'sentence_id': 'DDI-MedLine.d83.s19'}	The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response
The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.	haloperidol	olanzapine	none	{'e1': {'word': 'haloperidol', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d83.s19.e0'}, 'e2': {'word': 'olanzapine', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d83.s19.e2'}, 'sentence_id': 'DDI-MedLine.d83.s19'}	The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response
The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.	risperidone	olanzapine	none	{'e1': {'word': 'risperidone', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d83.s19.e1'}, 'e2': {'word': 'olanzapine', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d83.s19.e2'}, 'sentence_id': 'DDI-MedLine.d83.s19'}	The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response
Numerous drug interactions are possible with some anticonvulsant agents, such as phenobarbitone and phenytoin, which affect hepatic microsomal enzyme systems. 	anticonvulsant agents	phenobarbitone	none	{'e1': {'word': 'anticonvulsant agents', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d19.s4.e0'}, 'e2': {'word': 'phenobarbitone', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d19.s4.e1'}, 'sentence_id': 'DDI-MedLine.d19.s4'}	Numerous drug interactions are possible with some anticonvulsant agents such as phenobarbitone and phenytoin which affect hepatic microsomal enzyme systems
Numerous drug interactions are possible with some anticonvulsant agents, such as phenobarbitone and phenytoin, which affect hepatic microsomal enzyme systems. 	anticonvulsant agents	phenytoin	none	{'e1': {'word': 'anticonvulsant agents', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d19.s4.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d19.s4.e2'}, 'sentence_id': 'DDI-MedLine.d19.s4'}	Numerous drug interactions are possible with some anticonvulsant agents such as phenobarbitone and phenytoin which affect hepatic microsomal enzyme systems
Numerous drug interactions are possible with some anticonvulsant agents, such as phenobarbitone and phenytoin, which affect hepatic microsomal enzyme systems. 	phenobarbitone	phenytoin	none	{'e1': {'word': 'phenobarbitone', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d19.s4.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d19.s4.e2'}, 'sentence_id': 'DDI-MedLine.d19.s4'}	Numerous drug interactions are possible with some anticonvulsant agents such as phenobarbitone and phenytoin which affect hepatic microsomal enzyme systems
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	cyclophosphamide	doxorubicin	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d115.s0.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d115.s0.e1'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	Concomitant cyclophosphamide doxorubicin vincristine and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus related non-Hodgkin lymphoma
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	cyclophosphamide	vincristine	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d115.s0.e0'}, 'e2': {'word': 'vincristine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d115.s0.e2'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	Concomitant cyclophosphamide doxorubicin vincristine and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus related non-Hodgkin lymphoma
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	cyclophosphamide	prednisone	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d115.s0.e0'}, 'e2': {'word': 'prednisone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d115.s0.e3'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	Concomitant cyclophosphamide doxorubicin vincristine and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus related non-Hodgkin lymphoma
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	cyclophosphamide	highly active antiretroviral	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d115.s0.e0'}, 'e2': {'word': 'highly active antiretroviral', 'word_index': [(8, 10)], 'id': 'DDI-MedLine.d115.s0.e4'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	Concomitant cyclophosphamide doxorubicin vincristine and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus related non-Hodgkin lymphoma
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	doxorubicin	vincristine	none	{'e1': {'word': 'doxorubicin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d115.s0.e1'}, 'e2': {'word': 'vincristine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d115.s0.e2'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	Concomitant cyclophosphamide doxorubicin vincristine and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus related non-Hodgkin lymphoma
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	doxorubicin	prednisone	none	{'e1': {'word': 'doxorubicin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d115.s0.e1'}, 'e2': {'word': 'prednisone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d115.s0.e3'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	Concomitant cyclophosphamide doxorubicin vincristine and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus related non-Hodgkin lymphoma
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	doxorubicin	highly active antiretroviral	none	{'e1': {'word': 'doxorubicin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d115.s0.e1'}, 'e2': {'word': 'highly active antiretroviral', 'word_index': [(8, 10)], 'id': 'DDI-MedLine.d115.s0.e4'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	Concomitant cyclophosphamide doxorubicin vincristine and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus related non-Hodgkin lymphoma
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	vincristine	prednisone	none	{'e1': {'word': 'vincristine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d115.s0.e2'}, 'e2': {'word': 'prednisone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d115.s0.e3'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	Concomitant cyclophosphamide doxorubicin vincristine and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus related non-Hodgkin lymphoma
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	vincristine	highly active antiretroviral	none	{'e1': {'word': 'vincristine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d115.s0.e2'}, 'e2': {'word': 'highly active antiretroviral', 'word_index': [(8, 10)], 'id': 'DDI-MedLine.d115.s0.e4'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	Concomitant cyclophosphamide doxorubicin vincristine and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus related non-Hodgkin lymphoma
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	prednisone	highly active antiretroviral	none	{'e1': {'word': 'prednisone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d115.s0.e3'}, 'e2': {'word': 'highly active antiretroviral', 'word_index': [(8, 10)], 'id': 'DDI-MedLine.d115.s0.e4'}, 'sentence_id': 'DDI-MedLine.d115.s0'}	Concomitant cyclophosphamide doxorubicin vincristine and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus related non-Hodgkin lymphoma
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	doxorubicin	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	vincristine	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'vincristine', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	prednisone	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'prednisone', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	cyclophosphamide	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(67, 67)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	doxorubicin	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(68, 68)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	teniposide	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'teniposide', 'word_index': [(69, 69)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	prednisone	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'prednisone', 'word_index': [(71, 71)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	vincristine	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'vincristine', 'word_index': [(73, 73)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	bleomycin	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'bleomycin', 'word_index': [(75, 75)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	antiretroviral	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d115.s2.e0'}, 'e2': {'word': 'antiretroviral', 'word_index': [(78, 78)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	vincristine	none	{'e1': {'word': 'doxorubicin', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'vincristine', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	prednisone	none	{'e1': {'word': 'doxorubicin', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'prednisone', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	cyclophosphamide	none	{'e1': {'word': 'doxorubicin', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(67, 67)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	doxorubicin	none	{'e1': {'word': 'doxorubicin', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'doxorubicin', 'word_index': [(68, 68)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	teniposide	none	{'e1': {'word': 'doxorubicin', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'teniposide', 'word_index': [(69, 69)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	prednisone	none	{'e1': {'word': 'doxorubicin', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'prednisone', 'word_index': [(71, 71)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	vincristine	none	{'e1': {'word': 'doxorubicin', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'vincristine', 'word_index': [(73, 73)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	bleomycin	none	{'e1': {'word': 'doxorubicin', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'bleomycin', 'word_index': [(75, 75)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	antiretroviral	none	{'e1': {'word': 'doxorubicin', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d115.s2.e1'}, 'e2': {'word': 'antiretroviral', 'word_index': [(78, 78)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	prednisone	none	{'e1': {'word': 'vincristine', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'prednisone', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	cyclophosphamide	none	{'e1': {'word': 'vincristine', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(67, 67)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	doxorubicin	none	{'e1': {'word': 'vincristine', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'doxorubicin', 'word_index': [(68, 68)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	teniposide	none	{'e1': {'word': 'vincristine', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'teniposide', 'word_index': [(69, 69)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	prednisone	none	{'e1': {'word': 'vincristine', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'prednisone', 'word_index': [(71, 71)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	vincristine	none	{'e1': {'word': 'vincristine', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'vincristine', 'word_index': [(73, 73)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	bleomycin	none	{'e1': {'word': 'vincristine', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'bleomycin', 'word_index': [(75, 75)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	antiretroviral	none	{'e1': {'word': 'vincristine', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d115.s2.e2'}, 'e2': {'word': 'antiretroviral', 'word_index': [(78, 78)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	cyclophosphamide	none	{'e1': {'word': 'prednisone', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'e2': {'word': 'cyclophosphamide', 'word_index': [(67, 67)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	doxorubicin	none	{'e1': {'word': 'prednisone', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'e2': {'word': 'doxorubicin', 'word_index': [(68, 68)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	teniposide	none	{'e1': {'word': 'prednisone', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'e2': {'word': 'teniposide', 'word_index': [(69, 69)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	prednisone	none	{'e1': {'word': 'prednisone', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'e2': {'word': 'prednisone', 'word_index': [(71, 71)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	vincristine	none	{'e1': {'word': 'prednisone', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'e2': {'word': 'vincristine', 'word_index': [(73, 73)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	bleomycin	none	{'e1': {'word': 'prednisone', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'e2': {'word': 'bleomycin', 'word_index': [(75, 75)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	antiretroviral	none	{'e1': {'word': 'prednisone', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d115.s2.e3'}, 'e2': {'word': 'antiretroviral', 'word_index': [(78, 78)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	doxorubicin	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(67, 67)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'e2': {'word': 'doxorubicin', 'word_index': [(68, 68)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	teniposide	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(67, 67)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'e2': {'word': 'teniposide', 'word_index': [(69, 69)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	prednisone	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(67, 67)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'e2': {'word': 'prednisone', 'word_index': [(71, 71)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	vincristine	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(67, 67)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'e2': {'word': 'vincristine', 'word_index': [(73, 73)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	bleomycin	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(67, 67)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'e2': {'word': 'bleomycin', 'word_index': [(75, 75)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	cyclophosphamide	antiretroviral	none	{'e1': {'word': 'cyclophosphamide', 'word_index': [(67, 67)], 'id': 'DDI-MedLine.d115.s2.e4'}, 'e2': {'word': 'antiretroviral', 'word_index': [(78, 78)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	teniposide	none	{'e1': {'word': 'doxorubicin', 'word_index': [(68, 68)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'e2': {'word': 'teniposide', 'word_index': [(69, 69)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	prednisone	none	{'e1': {'word': 'doxorubicin', 'word_index': [(68, 68)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'e2': {'word': 'prednisone', 'word_index': [(71, 71)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	vincristine	none	{'e1': {'word': 'doxorubicin', 'word_index': [(68, 68)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'e2': {'word': 'vincristine', 'word_index': [(73, 73)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	bleomycin	none	{'e1': {'word': 'doxorubicin', 'word_index': [(68, 68)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'e2': {'word': 'bleomycin', 'word_index': [(75, 75)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	doxorubicin	antiretroviral	none	{'e1': {'word': 'doxorubicin', 'word_index': [(68, 68)], 'id': 'DDI-MedLine.d115.s2.e5'}, 'e2': {'word': 'antiretroviral', 'word_index': [(78, 78)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	teniposide	prednisone	none	{'e1': {'word': 'teniposide', 'word_index': [(69, 69)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'e2': {'word': 'prednisone', 'word_index': [(71, 71)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	teniposide	vincristine	none	{'e1': {'word': 'teniposide', 'word_index': [(69, 69)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'e2': {'word': 'vincristine', 'word_index': [(73, 73)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	teniposide	bleomycin	none	{'e1': {'word': 'teniposide', 'word_index': [(69, 69)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'e2': {'word': 'bleomycin', 'word_index': [(75, 75)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	teniposide	antiretroviral	none	{'e1': {'word': 'teniposide', 'word_index': [(69, 69)], 'id': 'DDI-MedLine.d115.s2.e6'}, 'e2': {'word': 'antiretroviral', 'word_index': [(78, 78)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	vincristine	none	{'e1': {'word': 'prednisone', 'word_index': [(71, 71)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'e2': {'word': 'vincristine', 'word_index': [(73, 73)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	bleomycin	none	{'e1': {'word': 'prednisone', 'word_index': [(71, 71)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'e2': {'word': 'bleomycin', 'word_index': [(75, 75)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	prednisone	antiretroviral	none	{'e1': {'word': 'prednisone', 'word_index': [(71, 71)], 'id': 'DDI-MedLine.d115.s2.e7'}, 'e2': {'word': 'antiretroviral', 'word_index': [(78, 78)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	bleomycin	none	{'e1': {'word': 'vincristine', 'word_index': [(73, 73)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'e2': {'word': 'bleomycin', 'word_index': [(75, 75)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	vincristine	antiretroviral	none	{'e1': {'word': 'vincristine', 'word_index': [(73, 73)], 'id': 'DDI-MedLine.d115.s2.e8'}, 'e2': {'word': 'antiretroviral', 'word_index': [(78, 78)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 	bleomycin	antiretroviral	none	{'e1': {'word': 'bleomycin', 'word_index': [(75, 75)], 'id': 'DDI-MedLine.d115.s2.e9'}, 'e2': {'word': 'antiretroviral', 'word_index': [(78, 78)], 'id': 'DDI-MedLine.d115.s2.e10'}, 'sentence_id': 'DDI-MedLine.d115.s2'}	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV related systemic non-Hodgkin lymphoma HIV NHL the authors compared retrospectively a group of NUMBER patients with HIV NHL who were treated with the cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy regimen plus HAART with a group of NUMBER patients who were treated with CHOP chemotherapy or a CHOP like regimen i.e. cyclophosphamide doxorubicin teniposide and prednisone with vincristine plus bleomycin without receiving antiretroviral therapy
Antiretroviral regimens consisted of two reverse transcriptase inhibitors and one protease inhibitor. 	Antiretroviral	reverse transcriptase inhibitors	none	{'e1': {'word': 'Antiretroviral', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s5.e0'}, 'e2': {'word': 'reverse transcriptase inhibitors', 'word_index': [(5, 7)], 'id': 'DDI-MedLine.d115.s5.e1'}, 'sentence_id': 'DDI-MedLine.d115.s5'}	Antiretroviral regimens consisted of NUMBER reverse transcriptase inhibitors and NUMBER protease inhibitor
Antiretroviral regimens consisted of two reverse transcriptase inhibitors and one protease inhibitor. 	Antiretroviral	protease inhibitor	none	{'e1': {'word': 'Antiretroviral', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d115.s5.e0'}, 'e2': {'word': 'protease inhibitor', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d115.s5.e2'}, 'sentence_id': 'DDI-MedLine.d115.s5'}	Antiretroviral regimens consisted of NUMBER reverse transcriptase inhibitors and NUMBER protease inhibitor
Antiretroviral regimens consisted of two reverse transcriptase inhibitors and one protease inhibitor. 	reverse transcriptase inhibitors	protease inhibitor	none	{'e1': {'word': 'reverse transcriptase inhibitors', 'word_index': [(5, 7)], 'id': 'DDI-MedLine.d115.s5.e1'}, 'e2': {'word': 'protease inhibitor', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d115.s5.e2'}, 'sentence_id': 'DDI-MedLine.d115.s5'}	Antiretroviral regimens consisted of NUMBER reverse transcriptase inhibitors and NUMBER protease inhibitor
However, careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between antiretroviral and antineoplastic drugs. 	antiretroviral drugs	antineoplastic drugs	advise	{'e1': {'word': 'antiretroviral drugs', 'word_index': [(14, 14), (18, 18)], 'id': 'DDI-MedLine.d115.s14.e0'}, 'e2': {'word': 'antineoplastic drugs', 'word_index': [(16, 17)], 'id': 'DDI-MedLine.d115.s14.e1'}, 'sentence_id': 'DDI-MedLine.d115.s14'}	However careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between antiretroviral and antineoplastic drugs drugs
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	cimetidine	verografin	none	{'e1': {'word': 'cimetidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d68.s0.e0'}, 'e2': {'word': 'verografin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d68.s0.e1'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	The effect of cimetidine on the renal excretion of verografin and iodamide in dogs The intravenous injection of cimetidine in a dose of NUMBER mg / kg enhanced verografine and iodamide excretion in chronic canine experiments
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	cimetidine	iodamide	none	{'e1': {'word': 'cimetidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d68.s0.e0'}, 'e2': {'word': 'iodamide', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d68.s0.e2'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	The effect of cimetidine on the renal excretion of verografin and iodamide in dogs The intravenous injection of cimetidine in a dose of NUMBER mg / kg enhanced verografine and iodamide excretion in chronic canine experiments
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	cimetidine	cimetidine	none	{'e1': {'word': 'cimetidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d68.s0.e0'}, 'e2': {'word': 'cimetidine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d68.s0.e3'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	The effect of cimetidine on the renal excretion of verografin and iodamide in dogs The intravenous injection of cimetidine in a dose of NUMBER mg / kg enhanced verografine and iodamide excretion in chronic canine experiments
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	cimetidine	verografine	none	{'e1': {'word': 'cimetidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d68.s0.e0'}, 'e2': {'word': 'verografine', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d68.s0.e4'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	The effect of cimetidine on the renal excretion of verografin and iodamide in dogs The intravenous injection of cimetidine in a dose of NUMBER mg / kg enhanced verografine and iodamide excretion in chronic canine experiments
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	cimetidine	iodamide	none	{'e1': {'word': 'cimetidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d68.s0.e0'}, 'e2': {'word': 'iodamide', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d68.s0.e5'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	The effect of cimetidine on the renal excretion of verografin and iodamide in dogs The intravenous injection of cimetidine in a dose of NUMBER mg / kg enhanced verografine and iodamide excretion in chronic canine experiments
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	verografin	iodamide	none	{'e1': {'word': 'verografin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d68.s0.e1'}, 'e2': {'word': 'iodamide', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d68.s0.e2'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	The effect of cimetidine on the renal excretion of verografin and iodamide in dogs The intravenous injection of cimetidine in a dose of NUMBER mg / kg enhanced verografine and iodamide excretion in chronic canine experiments
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	verografin	cimetidine	none	{'e1': {'word': 'verografin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d68.s0.e1'}, 'e2': {'word': 'cimetidine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d68.s0.e3'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	The effect of cimetidine on the renal excretion of verografin and iodamide in dogs The intravenous injection of cimetidine in a dose of NUMBER mg / kg enhanced verografine and iodamide excretion in chronic canine experiments
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	verografin	verografine	none	{'e1': {'word': 'verografin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d68.s0.e1'}, 'e2': {'word': 'verografine', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d68.s0.e4'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	The effect of cimetidine on the renal excretion of verografin and iodamide in dogs The intravenous injection of cimetidine in a dose of NUMBER mg / kg enhanced verografine and iodamide excretion in chronic canine experiments
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	verografin	iodamide	none	{'e1': {'word': 'verografin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d68.s0.e1'}, 'e2': {'word': 'iodamide', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d68.s0.e5'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	The effect of cimetidine on the renal excretion of verografin and iodamide in dogs The intravenous injection of cimetidine in a dose of NUMBER mg / kg enhanced verografine and iodamide excretion in chronic canine experiments
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	iodamide	cimetidine	none	{'e1': {'word': 'iodamide', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d68.s0.e2'}, 'e2': {'word': 'cimetidine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d68.s0.e3'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	The effect of cimetidine on the renal excretion of verografin and iodamide in dogs The intravenous injection of cimetidine in a dose of NUMBER mg / kg enhanced verografine and iodamide excretion in chronic canine experiments
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	iodamide	verografine	none	{'e1': {'word': 'iodamide', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d68.s0.e2'}, 'e2': {'word': 'verografine', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d68.s0.e4'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	The effect of cimetidine on the renal excretion of verografin and iodamide in dogs The intravenous injection of cimetidine in a dose of NUMBER mg / kg enhanced verografine and iodamide excretion in chronic canine experiments
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	iodamide	iodamide	none	{'e1': {'word': 'iodamide', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d68.s0.e2'}, 'e2': {'word': 'iodamide', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d68.s0.e5'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	The effect of cimetidine on the renal excretion of verografin and iodamide in dogs The intravenous injection of cimetidine in a dose of NUMBER mg / kg enhanced verografine and iodamide excretion in chronic canine experiments
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	cimetidine	verografine	mechanism	{'e1': {'word': 'cimetidine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d68.s0.e3'}, 'e2': {'word': 'verografine', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d68.s0.e4'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	The effect of cimetidine on the renal excretion of verografin and iodamide in dogs The intravenous injection of cimetidine in a dose of NUMBER mg / kg enhanced verografine and iodamide excretion in chronic canine experiments
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	cimetidine	iodamide	mechanism	{'e1': {'word': 'cimetidine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d68.s0.e3'}, 'e2': {'word': 'iodamide', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d68.s0.e5'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	The effect of cimetidine on the renal excretion of verografin and iodamide in dogs The intravenous injection of cimetidine in a dose of NUMBER mg / kg enhanced verografine and iodamide excretion in chronic canine experiments
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	verografine	iodamide	none	{'e1': {'word': 'verografine', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d68.s0.e4'}, 'e2': {'word': 'iodamide', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d68.s0.e5'}, 'sentence_id': 'DDI-MedLine.d68.s0'}	The effect of cimetidine on the renal excretion of verografin and iodamide in dogs The intravenous injection of cimetidine in a dose of NUMBER mg / kg enhanced verografine and iodamide excretion in chronic canine experiments
The higher verografine and iodamide excretion was due to their increased renal tubular secretion. 	verografine	iodamide	none	{'e1': {'word': 'verografine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d68.s1.e0'}, 'e2': {'word': 'iodamide', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d68.s1.e1'}, 'sentence_id': 'DDI-MedLine.d68.s1'}	The higher verografine and iodamide excretion was due to their increased renal tubular secretion
In dogs, cimetidine unchanged the secretion of cardiotrast, a test agent for anionic transport. 	cimetidine	cardiotrast	none	{'e1': {'word': 'cimetidine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d68.s2.e0'}, 'e2': {'word': 'cardiotrast', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d68.s2.e1'}, 'sentence_id': 'DDI-MedLine.d68.s2'}	In dogs cimetidine unchanged the secretion of cardiotrast a test agent for anionic transport
Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined.	cimetidine	verografine	none	{'e1': {'word': 'cimetidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d68.s3.e0'}, 'e2': {'word': 'verografine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d68.s3.e1'}, 'sentence_id': 'DDI-MedLine.d68.s3'}	Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined
Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined.	cimetidine	iodamide	none	{'e1': {'word': 'cimetidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d68.s3.e0'}, 'e2': {'word': 'iodamide', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d68.s3.e2'}, 'sentence_id': 'DDI-MedLine.d68.s3'}	Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined
Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined.	verografine	iodamide	none	{'e1': {'word': 'verografine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d68.s3.e1'}, 'e2': {'word': 'iodamide', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d68.s3.e2'}, 'sentence_id': 'DDI-MedLine.d68.s3'}	Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined
"Acute hydrocortisone administration does not affect subjective responses to d-amphetamine in humans.
"	hydrocortisone	d-amphetamine	none	{'e1': {'word': 'hydrocortisone', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d38.s0.e0'}, 'e2': {'word': 'd-amphetamine', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d38.s0.e1'}, 'sentence_id': 'DDI-MedLine.d38.s0'}	Acute hydrocortisone administration does not affect subjective responses to d amphetamine in humans
However, the effects of stress and glucocorticoids on the subjective and behavioral effects of psychostimulants have not been well studied in humans. 	glucocorticoids	psychostimulants	none	{'e1': {'word': 'glucocorticoids', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d38.s2.e0'}, 'e2': {'word': 'psychostimulants', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d38.s2.e1'}, 'sentence_id': 'DDI-MedLine.d38.s2'}	However the effects of stress and glucocorticoids on the subjective and behavioral effects of psychostimulants have not been well studied in humans
OBJECTIVES: To examine the effects of acute hydrocortisone pretreatment on the subjective and behavioral effects of d-amphetamine. 	hydrocortisone	d-amphetamine	none	{'e1': {'word': 'hydrocortisone', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d38.s3.e0'}, 'e2': {'word': 'd-amphetamine', 'word_index': [(16, 17)], 'id': 'DDI-MedLine.d38.s3.e1'}, 'sentence_id': 'DDI-MedLine.d38.s3'}	OBJECTIVES To examine the effects of acute hydrocortisone pretreatment on the subjective and behavioral effects of d- amphetamine
METHODS: Hydrocortisone (100 mg) and d-amphetamine (20 mg) were administered orally to 16 healthy male and female volunteers in a four-session, placebo-controlled, within-subject, crossover design. 	Hydrocortisone	d-amphetamine	none	{'e1': {'word': 'Hydrocortisone', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d38.s4.e0'}, 'e2': {'word': 'd-amphetamine', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d38.s4.e1'}, 'sentence_id': 'DDI-MedLine.d38.s4'}	METHODS Hydrocortisone NUMBER mg and d amphetamine NUMBER mg were administered orally to NUMBER healthy male and female volunteers in a NUMBER session placebo controlled within subject crossover design
However, hydrocortisone pretreatment did not affect any of the physiological, behavioral, or subjective effects of d-amphetamine. 	hydrocortisone	d-amphetamine	none	{'e1': {'word': 'hydrocortisone', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d38.s8.e0'}, 'e2': {'word': 'd-amphetamine', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d38.s8.e1'}, 'sentence_id': 'DDI-MedLine.d38.s8'}	However hydrocortisone pretreatment did not affect any of the physiological behavioral or subjective effects of d amphetamine
CONCLUSIONS: In contrast to the effects of glucocorticoids in rodent studies, these results indicate that an acute increase in cortisol does not enhance the psychostimulant effects of d-amphetamine in humans.	glucocorticoids	d-amphetamine	none	{'e1': {'word': 'glucocorticoids', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d38.s9.e0'}, 'e2': {'word': 'd-amphetamine', 'word_index': [(27, 28)], 'id': 'DDI-MedLine.d38.s9.e1'}, 'sentence_id': 'DDI-MedLine.d38.s9'}	CONCLUSIONS In contrast to the effects of glucocorticoids in rodent studies these results indicate that an acute increase in cortisol does not enhance the psychostimulant effects of d amphetamine in humans
[Quantitative approach to treatment with incisive neuroleptics by therapeutic monitoring]; The problems encountered during the longterm treatment of psychotic patients with neuroleptics are illustrated by six typical case reports. 	neuroleptics	neuroleptics	none	{'e1': {'word': 'neuroleptics', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d139.s0.e0'}, 'e2': {'word': 'neuroleptics', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d139.s0.e1'}, 'sentence_id': 'DDI-MedLine.d139.s0'}	Quantitative approach to treatment with incisive neuroleptics by therapeutic monitoring The problems encountered during the longterm treatment of psychotic patients with neuroleptics are illustrated by NUMBER typical case reports
"Combinations of clozapine and phencyclidine: effects on drug discrimination and behavioral inhibition in rats.
"	clozapine	phencyclidine	none	{'e1': {'word': 'clozapine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d135.s0.e0'}, 'e2': {'word': 'phencyclidine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d135.s0.e1'}, 'sentence_id': 'DDI-MedLine.d135.s0'}	Combinations of clozapine and phencyclidine effects on drug discrimination and behavioral inhibition in rats
Phencyclidine (PCP) produces psychotomimetic effects in humans that resemble schizophrenia symptoms. 	Phencyclidine	PCP	none	{'e1': {'word': 'Phencyclidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d135.s1.e0'}, 'e2': {'word': 'PCP', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d135.s1.e1'}, 'sentence_id': 'DDI-MedLine.d135.s1'}	Phencyclidine PCP produces psychotomimetic effects in humans that resemble schizophrenia symptoms
In the present study, the atypical antipsychotic clozapine was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures. 	atypical antipsychotic	clozapine	none	{'e1': {'word': 'atypical antipsychotic', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d135.s3.e0'}, 'e2': {'word': 'clozapine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d135.s3.e1'}, 'sentence_id': 'DDI-MedLine.d135.s3'}	In the present study the atypical antipsychotic clozapine was tested in combination with an active dose of PCP in NUMBER lever drug discrimination and mixed signalled unsignalled differential reinforcement of low rates DRL procedures
In the present study, the atypical antipsychotic clozapine was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures. 	atypical antipsychotic	PCP	none	{'e1': {'word': 'atypical antipsychotic', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d135.s3.e0'}, 'e2': {'word': 'PCP', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d135.s3.e2'}, 'sentence_id': 'DDI-MedLine.d135.s3'}	In the present study the atypical antipsychotic clozapine was tested in combination with an active dose of PCP in NUMBER lever drug discrimination and mixed signalled unsignalled differential reinforcement of low rates DRL procedures
In the present study, the atypical antipsychotic clozapine was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures. 	clozapine	PCP	none	{'e1': {'word': 'clozapine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d135.s3.e1'}, 'e2': {'word': 'PCP', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d135.s3.e2'}, 'sentence_id': 'DDI-MedLine.d135.s3'}	In the present study the atypical antipsychotic clozapine was tested in combination with an active dose of PCP in NUMBER lever drug discrimination and mixed signalled unsignalled differential reinforcement of low rates DRL procedures
PCP produced distinctive effects in each task: it substituted for the training dose in PCP discrimination and it increased the number of responses with short (<3 s) interresponse times as well as increasing overall response rates in the DRL schedule. 	PCP	PCP	none	{'e1': {'word': 'PCP', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d135.s4.e0'}, 'e2': {'word': 'PCP', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d135.s4.e1'}, 'sentence_id': 'DDI-MedLine.d135.s4'}	PCP produced distinctive effects in each task it substituted for the training dose in PCP discrimination and it increased the number of responses with short < NUMBER s interresponse times as well as increasing overall response rates in the DRL schedule
Acute dosing with clozapine failed to alter the behavioral effects of PCP in either procedure even when tested up to doses that produced pharmacological effects alone. 	clozapine	PCP	none	{'e1': {'word': 'clozapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d135.s5.e0'}, 'e2': {'word': 'PCP', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d135.s5.e1'}, 'sentence_id': 'DDI-MedLine.d135.s5'}	Acute dosing with clozapine failed to alter the behavioral effects of PCP in either procedure even when tested up to doses that produced pharmacological effects alone
These results suggest that acute dosing with clozapine would not affect behaviors most closely associated with PCP intoxication. 	clozapine	PCP	none	{'e1': {'word': 'clozapine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d135.s6.e0'}, 'e2': {'word': 'PCP', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d135.s6.e1'}, 'sentence_id': 'DDI-MedLine.d135.s6'}	These results suggest that acute dosing with clozapine would not affect behaviors most closely associated with PCP intoxication
Since chronic dosing is required for therapeutic efficacy of antipsychotics, future studies should focus on investigation of chronic dosing effects of these drugs in combination with PCP.	antipsychotics	PCP	none	{'e1': {'word': 'antipsychotics', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d135.s8.e0'}, 'e2': {'word': 'PCP', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d135.s8.e1'}, 'sentence_id': 'DDI-MedLine.d135.s8'}	Since chronic dosing is required for therapeutic efficacy of antipsychotics future studies should focus on investigation of chronic dosing effects of these drugs in combination with PCP
"Pharmacokinetic evaluation of the digoxin-amiodarone interaction.
"	digoxin	amiodarone	none	{'e1': {'word': 'digoxin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d61.s0.e0'}, 'e2': {'word': 'amiodarone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d61.s0.e1'}, 'sentence_id': 'DDI-MedLine.d61.s0'}	Pharmacokinetic evaluation of the digoxin amiodarone interaction
Amiodarone is known to raise serum digoxin levels. 	Amiodarone	digoxin	mechanism	{'e1': {'word': 'Amiodarone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d61.s1.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d61.s1.e1'}, 'sentence_id': 'DDI-MedLine.d61.s1'}	Amiodarone is known to raise serum digoxin levels
The pharmacokinetic variables for digoxin were determined after a 1.0 mg intravenous dose of digoxin in each subject, before and after oral amiodarone, 400 mg daily for 3 weeks. 	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d61.s3.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d61.s3.e1'}, 'sentence_id': 'DDI-MedLine.d61.s3'}	The pharmacokinetic variables for digoxin were determined after a NUMBER mg intravenous dose of digoxin in each subject before and after oral amiodarone NUMBER mg daily for NUMBER weeks
The pharmacokinetic variables for digoxin were determined after a 1.0 mg intravenous dose of digoxin in each subject, before and after oral amiodarone, 400 mg daily for 3 weeks. 	digoxin	amiodarone	none	{'e1': {'word': 'digoxin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d61.s3.e0'}, 'e2': {'word': 'amiodarone', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d61.s3.e2'}, 'sentence_id': 'DDI-MedLine.d61.s3'}	The pharmacokinetic variables for digoxin were determined after a NUMBER mg intravenous dose of digoxin in each subject before and after oral amiodarone NUMBER mg daily for NUMBER weeks
The pharmacokinetic variables for digoxin were determined after a 1.0 mg intravenous dose of digoxin in each subject, before and after oral amiodarone, 400 mg daily for 3 weeks. 	digoxin	amiodarone	none	{'e1': {'word': 'digoxin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d61.s3.e1'}, 'e2': {'word': 'amiodarone', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d61.s3.e2'}, 'sentence_id': 'DDI-MedLine.d61.s3'}	The pharmacokinetic variables for digoxin were determined after a NUMBER mg intravenous dose of digoxin in each subject before and after oral amiodarone NUMBER mg daily for NUMBER weeks
During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01). 	amiodarone	digoxin	mechanism	{'e1': {'word': 'amiodarone', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d61.s4.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d61.s4.e1'}, 'sentence_id': 'DDI-MedLine.d61.s4'}	During amiodarone administration systemic clearance of digoxin was reduced from NUMBER + - NUMBER ml / min mean + - standard deviation to NUMBER + - NUMBER ml / min p less than NUMBER
Amiodarone caused a three- to fivefold increase in serum reverse triiodothyronine levels, but changes in thyroid function were not quantitatively related to the changes in digoxin pharmacokinetics. 	Amiodarone	digoxin	none	{'e1': {'word': 'Amiodarone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d61.s8.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d61.s8.e1'}, 'sentence_id': 'DDI-MedLine.d61.s8'}	Amiodarone caused a NUMBER to fivefold increase in serum reverse triiodothyronine levels but changes in thyroid function were not quantitatively related to the changes in digoxin pharmacokinetics
These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.	digoxin	amiodarone	mechanism	{'e1': {'word': 'digoxin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d61.s9.e0'}, 'e2': {'word': 'amiodarone', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d61.s9.e1'}, 'sentence_id': 'DDI-MedLine.d61.s9'}	These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically
These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d61.s9.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d61.s9.e2'}, 'sentence_id': 'DDI-MedLine.d61.s9'}	These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically
These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.	amiodarone	digoxin	none	{'e1': {'word': 'amiodarone', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d61.s9.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d61.s9.e2'}, 'sentence_id': 'DDI-MedLine.d61.s9'}	These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically
Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin, a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin.	contortrostatin	echistatin	none	{'e1': {'word': 'contortrostatin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d69.s0.e0'}, 'e2': {'word': 'echistatin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d69.s0.e1'}, 'sentence_id': 'DDI-MedLine.d69.s0'}	Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin a homodimeric disintegrin and monomeric disintegrins echistatin and flavoridin
Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin, a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin.	contortrostatin	flavoridin	none	{'e1': {'word': 'contortrostatin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d69.s0.e0'}, 'e2': {'word': 'flavoridin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d69.s0.e2'}, 'sentence_id': 'DDI-MedLine.d69.s0'}	Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin a homodimeric disintegrin and monomeric disintegrins echistatin and flavoridin
Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin, a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin.	echistatin	flavoridin	none	{'e1': {'word': 'echistatin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d69.s0.e1'}, 'e2': {'word': 'flavoridin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d69.s0.e2'}, 'sentence_id': 'DDI-MedLine.d69.s0'}	Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin a homodimeric disintegrin and monomeric disintegrins echistatin and flavoridin
The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins echistatin and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells. 	contortrostatin	echistatin	none	{'e1': {'word': 'contortrostatin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d69.s1.e0'}, 'e2': {'word': 'echistatin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d69.s1.e1'}, 'sentence_id': 'DDI-MedLine.d69.s1'}	The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins echistatin and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells
The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins echistatin and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells. 	contortrostatin	flavoridin	none	{'e1': {'word': 'contortrostatin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d69.s1.e0'}, 'e2': {'word': 'flavoridin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d69.s1.e2'}, 'sentence_id': 'DDI-MedLine.d69.s1'}	The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins echistatin and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells
The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins echistatin and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells. 	echistatin	flavoridin	none	{'e1': {'word': 'echistatin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d69.s1.e1'}, 'e2': {'word': 'flavoridin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d69.s1.e2'}, 'sentence_id': 'DDI-MedLine.d69.s1'}	The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins echistatin and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells
Echistatin alone had no effect on tyrosine phosphorylation in T24 cells, but dose-dependently inhibits the effects of contortrostatin when both are added simultaneously. 	Echistatin	contortrostatin	effect	{'e1': {'word': 'Echistatin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d69.s3.e0'}, 'e2': {'word': 'contortrostatin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d69.s3.e1'}, 'sentence_id': 'DDI-MedLine.d69.s3'}	Echistatin alone had no effect on tyrosine phosphorylation in T24 cells but dose dependently inhibits the effects of contortrostatin when both are added simultaneously
Flavoridin alone was found to have no effect on CAS, but can completely block contortrostatin-induced phosphorylation of this protein in MDA-MB-435 cells. 	Flavoridin	contortrostatin	effect	{'e1': {'word': 'Flavoridin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d69.s5.e0'}, 'e2': {'word': 'contortrostatin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d69.s5.e1'}, 'sentence_id': 'DDI-MedLine.d69.s5'}	Flavoridin alone was found to have no effect on CAS but can completely block contortrostatin induced phosphorylation of this protein in MDA MB NUMBER cells
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	coumaphos	coumaphos	none	{'e1': {'word': 'coumaphos', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d5.s0.e0'}, 'e2': {'word': 'coumaphos', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d5.s0.e1'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	Repeated oral administration of coumaphos in sheep interactions of coumaphos with bishydroxycoumarin trichlorfon and phenobarbital sodium
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	coumaphos	bishydroxycoumarin	none	{'e1': {'word': 'coumaphos', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d5.s0.e0'}, 'e2': {'word': 'bishydroxycoumarin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d5.s0.e2'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	Repeated oral administration of coumaphos in sheep interactions of coumaphos with bishydroxycoumarin trichlorfon and phenobarbital sodium
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	coumaphos	trichlorfon	none	{'e1': {'word': 'coumaphos', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d5.s0.e0'}, 'e2': {'word': 'trichlorfon', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d5.s0.e3'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	Repeated oral administration of coumaphos in sheep interactions of coumaphos with bishydroxycoumarin trichlorfon and phenobarbital sodium
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	coumaphos	phenobarbital sodium	none	{'e1': {'word': 'coumaphos', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d5.s0.e0'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(14, 15)], 'id': 'DDI-MedLine.d5.s0.e4'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	Repeated oral administration of coumaphos in sheep interactions of coumaphos with bishydroxycoumarin trichlorfon and phenobarbital sodium
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	coumaphos	bishydroxycoumarin	none	{'e1': {'word': 'coumaphos', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d5.s0.e1'}, 'e2': {'word': 'bishydroxycoumarin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d5.s0.e2'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	Repeated oral administration of coumaphos in sheep interactions of coumaphos with bishydroxycoumarin trichlorfon and phenobarbital sodium
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	coumaphos	trichlorfon	none	{'e1': {'word': 'coumaphos', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d5.s0.e1'}, 'e2': {'word': 'trichlorfon', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d5.s0.e3'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	Repeated oral administration of coumaphos in sheep interactions of coumaphos with bishydroxycoumarin trichlorfon and phenobarbital sodium
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	coumaphos	phenobarbital sodium	none	{'e1': {'word': 'coumaphos', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d5.s0.e1'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(14, 15)], 'id': 'DDI-MedLine.d5.s0.e4'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	Repeated oral administration of coumaphos in sheep interactions of coumaphos with bishydroxycoumarin trichlorfon and phenobarbital sodium
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	bishydroxycoumarin	trichlorfon	none	{'e1': {'word': 'bishydroxycoumarin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d5.s0.e2'}, 'e2': {'word': 'trichlorfon', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d5.s0.e3'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	Repeated oral administration of coumaphos in sheep interactions of coumaphos with bishydroxycoumarin trichlorfon and phenobarbital sodium
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	bishydroxycoumarin	phenobarbital sodium	none	{'e1': {'word': 'bishydroxycoumarin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d5.s0.e2'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(14, 15)], 'id': 'DDI-MedLine.d5.s0.e4'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	Repeated oral administration of coumaphos in sheep interactions of coumaphos with bishydroxycoumarin trichlorfon and phenobarbital sodium
"Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
"	trichlorfon	phenobarbital sodium	none	{'e1': {'word': 'trichlorfon', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d5.s0.e3'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(14, 15)], 'id': 'DDI-MedLine.d5.s0.e4'}, 'sentence_id': 'DDI-MedLine.d5.s0'}	Repeated oral administration of coumaphos in sheep interactions of coumaphos with bishydroxycoumarin trichlorfon and phenobarbital sodium
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	coumaphos	bishydroxycoumarin	none	{'e1': {'word': 'coumaphos', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d5.s1.e0'}, 'e2': {'word': 'bishydroxycoumarin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d5.s1.e1'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with coumaphos bishydroxycoumarin an anticoagulant trichlorfon an organophosphorous compound and phenobarbital sodium an inducer of microsomal enzymes were investigated in sheep
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	coumaphos	anticoagulant	none	{'e1': {'word': 'coumaphos', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d5.s1.e0'}, 'e2': {'word': 'anticoagulant', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d5.s1.e2'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with coumaphos bishydroxycoumarin an anticoagulant trichlorfon an organophosphorous compound and phenobarbital sodium an inducer of microsomal enzymes were investigated in sheep
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	coumaphos	trichlorfon	none	{'e1': {'word': 'coumaphos', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d5.s1.e0'}, 'e2': {'word': 'trichlorfon', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d5.s1.e3'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with coumaphos bishydroxycoumarin an anticoagulant trichlorfon an organophosphorous compound and phenobarbital sodium an inducer of microsomal enzymes were investigated in sheep
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	coumaphos	organophosphorous compound	none	{'e1': {'word': 'coumaphos', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d5.s1.e0'}, 'e2': {'word': 'organophosphorous compound', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d5.s1.e4'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with coumaphos bishydroxycoumarin an anticoagulant trichlorfon an organophosphorous compound and phenobarbital sodium an inducer of microsomal enzymes were investigated in sheep
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	coumaphos	phenobarbital sodium	none	{'e1': {'word': 'coumaphos', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d5.s1.e0'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(13, 14)], 'id': 'DDI-MedLine.d5.s1.e5'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with coumaphos bishydroxycoumarin an anticoagulant trichlorfon an organophosphorous compound and phenobarbital sodium an inducer of microsomal enzymes were investigated in sheep
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	bishydroxycoumarin	anticoagulant	none	{'e1': {'word': 'bishydroxycoumarin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d5.s1.e1'}, 'e2': {'word': 'anticoagulant', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d5.s1.e2'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with coumaphos bishydroxycoumarin an anticoagulant trichlorfon an organophosphorous compound and phenobarbital sodium an inducer of microsomal enzymes were investigated in sheep
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	bishydroxycoumarin	trichlorfon	none	{'e1': {'word': 'bishydroxycoumarin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d5.s1.e1'}, 'e2': {'word': 'trichlorfon', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d5.s1.e3'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with coumaphos bishydroxycoumarin an anticoagulant trichlorfon an organophosphorous compound and phenobarbital sodium an inducer of microsomal enzymes were investigated in sheep
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	bishydroxycoumarin	organophosphorous compound	none	{'e1': {'word': 'bishydroxycoumarin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d5.s1.e1'}, 'e2': {'word': 'organophosphorous compound', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d5.s1.e4'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with coumaphos bishydroxycoumarin an anticoagulant trichlorfon an organophosphorous compound and phenobarbital sodium an inducer of microsomal enzymes were investigated in sheep
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	bishydroxycoumarin	phenobarbital sodium	none	{'e1': {'word': 'bishydroxycoumarin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d5.s1.e1'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(13, 14)], 'id': 'DDI-MedLine.d5.s1.e5'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with coumaphos bishydroxycoumarin an anticoagulant trichlorfon an organophosphorous compound and phenobarbital sodium an inducer of microsomal enzymes were investigated in sheep
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	anticoagulant	trichlorfon	none	{'e1': {'word': 'anticoagulant', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d5.s1.e2'}, 'e2': {'word': 'trichlorfon', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d5.s1.e3'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with coumaphos bishydroxycoumarin an anticoagulant trichlorfon an organophosphorous compound and phenobarbital sodium an inducer of microsomal enzymes were investigated in sheep
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	anticoagulant	organophosphorous compound	none	{'e1': {'word': 'anticoagulant', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d5.s1.e2'}, 'e2': {'word': 'organophosphorous compound', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d5.s1.e4'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with coumaphos bishydroxycoumarin an anticoagulant trichlorfon an organophosphorous compound and phenobarbital sodium an inducer of microsomal enzymes were investigated in sheep
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	anticoagulant	phenobarbital sodium	none	{'e1': {'word': 'anticoagulant', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d5.s1.e2'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(13, 14)], 'id': 'DDI-MedLine.d5.s1.e5'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with coumaphos bishydroxycoumarin an anticoagulant trichlorfon an organophosphorous compound and phenobarbital sodium an inducer of microsomal enzymes were investigated in sheep
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	trichlorfon	organophosphorous compound	none	{'e1': {'word': 'trichlorfon', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d5.s1.e3'}, 'e2': {'word': 'organophosphorous compound', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d5.s1.e4'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with coumaphos bishydroxycoumarin an anticoagulant trichlorfon an organophosphorous compound and phenobarbital sodium an inducer of microsomal enzymes were investigated in sheep
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	trichlorfon	phenobarbital sodium	none	{'e1': {'word': 'trichlorfon', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d5.s1.e3'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(13, 14)], 'id': 'DDI-MedLine.d5.s1.e5'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with coumaphos bishydroxycoumarin an anticoagulant trichlorfon an organophosphorous compound and phenobarbital sodium an inducer of microsomal enzymes were investigated in sheep
Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 	organophosphorous compound	phenobarbital sodium	none	{'e1': {'word': 'organophosphorous compound', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d5.s1.e4'}, 'e2': {'word': 'phenobarbital sodium', 'word_index': [(13, 14)], 'id': 'DDI-MedLine.d5.s1.e5'}, 'sentence_id': 'DDI-MedLine.d5.s1'}	Interactions between treatments with coumaphos bishydroxycoumarin an anticoagulant trichlorfon an organophosphorous compound and phenobarbital sodium an inducer of microsomal enzymes were investigated in sheep
A daily dose of 2 mg of coumaphos/kg of body weight for 6 days did not affect the plasma enzymes or the antiprothrombinemic effect of bishydroxy-coumarin in wethers. 	coumaphos	bishydroxy-coumarin	none	{'e1': {'word': 'coumaphos', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d5.s2.e0'}, 'e2': {'word': 'bishydroxy-coumarin', 'word_index': [(27, 28)], 'id': 'DDI-MedLine.d5.s2.e1'}, 'sentence_id': 'DDI-MedLine.d5.s2'}	A daily dose of NUMBER mg of coumaphos / kg of body weight for NUMBER days did not affect the plasma enzymes or the antiprothrombinemic effect of bishydroxy coumarin in wethers
The treatment of ewes with an intravenous (IV) injection of trichlorfon, insufficient to produce significant inhibition of erythrocyte acetylcholinesterase (AChE) activity, appeared to produce additive effects with those produced by subsequent treatment with 4 mg of coumaphos/kg/day. 	trichlorfon	coumaphos	effect	{'e1': {'word': 'trichlorfon', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d5.s3.e0'}, 'e2': {'word': 'coumaphos', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d5.s3.e1'}, 'sentence_id': 'DDI-MedLine.d5.s3'}	The treatment of ewes with an intravenous NUMBER injection of trichlorfon insufficient to produce significant inhibition of erythrocyte acetylcholinesterase AChE activity appeared to produce additive effects with those produced by subsequent treatment with NUMBER mg of coumaphos / kg day
In ewes given 40 mg of phenobarbital sodium/kg for 5 days intraperitoneally (IP), the anticholinesterase effect of 4 mg of coumaphos/kg was significantly reduced and signs of toxicity were not present. 	phenobarbital sodium	coumaphos	effect	{'e1': {'word': 'phenobarbital sodium', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d5.s4.e0'}, 'e2': {'word': 'coumaphos', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d5.s4.e1'}, 'sentence_id': 'DDI-MedLine.d5.s4'}	In ewes given NUMBER mg of phenobarbital sodium / kg for NUMBER days intraperitoneally IP the anticholinesterase effect of NUMBER mg of coumaphos / kg was significantly reduced and signs of toxicity were not present
Molecular basis for the selective toxicity of amphotericin B for yeast and filipin for animal cells.	amphotericin B	filipin	none	{'e1': {'word': 'amphotericin B', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d120.s0.e0'}, 'e2': {'word': 'filipin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d120.s0.e1'}, 'sentence_id': 'DDI-MedLine.d120.s0'}	Molecular basis for the selective toxicity of amphotericin B for yeast and filipin for animal cells
Among the polyene antibiotics, many, like filipin, cannot be used clinically because they are toxic; 	polyene antibiotics	filipin	none	{'e1': {'word': 'polyene antibiotics', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d120.s1.e0'}, 'e2': {'word': 'filipin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d120.s1.e1'}, 'sentence_id': 'DDI-MedLine.d120.s1'}	Among the polyene antibiotics many like filipin can not be used clinically because they are toxic
Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells; 	filipin	amphotericin B	none	{'e1': {'word': 'filipin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d120.s3.e0'}, 'e2': {'word': 'amphotericin B', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d120.s3.e1'}, 'sentence_id': 'DDI-MedLine.d120.s3'}	Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations i these polyene antibiotics showed differential effects on cells
Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells; 	filipin	polyene antibiotics	none	{'e1': {'word': 'filipin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d120.s3.e0'}, 'e2': {'word': 'polyene antibiotics', 'word_index': [(27, 28)], 'id': 'DDI-MedLine.d120.s3.e2'}, 'sentence_id': 'DDI-MedLine.d120.s3'}	Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations i these polyene antibiotics showed differential effects on cells
Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells; 	amphotericin B	polyene antibiotics	none	{'e1': {'word': 'amphotericin B', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d120.s3.e1'}, 'e2': {'word': 'polyene antibiotics', 'word_index': [(27, 28)], 'id': 'DDI-MedLine.d120.s3.e2'}, 'sentence_id': 'DDI-MedLine.d120.s3'}	Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations i these polyene antibiotics showed differential effects on cells
filipin was more potent in lysing human red blood cells, whereas amphotericin B was more potent in inhibiting yeast cell growth; 	filipin	amphotericin B	none	{'e1': {'word': 'filipin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d120.s4.e0'}, 'e2': {'word': 'amphotericin B', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d120.s4.e1'}, 'sentence_id': 'DDI-MedLine.d120.s4'}	filipin was more potent in lysing human red blood cells whereas amphotericin B was more potent in inhibiting yeast cell growth
and (ii) the effects of filipin were more efficiently inhibited by added cholesterol, the major membrane sterol in human cells, whereas the effects of amphotericin B were more efficiently inhibited by ergosterol, the major membrane sterol in yeast. 	filipin	amphotericin B	none	{'e1': {'word': 'filipin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d120.s5.e0'}, 'e2': {'word': 'amphotericin B', 'word_index': [(24, 25)], 'id': 'DDI-MedLine.d120.s5.e1'}, 'sentence_id': 'DDI-MedLine.d120.s5'}	and ii the effects of filipin were more efficiently inhibited by added cholesterol the major membrane sterol in human cells whereas the effects of amphotericin B were more efficiently inhibited by ergosterol the major membrane sterol in yeast
"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
"	indinavir	IDV	none	{'e1': {'word': 'indinavir', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d79.s0.e0'}, 'e2': {'word': 'IDV', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d79.s0.e1'}, 'sentence_id': 'DDI-MedLine.d79.s0'}	If taken NUMBER hour before indinavir IDV didanosine does not affect IDV exposure despite persistent buffering effects
"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
"	indinavir	didanosine	none	{'e1': {'word': 'indinavir', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d79.s0.e0'}, 'e2': {'word': 'didanosine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d79.s0.e2'}, 'sentence_id': 'DDI-MedLine.d79.s0'}	If taken NUMBER hour before indinavir IDV didanosine does not affect IDV exposure despite persistent buffering effects
"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
"	indinavir	IDV	none	{'e1': {'word': 'indinavir', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d79.s0.e0'}, 'e2': {'word': 'IDV', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d79.s0.e3'}, 'sentence_id': 'DDI-MedLine.d79.s0'}	If taken NUMBER hour before indinavir IDV didanosine does not affect IDV exposure despite persistent buffering effects
"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
"	IDV	didanosine	none	{'e1': {'word': 'IDV', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d79.s0.e1'}, 'e2': {'word': 'didanosine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d79.s0.e2'}, 'sentence_id': 'DDI-MedLine.d79.s0'}	If taken NUMBER hour before indinavir IDV didanosine does not affect IDV exposure despite persistent buffering effects
"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
"	IDV	IDV	none	{'e1': {'word': 'IDV', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d79.s0.e1'}, 'e2': {'word': 'IDV', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d79.s0.e3'}, 'sentence_id': 'DDI-MedLine.d79.s0'}	If taken NUMBER hour before indinavir IDV didanosine does not affect IDV exposure despite persistent buffering effects
"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
"	didanosine	IDV	none	{'e1': {'word': 'didanosine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d79.s0.e2'}, 'e2': {'word': 'IDV', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d79.s0.e3'}, 'sentence_id': 'DDI-MedLine.d79.s0'}	If taken NUMBER hour before indinavir IDV didanosine does not affect IDV exposure despite persistent buffering effects
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	indinavir	didanosine	mechanism	{'e1': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s1.e0'}, 'e2': {'word': 'didanosine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d79.s1.e1'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir but it is unclear how soon after didanosine administration indinavir may be given safely
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	indinavir	indinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s1.e0'}, 'e2': {'word': 'indinavir', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d79.s1.e2'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir but it is unclear how soon after didanosine administration indinavir may be given safely
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	indinavir	didanosine	none	{'e1': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s1.e0'}, 'e2': {'word': 'didanosine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d79.s1.e3'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir but it is unclear how soon after didanosine administration indinavir may be given safely
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	indinavir	indinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d79.s1.e0'}, 'e2': {'word': 'indinavir', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d79.s1.e4'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir but it is unclear how soon after didanosine administration indinavir may be given safely
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	didanosine	indinavir	none	{'e1': {'word': 'didanosine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d79.s1.e1'}, 'e2': {'word': 'indinavir', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d79.s1.e2'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir but it is unclear how soon after didanosine administration indinavir may be given safely
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	didanosine	didanosine	none	{'e1': {'word': 'didanosine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d79.s1.e1'}, 'e2': {'word': 'didanosine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d79.s1.e3'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir but it is unclear how soon after didanosine administration indinavir may be given safely
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	didanosine	indinavir	none	{'e1': {'word': 'didanosine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d79.s1.e1'}, 'e2': {'word': 'indinavir', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d79.s1.e4'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir but it is unclear how soon after didanosine administration indinavir may be given safely
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	indinavir	didanosine	none	{'e1': {'word': 'indinavir', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d79.s1.e2'}, 'e2': {'word': 'didanosine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d79.s1.e3'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir but it is unclear how soon after didanosine administration indinavir may be given safely
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	indinavir	indinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d79.s1.e2'}, 'e2': {'word': 'indinavir', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d79.s1.e4'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir but it is unclear how soon after didanosine administration indinavir may be given safely
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	didanosine	indinavir	none	{'e1': {'word': 'didanosine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d79.s1.e3'}, 'e2': {'word': 'indinavir', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d79.s1.e4'}, 'sentence_id': 'DDI-MedLine.d79.s1'}	Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir but it is unclear how soon after didanosine administration indinavir may be given safely
We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. 	indinavir	indinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d79.s2.e0'}, 'e2': {'word': 'indinavir', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d79.s2.e1'}, 'sentence_id': 'DDI-MedLine.d79.s2'}	We compared indinavir pharmacokinetics and gastric pH in NUMBER human immunodeficiency virus positive patients by use of NUMBER mg of indinavir alone versus NUMBER mg of indinavir administered NUMBER h after didanosine administration
We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. 	indinavir	indinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d79.s2.e0'}, 'e2': {'word': 'indinavir', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d79.s2.e2'}, 'sentence_id': 'DDI-MedLine.d79.s2'}	We compared indinavir pharmacokinetics and gastric pH in NUMBER human immunodeficiency virus positive patients by use of NUMBER mg of indinavir alone versus NUMBER mg of indinavir administered NUMBER h after didanosine administration
We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. 	indinavir	didanosine	none	{'e1': {'word': 'indinavir', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d79.s2.e0'}, 'e2': {'word': 'didanosine', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d79.s2.e3'}, 'sentence_id': 'DDI-MedLine.d79.s2'}	We compared indinavir pharmacokinetics and gastric pH in NUMBER human immunodeficiency virus positive patients by use of NUMBER mg of indinavir alone versus NUMBER mg of indinavir administered NUMBER h after didanosine administration
We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. 	indinavir	indinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d79.s2.e1'}, 'e2': {'word': 'indinavir', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d79.s2.e2'}, 'sentence_id': 'DDI-MedLine.d79.s2'}	We compared indinavir pharmacokinetics and gastric pH in NUMBER human immunodeficiency virus positive patients by use of NUMBER mg of indinavir alone versus NUMBER mg of indinavir administered NUMBER h after didanosine administration
We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. 	indinavir	didanosine	none	{'e1': {'word': 'indinavir', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d79.s2.e1'}, 'e2': {'word': 'didanosine', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d79.s2.e3'}, 'sentence_id': 'DDI-MedLine.d79.s2'}	We compared indinavir pharmacokinetics and gastric pH in NUMBER human immunodeficiency virus positive patients by use of NUMBER mg of indinavir alone versus NUMBER mg of indinavir administered NUMBER h after didanosine administration
We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. 	indinavir	didanosine	none	{'e1': {'word': 'indinavir', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d79.s2.e2'}, 'e2': {'word': 'didanosine', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d79.s2.e3'}, 'sentence_id': 'DDI-MedLine.d79.s2'}	We compared indinavir pharmacokinetics and gastric pH in NUMBER human immunodeficiency virus positive patients by use of NUMBER mg of indinavir alone versus NUMBER mg of indinavir administered NUMBER h after didanosine administration
Median gastric pH was significantly higher when indinavir was taken after didanosine administration; 	indinavir	didanosine	mechanism	{'e1': {'word': 'indinavir', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d79.s3.e0'}, 'e2': {'word': 'didanosine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d79.s3.e1'}, 'sentence_id': 'DDI-MedLine.d79.s3'}	Median gastric pH was significantly higher when indinavir was taken after didanosine administration
Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.	Indinavir	didanosine	advise	{'e1': {'word': 'Indinavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d79.s5.e0'}, 'e2': {'word': 'didanosine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d79.s5.e1'}, 'sentence_id': 'DDI-MedLine.d79.s5'}	Indinavir may be taken with a light meal NUMBER h following the administration of NUMBER mg of didanosine
"Green tea polyphenols as potent enhancers of glucocorticoid-induced mouse mammary tumor virus gene expression.
"	Green tea polyphenols	enhancers	none	{'e1': {'word': 'Green tea polyphenols', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d129.s0.e0'}, 'e2': {'word': 'enhancers', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d129.s0.e1'}, 'sentence_id': 'DDI-MedLine.d129.s0'}	Green tea polyphenols as potent enhancers of glucocorticoid induced mouse mammary tumor virus gene expression
n-dodecyl gallate showed the most potent inhibition (66% inhibition at 10 microM), which was far more potent than that of crude tannic acid. 	n-dodecyl gallate	tannic acid	none	{'e1': {'word': 'n-dodecyl gallate', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d129.s3.e0'}, 'e2': {'word': 'tannic acid', 'word_index': [(23, 24)], 'id': 'DDI-MedLine.d129.s3.e1'}, 'sentence_id': 'DDI-MedLine.d129.s3'}	n dodecyl gallate showed the most potent inhibition NUMBER % inhibition at NUMBER microM which was far more potent than that of crude tannic acid
As immediate-early genes (IEGs) are thought to play a critical role in mediating stimulus-induced neural plasticity, IEG response induced by methamphetamine (METH) has been characterized to define the changes in gene expression that may underlie its long-lasting behavioral effects. 	methamphetamine	METH	none	{'e1': {'word': 'methamphetamine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d62.s1.e0'}, 'e2': {'word': 'METH', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d62.s1.e1'}, 'sentence_id': 'DDI-MedLine.d62.s1'}	As immediate early genes IEGs are thought to play a critical role in mediating stimulus induced neural plasticity IEG response induced by methamphetamine METH has been characterized to define the changes in gene expression that may underlie its long lasting behavioral effects
Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. 	METH	SCH-23390	effect	{'e1': {'word': 'METH', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d62.s4.e0'}, 'e2': {'word': 'SCH-23390', 'word_index': [(37, 38)], 'id': 'DDI-MedLine.d62.s4.e1'}, 'sentence_id': 'DDI-MedLine.d62.s4'}	Using in situ hybridization we observed that METH caused a rapid and transient dose dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH 23390 but not by an atypical neuroleptic clozapine
Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. 	METH	atypical neuroleptic	none	{'e1': {'word': 'METH', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d62.s4.e0'}, 'e2': {'word': 'atypical neuroleptic', 'word_index': [(43, 44)], 'id': 'DDI-MedLine.d62.s4.e2'}, 'sentence_id': 'DDI-MedLine.d62.s4'}	Using in situ hybridization we observed that METH caused a rapid and transient dose dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH 23390 but not by an atypical neuroleptic clozapine
Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. 	METH	clozapine	none	{'e1': {'word': 'METH', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d62.s4.e0'}, 'e2': {'word': 'clozapine', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d62.s4.e3'}, 'sentence_id': 'DDI-MedLine.d62.s4'}	Using in situ hybridization we observed that METH caused a rapid and transient dose dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH 23390 but not by an atypical neuroleptic clozapine
Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. 	SCH-23390	atypical neuroleptic	none	{'e1': {'word': 'SCH-23390', 'word_index': [(37, 38)], 'id': 'DDI-MedLine.d62.s4.e1'}, 'e2': {'word': 'atypical neuroleptic', 'word_index': [(43, 44)], 'id': 'DDI-MedLine.d62.s4.e2'}, 'sentence_id': 'DDI-MedLine.d62.s4'}	Using in situ hybridization we observed that METH caused a rapid and transient dose dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH 23390 but not by an atypical neuroleptic clozapine
Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. 	SCH-23390	clozapine	none	{'e1': {'word': 'SCH-23390', 'word_index': [(37, 38)], 'id': 'DDI-MedLine.d62.s4.e1'}, 'e2': {'word': 'clozapine', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d62.s4.e3'}, 'sentence_id': 'DDI-MedLine.d62.s4'}	Using in situ hybridization we observed that METH caused a rapid and transient dose dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH 23390 but not by an atypical neuroleptic clozapine
Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. 	atypical neuroleptic	clozapine	none	{'e1': {'word': 'atypical neuroleptic', 'word_index': [(43, 44)], 'id': 'DDI-MedLine.d62.s4.e2'}, 'e2': {'word': 'clozapine', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d62.s4.e3'}, 'sentence_id': 'DDI-MedLine.d62.s4'}	Using in situ hybridization we observed that METH caused a rapid and transient dose dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH 23390 but not by an atypical neuroleptic clozapine
Since photic evoked potential components are representations of neural pathways which are activated during photic stimulation, study of the effects of alcohol on these components may help to trace pathways which are affected by alcohol. 	alcohol	alcohol	none	{'e1': {'word': 'alcohol', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d54.s2.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d54.s2.e1'}, 'sentence_id': 'DDI-MedLine.d54.s2'}	Since photic evoked potential components are representations of neural pathways which are activated during photic stimulation study of the effects of alcohol on these components may help to trace pathways which are affected by alcohol
In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, ethanol (2.0 g/kg), physostigmine (0.6 mg/kg) or atropine (15.0 mg/kg) on separate days. 	ethanol	physostigmine	none	{'e1': {'word': 'ethanol', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d54.s3.e0'}, 'e2': {'word': 'physostigmine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d54.s3.e1'}, 'sentence_id': 'DDI-MedLine.d54.s3'}	In the present study evoked potentials were recorded at NUMBER NUMBER and NUMBER min following IP injections of saline ethanol NUMBER g / kg physostigmine NUMBER mg / kg or atropine NUMBER mg / kg on separate days
In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, ethanol (2.0 g/kg), physostigmine (0.6 mg/kg) or atropine (15.0 mg/kg) on separate days. 	ethanol	atropine	none	{'e1': {'word': 'ethanol', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d54.s3.e0'}, 'e2': {'word': 'atropine', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d54.s3.e2'}, 'sentence_id': 'DDI-MedLine.d54.s3'}	In the present study evoked potentials were recorded at NUMBER NUMBER and NUMBER min following IP injections of saline ethanol NUMBER g / kg physostigmine NUMBER mg / kg or atropine NUMBER mg / kg on separate days
In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, ethanol (2.0 g/kg), physostigmine (0.6 mg/kg) or atropine (15.0 mg/kg) on separate days. 	physostigmine	atropine	none	{'e1': {'word': 'physostigmine', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d54.s3.e1'}, 'e2': {'word': 'atropine', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d54.s3.e2'}, 'sentence_id': 'DDI-MedLine.d54.s3'}	In the present study evoked potentials were recorded at NUMBER NUMBER and NUMBER min following IP injections of saline ethanol NUMBER g / kg physostigmine NUMBER mg / kg or atropine NUMBER mg / kg on separate days
Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. 	Physostigmine	alcohol	effect	{'e1': {'word': 'Physostigmine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d54.s8.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d54.s8.e1'}, 'sentence_id': 'DDI-MedLine.d54.s8'}	Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1 while attenuating alcohol 's influence on components P2 and P3
Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. 	Physostigmine	alcohol	effect	{'e1': {'word': 'Physostigmine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d54.s8.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d54.s8.e2'}, 'sentence_id': 'DDI-MedLine.d54.s8'}	Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1 while attenuating alcohol 's influence on components P2 and P3
Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. 	alcohol	alcohol	none	{'e1': {'word': 'alcohol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d54.s8.e1'}, 'e2': {'word': 'alcohol', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d54.s8.e2'}, 'sentence_id': 'DDI-MedLine.d54.s8'}	Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1 while attenuating alcohol 's influence on components P2 and P3
Atropine, either alone or in combination with alcohol, produced approximately the same degree of enhancement of component P2. 	Atropine	alcohol	none	{'e1': {'word': 'Atropine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d54.s10.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d54.s10.e1'}, 'sentence_id': 'DDI-MedLine.d54.s10'}	Atropine either alone or in combination with alcohol produced approximately the same degree of enhancement of component P2
"Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture.
"	buforin II	azithromycin	none	{'e1': {'word': 'buforin II', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d47.s0.e0'}, 'e2': {'word': 'azithromycin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d47.s0.e1'}, 'sentence_id': 'DDI-MedLine.d47.s0'}	Activity of buforin NUMBER alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture
"Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture.
"	buforin II	minocycline	none	{'e1': {'word': 'buforin II', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d47.s0.e0'}, 'e2': {'word': 'minocycline', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d47.s0.e2'}, 'sentence_id': 'DDI-MedLine.d47.s0'}	Activity of buforin NUMBER alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture
"Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture.
"	azithromycin	minocycline	none	{'e1': {'word': 'azithromycin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d47.s0.e1'}, 'e2': {'word': 'minocycline', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d47.s0.e2'}, 'sentence_id': 'DDI-MedLine.d47.s0'}	Activity of buforin NUMBER alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture
The in vitro anti-cryptosporidial activity of buforin II alone and in combination with azithromycin and minocycline was investigated. 	buforin II	azithromycin	none	{'e1': {'word': 'buforin II', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d47.s1.e0'}, 'e2': {'word': 'azithromycin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d47.s1.e1'}, 'sentence_id': 'DDI-MedLine.d47.s1'}	The in vitro anti-cryptosporidial activity of buforin NUMBER alone and in combination with azithromycin and minocycline was investigated
The in vitro anti-cryptosporidial activity of buforin II alone and in combination with azithromycin and minocycline was investigated. 	buforin II	minocycline	none	{'e1': {'word': 'buforin II', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d47.s1.e0'}, 'e2': {'word': 'minocycline', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d47.s1.e2'}, 'sentence_id': 'DDI-MedLine.d47.s1'}	The in vitro anti-cryptosporidial activity of buforin NUMBER alone and in combination with azithromycin and minocycline was investigated
The in vitro anti-cryptosporidial activity of buforin II alone and in combination with azithromycin and minocycline was investigated. 	azithromycin	minocycline	none	{'e1': {'word': 'azithromycin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d47.s1.e1'}, 'e2': {'word': 'minocycline', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d47.s1.e2'}, 'sentence_id': 'DDI-MedLine.d47.s1'}	The in vitro anti-cryptosporidial activity of buforin NUMBER alone and in combination with azithromycin and minocycline was investigated
Moreover, its activity was enhanced when it was combined with either azithromycin or minocycline with 90% parasite reduction at the highest concentration tested. 	azithromycin	minocycline	none	{'e1': {'word': 'azithromycin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d47.s3.e0'}, 'e2': {'word': 'minocycline', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d47.s3.e1'}, 'sentence_id': 'DDI-MedLine.d47.s3'}	Moreover its activity was enhanced when it was combined with either azithromycin or minocycline with NUMBER % parasite reduction at the highest concentration tested
Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.	Buforin II	azithromycin	effect	{'e1': {'word': 'Buforin II', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d47.s4.e0'}, 'e2': {'word': 'azithromycin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d47.s4.e1'}, 'sentence_id': 'DDI-MedLine.d47.s4'}	Buforin NUMBER may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline
Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.	Buforin II	minocycline	effect	{'e1': {'word': 'Buforin II', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d47.s4.e0'}, 'e2': {'word': 'minocycline', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d47.s4.e2'}, 'sentence_id': 'DDI-MedLine.d47.s4'}	Buforin NUMBER may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline
Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.	azithromycin	minocycline	none	{'e1': {'word': 'azithromycin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d47.s4.e1'}, 'e2': {'word': 'minocycline', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d47.s4.e2'}, 'sentence_id': 'DDI-MedLine.d47.s4'}	Buforin NUMBER may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline
"The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.
"	ketamine	Innovar	none	{'e1': {'word': 'ketamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s0.e0'}, 'e2': {'word': 'Innovar', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s0.e1'}, 'sentence_id': 'DDI-MedLine.d23.s0'}	The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs
"The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.
"	ketamine	digitalis	none	{'e1': {'word': 'ketamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d23.s0.e0'}, 'e2': {'word': 'digitalis', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d23.s0.e2'}, 'sentence_id': 'DDI-MedLine.d23.s0'}	The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs
"The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.
"	Innovar	digitalis	none	{'e1': {'word': 'Innovar', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d23.s0.e1'}, 'e2': {'word': 'digitalis', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d23.s0.e2'}, 'sentence_id': 'DDI-MedLine.d23.s0'}	The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	ketamine	none	{'e1': {'word': 'digitalis', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	Innovar Vet	none	{'e1': {'word': 'digitalis', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'Innovar Vet', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	pentobarbital	none	{'e1': {'word': 'digitalis', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'pentobarbital', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	ouabain	none	{'e1': {'word': 'digitalis', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'ouabain', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	ouabain	none	{'e1': {'word': 'digitalis', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'ouabain', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	ketamine	none	{'e1': {'word': 'digitalis', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	Innovar	none	{'e1': {'word': 'digitalis', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'Innovar', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	digitalis	pentobarbital	none	{'e1': {'word': 'digitalis', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s1.e0'}, 'e2': {'word': 'pentobarbital', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	Innovar Vet	none	{'e1': {'word': 'ketamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'e2': {'word': 'Innovar Vet', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	pentobarbital	none	{'e1': {'word': 'ketamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'e2': {'word': 'pentobarbital', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	ouabain	effect	{'e1': {'word': 'ketamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'e2': {'word': 'ouabain', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	ouabain	none	{'e1': {'word': 'ketamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'e2': {'word': 'ouabain', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	ketamine	none	{'e1': {'word': 'ketamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'e2': {'word': 'ketamine', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	Innovar	none	{'e1': {'word': 'ketamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'e2': {'word': 'Innovar', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	pentobarbital	none	{'e1': {'word': 'ketamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d23.s1.e1'}, 'e2': {'word': 'pentobarbital', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	Innovar Vet	pentobarbital	none	{'e1': {'word': 'Innovar Vet', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'e2': {'word': 'pentobarbital', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	Innovar Vet	ouabain	effect	{'e1': {'word': 'Innovar Vet', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'e2': {'word': 'ouabain', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	Innovar Vet	ouabain	none	{'e1': {'word': 'Innovar Vet', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'e2': {'word': 'ouabain', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	Innovar Vet	ketamine	none	{'e1': {'word': 'Innovar Vet', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'e2': {'word': 'ketamine', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	Innovar Vet	Innovar	none	{'e1': {'word': 'Innovar Vet', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'e2': {'word': 'Innovar', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	Innovar Vet	pentobarbital	none	{'e1': {'word': 'Innovar Vet', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d23.s1.e2'}, 'e2': {'word': 'pentobarbital', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	pentobarbital	ouabain	effect	{'e1': {'word': 'pentobarbital', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'e2': {'word': 'ouabain', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	pentobarbital	ouabain	none	{'e1': {'word': 'pentobarbital', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'e2': {'word': 'ouabain', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	pentobarbital	ketamine	none	{'e1': {'word': 'pentobarbital', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'e2': {'word': 'ketamine', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	pentobarbital	Innovar	none	{'e1': {'word': 'pentobarbital', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'e2': {'word': 'Innovar', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	pentobarbital	pentobarbital	none	{'e1': {'word': 'pentobarbital', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d23.s1.e3'}, 'e2': {'word': 'pentobarbital', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ouabain	ouabain	none	{'e1': {'word': 'ouabain', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'e2': {'word': 'ouabain', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ouabain	ketamine	none	{'e1': {'word': 'ouabain', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'e2': {'word': 'ketamine', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ouabain	Innovar	none	{'e1': {'word': 'ouabain', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'e2': {'word': 'Innovar', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ouabain	pentobarbital	none	{'e1': {'word': 'ouabain', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d23.s1.e4'}, 'e2': {'word': 'pentobarbital', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ouabain	ketamine	none	{'e1': {'word': 'ouabain', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'e2': {'word': 'ketamine', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ouabain	Innovar	none	{'e1': {'word': 'ouabain', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'e2': {'word': 'Innovar', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ouabain	pentobarbital	none	{'e1': {'word': 'ouabain', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d23.s1.e5'}, 'e2': {'word': 'pentobarbital', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	Innovar	none	{'e1': {'word': 'ketamine', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'e2': {'word': 'Innovar', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	ketamine	pentobarbital	none	{'e1': {'word': 'ketamine', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d23.s1.e6'}, 'e2': {'word': 'pentobarbital', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	Innovar	pentobarbital	none	{'e1': {'word': 'Innovar', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d23.s1.e7'}, 'e2': {'word': 'pentobarbital', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d23.s1.e8'}, 'sentence_id': 'DDI-MedLine.d23.s1'}	In a comparison of digitalis tolerance in dogs anesthetized with ketamine Innovar Vet or pentobarbital the dosage of ouabain needed to cause ventricular tachycardia was significantly higher as was the LD50 of ouabain with ketamine or Innovar than with pentobarbital
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ouabain	Innovar	effect	{'e1': {'word': 'ouabain', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s2.e0'}, 'e2': {'word': 'Innovar', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d23.s2.e1'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar ketamine or droperidol but not after administration of fentayl alone or after pentobarbital
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ouabain	ketamine	effect	{'e1': {'word': 'ouabain', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s2.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s2.e2'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar ketamine or droperidol but not after administration of fentayl alone or after pentobarbital
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ouabain	droperidol	effect	{'e1': {'word': 'ouabain', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s2.e0'}, 'e2': {'word': 'droperidol', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d23.s2.e3'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar ketamine or droperidol but not after administration of fentayl alone or after pentobarbital
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ouabain	fentayl	none	{'e1': {'word': 'ouabain', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s2.e0'}, 'e2': {'word': 'fentayl', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d23.s2.e4'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar ketamine or droperidol but not after administration of fentayl alone or after pentobarbital
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ouabain	pentobarbital	none	{'e1': {'word': 'ouabain', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d23.s2.e0'}, 'e2': {'word': 'pentobarbital', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d23.s2.e5'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar ketamine or droperidol but not after administration of fentayl alone or after pentobarbital
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	Innovar	ketamine	none	{'e1': {'word': 'Innovar', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d23.s2.e1'}, 'e2': {'word': 'ketamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s2.e2'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar ketamine or droperidol but not after administration of fentayl alone or after pentobarbital
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	Innovar	droperidol	none	{'e1': {'word': 'Innovar', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d23.s2.e1'}, 'e2': {'word': 'droperidol', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d23.s2.e3'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar ketamine or droperidol but not after administration of fentayl alone or after pentobarbital
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	Innovar	fentayl	none	{'e1': {'word': 'Innovar', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d23.s2.e1'}, 'e2': {'word': 'fentayl', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d23.s2.e4'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar ketamine or droperidol but not after administration of fentayl alone or after pentobarbital
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	Innovar	pentobarbital	none	{'e1': {'word': 'Innovar', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d23.s2.e1'}, 'e2': {'word': 'pentobarbital', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d23.s2.e5'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar ketamine or droperidol but not after administration of fentayl alone or after pentobarbital
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ketamine	droperidol	none	{'e1': {'word': 'ketamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s2.e2'}, 'e2': {'word': 'droperidol', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d23.s2.e3'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar ketamine or droperidol but not after administration of fentayl alone or after pentobarbital
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ketamine	fentayl	none	{'e1': {'word': 'ketamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s2.e2'}, 'e2': {'word': 'fentayl', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d23.s2.e4'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar ketamine or droperidol but not after administration of fentayl alone or after pentobarbital
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	ketamine	pentobarbital	none	{'e1': {'word': 'ketamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d23.s2.e2'}, 'e2': {'word': 'pentobarbital', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d23.s2.e5'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar ketamine or droperidol but not after administration of fentayl alone or after pentobarbital
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	droperidol	fentayl	none	{'e1': {'word': 'droperidol', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d23.s2.e3'}, 'e2': {'word': 'fentayl', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d23.s2.e4'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar ketamine or droperidol but not after administration of fentayl alone or after pentobarbital
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	droperidol	pentobarbital	none	{'e1': {'word': 'droperidol', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d23.s2.e3'}, 'e2': {'word': 'pentobarbital', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d23.s2.e5'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar ketamine or droperidol but not after administration of fentayl alone or after pentobarbital
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	fentayl	pentobarbital	none	{'e1': {'word': 'fentayl', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d23.s2.e4'}, 'e2': {'word': 'pentobarbital', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d23.s2.e5'}, 'sentence_id': 'DDI-MedLine.d23.s2'}	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar ketamine or droperidol but not after administration of fentayl alone or after pentobarbital
The literature provides considerable evidence indicating that several, but not all antihistaminics, are indeed analgesic agents and some are analgesic adjuvants as well.	antihistaminics	analgesic agents	none	{'e1': {'word': 'antihistaminics', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d57.s1.e0'}, 'e2': {'word': 'analgesic agents', 'word_index': [(14, 15)], 'id': 'DDI-MedLine.d57.s1.e1'}, 'sentence_id': 'DDI-MedLine.d57.s1'}	The literature provides considerable evidence indicating that several but not all antihistaminics are indeed analgesic agents and some are analgesic adjuvants as well
The literature provides considerable evidence indicating that several, but not all antihistaminics, are indeed analgesic agents and some are analgesic adjuvants as well.	antihistaminics	analgesic adjuvants	none	{'e1': {'word': 'antihistaminics', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d57.s1.e0'}, 'e2': {'word': 'analgesic adjuvants', 'word_index': [(19, 20)], 'id': 'DDI-MedLine.d57.s1.e2'}, 'sentence_id': 'DDI-MedLine.d57.s1'}	The literature provides considerable evidence indicating that several but not all antihistaminics are indeed analgesic agents and some are analgesic adjuvants as well
The literature provides considerable evidence indicating that several, but not all antihistaminics, are indeed analgesic agents and some are analgesic adjuvants as well.	analgesic agents	analgesic adjuvants	none	{'e1': {'word': 'analgesic agents', 'word_index': [(14, 15)], 'id': 'DDI-MedLine.d57.s1.e1'}, 'e2': {'word': 'analgesic adjuvants', 'word_index': [(19, 20)], 'id': 'DDI-MedLine.d57.s1.e2'}, 'sentence_id': 'DDI-MedLine.d57.s1'}	The literature provides considerable evidence indicating that several but not all antihistaminics are indeed analgesic agents and some are analgesic adjuvants as well
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	diphenhydramine	hydroxyzine	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d57.s2.e0'}, 'e2': {'word': 'hydroxyzine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d57.s2.e1'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	diphenhydramine	orphenadrine	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d57.s2.e0'}, 'e2': {'word': 'orphenadrine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e2'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	diphenhydramine	pyrilamine	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d57.s2.e0'}, 'e2': {'word': 'pyrilamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d57.s2.e3'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	diphenhydramine	phenyltoloxamine	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d57.s2.e0'}, 'e2': {'word': 'phenyltoloxamine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d57.s2.e4'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	diphenhydramine	promethazine	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d57.s2.e0'}, 'e2': {'word': 'promethazine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d57.s2.e5'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	diphenhydramine	methdilazine	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d57.s2.e0'}, 'e2': {'word': 'methdilazine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d57.s2.e6'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	diphenhydramine	tripelennamine	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d57.s2.e0'}, 'e2': {'word': 'tripelennamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d57.s2.e7'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	hydroxyzine	orphenadrine	none	{'e1': {'word': 'hydroxyzine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d57.s2.e1'}, 'e2': {'word': 'orphenadrine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e2'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	hydroxyzine	pyrilamine	none	{'e1': {'word': 'hydroxyzine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d57.s2.e1'}, 'e2': {'word': 'pyrilamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d57.s2.e3'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	hydroxyzine	phenyltoloxamine	none	{'e1': {'word': 'hydroxyzine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d57.s2.e1'}, 'e2': {'word': 'phenyltoloxamine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d57.s2.e4'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	hydroxyzine	promethazine	none	{'e1': {'word': 'hydroxyzine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d57.s2.e1'}, 'e2': {'word': 'promethazine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d57.s2.e5'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	hydroxyzine	methdilazine	none	{'e1': {'word': 'hydroxyzine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d57.s2.e1'}, 'e2': {'word': 'methdilazine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d57.s2.e6'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	hydroxyzine	tripelennamine	none	{'e1': {'word': 'hydroxyzine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d57.s2.e1'}, 'e2': {'word': 'tripelennamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d57.s2.e7'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	orphenadrine	pyrilamine	none	{'e1': {'word': 'orphenadrine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e2'}, 'e2': {'word': 'pyrilamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d57.s2.e3'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	orphenadrine	phenyltoloxamine	none	{'e1': {'word': 'orphenadrine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e2'}, 'e2': {'word': 'phenyltoloxamine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d57.s2.e4'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	orphenadrine	promethazine	none	{'e1': {'word': 'orphenadrine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e2'}, 'e2': {'word': 'promethazine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d57.s2.e5'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	orphenadrine	methdilazine	none	{'e1': {'word': 'orphenadrine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e2'}, 'e2': {'word': 'methdilazine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d57.s2.e6'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	orphenadrine	tripelennamine	none	{'e1': {'word': 'orphenadrine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d57.s2.e2'}, 'e2': {'word': 'tripelennamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d57.s2.e7'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	pyrilamine	phenyltoloxamine	none	{'e1': {'word': 'pyrilamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d57.s2.e3'}, 'e2': {'word': 'phenyltoloxamine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d57.s2.e4'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	pyrilamine	promethazine	none	{'e1': {'word': 'pyrilamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d57.s2.e3'}, 'e2': {'word': 'promethazine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d57.s2.e5'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	pyrilamine	methdilazine	none	{'e1': {'word': 'pyrilamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d57.s2.e3'}, 'e2': {'word': 'methdilazine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d57.s2.e6'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	pyrilamine	tripelennamine	none	{'e1': {'word': 'pyrilamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d57.s2.e3'}, 'e2': {'word': 'tripelennamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d57.s2.e7'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	phenyltoloxamine	promethazine	none	{'e1': {'word': 'phenyltoloxamine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d57.s2.e4'}, 'e2': {'word': 'promethazine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d57.s2.e5'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	phenyltoloxamine	methdilazine	none	{'e1': {'word': 'phenyltoloxamine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d57.s2.e4'}, 'e2': {'word': 'methdilazine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d57.s2.e6'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	phenyltoloxamine	tripelennamine	none	{'e1': {'word': 'phenyltoloxamine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d57.s2.e4'}, 'e2': {'word': 'tripelennamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d57.s2.e7'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	promethazine	methdilazine	none	{'e1': {'word': 'promethazine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d57.s2.e5'}, 'e2': {'word': 'methdilazine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d57.s2.e6'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	promethazine	tripelennamine	none	{'e1': {'word': 'promethazine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d57.s2.e5'}, 'e2': {'word': 'tripelennamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d57.s2.e7'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 	methdilazine	tripelennamine	none	{'e1': {'word': 'methdilazine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d57.s2.e6'}, 'e2': {'word': 'tripelennamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d57.s2.e7'}, 'sentence_id': 'DDI-MedLine.d57.s2'}	Those for which effectiveness is reported includes diphenhydramine hydroxyzine orphenadrine pyrilamine phenyltoloxamine promethazine methdilazine and tripelennamine
"Influence of coadministration of fluoxetine on cisapride pharmacokinetics and QTc intervals in healthy volunteers.
"	fluoxetine	cisapride	none	{'e1': {'word': 'fluoxetine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d46.s0.e0'}, 'e2': {'word': 'cisapride', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d46.s0.e1'}, 'sentence_id': 'DDI-MedLine.d46.s0'}	Influence of coadministration of fluoxetine on cisapride pharmacokinetics and QTc intervals in healthy volunteers
STUDY OBJECTIVE: To evaluate the effect of fluoxetine on the pharmacokinetics and cardiovascular safety of cisapride at steady state in healthy men. 	fluoxetine	cisapride	none	{'e1': {'word': 'fluoxetine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d46.s1.e0'}, 'e2': {'word': 'cisapride', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d46.s1.e1'}, 'sentence_id': 'DDI-MedLine.d46.s1'}	STUDY OBJECTIVE To evaluate the effect of fluoxetine on the pharmacokinetics and cardiovascular safety of cisapride at steady state in healthy men
and phase 3 (days 45-52): cisapride 10 mg 4 times/day (days 45-51) plus fluoxetine 20 mg/day (days 45-52). 	cisapride	fluoxetine	none	{'e1': {'word': 'cisapride', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d46.s9.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d46.s9.e1'}, 'sentence_id': 'DDI-MedLine.d46.s9'}	and phase NUMBER days NUMBER - NUMBER cisapride NUMBER mg NUMBER times / day days NUMBER - NUMBER plus fluoxetine NUMBER mg / day days NUMBER - NUMBER
Coadministration of fluoxetine significantly decreased cisapride plasma concentrations. 	fluoxetine	cisapride	mechanism	{'e1': {'word': 'fluoxetine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d46.s13.e0'}, 'e2': {'word': 'cisapride', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d46.s13.e1'}, 'sentence_id': 'DDI-MedLine.d46.s13'}	Coadministration of fluoxetine significantly decreased cisapride plasma concentrations
There were no clinically significant changes in corrected QT intervals during administration of cisapride alone or with fluoxetine. 	cisapride	fluoxetine	none	{'e1': {'word': 'cisapride', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d46.s14.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d46.s14.e1'}, 'sentence_id': 'DDI-MedLine.d46.s14'}	There were no clinically significant changes in corrected QT intervals during administration of cisapride alone or with fluoxetine
Cisapride was well tolerated when administered alone or with fluoxetine. 	Cisapride	fluoxetine	none	{'e1': {'word': 'Cisapride', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d46.s15.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d46.s15.e1'}, 'sentence_id': 'DDI-MedLine.d46.s15'}	Cisapride was well tolerated when administered alone or with fluoxetine
CONCLUSION: Cisapride can be administered safely to patients receiving low therapeutic dosages of fluoxetine.	Cisapride	fluoxetine	none	{'e1': {'word': 'Cisapride', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d46.s16.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d46.s16.e1'}, 'sentence_id': 'DDI-MedLine.d46.s16'}	CONCLUSION Cisapride can be administered safely to patients receiving low therapeutic dosages of fluoxetine
"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
"	DCG-IV	L-CCG-1	none	{'e1': {'word': 'DCG-IV', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d104.s0.e0'}, 'e2': {'word': 'L-CCG-1', 'word_index': [(6, 8)], 'id': 'DDI-MedLine.d104.s0.e1'}, 'sentence_id': 'DDI-MedLine.d104.s0'}	The effects of DCG NUMBER and L CCG NUMBER upon phencyclidine PCP induced locomotion and behavioral changes in mice
"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
"	DCG-IV	phencyclidine	none	{'e1': {'word': 'DCG-IV', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d104.s0.e0'}, 'e2': {'word': 'phencyclidine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d104.s0.e2'}, 'sentence_id': 'DDI-MedLine.d104.s0'}	The effects of DCG NUMBER and L CCG NUMBER upon phencyclidine PCP induced locomotion and behavioral changes in mice
"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
"	DCG-IV	PCP	none	{'e1': {'word': 'DCG-IV', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d104.s0.e0'}, 'e2': {'word': 'PCP', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d104.s0.e3'}, 'sentence_id': 'DDI-MedLine.d104.s0'}	The effects of DCG NUMBER and L CCG NUMBER upon phencyclidine PCP induced locomotion and behavioral changes in mice
"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
"	L-CCG-1	phencyclidine	none	{'e1': {'word': 'L-CCG-1', 'word_index': [(6, 8)], 'id': 'DDI-MedLine.d104.s0.e1'}, 'e2': {'word': 'phencyclidine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d104.s0.e2'}, 'sentence_id': 'DDI-MedLine.d104.s0'}	The effects of DCG NUMBER and L CCG NUMBER upon phencyclidine PCP induced locomotion and behavioral changes in mice
"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
"	L-CCG-1	PCP	none	{'e1': {'word': 'L-CCG-1', 'word_index': [(6, 8)], 'id': 'DDI-MedLine.d104.s0.e1'}, 'e2': {'word': 'PCP', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d104.s0.e3'}, 'sentence_id': 'DDI-MedLine.d104.s0'}	The effects of DCG NUMBER and L CCG NUMBER upon phencyclidine PCP induced locomotion and behavioral changes in mice
"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
"	phencyclidine	PCP	none	{'e1': {'word': 'phencyclidine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d104.s0.e2'}, 'e2': {'word': 'PCP', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d104.s0.e3'}, 'sentence_id': 'DDI-MedLine.d104.s0'}	The effects of DCG NUMBER and L CCG NUMBER upon phencyclidine PCP induced locomotion and behavioral changes in mice
injection of phencyclidine (PCP) were observed by measuring locomotor activity and stereotyped behavior. 	phencyclidine	PCP	none	{'e1': {'word': 'phencyclidine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d104.s2.e0'}, 'e2': {'word': 'PCP', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d104.s2.e1'}, 'sentence_id': 'DDI-MedLine.d104.s2'}	injection of phencyclidine PCP were observed by measuring locomotor activity and stereotyped behavior
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and L-CCG-1, on the above behavioral changes induced by PCP were found. 	DCG-IV	L-CCG-1	none	{'e1': {'word': 'DCG-IV', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d104.s3.e0'}, 'e2': {'word': 'L-CCG-1', 'word_index': [(12, 14)], 'id': 'DDI-MedLine.d104.s3.e1'}, 'sentence_id': 'DDI-MedLine.d104.s3'}	Then the effects of metabotropic glutamate receptor mGluR agonists DCG NUMBER and L CCG NUMBER on the above behavioral changes induced by PCP were found
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and L-CCG-1, on the above behavioral changes induced by PCP were found. 	DCG-IV	PCP	none	{'e1': {'word': 'DCG-IV', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d104.s3.e0'}, 'e2': {'word': 'PCP', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d104.s3.e2'}, 'sentence_id': 'DDI-MedLine.d104.s3'}	Then the effects of metabotropic glutamate receptor mGluR agonists DCG NUMBER and L CCG NUMBER on the above behavioral changes induced by PCP were found
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and L-CCG-1, on the above behavioral changes induced by PCP were found. 	L-CCG-1	PCP	none	{'e1': {'word': 'L-CCG-1', 'word_index': [(12, 14)], 'id': 'DDI-MedLine.d104.s3.e1'}, 'e2': {'word': 'PCP', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d104.s3.e2'}, 'sentence_id': 'DDI-MedLine.d104.s3'}	Then the effects of metabotropic glutamate receptor mGluR agonists DCG NUMBER and L CCG NUMBER on the above behavioral changes induced by PCP were found
The effects of DCG-IV were very strong and completely depressed the PCP-induced hyperlocomotion. 	DCG-IV	PCP	effect	{'e1': {'word': 'DCG-IV', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d104.s4.e0'}, 'e2': {'word': 'PCP', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d104.s4.e1'}, 'sentence_id': 'DDI-MedLine.d104.s4'}	The effects of DCG NUMBER were very strong and completely depressed the PCP induced hyperlocomotion
In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.	PCP	PCP	none	{'e1': {'word': 'PCP', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d104.s8.e0'}, 'e2': {'word': 'PCP', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d104.s8.e1'}, 'sentence_id': 'DDI-MedLine.d104.s8'}	In order to examine some molecular mechanisms of PCP induced behavioral changes Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP DCG NUMBER and L CCG NUMBER was carried out
In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.	PCP	DCG-IV	none	{'e1': {'word': 'PCP', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d104.s8.e0'}, 'e2': {'word': 'DCG-IV', 'word_index': [(27, 28)], 'id': 'DDI-MedLine.d104.s8.e2'}, 'sentence_id': 'DDI-MedLine.d104.s8'}	In order to examine some molecular mechanisms of PCP induced behavioral changes Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP DCG NUMBER and L CCG NUMBER was carried out
In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.	PCP	L-CCG-1	none	{'e1': {'word': 'PCP', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d104.s8.e0'}, 'e2': {'word': 'L-CCG-1', 'word_index': [(30, 32)], 'id': 'DDI-MedLine.d104.s8.e3'}, 'sentence_id': 'DDI-MedLine.d104.s8'}	In order to examine some molecular mechanisms of PCP induced behavioral changes Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP DCG NUMBER and L CCG NUMBER was carried out
In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.	PCP	DCG-IV	none	{'e1': {'word': 'PCP', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d104.s8.e1'}, 'e2': {'word': 'DCG-IV', 'word_index': [(27, 28)], 'id': 'DDI-MedLine.d104.s8.e2'}, 'sentence_id': 'DDI-MedLine.d104.s8'}	In order to examine some molecular mechanisms of PCP induced behavioral changes Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP DCG NUMBER and L CCG NUMBER was carried out
In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.	PCP	L-CCG-1	none	{'e1': {'word': 'PCP', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d104.s8.e1'}, 'e2': {'word': 'L-CCG-1', 'word_index': [(30, 32)], 'id': 'DDI-MedLine.d104.s8.e3'}, 'sentence_id': 'DDI-MedLine.d104.s8'}	In order to examine some molecular mechanisms of PCP induced behavioral changes Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP DCG NUMBER and L CCG NUMBER was carried out
In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.	DCG-IV	L-CCG-1	none	{'e1': {'word': 'DCG-IV', 'word_index': [(27, 28)], 'id': 'DDI-MedLine.d104.s8.e2'}, 'e2': {'word': 'L-CCG-1', 'word_index': [(30, 32)], 'id': 'DDI-MedLine.d104.s8.e3'}, 'sentence_id': 'DDI-MedLine.d104.s8'}	In order to examine some molecular mechanisms of PCP induced behavioral changes Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP DCG NUMBER and L CCG NUMBER was carried out
Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients.	azithromycin	zidovudine	none	{'e1': {'word': 'azithromycin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d105.s0.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d105.s0.e1'}, 'sentence_id': 'DDI-MedLine.d105.s0'}	Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV infected patients
Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients.	azithromycin	dideoxyinosine	none	{'e1': {'word': 'azithromycin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d105.s0.e0'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d105.s0.e2'}, 'sentence_id': 'DDI-MedLine.d105.s0'}	Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV infected patients
Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients.	zidovudine	dideoxyinosine	none	{'e1': {'word': 'zidovudine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d105.s0.e1'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d105.s0.e2'}, 'sentence_id': 'DDI-MedLine.d105.s0'}	Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV infected patients
Two studies were conducted in HIV-infected subjects to assess the potential for azithromycin to interact with zidovudine and dideoxyinosine. 	azithromycin	zidovudine	none	{'e1': {'word': 'azithromycin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d105.s1.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d105.s1.e1'}, 'sentence_id': 'DDI-MedLine.d105.s1'}	NUMBER studies were conducted in HIV infected subjects to assess the potential for azithromycin to interact with zidovudine and dideoxyinosine
Two studies were conducted in HIV-infected subjects to assess the potential for azithromycin to interact with zidovudine and dideoxyinosine. 	azithromycin	dideoxyinosine	none	{'e1': {'word': 'azithromycin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d105.s1.e0'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d105.s1.e2'}, 'sentence_id': 'DDI-MedLine.d105.s1'}	NUMBER studies were conducted in HIV infected subjects to assess the potential for azithromycin to interact with zidovudine and dideoxyinosine
Two studies were conducted in HIV-infected subjects to assess the potential for azithromycin to interact with zidovudine and dideoxyinosine. 	zidovudine	dideoxyinosine	none	{'e1': {'word': 'zidovudine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d105.s1.e1'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d105.s1.e2'}, 'sentence_id': 'DDI-MedLine.d105.s1'}	NUMBER studies were conducted in HIV infected subjects to assess the potential for azithromycin to interact with zidovudine and dideoxyinosine
The zidovudine study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine. 	zidovudine	azithromycin	none	{'e1': {'word': 'zidovudine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d105.s3.e0'}, 'e2': {'word': 'azithromycin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d105.s3.e1'}, 'sentence_id': 'DDI-MedLine.d105.s3'}	The zidovudine study dosed subjects with NUMBER mg / day of azithromycin n = NUMBER later changed to NUMBER mg / day n = NUMBER for Days NUMBER to NUMBER of a NUMBER day course of NUMBER mg NUMBER times / day of zidovudine
The zidovudine study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine. 	zidovudine	zidovudine	none	{'e1': {'word': 'zidovudine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d105.s3.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d105.s3.e2'}, 'sentence_id': 'DDI-MedLine.d105.s3'}	The zidovudine study dosed subjects with NUMBER mg / day of azithromycin n = NUMBER later changed to NUMBER mg / day n = NUMBER for Days NUMBER to NUMBER of a NUMBER day course of NUMBER mg NUMBER times / day of zidovudine
The zidovudine study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine. 	azithromycin	zidovudine	none	{'e1': {'word': 'azithromycin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d105.s3.e1'}, 'e2': {'word': 'zidovudine', 'word_index': [(43, 43)], 'id': 'DDI-MedLine.d105.s3.e2'}, 'sentence_id': 'DDI-MedLine.d105.s3'}	The zidovudine study dosed subjects with NUMBER mg / day of azithromycin n = NUMBER later changed to NUMBER mg / day n = NUMBER for Days NUMBER to NUMBER of a NUMBER day course of NUMBER mg NUMBER times / day of zidovudine
Subjects treated with 200 mg of dideoxyinosine twice daily for 21 days received 1200 mg of azithromycin or an equivalent amount of placebo/day for Days 8 to 21. 	dideoxyinosine	azithromycin	none	{'e1': {'word': 'dideoxyinosine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d105.s4.e0'}, 'e2': {'word': 'azithromycin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d105.s4.e1'}, 'sentence_id': 'DDI-MedLine.d105.s4'}	Subjects treated with NUMBER mg of dideoxyinosine twice daily for NUMBER days received NUMBER mg of azithromycin or an equivalent amount of placebo day for Days NUMBER to NUMBER
Antiretroviral plasma and urine sampling were conducted on Days 1, 7, and 21 for zidovudine and on Days 7 and 21 for dideoxyinosine. 	Antiretroviral	zidovudine	none	{'e1': {'word': 'Antiretroviral', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s5.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d105.s5.e1'}, 'sentence_id': 'DDI-MedLine.d105.s5'}	Antiretroviral plasma and urine sampling were conducted on Days NUMBER NUMBER and NUMBER for zidovudine and on Days NUMBER and NUMBER for dideoxyinosine
Antiretroviral plasma and urine sampling were conducted on Days 1, 7, and 21 for zidovudine and on Days 7 and 21 for dideoxyinosine. 	Antiretroviral	dideoxyinosine	none	{'e1': {'word': 'Antiretroviral', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s5.e0'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d105.s5.e2'}, 'sentence_id': 'DDI-MedLine.d105.s5'}	Antiretroviral plasma and urine sampling were conducted on Days NUMBER NUMBER and NUMBER for zidovudine and on Days NUMBER and NUMBER for dideoxyinosine
Antiretroviral plasma and urine sampling were conducted on Days 1, 7, and 21 for zidovudine and on Days 7 and 21 for dideoxyinosine. 	zidovudine	dideoxyinosine	none	{'e1': {'word': 'zidovudine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d105.s5.e1'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d105.s5.e2'}, 'sentence_id': 'DDI-MedLine.d105.s5'}	Antiretroviral plasma and urine sampling were conducted on Days NUMBER NUMBER and NUMBER for zidovudine and on Days NUMBER and NUMBER for dideoxyinosine
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. 	Azithromycin	zidovudine	none	{'e1': {'word': 'Azithromycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s7.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d105.s7.e1'}, 'sentence_id': 'DDI-MedLine.d105.s7'}	Azithromycin had no significant impact on the Cmax and AUC of zidovudine although it significantly decreased the zidovudine tmax by NUMBER % and increased the intracellular exposure to phosphorylated zidovudine by NUMBER %
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. 	Azithromycin	zidovudine	mechanism	{'e1': {'word': 'Azithromycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s7.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d105.s7.e2'}, 'sentence_id': 'DDI-MedLine.d105.s7'}	Azithromycin had no significant impact on the Cmax and AUC of zidovudine although it significantly decreased the zidovudine tmax by NUMBER % and increased the intracellular exposure to phosphorylated zidovudine by NUMBER %
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. 	Azithromycin	zidovudine	mechanism	{'e1': {'word': 'Azithromycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s7.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d105.s7.e3'}, 'sentence_id': 'DDI-MedLine.d105.s7'}	Azithromycin had no significant impact on the Cmax and AUC of zidovudine although it significantly decreased the zidovudine tmax by NUMBER % and increased the intracellular exposure to phosphorylated zidovudine by NUMBER %
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. 	zidovudine	zidovudine	none	{'e1': {'word': 'zidovudine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d105.s7.e1'}, 'e2': {'word': 'zidovudine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d105.s7.e2'}, 'sentence_id': 'DDI-MedLine.d105.s7'}	Azithromycin had no significant impact on the Cmax and AUC of zidovudine although it significantly decreased the zidovudine tmax by NUMBER % and increased the intracellular exposure to phosphorylated zidovudine by NUMBER %
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. 	zidovudine	zidovudine	none	{'e1': {'word': 'zidovudine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d105.s7.e1'}, 'e2': {'word': 'zidovudine', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d105.s7.e3'}, 'sentence_id': 'DDI-MedLine.d105.s7'}	Azithromycin had no significant impact on the Cmax and AUC of zidovudine although it significantly decreased the zidovudine tmax by NUMBER % and increased the intracellular exposure to phosphorylated zidovudine by NUMBER %
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. 	zidovudine	zidovudine	none	{'e1': {'word': 'zidovudine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d105.s7.e2'}, 'e2': {'word': 'zidovudine', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d105.s7.e3'}, 'sentence_id': 'DDI-MedLine.d105.s7'}	Azithromycin had no significant impact on the Cmax and AUC of zidovudine although it significantly decreased the zidovudine tmax by NUMBER % and increased the intracellular exposure to phosphorylated zidovudine by NUMBER %
Azithromycin had no significant effect on dideoxyinosine pharmacokinetics. 	Azithromycin	dideoxyinosine	none	{'e1': {'word': 'Azithromycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d105.s8.e0'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d105.s8.e1'}, 'sentence_id': 'DDI-MedLine.d105.s8'}	Azithromycin had no significant effect on dideoxyinosine pharmacokinetics
Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both zidovudine and dideoxyinosine.	azithromycin	zidovudine	none	{'e1': {'word': 'azithromycin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d105.s9.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d105.s9.e1'}, 'sentence_id': 'DDI-MedLine.d105.s9'}	Based on the results of these studies it is concluded that azithromycin may be safely coadministered with both zidovudine and dideoxyinosine
Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both zidovudine and dideoxyinosine.	azithromycin	dideoxyinosine	none	{'e1': {'word': 'azithromycin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d105.s9.e0'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d105.s9.e2'}, 'sentence_id': 'DDI-MedLine.d105.s9'}	Based on the results of these studies it is concluded that azithromycin may be safely coadministered with both zidovudine and dideoxyinosine
Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both zidovudine and dideoxyinosine.	zidovudine	dideoxyinosine	none	{'e1': {'word': 'zidovudine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d105.s9.e1'}, 'e2': {'word': 'dideoxyinosine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d105.s9.e2'}, 'sentence_id': 'DDI-MedLine.d105.s9'}	Based on the results of these studies it is concluded that azithromycin may be safely coadministered with both zidovudine and dideoxyinosine
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	Acetaminophen	lidocaine	none	{'e1': {'word': 'Acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e0'}, 'e2': {'word': 'lidocaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d111.s2.e1'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	Acetaminophen lidocaine phenobarbital quinidine theophylline and valproic acid were added to pooled human serum at therapeutic concentrations
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	Acetaminophen	phenobarbital	none	{'e1': {'word': 'Acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s2.e2'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	Acetaminophen lidocaine phenobarbital quinidine theophylline and valproic acid were added to pooled human serum at therapeutic concentrations
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	Acetaminophen	quinidine	none	{'e1': {'word': 'Acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e0'}, 'e2': {'word': 'quinidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s2.e3'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	Acetaminophen lidocaine phenobarbital quinidine theophylline and valproic acid were added to pooled human serum at therapeutic concentrations
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	Acetaminophen	theophylline	none	{'e1': {'word': 'Acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s2.e4'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	Acetaminophen lidocaine phenobarbital quinidine theophylline and valproic acid were added to pooled human serum at therapeutic concentrations
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	Acetaminophen	valproic acid	none	{'e1': {'word': 'Acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s2.e0'}, 'e2': {'word': 'valproic acid', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d111.s2.e5'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	Acetaminophen lidocaine phenobarbital quinidine theophylline and valproic acid were added to pooled human serum at therapeutic concentrations
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	lidocaine	phenobarbital	none	{'e1': {'word': 'lidocaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d111.s2.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s2.e2'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	Acetaminophen lidocaine phenobarbital quinidine theophylline and valproic acid were added to pooled human serum at therapeutic concentrations
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	lidocaine	quinidine	none	{'e1': {'word': 'lidocaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d111.s2.e1'}, 'e2': {'word': 'quinidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s2.e3'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	Acetaminophen lidocaine phenobarbital quinidine theophylline and valproic acid were added to pooled human serum at therapeutic concentrations
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	lidocaine	theophylline	none	{'e1': {'word': 'lidocaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d111.s2.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s2.e4'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	Acetaminophen lidocaine phenobarbital quinidine theophylline and valproic acid were added to pooled human serum at therapeutic concentrations
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	lidocaine	valproic acid	none	{'e1': {'word': 'lidocaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d111.s2.e1'}, 'e2': {'word': 'valproic acid', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d111.s2.e5'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	Acetaminophen lidocaine phenobarbital quinidine theophylline and valproic acid were added to pooled human serum at therapeutic concentrations
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	phenobarbital	quinidine	none	{'e1': {'word': 'phenobarbital', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s2.e2'}, 'e2': {'word': 'quinidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s2.e3'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	Acetaminophen lidocaine phenobarbital quinidine theophylline and valproic acid were added to pooled human serum at therapeutic concentrations
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	phenobarbital	theophylline	none	{'e1': {'word': 'phenobarbital', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s2.e2'}, 'e2': {'word': 'theophylline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s2.e4'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	Acetaminophen lidocaine phenobarbital quinidine theophylline and valproic acid were added to pooled human serum at therapeutic concentrations
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	phenobarbital	valproic acid	none	{'e1': {'word': 'phenobarbital', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s2.e2'}, 'e2': {'word': 'valproic acid', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d111.s2.e5'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	Acetaminophen lidocaine phenobarbital quinidine theophylline and valproic acid were added to pooled human serum at therapeutic concentrations
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	quinidine	theophylline	none	{'e1': {'word': 'quinidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s2.e3'}, 'e2': {'word': 'theophylline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s2.e4'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	Acetaminophen lidocaine phenobarbital quinidine theophylline and valproic acid were added to pooled human serum at therapeutic concentrations
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	quinidine	valproic acid	none	{'e1': {'word': 'quinidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s2.e3'}, 'e2': {'word': 'valproic acid', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d111.s2.e5'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	Acetaminophen lidocaine phenobarbital quinidine theophylline and valproic acid were added to pooled human serum at therapeutic concentrations
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 	theophylline	valproic acid	none	{'e1': {'word': 'theophylline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s2.e4'}, 'e2': {'word': 'valproic acid', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d111.s2.e5'}, 'sentence_id': 'DDI-MedLine.d111.s2'}	Acetaminophen lidocaine phenobarbital quinidine theophylline and valproic acid were added to pooled human serum at therapeutic concentrations
The following eight target drug/added drug combinations were studied: acetaminophen/phenobarbital. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s4.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s4.e1'}, 'sentence_id': 'DDI-MedLine.d111.s4'}	The following NUMBER target drug added drug combinations were studied acetaminophen phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	theophylline	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	lidocaine	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'lidocaine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	quinidine	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'quinidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	acetaminophen	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'acetaminophen', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	valproic acid	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'valproic acid', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	quinidine	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'quinidine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	lidocaine	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'lidocaine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	theophylline	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	acetaminophen	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'acetaminophen', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	valproic acid	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'valproic acid', 'word_index': [(14, 15)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s5.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	lidocaine	none	{'e1': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'lidocaine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	quinidine	none	{'e1': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'quinidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	phenobarbital	none	{'e1': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	acetaminophen	none	{'e1': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'acetaminophen', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	phenobarbital	none	{'e1': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	valproic acid	none	{'e1': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'valproic acid', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	quinidine	none	{'e1': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'quinidine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	lidocaine	none	{'e1': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'lidocaine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	theophylline	none	{'e1': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	acetaminophen	none	{'e1': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'acetaminophen', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	valproic acid	none	{'e1': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'valproic acid', 'word_index': [(14, 15)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	phenobarbital	none	{'e1': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d111.s5.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	quinidine	none	{'e1': {'word': 'lidocaine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'quinidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	phenobarbital	none	{'e1': {'word': 'lidocaine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	acetaminophen	none	{'e1': {'word': 'lidocaine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'acetaminophen', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	phenobarbital	none	{'e1': {'word': 'lidocaine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	valproic acid	none	{'e1': {'word': 'lidocaine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'valproic acid', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	quinidine	none	{'e1': {'word': 'lidocaine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'quinidine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	lidocaine	none	{'e1': {'word': 'lidocaine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'lidocaine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	theophylline	none	{'e1': {'word': 'lidocaine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'theophylline', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	acetaminophen	none	{'e1': {'word': 'lidocaine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'acetaminophen', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	valproic acid	none	{'e1': {'word': 'lidocaine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'valproic acid', 'word_index': [(14, 15)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	phenobarbital	none	{'e1': {'word': 'lidocaine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s5.e2'}, 'e2': {'word': 'phenobarbital', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	phenobarbital	none	{'e1': {'word': 'quinidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	acetaminophen	none	{'e1': {'word': 'quinidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'acetaminophen', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	phenobarbital	none	{'e1': {'word': 'quinidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	valproic acid	none	{'e1': {'word': 'quinidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'valproic acid', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	quinidine	none	{'e1': {'word': 'quinidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'quinidine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	lidocaine	none	{'e1': {'word': 'quinidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'lidocaine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	theophylline	none	{'e1': {'word': 'quinidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'theophylline', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	acetaminophen	none	{'e1': {'word': 'quinidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'acetaminophen', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	valproic acid	none	{'e1': {'word': 'quinidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'valproic acid', 'word_index': [(14, 15)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	phenobarbital	none	{'e1': {'word': 'quinidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s5.e3'}, 'e2': {'word': 'phenobarbital', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	acetaminophen	none	{'e1': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'acetaminophen', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	phenobarbital	none	{'e1': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	valproic acid	none	{'e1': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'valproic acid', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	quinidine	none	{'e1': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'quinidine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	lidocaine	none	{'e1': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'lidocaine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	theophylline	none	{'e1': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'theophylline', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	acetaminophen	none	{'e1': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'acetaminophen', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	valproic acid	none	{'e1': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'valproic acid', 'word_index': [(14, 15)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	phenobarbital	none	{'e1': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s5.e4'}, 'e2': {'word': 'phenobarbital', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	valproic acid	none	{'e1': {'word': 'acetaminophen', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'valproic acid', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	quinidine	none	{'e1': {'word': 'acetaminophen', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'quinidine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	lidocaine	none	{'e1': {'word': 'acetaminophen', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'lidocaine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	theophylline	none	{'e1': {'word': 'acetaminophen', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'theophylline', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	acetaminophen	none	{'e1': {'word': 'acetaminophen', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'acetaminophen', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	valproic acid	none	{'e1': {'word': 'acetaminophen', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'valproic acid', 'word_index': [(14, 15)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s5.e5'}, 'e2': {'word': 'phenobarbital', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	valproic acid	none	{'e1': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'e2': {'word': 'valproic acid', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	quinidine	none	{'e1': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'e2': {'word': 'quinidine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	lidocaine	none	{'e1': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'e2': {'word': 'lidocaine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	theophylline	none	{'e1': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'e2': {'word': 'theophylline', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	acetaminophen	none	{'e1': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'e2': {'word': 'acetaminophen', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	valproic acid	none	{'e1': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'e2': {'word': 'valproic acid', 'word_index': [(14, 15)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	phenobarbital	phenobarbital	none	{'e1': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s5.e6'}, 'e2': {'word': 'phenobarbital', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	valproic acid	quinidine	none	{'e1': {'word': 'valproic acid', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'e2': {'word': 'quinidine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	valproic acid	lidocaine	none	{'e1': {'word': 'valproic acid', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'e2': {'word': 'lidocaine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	valproic acid	theophylline	none	{'e1': {'word': 'valproic acid', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'e2': {'word': 'theophylline', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	valproic acid	acetaminophen	none	{'e1': {'word': 'valproic acid', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'e2': {'word': 'acetaminophen', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	valproic acid	valproic acid	none	{'e1': {'word': 'valproic acid', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'e2': {'word': 'valproic acid', 'word_index': [(14, 15)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	valproic acid	phenobarbital	none	{'e1': {'word': 'valproic acid', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d111.s5.e7'}, 'e2': {'word': 'phenobarbital', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	lidocaine	none	{'e1': {'word': 'quinidine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'e2': {'word': 'lidocaine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	theophylline	none	{'e1': {'word': 'quinidine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'e2': {'word': 'theophylline', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	acetaminophen	none	{'e1': {'word': 'quinidine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'e2': {'word': 'acetaminophen', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	valproic acid	none	{'e1': {'word': 'quinidine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'e2': {'word': 'valproic acid', 'word_index': [(14, 15)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	quinidine	phenobarbital	none	{'e1': {'word': 'quinidine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d111.s5.e8'}, 'e2': {'word': 'phenobarbital', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	theophylline	none	{'e1': {'word': 'lidocaine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'e2': {'word': 'theophylline', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	acetaminophen	none	{'e1': {'word': 'lidocaine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'e2': {'word': 'acetaminophen', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	valproic acid	none	{'e1': {'word': 'lidocaine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'e2': {'word': 'valproic acid', 'word_index': [(14, 15)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	lidocaine	phenobarbital	none	{'e1': {'word': 'lidocaine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d111.s5.e9'}, 'e2': {'word': 'phenobarbital', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	acetaminophen	none	{'e1': {'word': 'theophylline', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'e2': {'word': 'acetaminophen', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	valproic acid	none	{'e1': {'word': 'theophylline', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'e2': {'word': 'valproic acid', 'word_index': [(14, 15)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	theophylline	phenobarbital	none	{'e1': {'word': 'theophylline', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d111.s5.e10'}, 'e2': {'word': 'phenobarbital', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	valproic acid	none	{'e1': {'word': 'acetaminophen', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'e2': {'word': 'valproic acid', 'word_index': [(14, 15)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s5.e11'}, 'e2': {'word': 'phenobarbital', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 	valproic acid	phenobarbital	none	{'e1': {'word': 'valproic acid', 'word_index': [(14, 15)], 'id': 'DDI-MedLine.d111.s5.e12'}, 'e2': {'word': 'phenobarbital', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s5.e13'}, 'sentence_id': 'DDI-MedLine.d111.s5'}	acetaminophen theophylline lidocaine quinidine phenobarbital acetaminophen phenobarbital valproic acid quinidine lidocaine theophylline acetaminophen and valproic acid phenobarbital
Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum. 	phenobarbital	quinidine	none	{'e1': {'word': 'phenobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s7.e0'}, 'e2': {'word': 'quinidine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s7.e1'}, 'sentence_id': 'DDI-MedLine.d111.s7'}	Similarly dialyzed were phenobarbital quinidine and theophylline both alone at therapeutic concentrations in serum and with ethanol at NUMBER different concentrations in serum
Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum. 	phenobarbital	theophylline	none	{'e1': {'word': 'phenobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s7.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s7.e2'}, 'sentence_id': 'DDI-MedLine.d111.s7'}	Similarly dialyzed were phenobarbital quinidine and theophylline both alone at therapeutic concentrations in serum and with ethanol at NUMBER different concentrations in serum
Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum. 	phenobarbital	ethanol	none	{'e1': {'word': 'phenobarbital', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d111.s7.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s7.e3'}, 'sentence_id': 'DDI-MedLine.d111.s7'}	Similarly dialyzed were phenobarbital quinidine and theophylline both alone at therapeutic concentrations in serum and with ethanol at NUMBER different concentrations in serum
Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum. 	quinidine	theophylline	none	{'e1': {'word': 'quinidine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s7.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s7.e2'}, 'sentence_id': 'DDI-MedLine.d111.s7'}	Similarly dialyzed were phenobarbital quinidine and theophylline both alone at therapeutic concentrations in serum and with ethanol at NUMBER different concentrations in serum
Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum. 	quinidine	ethanol	none	{'e1': {'word': 'quinidine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s7.e1'}, 'e2': {'word': 'ethanol', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s7.e3'}, 'sentence_id': 'DDI-MedLine.d111.s7'}	Similarly dialyzed were phenobarbital quinidine and theophylline both alone at therapeutic concentrations in serum and with ethanol at NUMBER different concentrations in serum
Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum. 	theophylline	ethanol	none	{'e1': {'word': 'theophylline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d111.s7.e2'}, 'e2': {'word': 'ethanol', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d111.s7.e3'}, 'sentence_id': 'DDI-MedLine.d111.s7'}	Similarly dialyzed were phenobarbital quinidine and theophylline both alone at therapeutic concentrations in serum and with ethanol at NUMBER different concentrations in serum
Acetaminophen diminished the binding of theophylline to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L. 	Acetaminophen	theophylline	mechanism	{'e1': {'word': 'Acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s9.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s9.e1'}, 'sentence_id': 'DDI-MedLine.d111.s9'}	Acetaminophen diminished the binding of theophylline to human serum by a net change of NUMBER % percentage increase in free drug fraction FDF NUMBER % at NUMBER micromol / L and by a net change of NUMBER % percentage increase in FDF NUMBER % at NUMBER micromol / L.
Theophylline decreased the binding of acetaminophen by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L; 	Theophylline	acetaminophen	mechanism	{'e1': {'word': 'Theophylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d111.s10.e0'}, 'e2': {'word': 'acetaminophen', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s10.e1'}, 'sentence_id': 'DDI-MedLine.d111.s10'}	Theophylline decreased the binding of acetaminophen by a net change of NUMBER % percentage increase in FDF NUMBER % at NUMBER micromol / L
Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. 	Valproic acid	phenobarbital	mechanism	{'e1': {'word': 'Valproic acid', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d111.s12.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s12.e1'}, 'sentence_id': 'DDI-MedLine.d111.s12'}	Valproic acid diminished binding of phenobarbital by a net change of NUMBER % percentage increase in FDF NUMBER % at NUMBER micromol / L.
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	acetaminophen	theophylline	effect	{'e1': {'word': 'acetaminophen', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s14.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s14.e1'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of acetaminophen with theophylline phenobarbital with acetaminophen and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s14.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s14.e2'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of acetaminophen with theophylline phenobarbital with acetaminophen and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	acetaminophen	acetaminophen	none	{'e1': {'word': 'acetaminophen', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s14.e0'}, 'e2': {'word': 'acetaminophen', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d111.s14.e3'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of acetaminophen with theophylline phenobarbital with acetaminophen and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	acetaminophen	valproic acid	none	{'e1': {'word': 'acetaminophen', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s14.e0'}, 'e2': {'word': 'valproic acid', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d111.s14.e4'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of acetaminophen with theophylline phenobarbital with acetaminophen and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d111.s14.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s14.e5'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of acetaminophen with theophylline phenobarbital with acetaminophen and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	theophylline	phenobarbital	none	{'e1': {'word': 'theophylline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s14.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s14.e2'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of acetaminophen with theophylline phenobarbital with acetaminophen and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	theophylline	acetaminophen	none	{'e1': {'word': 'theophylline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s14.e1'}, 'e2': {'word': 'acetaminophen', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d111.s14.e3'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of acetaminophen with theophylline phenobarbital with acetaminophen and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	theophylline	valproic acid	none	{'e1': {'word': 'theophylline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s14.e1'}, 'e2': {'word': 'valproic acid', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d111.s14.e4'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of acetaminophen with theophylline phenobarbital with acetaminophen and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	theophylline	phenobarbital	none	{'e1': {'word': 'theophylline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d111.s14.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s14.e5'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of acetaminophen with theophylline phenobarbital with acetaminophen and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	phenobarbital	acetaminophen	effect	{'e1': {'word': 'phenobarbital', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s14.e2'}, 'e2': {'word': 'acetaminophen', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d111.s14.e3'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of acetaminophen with theophylline phenobarbital with acetaminophen and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	phenobarbital	valproic acid	none	{'e1': {'word': 'phenobarbital', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s14.e2'}, 'e2': {'word': 'valproic acid', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d111.s14.e4'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of acetaminophen with theophylline phenobarbital with acetaminophen and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	phenobarbital	phenobarbital	none	{'e1': {'word': 'phenobarbital', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d111.s14.e2'}, 'e2': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s14.e5'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of acetaminophen with theophylline phenobarbital with acetaminophen and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	acetaminophen	valproic acid	none	{'e1': {'word': 'acetaminophen', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d111.s14.e3'}, 'e2': {'word': 'valproic acid', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d111.s14.e4'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of acetaminophen with theophylline phenobarbital with acetaminophen and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	acetaminophen	phenobarbital	none	{'e1': {'word': 'acetaminophen', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d111.s14.e3'}, 'e2': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s14.e5'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of acetaminophen with theophylline phenobarbital with acetaminophen and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 	valproic acid	phenobarbital	effect	{'e1': {'word': 'valproic acid', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d111.s14.e4'}, 'e2': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d111.s14.e5'}, 'sentence_id': 'DDI-MedLine.d111.s14'}	Coingestion of acetaminophen with theophylline phenobarbital with acetaminophen and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug
"Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.
"	Fluvoxamine	tolbutamide	mechanism	{'e1': {'word': 'Fluvoxamine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d99.s0.e0'}, 'e2': {'word': 'tolbutamide', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d99.s0.e1'}, 'sentence_id': 'DDI-MedLine.d99.s0'}	Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide
OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. 	fluvoxamine	tolbutamide	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d99.s1.e0'}, 'e2': {'word': 'tolbutamide', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d99.s1.e1'}, 'sentence_id': 'DDI-MedLine.d99.s1'}	OBJECTIVE Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9
OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. 	fluvoxamine	fluvoxamine	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d99.s1.e0'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d99.s1.e2'}, 'sentence_id': 'DDI-MedLine.d99.s1'}	OBJECTIVE Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9
OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. 	tolbutamide	fluvoxamine	none	{'e1': {'word': 'tolbutamide', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d99.s1.e1'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d99.s1.e2'}, 'sentence_id': 'DDI-MedLine.d99.s1'}	OBJECTIVE Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9
Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. 	tolbutamide	tolbutamide	none	{'e1': {'word': 'tolbutamide', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d99.s8.e0'}, 'e2': {'word': 'tolbutamide', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d99.s8.e1'}, 'sentence_id': 'DDI-MedLine.d99.s8'}	Plasma was analyzed for tolbutamide and urine was analyzed for tolbutamide and its NUMBER metabolites NUMBER hydroxytolbutamide and carboxytolbutamide by means of HPLC
Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. 	tolbutamide	4-hydroxytolbutamide	none	{'e1': {'word': 'tolbutamide', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d99.s8.e0'}, 'e2': {'word': '4-hydroxytolbutamide', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d99.s8.e2'}, 'sentence_id': 'DDI-MedLine.d99.s8'}	Plasma was analyzed for tolbutamide and urine was analyzed for tolbutamide and its NUMBER metabolites NUMBER hydroxytolbutamide and carboxytolbutamide by means of HPLC
Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. 	tolbutamide	carboxytolbutamide	none	{'e1': {'word': 'tolbutamide', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d99.s8.e0'}, 'e2': {'word': 'carboxytolbutamide', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d99.s8.e3'}, 'sentence_id': 'DDI-MedLine.d99.s8'}	Plasma was analyzed for tolbutamide and urine was analyzed for tolbutamide and its NUMBER metabolites NUMBER hydroxytolbutamide and carboxytolbutamide by means of HPLC
Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. 	tolbutamide	4-hydroxytolbutamide	none	{'e1': {'word': 'tolbutamide', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d99.s8.e1'}, 'e2': {'word': '4-hydroxytolbutamide', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d99.s8.e2'}, 'sentence_id': 'DDI-MedLine.d99.s8'}	Plasma was analyzed for tolbutamide and urine was analyzed for tolbutamide and its NUMBER metabolites NUMBER hydroxytolbutamide and carboxytolbutamide by means of HPLC
Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. 	tolbutamide	carboxytolbutamide	none	{'e1': {'word': 'tolbutamide', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d99.s8.e1'}, 'e2': {'word': 'carboxytolbutamide', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d99.s8.e3'}, 'sentence_id': 'DDI-MedLine.d99.s8'}	Plasma was analyzed for tolbutamide and urine was analyzed for tolbutamide and its NUMBER metabolites NUMBER hydroxytolbutamide and carboxytolbutamide by means of HPLC
Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. 	4-hydroxytolbutamide	carboxytolbutamide	none	{'e1': {'word': '4-hydroxytolbutamide', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d99.s8.e2'}, 'e2': {'word': 'carboxytolbutamide', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d99.s8.e3'}, 'sentence_id': 'DDI-MedLine.d99.s8'}	Plasma was analyzed for tolbutamide and urine was analyzed for tolbutamide and its NUMBER metabolites NUMBER hydroxytolbutamide and carboxytolbutamide by means of HPLC
RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. 	fluvoxamine	tolbutamide	mechanism	{'e1': {'word': 'fluvoxamine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d99.s9.e0'}, 'e2': {'word': 'tolbutamide', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d99.s9.e1'}, 'sentence_id': 'DDI-MedLine.d99.s9'}	RESULTS During treatment with fluvoxamine there was a statistically significant decrease in the median of the total clearance of tolbutamide from NUMBER mL / h to NUMBER mL / h among the volunteers who received NUMBER mg / d
The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). 	4-hydroxytolbutamide	carboxytolbutamide	none	{'e1': {'word': '4-hydroxytolbutamide', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d99.s11.e0'}, 'e2': {'word': 'carboxytolbutamide', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d99.s11.e1'}, 'sentence_id': 'DDI-MedLine.d99.s11'}	The clearance by means of NUMBER hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups ie from NUMBER mL / h to NUMBER mL / h in the group that received NUMBER mg of tolbutamide per day and from NUMBER mL / h to NUMBER mL / h in the group that received NUMBER mg of tolbutamide per day
The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). 	4-hydroxytolbutamide	tolbutamide	none	{'e1': {'word': '4-hydroxytolbutamide', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d99.s11.e0'}, 'e2': {'word': 'tolbutamide', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d99.s11.e2'}, 'sentence_id': 'DDI-MedLine.d99.s11'}	The clearance by means of NUMBER hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups ie from NUMBER mL / h to NUMBER mL / h in the group that received NUMBER mg of tolbutamide per day and from NUMBER mL / h to NUMBER mL / h in the group that received NUMBER mg of tolbutamide per day
The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). 	4-hydroxytolbutamide	tolbutamide	none	{'e1': {'word': '4-hydroxytolbutamide', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d99.s11.e0'}, 'e2': {'word': 'tolbutamide', 'word_index': [(56, 56)], 'id': 'DDI-MedLine.d99.s11.e3'}, 'sentence_id': 'DDI-MedLine.d99.s11'}	The clearance by means of NUMBER hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups ie from NUMBER mL / h to NUMBER mL / h in the group that received NUMBER mg of tolbutamide per day and from NUMBER mL / h to NUMBER mL / h in the group that received NUMBER mg of tolbutamide per day
The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). 	carboxytolbutamide	tolbutamide	none	{'e1': {'word': 'carboxytolbutamide', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d99.s11.e1'}, 'e2': {'word': 'tolbutamide', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d99.s11.e2'}, 'sentence_id': 'DDI-MedLine.d99.s11'}	The clearance by means of NUMBER hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups ie from NUMBER mL / h to NUMBER mL / h in the group that received NUMBER mg of tolbutamide per day and from NUMBER mL / h to NUMBER mL / h in the group that received NUMBER mg of tolbutamide per day
The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). 	carboxytolbutamide	tolbutamide	none	{'e1': {'word': 'carboxytolbutamide', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d99.s11.e1'}, 'e2': {'word': 'tolbutamide', 'word_index': [(56, 56)], 'id': 'DDI-MedLine.d99.s11.e3'}, 'sentence_id': 'DDI-MedLine.d99.s11'}	The clearance by means of NUMBER hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups ie from NUMBER mL / h to NUMBER mL / h in the group that received NUMBER mg of tolbutamide per day and from NUMBER mL / h to NUMBER mL / h in the group that received NUMBER mg of tolbutamide per day
The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). 	tolbutamide	tolbutamide	none	{'e1': {'word': 'tolbutamide', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d99.s11.e2'}, 'e2': {'word': 'tolbutamide', 'word_index': [(56, 56)], 'id': 'DDI-MedLine.d99.s11.e3'}, 'sentence_id': 'DDI-MedLine.d99.s11'}	The clearance by means of NUMBER hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups ie from NUMBER mL / h to NUMBER mL / h in the group that received NUMBER mg of tolbutamide per day and from NUMBER mL / h to NUMBER mL / h in the group that received NUMBER mg of tolbutamide per day
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin	angiotensin 1	none	{'e1': {'word': 'angiotensin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d14.s0.e0'}, 'e2': {'word': 'angiotensin 1', 'word_index': [(27, 28)], 'id': 'DDI-MedLine.d14.s0.e1'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin NUMBER and angiotensin NUMBER on pentagastrin and histamine induced gastric acid secretion
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin	angiotensin 2	none	{'e1': {'word': 'angiotensin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d14.s0.e0'}, 'e2': {'word': 'angiotensin 2', 'word_index': [(30, 31)], 'id': 'DDI-MedLine.d14.s0.e2'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin NUMBER and angiotensin NUMBER on pentagastrin and histamine induced gastric acid secretion
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin	pentagastrin	none	{'e1': {'word': 'angiotensin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d14.s0.e0'}, 'e2': {'word': 'pentagastrin', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d14.s0.e3'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin NUMBER and angiotensin NUMBER on pentagastrin and histamine induced gastric acid secretion
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin	histamine	none	{'e1': {'word': 'angiotensin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d14.s0.e0'}, 'e2': {'word': 'histamine', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d14.s0.e4'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin NUMBER and angiotensin NUMBER on pentagastrin and histamine induced gastric acid secretion
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin 1	angiotensin 2	none	{'e1': {'word': 'angiotensin 1', 'word_index': [(27, 28)], 'id': 'DDI-MedLine.d14.s0.e1'}, 'e2': {'word': 'angiotensin 2', 'word_index': [(30, 31)], 'id': 'DDI-MedLine.d14.s0.e2'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin NUMBER and angiotensin NUMBER on pentagastrin and histamine induced gastric acid secretion
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin 1	pentagastrin	none	{'e1': {'word': 'angiotensin 1', 'word_index': [(27, 28)], 'id': 'DDI-MedLine.d14.s0.e1'}, 'e2': {'word': 'pentagastrin', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d14.s0.e3'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin NUMBER and angiotensin NUMBER on pentagastrin and histamine induced gastric acid secretion
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin 1	histamine	none	{'e1': {'word': 'angiotensin 1', 'word_index': [(27, 28)], 'id': 'DDI-MedLine.d14.s0.e1'}, 'e2': {'word': 'histamine', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d14.s0.e4'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin NUMBER and angiotensin NUMBER on pentagastrin and histamine induced gastric acid secretion
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin 2	pentagastrin	none	{'e1': {'word': 'angiotensin 2', 'word_index': [(30, 31)], 'id': 'DDI-MedLine.d14.s0.e2'}, 'e2': {'word': 'pentagastrin', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d14.s0.e3'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin NUMBER and angiotensin NUMBER on pentagastrin and histamine induced gastric acid secretion
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	angiotensin 2	histamine	none	{'e1': {'word': 'angiotensin 2', 'word_index': [(30, 31)], 'id': 'DDI-MedLine.d14.s0.e2'}, 'e2': {'word': 'histamine', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d14.s0.e4'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin NUMBER and angiotensin NUMBER on pentagastrin and histamine induced gastric acid secretion
[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 	pentagastrin	histamine	none	{'e1': {'word': 'pentagastrin', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d14.s0.e3'}, 'e2': {'word': 'histamine', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d14.s0.e4'}, 'sentence_id': 'DDI-MedLine.d14.s0'}	A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin NUMBER and angiotensin NUMBER on pentagastrin and histamine induced gastric acid secretion
It was established that both angiotensins inhibited gastric acid secretion stimulated by pentagastrin but not by histamine. 	pentagastrin	histamine	none	{'e1': {'word': 'pentagastrin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d14.s1.e0'}, 'e2': {'word': 'histamine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d14.s1.e1'}, 'sentence_id': 'DDI-MedLine.d14.s1'}	It was established that both angiotensins inhibited gastric acid secretion stimulated by pentagastrin but not by histamine
Comparative analysis of the effects of stimulation and inhibition of cholino- and adrenoreceptors on this inhibitory action of angiotensins suggested the mediation of angiotensin influence through the modulation of cholinergic reactions of parietal cells in the stomach.	angiotensins	angiotensin	none	{'e1': {'word': 'angiotensins', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d14.s2.e0'}, 'e2': {'word': 'angiotensin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d14.s2.e1'}, 'sentence_id': 'DDI-MedLine.d14.s2'}	Comparative analysis of the effects of stimulation and inhibition of cholino and adrenoreceptors on this inhibitory action of angiotensins suggested the mediation of angiotensin influence through the modulation of cholinergic reactions of parietal cells in the stomach
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	ginsenosides	selective Ca(2+) channel blockers	none	{'e1': {'word': 'ginsenosides', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d58.s3.e0'}, 'e2': {'word': 'selective Ca(2+) channel blockers', 'word_index': [(21, 26)], 'id': 'DDI-MedLine.d58.s3.e1'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	In this study we investigated the effect of ginsenosides on high threshold voltage dependent Ca NUMBER + channel subtypes using their selective Ca NUMBER + channel blockers nimodipine L type omega conotoxin GVIA N type or omega agatoxin IVA P type in bovine chromaffin cells
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	ginsenosides	nimodipine	none	{'e1': {'word': 'ginsenosides', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d58.s3.e0'}, 'e2': {'word': 'nimodipine', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d58.s3.e2'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	In this study we investigated the effect of ginsenosides on high threshold voltage dependent Ca NUMBER + channel subtypes using their selective Ca NUMBER + channel blockers nimodipine L type omega conotoxin GVIA N type or omega agatoxin IVA P type in bovine chromaffin cells
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	ginsenosides	omega-conotoxin GVIA	none	{'e1': {'word': 'ginsenosides', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d58.s3.e0'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(30, 32)], 'id': 'DDI-MedLine.d58.s3.e3'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	In this study we investigated the effect of ginsenosides on high threshold voltage dependent Ca NUMBER + channel subtypes using their selective Ca NUMBER + channel blockers nimodipine L type omega conotoxin GVIA N type or omega agatoxin IVA P type in bovine chromaffin cells
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	ginsenosides	omega-agatoxin IVA	none	{'e1': {'word': 'ginsenosides', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d58.s3.e0'}, 'e2': {'word': 'omega-agatoxin IVA', 'word_index': [(36, 38)], 'id': 'DDI-MedLine.d58.s3.e4'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	In this study we investigated the effect of ginsenosides on high threshold voltage dependent Ca NUMBER + channel subtypes using their selective Ca NUMBER + channel blockers nimodipine L type omega conotoxin GVIA N type or omega agatoxin IVA P type in bovine chromaffin cells
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	selective Ca(2+) channel blockers	nimodipine	none	{'e1': {'word': 'selective Ca(2+) channel blockers', 'word_index': [(21, 26)], 'id': 'DDI-MedLine.d58.s3.e1'}, 'e2': {'word': 'nimodipine', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d58.s3.e2'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	In this study we investigated the effect of ginsenosides on high threshold voltage dependent Ca NUMBER + channel subtypes using their selective Ca NUMBER + channel blockers nimodipine L type omega conotoxin GVIA N type or omega agatoxin IVA P type in bovine chromaffin cells
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	selective Ca(2+) channel blockers	omega-conotoxin GVIA	none	{'e1': {'word': 'selective Ca(2+) channel blockers', 'word_index': [(21, 26)], 'id': 'DDI-MedLine.d58.s3.e1'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(30, 32)], 'id': 'DDI-MedLine.d58.s3.e3'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	In this study we investigated the effect of ginsenosides on high threshold voltage dependent Ca NUMBER + channel subtypes using their selective Ca NUMBER + channel blockers nimodipine L type omega conotoxin GVIA N type or omega agatoxin IVA P type in bovine chromaffin cells
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	selective Ca(2+) channel blockers	omega-agatoxin IVA	none	{'e1': {'word': 'selective Ca(2+) channel blockers', 'word_index': [(21, 26)], 'id': 'DDI-MedLine.d58.s3.e1'}, 'e2': {'word': 'omega-agatoxin IVA', 'word_index': [(36, 38)], 'id': 'DDI-MedLine.d58.s3.e4'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	In this study we investigated the effect of ginsenosides on high threshold voltage dependent Ca NUMBER + channel subtypes using their selective Ca NUMBER + channel blockers nimodipine L type omega conotoxin GVIA N type or omega agatoxin IVA P type in bovine chromaffin cells
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	nimodipine	omega-conotoxin GVIA	none	{'e1': {'word': 'nimodipine', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d58.s3.e2'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(30, 32)], 'id': 'DDI-MedLine.d58.s3.e3'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	In this study we investigated the effect of ginsenosides on high threshold voltage dependent Ca NUMBER + channel subtypes using their selective Ca NUMBER + channel blockers nimodipine L type omega conotoxin GVIA N type or omega agatoxin IVA P type in bovine chromaffin cells
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	nimodipine	omega-agatoxin IVA	none	{'e1': {'word': 'nimodipine', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d58.s3.e2'}, 'e2': {'word': 'omega-agatoxin IVA', 'word_index': [(36, 38)], 'id': 'DDI-MedLine.d58.s3.e4'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	In this study we investigated the effect of ginsenosides on high threshold voltage dependent Ca NUMBER + channel subtypes using their selective Ca NUMBER + channel blockers nimodipine L type omega conotoxin GVIA N type or omega agatoxin IVA P type in bovine chromaffin cells
In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 	omega-conotoxin GVIA	omega-agatoxin IVA	none	{'e1': {'word': 'omega-conotoxin GVIA', 'word_index': [(30, 32)], 'id': 'DDI-MedLine.d58.s3.e3'}, 'e2': {'word': 'omega-agatoxin IVA', 'word_index': [(36, 38)], 'id': 'DDI-MedLine.d58.s3.e4'}, 'sentence_id': 'DDI-MedLine.d58.s3'}	In this study we investigated the effect of ginsenosides on high threshold voltage dependent Ca NUMBER + channel subtypes using their selective Ca NUMBER + channel blockers nimodipine L type omega conotoxin GVIA N type or omega agatoxin IVA P type in bovine chromaffin cells
Nimodipine had no effect on ginsenosides response. 	Nimodipine	ginsenosides	none	{'e1': {'word': 'Nimodipine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d58.s6.e0'}, 'e2': {'word': 'ginsenosides', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d58.s6.e1'}, 'sentence_id': 'DDI-MedLine.d58.s6'}	Nimodipine had no effect on ginsenosides response
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	ginsenosides	omega-conotoxin GVIA	none	{'e1': {'word': 'ginsenosides', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d58.s7.e0'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(20, 22)], 'id': 'DDI-MedLine.d58.s7.e1'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that ginsenosides are negatively coupled to NUMBER types of calcium channels in bovine chromaffin cell including an omega conotoxin GVIA sensitive N type channel an omega agatoxin IVA sensitive P type channel and nimodipine omega conotoxin GVIA omega agatoxin VIA resistant presumptive Q type channel
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	ginsenosides	omega-agatoxin IVA	none	{'e1': {'word': 'ginsenosides', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d58.s7.e0'}, 'e2': {'word': 'omega-agatoxin IVA', 'word_index': [(28, 30)], 'id': 'DDI-MedLine.d58.s7.e2'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that ginsenosides are negatively coupled to NUMBER types of calcium channels in bovine chromaffin cell including an omega conotoxin GVIA sensitive N type channel an omega agatoxin IVA sensitive P type channel and nimodipine omega conotoxin GVIA omega agatoxin VIA resistant presumptive Q type channel
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	ginsenosides	nimodipine	none	{'e1': {'word': 'ginsenosides', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d58.s7.e0'}, 'e2': {'word': 'nimodipine', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d58.s7.e3'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that ginsenosides are negatively coupled to NUMBER types of calcium channels in bovine chromaffin cell including an omega conotoxin GVIA sensitive N type channel an omega agatoxin IVA sensitive P type channel and nimodipine omega conotoxin GVIA omega agatoxin VIA resistant presumptive Q type channel
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	ginsenosides	omega-conotoxin GVIA	none	{'e1': {'word': 'ginsenosides', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d58.s7.e0'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(37, 39)], 'id': 'DDI-MedLine.d58.s7.e4'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that ginsenosides are negatively coupled to NUMBER types of calcium channels in bovine chromaffin cell including an omega conotoxin GVIA sensitive N type channel an omega agatoxin IVA sensitive P type channel and nimodipine omega conotoxin GVIA omega agatoxin VIA resistant presumptive Q type channel
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	ginsenosides	omega-agatoxin VIA	none	{'e1': {'word': 'ginsenosides', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d58.s7.e0'}, 'e2': {'word': 'omega-agatoxin VIA', 'word_index': [(40, 42)], 'id': 'DDI-MedLine.d58.s7.e5'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that ginsenosides are negatively coupled to NUMBER types of calcium channels in bovine chromaffin cell including an omega conotoxin GVIA sensitive N type channel an omega agatoxin IVA sensitive P type channel and nimodipine omega conotoxin GVIA omega agatoxin VIA resistant presumptive Q type channel
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-conotoxin GVIA	omega-agatoxin IVA	none	{'e1': {'word': 'omega-conotoxin GVIA', 'word_index': [(20, 22)], 'id': 'DDI-MedLine.d58.s7.e1'}, 'e2': {'word': 'omega-agatoxin IVA', 'word_index': [(28, 30)], 'id': 'DDI-MedLine.d58.s7.e2'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that ginsenosides are negatively coupled to NUMBER types of calcium channels in bovine chromaffin cell including an omega conotoxin GVIA sensitive N type channel an omega agatoxin IVA sensitive P type channel and nimodipine omega conotoxin GVIA omega agatoxin VIA resistant presumptive Q type channel
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-conotoxin GVIA	nimodipine	none	{'e1': {'word': 'omega-conotoxin GVIA', 'word_index': [(20, 22)], 'id': 'DDI-MedLine.d58.s7.e1'}, 'e2': {'word': 'nimodipine', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d58.s7.e3'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that ginsenosides are negatively coupled to NUMBER types of calcium channels in bovine chromaffin cell including an omega conotoxin GVIA sensitive N type channel an omega agatoxin IVA sensitive P type channel and nimodipine omega conotoxin GVIA omega agatoxin VIA resistant presumptive Q type channel
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-conotoxin GVIA	omega-conotoxin GVIA	none	{'e1': {'word': 'omega-conotoxin GVIA', 'word_index': [(20, 22)], 'id': 'DDI-MedLine.d58.s7.e1'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(37, 39)], 'id': 'DDI-MedLine.d58.s7.e4'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that ginsenosides are negatively coupled to NUMBER types of calcium channels in bovine chromaffin cell including an omega conotoxin GVIA sensitive N type channel an omega agatoxin IVA sensitive P type channel and nimodipine omega conotoxin GVIA omega agatoxin VIA resistant presumptive Q type channel
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-conotoxin GVIA	omega-agatoxin VIA	none	{'e1': {'word': 'omega-conotoxin GVIA', 'word_index': [(20, 22)], 'id': 'DDI-MedLine.d58.s7.e1'}, 'e2': {'word': 'omega-agatoxin VIA', 'word_index': [(40, 42)], 'id': 'DDI-MedLine.d58.s7.e5'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that ginsenosides are negatively coupled to NUMBER types of calcium channels in bovine chromaffin cell including an omega conotoxin GVIA sensitive N type channel an omega agatoxin IVA sensitive P type channel and nimodipine omega conotoxin GVIA omega agatoxin VIA resistant presumptive Q type channel
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-agatoxin IVA	nimodipine	none	{'e1': {'word': 'omega-agatoxin IVA', 'word_index': [(28, 30)], 'id': 'DDI-MedLine.d58.s7.e2'}, 'e2': {'word': 'nimodipine', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d58.s7.e3'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that ginsenosides are negatively coupled to NUMBER types of calcium channels in bovine chromaffin cell including an omega conotoxin GVIA sensitive N type channel an omega agatoxin IVA sensitive P type channel and nimodipine omega conotoxin GVIA omega agatoxin VIA resistant presumptive Q type channel
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-agatoxin IVA	omega-conotoxin GVIA	none	{'e1': {'word': 'omega-agatoxin IVA', 'word_index': [(28, 30)], 'id': 'DDI-MedLine.d58.s7.e2'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(37, 39)], 'id': 'DDI-MedLine.d58.s7.e4'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that ginsenosides are negatively coupled to NUMBER types of calcium channels in bovine chromaffin cell including an omega conotoxin GVIA sensitive N type channel an omega agatoxin IVA sensitive P type channel and nimodipine omega conotoxin GVIA omega agatoxin VIA resistant presumptive Q type channel
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-agatoxin IVA	omega-agatoxin VIA	none	{'e1': {'word': 'omega-agatoxin IVA', 'word_index': [(28, 30)], 'id': 'DDI-MedLine.d58.s7.e2'}, 'e2': {'word': 'omega-agatoxin VIA', 'word_index': [(40, 42)], 'id': 'DDI-MedLine.d58.s7.e5'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that ginsenosides are negatively coupled to NUMBER types of calcium channels in bovine chromaffin cell including an omega conotoxin GVIA sensitive N type channel an omega agatoxin IVA sensitive P type channel and nimodipine omega conotoxin GVIA omega agatoxin VIA resistant presumptive Q type channel
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	nimodipine	omega-conotoxin GVIA	none	{'e1': {'word': 'nimodipine', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d58.s7.e3'}, 'e2': {'word': 'omega-conotoxin GVIA', 'word_index': [(37, 39)], 'id': 'DDI-MedLine.d58.s7.e4'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that ginsenosides are negatively coupled to NUMBER types of calcium channels in bovine chromaffin cell including an omega conotoxin GVIA sensitive N type channel an omega agatoxin IVA sensitive P type channel and nimodipine omega conotoxin GVIA omega agatoxin VIA resistant presumptive Q type channel
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	nimodipine	omega-agatoxin VIA	none	{'e1': {'word': 'nimodipine', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d58.s7.e3'}, 'e2': {'word': 'omega-agatoxin VIA', 'word_index': [(40, 42)], 'id': 'DDI-MedLine.d58.s7.e5'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that ginsenosides are negatively coupled to NUMBER types of calcium channels in bovine chromaffin cell including an omega conotoxin GVIA sensitive N type channel an omega agatoxin IVA sensitive P type channel and nimodipine omega conotoxin GVIA omega agatoxin VIA resistant presumptive Q type channel
These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 	omega-conotoxin GVIA	omega-agatoxin VIA	none	{'e1': {'word': 'omega-conotoxin GVIA', 'word_index': [(37, 39)], 'id': 'DDI-MedLine.d58.s7.e4'}, 'e2': {'word': 'omega-agatoxin VIA', 'word_index': [(40, 42)], 'id': 'DDI-MedLine.d58.s7.e5'}, 'sentence_id': 'DDI-MedLine.d58.s7'}	These data suggest that ginsenosides are negatively coupled to NUMBER types of calcium channels in bovine chromaffin cell including an omega conotoxin GVIA sensitive N type channel an omega agatoxin IVA sensitive P type channel and nimodipine omega conotoxin GVIA omega agatoxin VIA resistant presumptive Q type channel
Thus, the selective regulation of voltage-dependent Ca(2+) subtypes by ginsenosides in bovine chromaffin cell could be the cellular basis of antistress effects induced by ginseng.	ginsenosides	ginseng	none	{'e1': {'word': 'ginsenosides', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d58.s8.e0'}, 'e2': {'word': 'ginseng', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d58.s8.e1'}, 'sentence_id': 'DDI-MedLine.d58.s8'}	Thus the selective regulation of voltage dependent Ca NUMBER + subtypes by ginsenosides in bovine chromaffin cell could be the cellular basis of antistress effects induced by ginseng
Acid-catalyzed ethanolysis of temazepam in anhydrous and aqueous ethanol solutions.	temazepam	ethanol	mechanism	{'e1': {'word': 'temazepam', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d113.s0.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d113.s0.e1'}, 'sentence_id': 'DDI-MedLine.d113.s0'}	Acid catalyzed ethanolysis of temazepam in anhydrous and aqueous ethanol solutions
The benzodiazepines are a family of anxiolytic and hypnotic drugs. 	benzodiazepines	anxiolytic	none	{'e1': {'word': 'benzodiazepines', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d113.s1.e0'}, 'e2': {'word': 'anxiolytic', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d113.s1.e1'}, 'sentence_id': 'DDI-MedLine.d113.s1'}	The benzodiazepines are a family of anxiolytic and hypnotic drugs
The benzodiazepines are a family of anxiolytic and hypnotic drugs. 	benzodiazepines	hypnotic drugs	none	{'e1': {'word': 'benzodiazepines', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d113.s1.e0'}, 'e2': {'word': 'hypnotic drugs', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d113.s1.e2'}, 'sentence_id': 'DDI-MedLine.d113.s1'}	The benzodiazepines are a family of anxiolytic and hypnotic drugs
The benzodiazepines are a family of anxiolytic and hypnotic drugs. 	anxiolytic	hypnotic drugs	none	{'e1': {'word': 'anxiolytic', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d113.s1.e1'}, 'e2': {'word': 'hypnotic drugs', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d113.s1.e2'}, 'sentence_id': 'DDI-MedLine.d113.s1'}	The benzodiazepines are a family of anxiolytic and hypnotic drugs
In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product. 	temazepam	benzodiazepine	none	{'e1': {'word': 'temazepam', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d113.s3.e0'}, 'e2': {'word': 'benzodiazepine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d113.s3.e1'}, 'sentence_id': 'DDI-MedLine.d113.s3'}	In addition to this pharmacological interaction this report describes a novel chemical reaction between temazepam a benzodiazepine and ethanol under acidic conditions similar to those found in vivo resulting in a NUMBER ethoxylated product
In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product. 	temazepam	ethanol	mechanism	{'e1': {'word': 'temazepam', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d113.s3.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d113.s3.e2'}, 'sentence_id': 'DDI-MedLine.d113.s3'}	In addition to this pharmacological interaction this report describes a novel chemical reaction between temazepam a benzodiazepine and ethanol under acidic conditions similar to those found in vivo resulting in a NUMBER ethoxylated product
In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product. 	benzodiazepine	ethanol	none	{'e1': {'word': 'benzodiazepine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d113.s3.e1'}, 'e2': {'word': 'ethanol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d113.s3.e2'}, 'sentence_id': 'DDI-MedLine.d113.s3'}	In addition to this pharmacological interaction this report describes a novel chemical reaction between temazepam a benzodiazepine and ethanol under acidic conditions similar to those found in vivo resulting in a NUMBER ethoxylated product
The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume alcohol and 3-hydroxy-1,4-benzodiazepine on a regular basis. 	alcohol	3-hydroxy-1,4-benzodiazepine	mechanism	{'e1': {'word': 'alcohol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d113.s5.e0'}, 'e2': {'word': '3-hydroxy-1,4-benzodiazepine', 'word_index': [(20, 24)], 'id': 'DDI-MedLine.d113.s5.e1'}, 'sentence_id': 'DDI-MedLine.d113.s5'}	The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume alcohol and NUMBER hydroxy NUMBER NUMBER benzodiazepine on a regular basis
[The effect of sandimmune on the activity of mixed-function mono-oxidases in the liver microsomes] The effects of the immunodepressant--the drug sandimmune--on hepatic microsomal monooxygenase activities were studied. 	sandimmune	immunodepressant	none	{'e1': {'word': 'sandimmune', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d4.s0.e0'}, 'e2': {'word': 'immunodepressant', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d4.s0.e1'}, 'sentence_id': 'DDI-MedLine.d4.s0'}	The effect of sandimmune on the activity of mixed function mono-oxidases in the liver microsomes The effects of the immunodepressant the drug sandimmune on hepatic microsomal monooxygenase activities were studied
[The effect of sandimmune on the activity of mixed-function mono-oxidases in the liver microsomes] The effects of the immunodepressant--the drug sandimmune--on hepatic microsomal monooxygenase activities were studied. 	sandimmune	sandimmune	none	{'e1': {'word': 'sandimmune', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d4.s0.e0'}, 'e2': {'word': 'sandimmune', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d4.s0.e2'}, 'sentence_id': 'DDI-MedLine.d4.s0'}	The effect of sandimmune on the activity of mixed function mono-oxidases in the liver microsomes The effects of the immunodepressant the drug sandimmune on hepatic microsomal monooxygenase activities were studied
[The effect of sandimmune on the activity of mixed-function mono-oxidases in the liver microsomes] The effects of the immunodepressant--the drug sandimmune--on hepatic microsomal monooxygenase activities were studied. 	immunodepressant	sandimmune	none	{'e1': {'word': 'immunodepressant', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d4.s0.e1'}, 'e2': {'word': 'sandimmune', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d4.s0.e2'}, 'sentence_id': 'DDI-MedLine.d4.s0'}	The effect of sandimmune on the activity of mixed function mono-oxidases in the liver microsomes The effects of the immunodepressant the drug sandimmune on hepatic microsomal monooxygenase activities were studied
"In vitro interaction of prostaglandin F2alpha and oxytocin in placental vessels.
"	prostaglandin F2alpha	oxytocin	int	{'e1': {'word': 'prostaglandin F2alpha', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d17.s0.e0'}, 'e2': {'word': 'oxytocin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d17.s0.e1'}, 'sentence_id': 'DDI-MedLine.d17.s0'}	In vitro interaction of prostaglandin F2alpha and oxytocin in placental vessels
The interaction of prostaglandin F2alpha and synthetic oxytocin on placental vessels was studied in vitro. 	prostaglandin F2alpha	oxytocin	none	{'e1': {'word': 'prostaglandin F2alpha', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d17.s1.e0'}, 'e2': {'word': 'oxytocin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d17.s1.e1'}, 'sentence_id': 'DDI-MedLine.d17.s1'}	The interaction of prostaglandin F2alpha and synthetic oxytocin on placental vessels was studied in vitro
In seven experiments reactions to norepinephrine and oxytocin were PGF2alpha. 	norepinephrine	oxytocin	none	{'e1': {'word': 'norepinephrine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d17.s3.e0'}, 'e2': {'word': 'oxytocin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d17.s3.e1'}, 'sentence_id': 'DDI-MedLine.d17.s3'}	In NUMBER experiments reactions to norepinephrine and oxytocin were PGF2alpha
In seven experiments reactions to norepinephrine and oxytocin were PGF2alpha. 	norepinephrine	PGF2alpha	none	{'e1': {'word': 'norepinephrine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d17.s3.e0'}, 'e2': {'word': 'PGF2alpha', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d17.s3.e2'}, 'sentence_id': 'DDI-MedLine.d17.s3'}	In NUMBER experiments reactions to norepinephrine and oxytocin were PGF2alpha
In seven experiments reactions to norepinephrine and oxytocin were PGF2alpha. 	oxytocin	PGF2alpha	none	{'e1': {'word': 'oxytocin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d17.s3.e1'}, 'e2': {'word': 'PGF2alpha', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d17.s3.e2'}, 'sentence_id': 'DDI-MedLine.d17.s3'}	In NUMBER experiments reactions to norepinephrine and oxytocin were PGF2alpha
PGF2alpha produced significantly increased vasoconstriction after a single administration of oxytocin. 	PGF2alpha	oxytocin	effect	{'e1': {'word': 'PGF2alpha', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d17.s4.e0'}, 'e2': {'word': 'oxytocin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d17.s4.e1'}, 'sentence_id': 'DDI-MedLine.d17.s4'}	PGF2alpha produced significantly increased vasoconstriction after a single administration of oxytocin
There is thus an enhancement effect of PGF2alpha upon the reaction of placental vessels to oxytocin in vitro.	PGF2alpha	oxytocin	effect	{'e1': {'word': 'PGF2alpha', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d17.s9.e0'}, 'e2': {'word': 'oxytocin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d17.s9.e1'}, 'sentence_id': 'DDI-MedLine.d17.s9'}	There is thus an enhancement effect of PGF2alpha upon the reaction of placental vessels to oxytocin in vitro
"Interaction of ketamine and halothane in rats.
"	ketamine	halothane	int	{'e1': {'word': 'ketamine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d16.s0.e0'}, 'e2': {'word': 'halothane', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d16.s0.e1'}, 'sentence_id': 'DDI-MedLine.d16.s0'}	Interaction of ketamine and halothane in rats
The interaction of intramuscularly injected ketamine and its N-demethylated metabolite (metabolite I) with halothane was evaluated in rats. 	ketamine	halothane	none	{'e1': {'word': 'ketamine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d16.s1.e0'}, 'e2': {'word': 'halothane', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d16.s1.e1'}, 'sentence_id': 'DDI-MedLine.d16.s1'}	The interaction of intramuscularly injected ketamine and its N demethylated metabolite metabolite NUMBER with halothane was evaluated in rats
However, halothane anesthetic requirement (i.e., MAC) was depressed in a dose-dependent fashion as much as 56% 1-2 hours and as much as 14% 5-6 hours after injection of ketamine, 50 mg/kg, im. 	halothane	ketamine	mechanism	{'e1': {'word': 'halothane', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d16.s3.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d16.s3.e1'}, 'sentence_id': 'DDI-MedLine.d16.s3'}	However halothane anesthetic requirement i.e. MAC was depressed in a dose dependent fashion as much as NUMBER % NUMBER - NUMBER hours and as much as NUMBER % NUMBER - NUMBER hours after injection of ketamine NUMBER mg / kg im
The reduction in MAC was correlated with brain levels of ketamine or metabolite I, suggesting a ketamine:metabolite I potency ration of 3:1. 	ketamine	ketamine	none	{'e1': {'word': 'ketamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d16.s4.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d16.s4.e1'}, 'sentence_id': 'DDI-MedLine.d16.s4'}	The reduction in MAC was correlated with brain levels of ketamine or metabolite NUMBER suggesting a ketamine metabolite NUMBER potency ration of NUMBER : NUMBER
The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone. 	ketamine	halothane	mechanism	{'e1': {'word': 'ketamine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d16.s5.e0'}, 'e2': {'word': 'halothane', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d16.s5.e1'}, 'sentence_id': 'DDI-MedLine.d16.s5'}	The half life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone
The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone. 	ketamine	ketamine	none	{'e1': {'word': 'ketamine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d16.s5.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d16.s5.e2'}, 'sentence_id': 'DDI-MedLine.d16.s5'}	The half life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone
The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone. 	halothane	ketamine	none	{'e1': {'word': 'halothane', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d16.s5.e1'}, 'e2': {'word': 'ketamine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d16.s5.e2'}, 'sentence_id': 'DDI-MedLine.d16.s5'}	The half life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone
It is concluded that ketamine is not a short-acting drug and that concomitant use with halothane would be expected to prolong further the duration of its action on the central nervous system.	ketamine	halothane	effect	{'e1': {'word': 'ketamine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d16.s6.e0'}, 'e2': {'word': 'halothane', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d16.s6.e1'}, 'sentence_id': 'DDI-MedLine.d16.s6'}	It is concluded that ketamine is not a short acting drug and that concomitant use with halothane would be expected to prolong further the duration of its action on the central nervous system
The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 	N-allylnormetazocine	NANM	none	{'e1': {'word': 'N-allylnormetazocine', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d30.s1.e0'}, 'e2': {'word': 'NANM', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d30.s1.e1'}, 'sentence_id': 'DDI-MedLine.d30.s1'}	The behavioral effects of the stereoisomers of N allylnormetazocine NANM were compared with those of phencyclidine PCP in pigeons and squirrel monkeys responding under a multiple fixed interval fixed ratio FI FR schedule of food presentation
The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 	N-allylnormetazocine	phencyclidine	none	{'e1': {'word': 'N-allylnormetazocine', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d30.s1.e0'}, 'e2': {'word': 'phencyclidine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d30.s1.e2'}, 'sentence_id': 'DDI-MedLine.d30.s1'}	The behavioral effects of the stereoisomers of N allylnormetazocine NANM were compared with those of phencyclidine PCP in pigeons and squirrel monkeys responding under a multiple fixed interval fixed ratio FI FR schedule of food presentation
The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 	N-allylnormetazocine	PCP	none	{'e1': {'word': 'N-allylnormetazocine', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d30.s1.e0'}, 'e2': {'word': 'PCP', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d30.s1.e3'}, 'sentence_id': 'DDI-MedLine.d30.s1'}	The behavioral effects of the stereoisomers of N allylnormetazocine NANM were compared with those of phencyclidine PCP in pigeons and squirrel monkeys responding under a multiple fixed interval fixed ratio FI FR schedule of food presentation
The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 	NANM	phencyclidine	none	{'e1': {'word': 'NANM', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d30.s1.e1'}, 'e2': {'word': 'phencyclidine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d30.s1.e2'}, 'sentence_id': 'DDI-MedLine.d30.s1'}	The behavioral effects of the stereoisomers of N allylnormetazocine NANM were compared with those of phencyclidine PCP in pigeons and squirrel monkeys responding under a multiple fixed interval fixed ratio FI FR schedule of food presentation
The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 	NANM	PCP	none	{'e1': {'word': 'NANM', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d30.s1.e1'}, 'e2': {'word': 'PCP', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d30.s1.e3'}, 'sentence_id': 'DDI-MedLine.d30.s1'}	The behavioral effects of the stereoisomers of N allylnormetazocine NANM were compared with those of phencyclidine PCP in pigeons and squirrel monkeys responding under a multiple fixed interval fixed ratio FI FR schedule of food presentation
The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 	phencyclidine	PCP	none	{'e1': {'word': 'phencyclidine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d30.s1.e2'}, 'e2': {'word': 'PCP', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d30.s1.e3'}, 'sentence_id': 'DDI-MedLine.d30.s1'}	The behavioral effects of the stereoisomers of N allylnormetazocine NANM were compared with those of phencyclidine PCP in pigeons and squirrel monkeys responding under a multiple fixed interval fixed ratio FI FR schedule of food presentation
Intermediate doses of (+)-NANM or PCP produced transient increases in FI responding in monkeys and sustained increases in FI responding in pigeons; 	(+)-NANM	PCP	none	{'e1': {'word': '(+)-NANM', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d30.s2.e0'}, 'e2': {'word': 'PCP', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d30.s2.e1'}, 'sentence_id': 'DDI-MedLine.d30.s2'}	Intermediate doses of + NANM or PCP produced transient increases in FI responding in monkeys and sustained increases in FI responding in pigeons
In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM. 	(-)-NANM	(+)-NANM	none	{'e1': {'word': '(-)-NANM', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d30.s6.e0'}, 'e2': {'word': '(+)-NANM', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d30.s6.e1'}, 'sentence_id': 'DDI-MedLine.d30.s6'}	In monkeys - NANM was about NUMBER times more potent than + NANM in decreasing responding whereas in pigeons - NANM was about equipotent with + NANM
In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM. 	(-)-NANM	(-)-NANM	none	{'e1': {'word': '(-)-NANM', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d30.s6.e0'}, 'e2': {'word': '(-)-NANM', 'word_index': [(19, 20)], 'id': 'DDI-MedLine.d30.s6.e2'}, 'sentence_id': 'DDI-MedLine.d30.s6'}	In monkeys - NANM was about NUMBER times more potent than + NANM in decreasing responding whereas in pigeons - NANM was about equipotent with + NANM
In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM. 	(-)-NANM	(+)-NANM	none	{'e1': {'word': '(-)-NANM', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d30.s6.e0'}, 'e2': {'word': '(+)-NANM', 'word_index': [(25, 26)], 'id': 'DDI-MedLine.d30.s6.e3'}, 'sentence_id': 'DDI-MedLine.d30.s6'}	In monkeys - NANM was about NUMBER times more potent than + NANM in decreasing responding whereas in pigeons - NANM was about equipotent with + NANM
In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM. 	(+)-NANM	(-)-NANM	none	{'e1': {'word': '(+)-NANM', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d30.s6.e1'}, 'e2': {'word': '(-)-NANM', 'word_index': [(19, 20)], 'id': 'DDI-MedLine.d30.s6.e2'}, 'sentence_id': 'DDI-MedLine.d30.s6'}	In monkeys - NANM was about NUMBER times more potent than + NANM in decreasing responding whereas in pigeons - NANM was about equipotent with + NANM
In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM. 	(+)-NANM	(+)-NANM	none	{'e1': {'word': '(+)-NANM', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d30.s6.e1'}, 'e2': {'word': '(+)-NANM', 'word_index': [(25, 26)], 'id': 'DDI-MedLine.d30.s6.e3'}, 'sentence_id': 'DDI-MedLine.d30.s6'}	In monkeys - NANM was about NUMBER times more potent than + NANM in decreasing responding whereas in pigeons - NANM was about equipotent with + NANM
In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM. 	(-)-NANM	(+)-NANM	none	{'e1': {'word': '(-)-NANM', 'word_index': [(19, 20)], 'id': 'DDI-MedLine.d30.s6.e2'}, 'e2': {'word': '(+)-NANM', 'word_index': [(25, 26)], 'id': 'DDI-MedLine.d30.s6.e3'}, 'sentence_id': 'DDI-MedLine.d30.s6'}	In monkeys - NANM was about NUMBER times more potent than + NANM in decreasing responding whereas in pigeons - NANM was about equipotent with + NANM
In both species, (-)-NANM, but not (+)-NANM, antagonized the rate-decreasing effects of morphine on FI and FR responding. 	(-)-NANM	(+)-NANM	none	{'e1': {'word': '(-)-NANM', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d30.s7.e0'}, 'e2': {'word': '(+)-NANM', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d30.s7.e1'}, 'sentence_id': 'DDI-MedLine.d30.s7'}	In both species - NANM but not + NANM antagonized the rate decreasing effects of morphine on FI and FR responding
In both species, (-)-NANM, but not (+)-NANM, antagonized the rate-decreasing effects of morphine on FI and FR responding. 	(-)-NANM	morphine	effect	{'e1': {'word': '(-)-NANM', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d30.s7.e0'}, 'e2': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d30.s7.e2'}, 'sentence_id': 'DDI-MedLine.d30.s7'}	In both species - NANM but not + NANM antagonized the rate decreasing effects of morphine on FI and FR responding
In both species, (-)-NANM, but not (+)-NANM, antagonized the rate-decreasing effects of morphine on FI and FR responding. 	(+)-NANM	morphine	none	{'e1': {'word': '(+)-NANM', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d30.s7.e1'}, 'e2': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d30.s7.e2'}, 'sentence_id': 'DDI-MedLine.d30.s7'}	In both species - NANM but not + NANM antagonized the rate decreasing effects of morphine on FI and FR responding
In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; 	(-)-NANM	(+)-NANM	none	{'e1': {'word': '(-)-NANM', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d30.s8.e0'}, 'e2': {'word': '(+)-NANM', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d30.s8.e1'}, 'sentence_id': 'DDI-MedLine.d30.s8'}	In monkeys the effects of - NANM but not + NANM or PCP were antagonized by naloxone
In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; 	(-)-NANM	PCP	none	{'e1': {'word': '(-)-NANM', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d30.s8.e0'}, 'e2': {'word': 'PCP', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d30.s8.e2'}, 'sentence_id': 'DDI-MedLine.d30.s8'}	In monkeys the effects of - NANM but not + NANM or PCP were antagonized by naloxone
In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; 	(-)-NANM	naloxone	effect	{'e1': {'word': '(-)-NANM', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d30.s8.e0'}, 'e2': {'word': 'naloxone', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d30.s8.e3'}, 'sentence_id': 'DDI-MedLine.d30.s8'}	In monkeys the effects of - NANM but not + NANM or PCP were antagonized by naloxone
In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; 	(+)-NANM	PCP	none	{'e1': {'word': '(+)-NANM', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d30.s8.e1'}, 'e2': {'word': 'PCP', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d30.s8.e2'}, 'sentence_id': 'DDI-MedLine.d30.s8'}	In monkeys the effects of - NANM but not + NANM or PCP were antagonized by naloxone
In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; 	(+)-NANM	naloxone	none	{'e1': {'word': '(+)-NANM', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d30.s8.e1'}, 'e2': {'word': 'naloxone', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d30.s8.e3'}, 'sentence_id': 'DDI-MedLine.d30.s8'}	In monkeys the effects of - NANM but not + NANM or PCP were antagonized by naloxone
In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; 	PCP	naloxone	none	{'e1': {'word': 'PCP', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d30.s8.e2'}, 'e2': {'word': 'naloxone', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d30.s8.e3'}, 'sentence_id': 'DDI-MedLine.d30.s8'}	In monkeys the effects of - NANM but not + NANM or PCP were antagonized by naloxone
the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine. 	naloxone	(-)-NANM	effect	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d30.s9.e0'}, 'e2': {'word': '(-)-NANM', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d30.s9.e1'}, 'sentence_id': 'DDI-MedLine.d30.s9'}	the doses of naloxone required to antagonize the effects of - NANM were more than NUMBER times higher than those required to antagonize the effects of morphine
the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine. 	naloxone	morphine	effect	{'e1': {'word': 'naloxone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d30.s9.e0'}, 'e2': {'word': 'morphine', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d30.s9.e2'}, 'sentence_id': 'DDI-MedLine.d30.s9'}	the doses of naloxone required to antagonize the effects of - NANM were more than NUMBER times higher than those required to antagonize the effects of morphine
the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine. 	(-)-NANM	morphine	none	{'e1': {'word': '(-)-NANM', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d30.s9.e1'}, 'e2': {'word': 'morphine', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d30.s9.e2'}, 'sentence_id': 'DDI-MedLine.d30.s9'}	the doses of naloxone required to antagonize the effects of - NANM were more than NUMBER times higher than those required to antagonize the effects of morphine
In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP. 	naloxone	(-)-NANM	none	{'e1': {'word': 'naloxone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d30.s10.e0'}, 'e2': {'word': '(-)-NANM', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d30.s10.e1'}, 'sentence_id': 'DDI-MedLine.d30.s10'}	In pigeons naloxone did not systematically alter the effects of - NANM + NANM or PCP
In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP. 	naloxone	(+)-NANM	none	{'e1': {'word': 'naloxone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d30.s10.e0'}, 'e2': {'word': '(+)-NANM', 'word_index': [(12, 13)], 'id': 'DDI-MedLine.d30.s10.e2'}, 'sentence_id': 'DDI-MedLine.d30.s10'}	In pigeons naloxone did not systematically alter the effects of - NANM + NANM or PCP
In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP. 	naloxone	PCP	none	{'e1': {'word': 'naloxone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d30.s10.e0'}, 'e2': {'word': 'PCP', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d30.s10.e3'}, 'sentence_id': 'DDI-MedLine.d30.s10'}	In pigeons naloxone did not systematically alter the effects of - NANM + NANM or PCP
In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP. 	(-)-NANM	(+)-NANM	none	{'e1': {'word': '(-)-NANM', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d30.s10.e1'}, 'e2': {'word': '(+)-NANM', 'word_index': [(12, 13)], 'id': 'DDI-MedLine.d30.s10.e2'}, 'sentence_id': 'DDI-MedLine.d30.s10'}	In pigeons naloxone did not systematically alter the effects of - NANM + NANM or PCP
In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP. 	(-)-NANM	PCP	none	{'e1': {'word': '(-)-NANM', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d30.s10.e1'}, 'e2': {'word': 'PCP', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d30.s10.e3'}, 'sentence_id': 'DDI-MedLine.d30.s10'}	In pigeons naloxone did not systematically alter the effects of - NANM + NANM or PCP
In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP. 	(+)-NANM	PCP	none	{'e1': {'word': '(+)-NANM', 'word_index': [(12, 13)], 'id': 'DDI-MedLine.d30.s10.e2'}, 'e2': {'word': 'PCP', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d30.s10.e3'}, 'sentence_id': 'DDI-MedLine.d30.s10'}	In pigeons naloxone did not systematically alter the effects of - NANM + NANM or PCP
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. 	Haloperidol	(+)-NANM	effect	{'e1': {'word': 'Haloperidol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d30.s11.e0'}, 'e2': {'word': '(+)-NANM', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d30.s11.e1'}, 'sentence_id': 'DDI-MedLine.d30.s11'}	Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either + NANM or PCP in pigeons but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. 	Haloperidol	PCP	effect	{'e1': {'word': 'Haloperidol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d30.s11.e0'}, 'e2': {'word': 'PCP', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d30.s11.e2'}, 'sentence_id': 'DDI-MedLine.d30.s11'}	Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either + NANM or PCP in pigeons but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. 	Haloperidol	NANM	none	{'e1': {'word': 'Haloperidol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d30.s11.e0'}, 'e2': {'word': 'NANM', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d30.s11.e3'}, 'sentence_id': 'DDI-MedLine.d30.s11'}	Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either + NANM or PCP in pigeons but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. 	(+)-NANM	PCP	none	{'e1': {'word': '(+)-NANM', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d30.s11.e1'}, 'e2': {'word': 'PCP', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d30.s11.e2'}, 'sentence_id': 'DDI-MedLine.d30.s11'}	Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either + NANM or PCP in pigeons but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. 	(+)-NANM	NANM	none	{'e1': {'word': '(+)-NANM', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d30.s11.e1'}, 'e2': {'word': 'NANM', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d30.s11.e3'}, 'sentence_id': 'DDI-MedLine.d30.s11'}	Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either + NANM or PCP in pigeons but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. 	PCP	NANM	none	{'e1': {'word': 'PCP', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d30.s11.e2'}, 'e2': {'word': 'NANM', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d30.s11.e3'}, 'sentence_id': 'DDI-MedLine.d30.s11'}	Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either + NANM or PCP in pigeons but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM
In this study, the effects of etofibrate upon chylomicron metabolism was tested by determination of the plasma kinetics of a chylomicron-like emulsion model in 12 patients with coronary artery disease, aged 59+/-11 years, (total cholesterol: 240+/-41 mg/dl; triglycerides: 188+/-42 mg/dl) submitted to a randomized, crossover, double-blind, placebo-controlled study with administration of 1 g per day etofibrate or placebo for 1-month. 	etofibrate	etofibrate	none	{'e1': {'word': 'etofibrate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d44.s2.e0'}, 'e2': {'word': 'etofibrate', 'word_index': [(71, 71)], 'id': 'DDI-MedLine.d44.s2.e1'}, 'sentence_id': 'DDI-MedLine.d44.s2'}	In this study the effects of etofibrate upon chylomicron metabolism was tested by determination of the plasma kinetics of a chylomicron like emulsion model in NUMBER patients with coronary artery disease aged NUMBER + - NUMBER years total cholesterol NUMBER + - NUMBER mg / dl triglycerides NUMBER + - NUMBER mg / dl submitted to a randomized crossover double blind placebo controlled study with administration of NUMBER g per day etofibrate or placebo for NUMBER month
Etofibrate elicited 62% enhancement of post-heparin lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment. 	Etofibrate	heparin	effect	{'e1': {'word': 'Etofibrate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d44.s6.e0'}, 'e2': {'word': 'heparin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d44.s6.e1'}, 'sentence_id': 'DDI-MedLine.d44.s6'}	Etofibrate elicited NUMBER % enhancement of post heparin lipolytic activity and NUMBER % increase of 3H triglyceride fractional clearance rate compared with placebo treatment
"Carbamazepine overdose recognized by a tricyclic antidepressant assay.
"	Carbamazepine	tricyclic antidepressant	none	{'e1': {'word': 'Carbamazepine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d36.s0.e0'}, 'e2': {'word': 'tricyclic antidepressant', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d36.s0.e1'}, 'sentence_id': 'DDI-MedLine.d36.s0'}	Carbamazepine overdose recognized by a tricyclic antidepressant assay
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.	carbamazepine	tricyclic antidepressant	effect	{'e1': {'word': 'carbamazepine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d36.s2.e0'}, 'e2': {'word': 'tricyclic antidepressant', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d36.s2.e1'}, 'sentence_id': 'DDI-MedLine.d36.s2'}	We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.	carbamazepine	carbamazepine	none	{'e1': {'word': 'carbamazepine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d36.s2.e0'}, 'e2': {'word': 'carbamazepine', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d36.s2.e2'}, 'sentence_id': 'DDI-MedLine.d36.s2'}	We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.	carbamazepine	tricyclic antidepressants	none	{'e1': {'word': 'carbamazepine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d36.s2.e0'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(33, 34)], 'id': 'DDI-MedLine.d36.s2.e3'}, 'sentence_id': 'DDI-MedLine.d36.s2'}	We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.	tricyclic antidepressant	carbamazepine	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d36.s2.e1'}, 'e2': {'word': 'carbamazepine', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d36.s2.e2'}, 'sentence_id': 'DDI-MedLine.d36.s2'}	We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.	tricyclic antidepressant	tricyclic antidepressants	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d36.s2.e1'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(33, 34)], 'id': 'DDI-MedLine.d36.s2.e3'}, 'sentence_id': 'DDI-MedLine.d36.s2'}	We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.	carbamazepine	tricyclic antidepressants	advise	{'e1': {'word': 'carbamazepine', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d36.s2.e2'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(33, 34)], 'id': 'DDI-MedLine.d36.s2.e3'}, 'sentence_id': 'DDI-MedLine.d36.s2'}	We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants
The 16,16-dimethylprostaglandin E2 (dmPGE2)-induced diarrhea was analyzed in cecectomized rats prepared by resecting the cecum and its vasculature without disturbing the ileocecal junction. 	16,16-dimethylprostaglandin E2	dmPGE2	none	{'e1': {'word': '16,16-dimethylprostaglandin E2', 'word_index': [(1, 4)], 'id': 'DDI-MedLine.d128.s1.e0'}, 'e2': {'word': 'dmPGE2', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d128.s1.e1'}, 'sentence_id': 'DDI-MedLine.d128.s1'}	The NUMBER NUMBER dimethylprostaglandin E2 dmPGE2 induced diarrhea was analyzed in cecectomized rats prepared by resecting the cecum and its vasculature without disturbing the ileocecal junction
On the other hand, the enhanced secretion of colonic fluid by dmPGE2, given intraluminally, was only half of that in control rats, whereas the colonic transit-enhancing effect of dmPGE2 in cecectomized rats was more pronounced than in control rats at 15 but not at 30 min after its administration. 	dmPGE2	dmPGE2	none	{'e1': {'word': 'dmPGE2', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d128.s10.e0'}, 'e2': {'word': 'dmPGE2', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d128.s10.e1'}, 'sentence_id': 'DDI-MedLine.d128.s10'}	On the other hand the enhanced secretion of colonic fluid by dmPGE2 given intraluminally was only half of that in control rats whereas the colonic transit enhancing effect of dmPGE2 in cecectomized rats was more pronounced than in control rats at NUMBER but not at NUMBER min after its administration
Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) 	Loperamide	morphine	none	{'e1': {'word': 'Loperamide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d128.s12.e0'}, 'e2': {'word': 'morphine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d128.s12.e1'}, 'sentence_id': 'DDI-MedLine.d128.s12'}	Loperamide and morphine NUMBER and NUMBER mg / kg s.c.
Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. 	Loperamide	morphine	none	{'e1': {'word': 'Loperamide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d128.s13.e0'}, 'e2': {'word': 'morphine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d128.s13.e1'}, 'sentence_id': 'DDI-MedLine.d128.s13'}	Loperamide and morphine NUMBER and NUMBER mg / kg s.c. inhibited the dmPGE2 NUMBER mg / kg p.o. induced diarrhea in cecectomized rats
Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. 	Loperamide	dmPGE2	effect	{'e1': {'word': 'Loperamide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d128.s13.e0'}, 'e2': {'word': 'dmPGE2', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d128.s13.e2'}, 'sentence_id': 'DDI-MedLine.d128.s13'}	Loperamide and morphine NUMBER and NUMBER mg / kg s.c. inhibited the dmPGE2 NUMBER mg / kg p.o. induced diarrhea in cecectomized rats
Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. 	morphine	dmPGE2	effect	{'e1': {'word': 'morphine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d128.s13.e1'}, 'e2': {'word': 'dmPGE2', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d128.s13.e2'}, 'sentence_id': 'DDI-MedLine.d128.s13'}	Loperamide and morphine NUMBER and NUMBER mg / kg s.c. inhibited the dmPGE2 NUMBER mg / kg p.o. induced diarrhea in cecectomized rats
N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine. 	N-methyllevallorphan	loperamide	effect	{'e1': {'word': 'N-methyllevallorphan', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d128.s15.e0'}, 'e2': {'word': 'loperamide', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d128.s15.e1'}, 'sentence_id': 'DDI-MedLine.d128.s15'}	N methyllevallorphan NUMBER mg / kg s.c. completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine
N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine. 	N-methyllevallorphan	morphine	effect	{'e1': {'word': 'N-methyllevallorphan', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d128.s15.e0'}, 'e2': {'word': 'morphine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d128.s15.e2'}, 'sentence_id': 'DDI-MedLine.d128.s15'}	N methyllevallorphan NUMBER mg / kg s.c. completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine
N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine. 	loperamide	morphine	none	{'e1': {'word': 'loperamide', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d128.s15.e1'}, 'e2': {'word': 'morphine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d128.s15.e2'}, 'sentence_id': 'DDI-MedLine.d128.s15'}	N-methyllevallorphan 5 NUMBER kg , s.c. completely the inhibitory effect of loperamide and partly antagonized the effect of morphine .
Cytochalasin D at 10 microM preferentially blocked the secretory effect of carbachol and its synergism with cAMP, whereas it had no effect on histamine- or cAMP-stimulated acid secretion within 15 min. 	Cytochalasin D	carbachol	effect	{'e1': {'word': 'Cytochalasin D', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d59.s4.e0'}, 'e2': {'word': 'carbachol', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d59.s4.e1'}, 'sentence_id': 'DDI-MedLine.d59.s4'}	Cytochalasin D at NUMBER microM preferentially blocked the secretory effect of carbachol and its synergism with cAMP whereas it had no effect on histamine or cAMP stimulated acid secretion within NUMBER min
Cytochalasin D inhibited the carbachol-stimulated intracellular Ca(2+) concentration ([Ca(2+)](i)) increase due to release from the Ca(2+) store. 	Cytochalasin D	carbachol	effect	{'e1': {'word': 'Cytochalasin D', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d59.s5.e0'}, 'e2': {'word': 'carbachol', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d59.s5.e1'}, 'sentence_id': 'DDI-MedLine.d59.s5'}	Cytochalasin D inhibited the carbachol stimulated intracellular Ca NUMBER + concentration Ca NUMBER + i increase due to release from the Ca NUMBER + store
"Antimicrobial activity of Ganoderma lucidum extract alone and in combination with some antibiotics.
"	Ganoderma lucidum extract	antibiotics	none	{'e1': {'word': 'Ganoderma lucidum extract', 'word_index': [(3, 5)], 'id': 'DDI-MedLine.d84.s0.e0'}, 'e2': {'word': 'antibiotics', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d84.s0.e1'}, 'sentence_id': 'DDI-MedLine.d84.s0'}	Antimicrobial activity of Ganoderma lucidum extract alone and in combination with some antibiotics
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	GL	antibiotics	none	{'e1': {'word': 'GL', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d84.s3.e0'}, 'e2': {'word': 'antibiotics', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d84.s3.e1'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of GL with NUMBER kinds of antibiotics ampicillin cefazolin oxytetracycline and chloramphenicol the fractional inhibitory concentration index FICI was determined by checkerboard assay for each strain
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	GL	ampicillin	none	{'e1': {'word': 'GL', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d84.s3.e0'}, 'e2': {'word': 'ampicillin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d84.s3.e2'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of GL with NUMBER kinds of antibiotics ampicillin cefazolin oxytetracycline and chloramphenicol the fractional inhibitory concentration index FICI was determined by checkerboard assay for each strain
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	GL	cefazolin	none	{'e1': {'word': 'GL', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d84.s3.e0'}, 'e2': {'word': 'cefazolin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d84.s3.e3'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of GL with NUMBER kinds of antibiotics ampicillin cefazolin oxytetracycline and chloramphenicol the fractional inhibitory concentration index FICI was determined by checkerboard assay for each strain
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	GL	oxytetracycline	none	{'e1': {'word': 'GL', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d84.s3.e0'}, 'e2': {'word': 'oxytetracycline', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d84.s3.e4'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of GL with NUMBER kinds of antibiotics ampicillin cefazolin oxytetracycline and chloramphenicol the fractional inhibitory concentration index FICI was determined by checkerboard assay for each strain
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	GL	chloramphenicol	none	{'e1': {'word': 'GL', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d84.s3.e0'}, 'e2': {'word': 'chloramphenicol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d84.s3.e5'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of GL with NUMBER kinds of antibiotics ampicillin cefazolin oxytetracycline and chloramphenicol the fractional inhibitory concentration index FICI was determined by checkerboard assay for each strain
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	antibiotics	ampicillin	none	{'e1': {'word': 'antibiotics', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d84.s3.e1'}, 'e2': {'word': 'ampicillin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d84.s3.e2'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of GL with NUMBER kinds of antibiotics ampicillin cefazolin oxytetracycline and chloramphenicol the fractional inhibitory concentration index FICI was determined by checkerboard assay for each strain
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	antibiotics	cefazolin	none	{'e1': {'word': 'antibiotics', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d84.s3.e1'}, 'e2': {'word': 'cefazolin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d84.s3.e3'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of GL with NUMBER kinds of antibiotics ampicillin cefazolin oxytetracycline and chloramphenicol the fractional inhibitory concentration index FICI was determined by checkerboard assay for each strain
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	antibiotics	oxytetracycline	none	{'e1': {'word': 'antibiotics', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d84.s3.e1'}, 'e2': {'word': 'oxytetracycline', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d84.s3.e4'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of GL with NUMBER kinds of antibiotics ampicillin cefazolin oxytetracycline and chloramphenicol the fractional inhibitory concentration index FICI was determined by checkerboard assay for each strain
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	antibiotics	chloramphenicol	none	{'e1': {'word': 'antibiotics', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d84.s3.e1'}, 'e2': {'word': 'chloramphenicol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d84.s3.e5'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of GL with NUMBER kinds of antibiotics ampicillin cefazolin oxytetracycline and chloramphenicol the fractional inhibitory concentration index FICI was determined by checkerboard assay for each strain
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	ampicillin	cefazolin	none	{'e1': {'word': 'ampicillin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d84.s3.e2'}, 'e2': {'word': 'cefazolin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d84.s3.e3'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of GL with NUMBER kinds of antibiotics ampicillin cefazolin oxytetracycline and chloramphenicol the fractional inhibitory concentration index FICI was determined by checkerboard assay for each strain
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	ampicillin	oxytetracycline	none	{'e1': {'word': 'ampicillin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d84.s3.e2'}, 'e2': {'word': 'oxytetracycline', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d84.s3.e4'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of GL with NUMBER kinds of antibiotics ampicillin cefazolin oxytetracycline and chloramphenicol the fractional inhibitory concentration index FICI was determined by checkerboard assay for each strain
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	ampicillin	chloramphenicol	none	{'e1': {'word': 'ampicillin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d84.s3.e2'}, 'e2': {'word': 'chloramphenicol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d84.s3.e5'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of GL with NUMBER kinds of antibiotics ampicillin cefazolin oxytetracycline and chloramphenicol the fractional inhibitory concentration index FICI was determined by checkerboard assay for each strain
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	cefazolin	oxytetracycline	none	{'e1': {'word': 'cefazolin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d84.s3.e3'}, 'e2': {'word': 'oxytetracycline', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d84.s3.e4'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of GL with NUMBER kinds of antibiotics ampicillin cefazolin oxytetracycline and chloramphenicol the fractional inhibitory concentration index FICI was determined by checkerboard assay for each strain
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	cefazolin	chloramphenicol	none	{'e1': {'word': 'cefazolin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d84.s3.e3'}, 'e2': {'word': 'chloramphenicol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d84.s3.e5'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of GL with NUMBER kinds of antibiotics ampicillin cefazolin oxytetracycline and chloramphenicol the fractional inhibitory concentration index FICI was determined by checkerboard assay for each strain
To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 	oxytetracycline	chloramphenicol	none	{'e1': {'word': 'oxytetracycline', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d84.s3.e4'}, 'e2': {'word': 'chloramphenicol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d84.s3.e5'}, 'sentence_id': 'DDI-MedLine.d84.s3'}	To investigate the effects of antimicrobial combinations of GL with NUMBER kinds of antibiotics ampicillin cefazolin oxytetracycline and chloramphenicol the fractional inhibitory concentration index FICI was determined by checkerboard assay for each strain
The antimicrobial combinations of GL with four antibiotics resulted in additive effect in most instances, synergism in two instances, and antagonism in two instances. 	GL	antibiotics	effect	{'e1': {'word': 'GL', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d84.s4.e0'}, 'e2': {'word': 'antibiotics', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d84.s4.e1'}, 'sentence_id': 'DDI-MedLine.d84.s4'}	The antimicrobial combinations of GL with NUMBER antibiotics resulted in additive effect in most instances synergism in NUMBER instances and antagonism in NUMBER instances
Synergism was observed when GL was combined with cefazolin against Bacillus subtilis and Klebsiella oxytoca.	GL	cefazolin	effect	{'e1': {'word': 'GL', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d84.s5.e0'}, 'e2': {'word': 'cefazolin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d84.s5.e1'}, 'sentence_id': 'DDI-MedLine.d84.s5'}	Synergism was observed when GL was combined with cefazolin against Bacillus subtilis and Klebsiella oxytoca
Here we show that a combination of galangin or 3,7-dihydroxyflavone with vancomycin may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of vancomycin-sensitive strains. 	galangin	vancomycin	none	{'e1': {'word': 'galangin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d123.s2.e0'}, 'e2': {'word': 'vancomycin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d123.s2.e1'}, 'sentence_id': 'DDI-MedLine.d123.s2'}	Here we show that a combination of galangin or NUMBER NUMBER dihydroxyflavone with vancomycin may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of vancomycin sensitive strains
METHODS: Clinical studies, case reports, and commentaries and editorials concerning sildenafil published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms sildenafil, Viagra, and erectile dysfunction. 	sildenafil	sildenafil	none	{'e1': {'word': 'sildenafil', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d42.s4.e0'}, 'e2': {'word': 'sildenafil', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d42.s4.e1'}, 'sentence_id': 'DDI-MedLine.d42.s4'}	METHODS Clinical studies case reports and commentaries and editorials concerning sildenafil published in the international literature between January NUMBER and August NUMBER were identified through searches of MEDLINE PREMEDLINE and International Pharmaceutical Abstracts using the terms sildenafil Viagra and erectile dysfunction
METHODS: Clinical studies, case reports, and commentaries and editorials concerning sildenafil published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms sildenafil, Viagra, and erectile dysfunction. 	sildenafil	Viagra	none	{'e1': {'word': 'sildenafil', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d42.s4.e0'}, 'e2': {'word': 'Viagra', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d42.s4.e2'}, 'sentence_id': 'DDI-MedLine.d42.s4'}	METHODS Clinical studies case reports and commentaries and editorials concerning sildenafil published in the international literature between January NUMBER and August NUMBER were identified through searches of MEDLINE PREMEDLINE and International Pharmaceutical Abstracts using the terms sildenafil Viagra and erectile dysfunction
METHODS: Clinical studies, case reports, and commentaries and editorials concerning sildenafil published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms sildenafil, Viagra, and erectile dysfunction. 	sildenafil	Viagra	none	{'e1': {'word': 'sildenafil', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d42.s4.e1'}, 'e2': {'word': 'Viagra', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d42.s4.e2'}, 'sentence_id': 'DDI-MedLine.d42.s4'}	METHODS Clinical studies case reports and commentaries and editorials concerning sildenafil published in the international literature between January NUMBER and August NUMBER were identified through searches of MEDLINE PREMEDLINE and International Pharmaceutical Abstracts using the terms sildenafil Viagra and erectile dysfunction
RESULTS: Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, selective serotonin reuptake inhibitors [SSRIs]). 	Sildenafil	selective serotonin reuptake inhibitors	none	{'e1': {'word': 'Sildenafil', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d42.s5.e0'}, 'e2': {'word': 'selective serotonin reuptake inhibitors', 'word_index': [(24, 27)], 'id': 'DDI-MedLine.d42.s5.e1'}, 'sentence_id': 'DDI-MedLine.d42.s5'}	RESULTS Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy radiation therapy diabetes mellitus certain neurologic disorders and drug therapy eg selective serotonin reuptake inhibitors SSRIs
RESULTS: Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, selective serotonin reuptake inhibitors [SSRIs]). 	Sildenafil	SSRIs	none	{'e1': {'word': 'Sildenafil', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d42.s5.e0'}, 'e2': {'word': 'SSRIs', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d42.s5.e2'}, 'sentence_id': 'DDI-MedLine.d42.s5'}	RESULTS Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy radiation therapy diabetes mellitus certain neurologic disorders and drug therapy eg selective serotonin reuptake inhibitors SSRIs
RESULTS: Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, selective serotonin reuptake inhibitors [SSRIs]). 	selective serotonin reuptake inhibitors	SSRIs	none	{'e1': {'word': 'selective serotonin reuptake inhibitors', 'word_index': [(24, 27)], 'id': 'DDI-MedLine.d42.s5.e1'}, 'e2': {'word': 'SSRIs', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d42.s5.e2'}, 'sentence_id': 'DDI-MedLine.d42.s5'}	RESULTS Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy radiation therapy diabetes mellitus certain neurologic disorders and drug therapy eg selective serotonin reuptake inhibitors SSRIs
however, patients with moderate to severe cardiovascular disease or those taking nitrate therapy are at increased risk for potentially serious cardiovascular adverse effects with sildenafil therapy. 	nitrate	sildenafil	effect	{'e1': {'word': 'nitrate', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d42.s9.e0'}, 'e2': {'word': 'sildenafil', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d42.s9.e1'}, 'sentence_id': 'DDI-MedLine.d42.s9'}	however patients with moderate to severe cardiovascular disease or those taking nitrate therapy are at increased risk for potentially serious cardiovascular adverse effects with sildenafil therapy
In addition, patients taking drugs that inhibit the cytochrome P450 3A4 isozyme, which metabolizes sildenafil, may experience increased drug concentrations and possible toxicity from normal doses of sildenafil. 	sildenafil	sildenafil	none	{'e1': {'word': 'sildenafil', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d42.s10.e0'}, 'e2': {'word': 'sildenafil', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d42.s10.e1'}, 'sentence_id': 'DDI-MedLine.d42.s10'}	In addition patients taking drugs that inhibit the cytochrome P450 3A4 isozyme which metabolizes sildenafil may experience increased drug concentrations and possible toxicity from normal doses of sildenafil
Little has been studied of the adverse effects of the exposure of the liver to the interaction of ethanol with its congeners and acetaldehyde, coexisting in the contents of alcoholic beverages. 	ethanol	acetaldehyde	none	{'e1': {'word': 'ethanol', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d107.s1.e0'}, 'e2': {'word': 'acetaldehyde', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d107.s1.e1'}, 'sentence_id': 'DDI-MedLine.d107.s1'}	Little has been studied of the adverse effects of the exposure of the liver to the interaction of ethanol with its congeners and acetaldehyde coexisting in the contents of alcoholic beverages
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages; 	ethanol	methanol	none	{'e1': {'word': 'ethanol', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d107.s3.e0'}, 'e2': {'word': 'methanol', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d107.s3.e1'}, 'sentence_id': 'DDI-MedLine.d107.s3'}	NUMBER groups SH DA SH FA were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol methanol higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages; 	ethanol	alcohols	none	{'e1': {'word': 'ethanol', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d107.s3.e0'}, 'e2': {'word': 'alcohols', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d107.s3.e2'}, 'sentence_id': 'DDI-MedLine.d107.s3'}	NUMBER groups SH DA SH FA were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol methanol higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages; 	ethanol	acetaldehyde	none	{'e1': {'word': 'ethanol', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d107.s3.e0'}, 'e2': {'word': 'acetaldehyde', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d107.s3.e3'}, 'sentence_id': 'DDI-MedLine.d107.s3'}	NUMBER groups SH DA SH FA were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol methanol higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages; 	methanol	alcohols	none	{'e1': {'word': 'methanol', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d107.s3.e1'}, 'e2': {'word': 'alcohols', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d107.s3.e2'}, 'sentence_id': 'DDI-MedLine.d107.s3'}	NUMBER groups SH DA SH FA were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol methanol higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages; 	methanol	acetaldehyde	none	{'e1': {'word': 'methanol', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d107.s3.e1'}, 'e2': {'word': 'acetaldehyde', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d107.s3.e3'}, 'sentence_id': 'DDI-MedLine.d107.s3'}	NUMBER groups SH DA SH FA were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol methanol higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages; 	alcohols	acetaldehyde	none	{'e1': {'word': 'alcohols', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d107.s3.e2'}, 'e2': {'word': 'acetaldehyde', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d107.s3.e3'}, 'sentence_id': 'DDI-MedLine.d107.s3'}	NUMBER groups SH DA SH FA were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol methanol higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages
These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde; 	ethanol	acetaldehyde	effect	{'e1': {'word': 'ethanol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d107.s9.e0'}, 'e2': {'word': 'acetaldehyde', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d107.s9.e1'}, 'sentence_id': 'DDI-MedLine.d107.s9'}	These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde
The fluoroquinolones are a rapidly growing class of antibiotics with a broad spectrum of activity against gram-negative and some gram-positive aerobic bacteria. 	fluoroquinolones	antibiotics	none	{'e1': {'word': 'fluoroquinolones', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d78.s1.e0'}, 'e2': {'word': 'antibiotics', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d78.s1.e1'}, 'sentence_id': 'DDI-MedLine.d78.s1'}	The fluoroquinolones are a rapidly growing class of antibiotics with a broad spectrum of activity against gram negative and some gram positive aerobic bacteria
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	norfloxacin	ciprofloxacin	none	{'e1': {'word': 'norfloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d78.s2.e0'}, 'e2': {'word': 'ciprofloxacin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d78.s2.e1'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	These agents including norfloxacin ciprofloxacin ofloxacin enoxacin and lomefloxacin have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	norfloxacin	ofloxacin	none	{'e1': {'word': 'norfloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d78.s2.e0'}, 'e2': {'word': 'ofloxacin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d78.s2.e2'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	These agents including norfloxacin ciprofloxacin ofloxacin enoxacin and lomefloxacin have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	norfloxacin	enoxacin	none	{'e1': {'word': 'norfloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d78.s2.e0'}, 'e2': {'word': 'enoxacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d78.s2.e3'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	These agents including norfloxacin ciprofloxacin ofloxacin enoxacin and lomefloxacin have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	norfloxacin	lomefloxacin	none	{'e1': {'word': 'norfloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d78.s2.e0'}, 'e2': {'word': 'lomefloxacin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d78.s2.e4'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	These agents including norfloxacin ciprofloxacin ofloxacin enoxacin and lomefloxacin have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	ciprofloxacin	ofloxacin	none	{'e1': {'word': 'ciprofloxacin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d78.s2.e1'}, 'e2': {'word': 'ofloxacin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d78.s2.e2'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	These agents including norfloxacin ciprofloxacin ofloxacin enoxacin and lomefloxacin have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	ciprofloxacin	enoxacin	none	{'e1': {'word': 'ciprofloxacin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d78.s2.e1'}, 'e2': {'word': 'enoxacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d78.s2.e3'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	These agents including norfloxacin ciprofloxacin ofloxacin enoxacin and lomefloxacin have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	ciprofloxacin	lomefloxacin	none	{'e1': {'word': 'ciprofloxacin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d78.s2.e1'}, 'e2': {'word': 'lomefloxacin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d78.s2.e4'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	These agents including norfloxacin ciprofloxacin ofloxacin enoxacin and lomefloxacin have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	ofloxacin	enoxacin	none	{'e1': {'word': 'ofloxacin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d78.s2.e2'}, 'e2': {'word': 'enoxacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d78.s2.e3'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	These agents including norfloxacin ciprofloxacin ofloxacin enoxacin and lomefloxacin have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	ofloxacin	lomefloxacin	none	{'e1': {'word': 'ofloxacin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d78.s2.e2'}, 'e2': {'word': 'lomefloxacin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d78.s2.e4'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	These agents including norfloxacin ciprofloxacin ofloxacin enoxacin and lomefloxacin have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis
These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 	enoxacin	lomefloxacin	none	{'e1': {'word': 'enoxacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d78.s2.e3'}, 'e2': {'word': 'lomefloxacin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d78.s2.e4'}, 'sentence_id': 'DDI-MedLine.d78.s2'}	These agents including norfloxacin ciprofloxacin ofloxacin enoxacin and lomefloxacin have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis
Advantages offered by this class of antibiotics include optimal pharmacokinetics, effectiveness against multidrug-resistant organisms, and oral administration even when parenteral antibiotics are generally used. 	antibiotics	antibiotics	none	{'e1': {'word': 'antibiotics', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d78.s3.e0'}, 'e2': {'word': 'antibiotics', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d78.s3.e1'}, 'sentence_id': 'DDI-MedLine.d78.s3'}	Advantages offered by this class of antibiotics include optimal pharmacokinetics effectiveness against multidrug resistant organisms and oral administration even when parenteral antibiotics are generally used
"Effect of probenecid on the apparent volume of distribution and elimination of cloxacillin.
"	probenecid	cloxacillin	none	{'e1': {'word': 'probenecid', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d29.s0.e0'}, 'e2': {'word': 'cloxacillin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d29.s0.e1'}, 'sentence_id': 'DDI-MedLine.d29.s0'}	Effect of probenecid on the apparent volume of distribution and elimination of cloxacillin
(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body. 	penicillins	cephaloridine	none	{'e1': {'word': 'penicillins', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d29.s2.e0'}, 'e2': {'word': 'cephaloridine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d29.s2.e1'}, 'sentence_id': 'DDI-MedLine.d29.s2'}	NUMBER NUMBER the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body
(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body. 	penicillins	probenecid	mechanism	{'e1': {'word': 'penicillins', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d29.s2.e0'}, 'e2': {'word': 'probenecid', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d29.s2.e2'}, 'sentence_id': 'DDI-MedLine.d29.s2'}	NUMBER NUMBER the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body
(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body. 	cephaloridine	probenecid	mechanism	{'e1': {'word': 'cephaloridine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d29.s2.e1'}, 'e2': {'word': 'probenecid', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d29.s2.e2'}, 'sentence_id': 'DDI-MedLine.d29.s2'}	NUMBER NUMBER the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body
To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. 	probenecid	cloxacillin	none	{'e1': {'word': 'probenecid', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d29.s3.e0'}, 'e2': {'word': 'cloxacillin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d29.s3.e1'}, 'sentence_id': 'DDI-MedLine.d29.s3'}	To determine whether probenecid has a direct effect on the distribution of cloxacillin the elimination and distribution of cloxacillin was studied in NUMBER patients NUMBER lacking kidney function and NUMBER with a partially impaired renal function in the presence or absence of probenecid
To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. 	probenecid	cloxacillin	none	{'e1': {'word': 'probenecid', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d29.s3.e0'}, 'e2': {'word': 'cloxacillin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d29.s3.e2'}, 'sentence_id': 'DDI-MedLine.d29.s3'}	To determine whether probenecid has a direct effect on the distribution of cloxacillin the elimination and distribution of cloxacillin was studied in NUMBER patients NUMBER lacking kidney function and NUMBER with a partially impaired renal function in the presence or absence of probenecid
To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. 	probenecid	probenecid	none	{'e1': {'word': 'probenecid', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d29.s3.e0'}, 'e2': {'word': 'probenecid', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d29.s3.e3'}, 'sentence_id': 'DDI-MedLine.d29.s3'}	To determine whether probenecid has a direct effect on the distribution of cloxacillin the elimination and distribution of cloxacillin was studied in NUMBER patients NUMBER lacking kidney function and NUMBER with a partially impaired renal function in the presence or absence of probenecid
To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. 	cloxacillin	cloxacillin	none	{'e1': {'word': 'cloxacillin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d29.s3.e1'}, 'e2': {'word': 'cloxacillin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d29.s3.e2'}, 'sentence_id': 'DDI-MedLine.d29.s3'}	To determine whether probenecid has a direct effect on the distribution of cloxacillin the elimination and distribution of cloxacillin was studied in NUMBER patients NUMBER lacking kidney function and NUMBER with a partially impaired renal function in the presence or absence of probenecid
To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. 	cloxacillin	probenecid	none	{'e1': {'word': 'cloxacillin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d29.s3.e1'}, 'e2': {'word': 'probenecid', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d29.s3.e3'}, 'sentence_id': 'DDI-MedLine.d29.s3'}	To determine whether probenecid has a direct effect on the distribution of cloxacillin the elimination and distribution of cloxacillin was studied in NUMBER patients NUMBER lacking kidney function and NUMBER with a partially impaired renal function in the presence or absence of probenecid
To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. 	cloxacillin	probenecid	none	{'e1': {'word': 'cloxacillin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d29.s3.e2'}, 'e2': {'word': 'probenecid', 'word_index': [(42, 42)], 'id': 'DDI-MedLine.d29.s3.e3'}, 'sentence_id': 'DDI-MedLine.d29.s3'}	To determine whether probenecid has a direct effect on the distribution of cloxacillin the elimination and distribution of cloxacillin was studied in NUMBER patients NUMBER lacking kidney function and NUMBER with a partially impaired renal function in the presence or absence of probenecid
No significant difference was found between the mean values of the volume of distribution of cloxacillin with and without probenecid (13.0 and 12.6 liters, respectively). 	cloxacillin	probenecid	none	{'e1': {'word': 'cloxacillin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d29.s4.e0'}, 'e2': {'word': 'probenecid', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d29.s4.e1'}, 'sentence_id': 'DDI-MedLine.d29.s4'}	No significant difference was found between the mean values of the volume of distribution of cloxacillin with and without probenecid NUMBER and NUMBER liters respectively
This might be explained by a blockade by probenecid of the elimination of cloxacillin by the liver.	probenecid	cloxacillin	mechanism	{'e1': {'word': 'probenecid', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d29.s8.e0'}, 'e2': {'word': 'cloxacillin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d29.s8.e1'}, 'sentence_id': 'DDI-MedLine.d29.s8'}	This might be explained by a blockade by probenecid of the elimination of cloxacillin by the liver
"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" "	thiazolidinediones	rosiglitazone	none	{'e1': {'word': 'thiazolidinediones', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d28.s7.e0'}, 'e2': {'word': 'rosiglitazone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d28.s7.e1'}, 'sentence_id': 'DDI-MedLine.d28.s7'}	The thiazolidinediones rosiglitazone and pioglitazone a new class of oral antidiabetic agents are insulin sensitizers
"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" "	thiazolidinediones	pioglitazone	none	{'e1': {'word': 'thiazolidinediones', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d28.s7.e0'}, 'e2': {'word': 'pioglitazone', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d28.s7.e2'}, 'sentence_id': 'DDI-MedLine.d28.s7'}	The thiazolidinediones rosiglitazone and pioglitazone a new class of oral antidiabetic agents are insulin sensitizers
"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" "	thiazolidinediones	antidiabetic agents	none	{'e1': {'word': 'thiazolidinediones', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d28.s7.e0'}, 'e2': {'word': 'antidiabetic agents', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d28.s7.e3'}, 'sentence_id': 'DDI-MedLine.d28.s7'}	The thiazolidinediones rosiglitazone and pioglitazone a new class of oral antidiabetic agents are insulin sensitizers
"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" "	rosiglitazone	pioglitazone	none	{'e1': {'word': 'rosiglitazone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d28.s7.e1'}, 'e2': {'word': 'pioglitazone', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d28.s7.e2'}, 'sentence_id': 'DDI-MedLine.d28.s7'}	The thiazolidinediones rosiglitazone and pioglitazone a new class of oral antidiabetic agents are insulin sensitizers
"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" "	rosiglitazone	antidiabetic agents	none	{'e1': {'word': 'rosiglitazone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d28.s7.e1'}, 'e2': {'word': 'antidiabetic agents', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d28.s7.e3'}, 'sentence_id': 'DDI-MedLine.d28.s7'}	The thiazolidinediones rosiglitazone and pioglitazone a new class of oral antidiabetic agents are insulin sensitizers
"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" "	pioglitazone	antidiabetic agents	none	{'e1': {'word': 'pioglitazone', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d28.s7.e2'}, 'e2': {'word': 'antidiabetic agents', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d28.s7.e3'}, 'sentence_id': 'DDI-MedLine.d28.s7'}	The thiazolidinediones rosiglitazone and pioglitazone a new class of oral antidiabetic agents are insulin sensitizers
Concomitantly given thiazide diuretics did not interfere with the absorption of a tablet of digoxin. 	thiazide diuretics	digoxin	none	{'e1': {'word': 'thiazide diuretics', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d127.s6.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d127.s6.e1'}, 'sentence_id': 'DDI-MedLine.d127.s6'}	Concomitantly given thiazide diuretics did not interfere with the absorption of a tablet of digoxin
"Glucose and insulin exert additive ocular and renal vasodilator effects on healthy humans.
"	Glucose	insulin	none	{'e1': {'word': 'Glucose', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d137.s0.e0'}, 'e2': {'word': 'insulin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d137.s0.e1'}, 'sentence_id': 'DDI-MedLine.d137.s0'}	Glucose and insulin exert additive ocular and renal vasodilator effects on healthy humans
AIMS/HYPOTHESIS: There is evidence that insulin and glucose cause renal and ocular vasodilation. 	insulin	glucose	none	{'e1': {'word': 'insulin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d137.s1.e0'}, 'e2': {'word': 'glucose', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d137.s1.e1'}, 'sentence_id': 'DDI-MedLine.d137.s1'}	AIMS HYPOTHESIS There is evidence that insulin and glucose cause renal and ocular vasodilation
Haemodynamic effects of glucose and insulin were additive when somatostatin was co-administered but not under basal conditions. 	glucose	insulin	none	{'e1': {'word': 'glucose', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d137.s9.e0'}, 'e2': {'word': 'insulin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d137.s9.e1'}, 'sentence_id': 'DDI-MedLine.d137.s9'}	Haemodynamic effects of glucose and insulin were additive when somatostatin was co-administered but not under basal conditions
Haemodynamic effects of glucose and insulin were additive when somatostatin was co-administered but not under basal conditions. 	glucose	somatostatin	none	{'e1': {'word': 'glucose', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d137.s9.e0'}, 'e2': {'word': 'somatostatin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d137.s9.e2'}, 'sentence_id': 'DDI-MedLine.d137.s9'}	Haemodynamic effects of glucose and insulin were additive when somatostatin was co-administered but not under basal conditions
Haemodynamic effects of glucose and insulin were additive when somatostatin was co-administered but not under basal conditions. 	insulin	somatostatin	none	{'e1': {'word': 'insulin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d137.s9.e1'}, 'e2': {'word': 'somatostatin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d137.s9.e2'}, 'sentence_id': 'DDI-MedLine.d137.s9'}	Haemodynamic effects of glucose and insulin were additive when somatostatin was co-administered but not under basal conditions
CONCLUSIONS/INTERPRETATION: Glucose and insulin can exert additive vasodilator properties on renal and ocular circulation. 	Glucose	insulin	none	{'e1': {'word': 'Glucose', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d137.s10.e0'}, 'e2': {'word': 'insulin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d137.s10.e1'}, 'sentence_id': 'DDI-MedLine.d137.s10'}	CONCLUSIONS INTERPRETATION Glucose and insulin can exert additive vasodilator properties on renal and ocular circulation
"Studies on the mechanism of action of miconazole: effect of miconazole on respiration and cell permeability of Candida albicans.
"	miconazole	miconazole	none	{'e1': {'word': 'miconazole', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d40.s0.e0'}, 'e2': {'word': 'miconazole', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d40.s0.e1'}, 'sentence_id': 'DDI-MedLine.d40.s0'}	Studies on the mechanism of action of miconazole effect of miconazole on respiration and cell permeability of Candida albicans
The antifungal drug, miconazole nitrate, inhibits the growth of several species of Candida. 	antifungal drug	miconazole nitrate	none	{'e1': {'word': 'antifungal drug', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d40.s1.e0'}, 'e2': {'word': 'miconazole nitrate', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d40.s1.e1'}, 'sentence_id': 'DDI-MedLine.d40.s1'}	The antifungal drug miconazole nitrate inhibits the growth of several species of Candida
The percentage of neurons hyperpolarized by mu-, delta(1)-, and kappa-selective opioids was significantly reduced when 1% but not < 	mu-selective opioids	delta(1)-selective opioids	none	{'e1': {'word': 'mu-selective opioids', 'word_index': [(6, 6), (13, 14)], 'id': 'DDI-MedLine.d75.s3.e0'}, 'e2': {'word': 'delta(1)-selective opioids', 'word_index': [(7, 8), (13, 14)], 'id': 'DDI-MedLine.d75.s3.e1'}, 'sentence_id': 'DDI-MedLine.d75.s3'}	The percentage of neurons hyperpolarized by mu delta NUMBER and kappa selective opioids selective opioids was significantly reduced when NUMBER % but not
The percentage of neurons hyperpolarized by mu-, delta(1)-, and kappa-selective opioids was significantly reduced when 1% but not < 	mu-selective opioids	kappa-selective opioids	none	{'e1': {'word': 'mu-selective opioids', 'word_index': [(6, 6), (13, 14)], 'id': 'DDI-MedLine.d75.s3.e0'}, 'e2': {'word': 'kappa-selective opioids', 'word_index': [(10, 12)], 'id': 'DDI-MedLine.d75.s3.e2'}, 'sentence_id': 'DDI-MedLine.d75.s3'}	The percentage of neurons hyperpolarized by mu delta NUMBER and kappa selective opioids selective opioids was significantly reduced when NUMBER % but not
The percentage of neurons hyperpolarized by mu-, delta(1)-, and kappa-selective opioids was significantly reduced when 1% but not < 	delta(1)-selective opioids	kappa-selective opioids	none	{'e1': {'word': 'delta(1)-selective opioids', 'word_index': [(7, 8), (13, 14)], 'id': 'DDI-MedLine.d75.s3.e1'}, 'e2': {'word': 'kappa-selective opioids', 'word_index': [(10, 12)], 'id': 'DDI-MedLine.d75.s3.e2'}, 'sentence_id': 'DDI-MedLine.d75.s3'}	The percentage of neurons hyperpolarized by mu delta NUMBER and kappa selective opioids selective opioids was significantly reduced when NUMBER % but not
Among the risk factors studied, two appear to increase the risk of ARE: the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients. 	thiabendazole	melarsoprol	effect	{'e1': {'word': 'thiabendazole', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d97.s8.e0'}, 'e2': {'word': 'melarsoprol', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d97.s8.e1'}, 'sentence_id': 'DDI-MedLine.d97.s8'}	Among the risk factors studied NUMBER appear to increase the risk of ARE the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients
Recommendations were to avoid administration of diffusible anti-helminthic treatment during the cure, and to improve the general conditions of patients before the cure of melarsoprol.	anti-helminthic	melarsoprol	none	{'e1': {'word': 'anti-helminthic', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d97.s10.e0'}, 'e2': {'word': 'melarsoprol', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d97.s10.e1'}, 'sentence_id': 'DDI-MedLine.d97.s10'}	Recommendations were to avoid administration of diffusible anti-helminthic treatment during the cure and to improve the general conditions of patients before the cure of melarsoprol
"Effect of dofetillide on the pharmacokinetics of digoxin.
"	dofetillide	digoxin	none	{'e1': {'word': 'dofetillide', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d112.s0.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d112.s0.e1'}, 'sentence_id': 'DDI-MedLine.d112.s0'}	Effect of dofetillide on the pharmacokinetics of digoxin
The effect of dofetilide on the steady-state pharmacokinetics of digoxin was evaluated in a randomized, double-blind study. 	dofetilide	digoxin	none	{'e1': {'word': 'dofetilide', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d112.s1.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d112.s1.e1'}, 'sentence_id': 'DDI-MedLine.d112.s1'}	The effect of dofetilide on the steady state pharmacokinetics of digoxin was evaluated in a randomized double blind study
Five days of dofetilide treatment did not significantly affect steady-state pharmacokinetic variables of digoxin compared with placebo; 	dofetilide	digoxin	none	{'e1': {'word': 'dofetilide', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d112.s2.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d112.s2.e1'}, 'sentence_id': 'DDI-MedLine.d112.s2'}	NUMBER days of dofetilide treatment did not significantly affect steady state pharmacokinetic variables of digoxin compared with placebo
therefore, the use of dofetilide does not necessitate an adjustment in digoxin dose to maintain therapeutic digoxin levels.	dofetilide	digoxin	none	{'e1': {'word': 'dofetilide', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d112.s3.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d112.s3.e1'}, 'sentence_id': 'DDI-MedLine.d112.s3'}	therefore the use of dofetilide does not necessitate an adjustment in digoxin dose to maintain therapeutic digoxin levels
"The mode of toxic action of the pesticide gliftor: the metabolism of 1,3-difluoroacetone to (-)-erythro-fluorocitrate.
"	gliftor	1,3-difluoroacetone	none	{'e1': {'word': 'gliftor', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d125.s0.e0'}, 'e2': {'word': '1,3-difluoroacetone', 'word_index': [(12, 14)], 'id': 'DDI-MedLine.d125.s0.e1'}, 'sentence_id': 'DDI-MedLine.d125.s0'}	The mode of toxic action of the pesticide gliftor the metabolism of NUMBER NUMBER difluoroacetone to erythro-fluorocitrate
"The mode of toxic action of the pesticide gliftor: the metabolism of 1,3-difluoroacetone to (-)-erythro-fluorocitrate.
"	gliftor	(-)-erythro-fluorocitrate	none	{'e1': {'word': 'gliftor', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d125.s0.e0'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d125.s0.e2'}, 'sentence_id': 'DDI-MedLine.d125.s0'}	The mode of toxic action of the pesticide gliftor the metabolism of NUMBER NUMBER difluoroacetone to erythro-fluorocitrate .
"The mode of toxic action of the pesticide gliftor: the metabolism of 1,3-difluoroacetone to (-)-erythro-fluorocitrate.
"	1,3-difluoroacetone	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(12, 14)], 'id': 'DDI-MedLine.d125.s0.e1'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d125.s0.e2'}, 'sentence_id': 'DDI-MedLine.d125.s0'}	The mode of toxic action of the pesticide gliftor the metabolism of NUMBER NUMBER difluoroacetone to erythro-fluorocitrate .
The biochemical toxicology of 1,3-difluoroacetone, a known metabolite of the major ingredient of the pesticide Gliftor (1,3-difluoro-2-propanol), was investigated in vivo and in vitro. 	1,3-difluoroacetone	Gliftor	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(4, 6)], 'id': 'DDI-MedLine.d125.s1.e0'}, 'e2': {'word': 'Gliftor', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d125.s1.e1'}, 'sentence_id': 'DDI-MedLine.d125.s1'}	The biochemical toxicology of NUMBER NUMBER difluoroacetone a known metabolite of the major ingredient of the pesticide Gliftor NUMBER NUMBER difluoro NUMBER propanol was investigated in vivo and in vitro
The biochemical toxicology of 1,3-difluoroacetone, a known metabolite of the major ingredient of the pesticide Gliftor (1,3-difluoro-2-propanol), was investigated in vivo and in vitro. 	1,3-difluoroacetone	1,3-difluoro-2-propanol	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(4, 6)], 'id': 'DDI-MedLine.d125.s1.e0'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(18, 22)], 'id': 'DDI-MedLine.d125.s1.e2'}, 'sentence_id': 'DDI-MedLine.d125.s1'}	The biochemical toxicology of NUMBER NUMBER difluoroacetone a known metabolite of the major ingredient of the pesticide Gliftor NUMBER NUMBER difluoro NUMBER propanol was investigated in vivo and in vitro
The biochemical toxicology of 1,3-difluoroacetone, a known metabolite of the major ingredient of the pesticide Gliftor (1,3-difluoro-2-propanol), was investigated in vivo and in vitro. 	Gliftor	1,3-difluoro-2-propanol	none	{'e1': {'word': 'Gliftor', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d125.s1.e1'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(18, 22)], 'id': 'DDI-MedLine.d125.s1.e2'}, 'sentence_id': 'DDI-MedLine.d125.s1'}	The biochemical toxicology of NUMBER NUMBER difluoroacetone a known metabolite of the major ingredient of the pesticide Gliftor NUMBER NUMBER difluoro NUMBER propanol was investigated in vivo and in vitro
Rat kidney homogenates supplemented with coenzyme A, ATP, oxaloacetate, and Mg2+ converted 1,3-difluoroacetone to (-)-erythro-fluorocitrate in vitro. 	1,3-difluoroacetone	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(13, 15)], 'id': 'DDI-MedLine.d125.s2.e0'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d125.s2.e1'}, 'sentence_id': 'DDI-MedLine.d125.s2'}	Rat kidney homogenates supplemented with coenzyme A ATP oxaloacetate and Mg2 + converted NUMBER NUMBER difluoroacetone to - erythro-fluorocitrate in vitro .
Administration of 1,3-difluoroacetone (100 mg kg(-1) body weight) to rats in vivo resulted in (-)-erythro-fluorocitrate synthesis in the kidney, which was preceded by an elevation in fluoride levels and followed by citrate accumulation. 	1,3-difluoroacetone	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(2, 4)], 'id': 'DDI-MedLine.d125.s3.e0'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(18, 19)], 'id': 'DDI-MedLine.d125.s3.e1'}, 'sentence_id': 'DDI-MedLine.d125.s3'}	Administration of NUMBER NUMBER difluoroacetone NUMBER mg kg - NUMBER body weight to rats in vivo resulted in - erythro- synthesis in the kidney , was preceded by an elevation in fluoride levels and followed by citrate accumulation .
Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol. 	1,3-difluoroacetone	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(3, 5)], 'id': 'DDI-MedLine.d125.s4.e0'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d125.s4.e1'}, 'sentence_id': 'DDI-MedLine.d125.s4'}	Animals dosed with NUMBER NUMBER difluoroacetone did not display the NUMBER NUMBER hour lag phase in either - erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1 , NUMBER NUMBER 2 NUMBER
Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol. 	1,3-difluoroacetone	1,3-difluoro-2-propanol	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(3, 5)], 'id': 'DDI-MedLine.d125.s4.e0'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(30, 35)], 'id': 'DDI-MedLine.d125.s4.e2'}, 'sentence_id': 'DDI-MedLine.d125.s4'}	Animals dosed with NUMBER NUMBER difluoroacetone did not display the NUMBER NUMBER hour lag phase in either - erythro-fluorocitrate or in citrate and fluoride accumulation characteristic of animals dosed with 1 , NUMBER NUMBER 2 NUMBER .
Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol. 	(-)-erythro-fluorocitrate	1,3-difluoro-2-propanol	none	{'e1': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d125.s4.e1'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(31, 36)], 'id': 'DDI-MedLine.d125.s4.e2'}, 'sentence_id': 'DDI-MedLine.d125.s4'}	Animals dosed with NUMBER NUMBER difluoroacetone did not display the NUMBER NUMBER hour lag phase in either - erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1 , NUMBER NUMBER 2 NUMBER .
We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. 	1,3-difluoro-2-propanol	1,3-difluoroacetone	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(6, 10)], 'id': 'DDI-MedLine.d125.s5.e0'}, 'e2': {'word': '1,3-difluoroacetone', 'word_index': [(12, 14)], 'id': 'DDI-MedLine.d125.s5.e1'}, 'sentence_id': 'DDI-MedLine.d125.s5'}	We demonstrate that the conversion of NUMBER NUMBER difluoro NUMBER propanol to NUMBER NUMBER difluoroacetone by an NAD+ - oxidation is the rate - step in the synthesis of the toxic product , ) from 1 NUMBER NUMBER - NUMBER .
We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. 	1,3-difluoro-2-propanol	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(6, 10)], 'id': 'DDI-MedLine.d125.s5.e0'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(33, 34)], 'id': 'DDI-MedLine.d125.s5.e2'}, 'sentence_id': 'DDI-MedLine.d125.s5'}	We demonstrate that the conversion of NUMBER NUMBER difluoro NUMBER propanol to NUMBER NUMBER difluoroacetone by an NAD+ - oxidation is the rate - step in the synthesis of the toxic product , ( ) from 1 NUMBER NUMBER - NUMBER .
We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. 	1,3-difluoro-2-propanol	1,3-difluoro-2-propanol	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(6, 10)], 'id': 'DDI-MedLine.d125.s5.e0'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(35, 40)], 'id': 'DDI-MedLine.d125.s5.e3'}, 'sentence_id': 'DDI-MedLine.d125.s5'}	We demonstrate that the conversion of NUMBER NUMBER difluoro NUMBER propanol to NUMBER NUMBER difluoroacetone by an NAD+ - oxidation is the rate - step in the synthesis of the toxic product , ) from 1 , NUMBER NUMBER 2 NUMBER .
We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. 	1,3-difluoroacetone	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(12, 14)], 'id': 'DDI-MedLine.d125.s5.e1'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(33, 34)], 'id': 'DDI-MedLine.d125.s5.e2'}, 'sentence_id': 'DDI-MedLine.d125.s5'}	We demonstrate that the conversion of NUMBER NUMBER difluoro NUMBER propanol to NUMBER NUMBER difluoroacetone by an NAD+ - oxidation is the rate - step in the synthesis of the toxic product , ( ) from 1 NUMBER NUMBER - NUMBER .
We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. 	1,3-difluoroacetone	1,3-difluoro-2-propanol	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(12, 14)], 'id': 'DDI-MedLine.d125.s5.e1'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(35, 40)], 'id': 'DDI-MedLine.d125.s5.e3'}, 'sentence_id': 'DDI-MedLine.d125.s5'}	We demonstrate that the conversion of NUMBER NUMBER difluoro NUMBER propanol to NUMBER NUMBER difluoroacetone by an NAD+ - oxidation is the rate - step in the synthesis of the toxic product , ) from 1 , NUMBER NUMBER 2 NUMBER .
We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. 	(-)-erythro-fluorocitrate	1,3-difluoro-2-propanol	none	{'e1': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(33, 34)], 'id': 'DDI-MedLine.d125.s5.e2'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(36, 40)], 'id': 'DDI-MedLine.d125.s5.e3'}, 'sentence_id': 'DDI-MedLine.d125.s5'}	We demonstrate that the conversion of NUMBER NUMBER difluoro NUMBER propanol to NUMBER NUMBER difluoroacetone by an NAD+ - oxidation is the rate - step in the synthesis of the toxic product , ( ) from 1 NUMBER NUMBER - NUMBER .
Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	4-methylpyrazole	1,3-difluoro-2-propanol	effect	{'e1': {'word': '4-methylpyrazole', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d125.s6.e0'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(18, 22)], 'id': 'DDI-MedLine.d125.s6.e1'}, 'sentence_id': 'DDI-MedLine.d125.s6'}	Prior administration of NUMBER methylpyrazole NUMBER mg kg NUMBER body weight was shown to prevent the conversion of NUMBER NUMBER difluoro NUMBER propanol NUMBER mg kg NUMBER body weight to - erythro-fluorocitrate vivo and to eliminate the fluoride and citrate elevations seen in 1 , NUMBER NUMBER 2 NUMBER intoxicated .
Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	4-methylpyrazole	(-)-erythro-fluorocitrate	none	{'e1': {'word': '4-methylpyrazole', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d125.s6.e0'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(30, 31)], 'id': 'DDI-MedLine.d125.s6.e2'}, 'sentence_id': 'DDI-MedLine.d125.s6'}	Prior administration of NUMBER methylpyrazole NUMBER mg kg NUMBER body weight was shown to prevent the conversion of NUMBER NUMBER difluoro NUMBER propanol NUMBER mg kg NUMBER body weight to - erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1 , NUMBER NUMBER 2 NUMBER intoxicated .
Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	4-methylpyrazole	1,3-difluoro-2-propanol	none	{'e1': {'word': '4-methylpyrazole', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d125.s6.e0'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(44, 49)], 'id': 'DDI-MedLine.d125.s6.e3'}, 'sentence_id': 'DDI-MedLine.d125.s6'}	Prior administration of NUMBER methylpyrazole NUMBER mg kg - NUMBER body weight was shown to prevent the conversion of NUMBER NUMBER difluoro NUMBER propanol NUMBER mg kg NUMBER body weight to - erythro-fluorocitrate vivo and to eliminate the fluoride and citrate elevations seen in 1 , NUMBER NUMBER 2 NUMBER - intoxicated .
Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	1,3-difluoro-2-propanol	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(19, 23)], 'id': 'DDI-MedLine.d125.s6.e1'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(31, 32)], 'id': 'DDI-MedLine.d125.s6.e2'}, 'sentence_id': 'DDI-MedLine.d125.s6'}	Prior administration of NUMBER methylpyrazole NUMBER mg kg - NUMBER body weight was shown to prevent the conversion of NUMBER NUMBER difluoro NUMBER propanol NUMBER mg kg NUMBER body weight to - erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1 NUMBER NUMBER - NUMBER - animals .
Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	1,3-difluoro-2-propanol	1,3-difluoro-2-propanol	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(19, 23)], 'id': 'DDI-MedLine.d125.s6.e1'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(44, 49)], 'id': 'DDI-MedLine.d125.s6.e3'}, 'sentence_id': 'DDI-MedLine.d125.s6'}	Prior administration of NUMBER methylpyrazole NUMBER mg kg - NUMBER body weight was shown to prevent the conversion of NUMBER NUMBER difluoro NUMBER propanol NUMBER mg kg NUMBER body weight to - erythro-fluorocitrate vivo and to eliminate the fluoride and citrate elevations seen in 1 , NUMBER NUMBER 2 NUMBER - intoxicated .
Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	(-)-erythro-fluorocitrate	1,3-difluoro-2-propanol	none	{'e1': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(31, 32)], 'id': 'DDI-MedLine.d125.s6.e2'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(45, 50)], 'id': 'DDI-MedLine.d125.s6.e3'}, 'sentence_id': 'DDI-MedLine.d125.s6'}	Prior administration of NUMBER methylpyrazole NUMBER mg kg - NUMBER body weight was shown to prevent the conversion of NUMBER NUMBER difluoro NUMBER propanol NUMBER mg kg NUMBER body weight to - erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1 , NUMBER NUMBER 2 NUMBER - intoxicated .
However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats 2 hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo. 	4-methylpyrazole	1,3-difluoroacetone	none	{'e1': {'word': '4-methylpyrazole', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d125.s7.e0'}, 'e2': {'word': '1,3-difluoroacetone', 'word_index': [(18, 20)], 'id': 'DDI-MedLine.d125.s7.e1'}, 'sentence_id': 'DDI-MedLine.d125.s7'}	However administration of NUMBER methylpyrazole NUMBER mg kg - NUMBER body weight to rats NUMBER hours prior to NUMBER NUMBER difluoroacetone NUMBER mg kg - NUMBER body weight was ineffective in preventing - erythro-fluorocitrate and did not diminish fluoride or citrate accumulation in vivo .
However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats 2 hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo. 	4-methylpyrazole	(-)-erythro-fluorocitrate	none	{'e1': {'word': '4-methylpyrazole', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d125.s7.e0'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(32, 33)], 'id': 'DDI-MedLine.d125.s7.e2'}, 'sentence_id': 'DDI-MedLine.d125.s7'}	However administration of NUMBER methylpyrazole NUMBER mg kg - NUMBER body weight to rats NUMBER hours prior to NUMBER NUMBER difluoroacetone NUMBER mg kg - NUMBER body weight was ineffective in preventing - erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo .
However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats 2 hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo. 	1,3-difluoroacetone	(-)-erythro-fluorocitrate	none	{'e1': {'word': '1,3-difluoroacetone', 'word_index': [(18, 20)], 'id': 'DDI-MedLine.d125.s7.e1'}, 'e2': {'word': '(-)-erythro-fluorocitrate', 'word_index': [(32, 33)], 'id': 'DDI-MedLine.d125.s7.e2'}, 'sentence_id': 'DDI-MedLine.d125.s7'}	However administration of NUMBER methylpyrazole NUMBER mg kg - NUMBER body weight to rats NUMBER hours prior to NUMBER NUMBER difluoroacetone NUMBER mg kg - NUMBER body weight was ineffective in preventing - erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo .
We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.	4-methylpyrazole	1,3-difluoro-2-propanol	effect	{'e1': {'word': '4-methylpyrazole', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d125.s8.e0'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(16, 20)], 'id': 'DDI-MedLine.d125.s8.e1'}, 'sentence_id': 'DDI-MedLine.d125.s8'}	We conclude that the prophylactic and antidotal properties of NUMBER methylpyrazole seen in animals treated with NUMBER NUMBER difluoro NUMBER propanol derive from its capacity to inhibit the NAD+ - oxidation responsible for converting 1 NUMBER NUMBER - NUMBER to 1 NUMBER NUMBER in the committed step of the toxic pathway .
We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.	4-methylpyrazole	1,3-difluoro-2-propanol	none	{'e1': {'word': '4-methylpyrazole', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d125.s8.e0'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(34, 38)], 'id': 'DDI-MedLine.d125.s8.e2'}, 'sentence_id': 'DDI-MedLine.d125.s8'}	We conclude that the prophylactic and antidotal properties of NUMBER methylpyrazole seen in animals treated with NUMBER NUMBER difluoro NUMBER propanol derive from its capacity to inhibit the NAD+ - oxidation responsible for converting 1 NUMBER NUMBER - NUMBER to 1 NUMBER NUMBER in the committed step of the toxic pathway .
We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.	4-methylpyrazole	1,3-difluoroacetone	none	{'e1': {'word': '4-methylpyrazole', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d125.s8.e0'}, 'e2': {'word': '1,3-difluoroacetone', 'word_index': [(40, 42)], 'id': 'DDI-MedLine.d125.s8.e3'}, 'sentence_id': 'DDI-MedLine.d125.s8'}	We conclude that the prophylactic and antidotal properties of NUMBER methylpyrazole seen in animals treated with NUMBER NUMBER difluoro NUMBER propanol derive from its capacity to inhibit the NAD+ - oxidation responsible for converting 1 NUMBER NUMBER - NUMBER to 1 NUMBER NUMBER in the committed step of the toxic pathway .
We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.	1,3-difluoro-2-propanol	1,3-difluoro-2-propanol	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(16, 20)], 'id': 'DDI-MedLine.d125.s8.e1'}, 'e2': {'word': '1,3-difluoro-2-propanol', 'word_index': [(34, 38)], 'id': 'DDI-MedLine.d125.s8.e2'}, 'sentence_id': 'DDI-MedLine.d125.s8'}	We conclude that the prophylactic and antidotal properties of NUMBER methylpyrazole seen in animals treated with NUMBER NUMBER difluoro NUMBER propanol derive from its capacity to inhibit the NAD+ - oxidation responsible for converting 1 NUMBER NUMBER - NUMBER to 1 NUMBER NUMBER in the committed step of the toxic pathway .
We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.	1,3-difluoro-2-propanol	1,3-difluoroacetone	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(16, 20)], 'id': 'DDI-MedLine.d125.s8.e1'}, 'e2': {'word': '1,3-difluoroacetone', 'word_index': [(40, 42)], 'id': 'DDI-MedLine.d125.s8.e3'}, 'sentence_id': 'DDI-MedLine.d125.s8'}	We conclude that the prophylactic and antidotal properties of NUMBER methylpyrazole seen in animals treated with NUMBER NUMBER difluoro NUMBER propanol derive from its capacity to inhibit the NAD+ - oxidation responsible for converting 1 NUMBER NUMBER - NUMBER to 1 NUMBER NUMBER in the committed step of the toxic pathway .
We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.	1,3-difluoro-2-propanol	1,3-difluoroacetone	none	{'e1': {'word': '1,3-difluoro-2-propanol', 'word_index': [(34, 38)], 'id': 'DDI-MedLine.d125.s8.e2'}, 'e2': {'word': '1,3-difluoroacetone', 'word_index': [(40, 42)], 'id': 'DDI-MedLine.d125.s8.e3'}, 'sentence_id': 'DDI-MedLine.d125.s8'}	We conclude that the prophylactic and antidotal properties of NUMBER methylpyrazole seen in animals treated with NUMBER NUMBER difluoro NUMBER propanol derive from its capacity to inhibit the NAD+ - oxidation responsible for converting 1 NUMBER NUMBER - NUMBER to 1 NUMBER NUMBER in the committed step of the toxic pathway .
Effect of estradiol on endotoxin-induced changes in steroid hormone levels and lethality in male rats.	estradiol	endotoxin	none	{'e1': {'word': 'estradiol', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d39.s0.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d39.s0.e1'}, 'sentence_id': 'DDI-MedLine.d39.s0'}	Effect of estradiol on endotoxin induced changes in steroid hormone levels and lethality in male rats
We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin. 	estradiol	endotoxin	none	{'e1': {'word': 'estradiol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d39.s1.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d39.s1.e1'}, 'sentence_id': 'DDI-MedLine.d39.s1'}	We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin
We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin. 	estradiol	endotoxin	none	{'e1': {'word': 'estradiol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d39.s1.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d39.s1.e2'}, 'sentence_id': 'DDI-MedLine.d39.s1'}	We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin
We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin. 	endotoxin	endotoxin	none	{'e1': {'word': 'endotoxin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d39.s1.e1'}, 'e2': {'word': 'endotoxin', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d39.s1.e2'}, 'sentence_id': 'DDI-MedLine.d39.s1'}	We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin
Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin. 	estradiol	endotoxin	effect	{'e1': {'word': 'estradiol', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d39.s2.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d39.s2.e1'}, 'sentence_id': 'DDI-MedLine.d39.s2'}	Injection of estradiol NUMBER min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin
Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin. 	estradiol	endotoxin	none	{'e1': {'word': 'estradiol', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d39.s2.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d39.s2.e2'}, 'sentence_id': 'DDI-MedLine.d39.s2'}	Injection of estradiol NUMBER min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin
Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin. 	endotoxin	endotoxin	none	{'e1': {'word': 'endotoxin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d39.s2.e1'}, 'e2': {'word': 'endotoxin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d39.s2.e2'}, 'sentence_id': 'DDI-MedLine.d39.s2'}	Injection of estradiol NUMBER min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin
The serum estrogen concentrations of estradiol + endotoxin-treated rats decreased by 50%, while those of the endotoxin-treated rats increased (2- to 5-fold). 	estradiol	endotoxin	mechanism	{'e1': {'word': 'estradiol', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d39.s3.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d39.s3.e1'}, 'sentence_id': 'DDI-MedLine.d39.s3'}	The serum estrogen concentrations of estradiol + endotoxin treated rats decreased by NUMBER % while those of the endotoxin treated rats increased NUMBER to 5-fold
The serum estrogen concentrations of estradiol + endotoxin-treated rats decreased by 50%, while those of the endotoxin-treated rats increased (2- to 5-fold). 	estradiol	endotoxin	none	{'e1': {'word': 'estradiol', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d39.s3.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d39.s3.e2'}, 'sentence_id': 'DDI-MedLine.d39.s3'}	The serum estrogen concentrations of estradiol + endotoxin treated rats decreased by NUMBER % while those of the endotoxin treated rats increased NUMBER to 5-fold
The serum estrogen concentrations of estradiol + endotoxin-treated rats decreased by 50%, while those of the endotoxin-treated rats increased (2- to 5-fold). 	endotoxin	endotoxin	none	{'e1': {'word': 'endotoxin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d39.s3.e1'}, 'e2': {'word': 'endotoxin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d39.s3.e2'}, 'sentence_id': 'DDI-MedLine.d39.s3'}	The serum estrogen concentrations of estradiol + endotoxin treated rats decreased by NUMBER % while those of the endotoxin treated rats increased NUMBER to 5-fold
The serum androgen concentrations of estradiol + endotoxin-treated rats did not change significantly, while those of endotoxin-treated rats dropped to 30-40%	estradiol	endotoxin	none	{'e1': {'word': 'estradiol', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d39.s4.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d39.s4.e1'}, 'sentence_id': 'DDI-MedLine.d39.s4'}	The serum androgen concentrations of estradiol + endotoxin treated rats did not change significantly while those of endotoxin treated rats dropped to NUMBER - NUMBER %
The serum androgen concentrations of estradiol + endotoxin-treated rats did not change significantly, while those of endotoxin-treated rats dropped to 30-40%	estradiol	endotoxin	none	{'e1': {'word': 'estradiol', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d39.s4.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d39.s4.e2'}, 'sentence_id': 'DDI-MedLine.d39.s4'}	The serum androgen concentrations of estradiol + endotoxin treated rats did not change significantly while those of endotoxin treated rats dropped to NUMBER - NUMBER %
The serum androgen concentrations of estradiol + endotoxin-treated rats did not change significantly, while those of endotoxin-treated rats dropped to 30-40%	endotoxin	endotoxin	none	{'e1': {'word': 'endotoxin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d39.s4.e1'}, 'e2': {'word': 'endotoxin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d39.s4.e2'}, 'sentence_id': 'DDI-MedLine.d39.s4'}	The serum androgen concentrations of estradiol + endotoxin treated rats did not change significantly while those of endotoxin treated rats dropped to NUMBER - NUMBER %
Exogenous estradiol also appeared to influence the percentage of endotoxin-induced deaths in a dose-dependent manner. 	estradiol	endotoxin	effect	{'e1': {'word': 'estradiol', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d39.s6.e0'}, 'e2': {'word': 'endotoxin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d39.s6.e1'}, 'sentence_id': 'DDI-MedLine.d39.s6'}	Exogenous estradiol also appeared to influence the percentage of endotoxin induced deaths in a dose dependent manner
These results, together with the known relationships between estrogen and the immune response, suggest that estrogens affect the course of septic shock in a complex fashion and may have either protective or deleterious effect.	estrogen	estrogens	none	{'e1': {'word': 'estrogen', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d39.s8.e0'}, 'e2': {'word': 'estrogens', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d39.s8.e1'}, 'sentence_id': 'DDI-MedLine.d39.s8'}	These results together with the known relationships between estrogen and the immune response suggest that estrogens affect the course of septic shock in a complex fashion and may have either protective or deleterious effect
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium carboxymethylcellulose	NaCMC	none	{'e1': {'word': 'sodium carboxymethylcellulose', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d76.s1.e0'}, 'e2': {'word': 'NaCMC', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d76.s1.e1'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium carboxymethylcellulose	carboxymethylcellulose-cysteine	none	{'e1': {'word': 'sodium carboxymethylcellulose', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d76.s1.e0'}, 'e2': {'word': 'carboxymethylcellulose-cysteine', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d76.s1.e2'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium carboxymethylcellulose	CMC-Cys	none	{'e1': {'word': 'sodium carboxymethylcellulose', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d76.s1.e0'}, 'e2': {'word': 'CMC-Cys', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d76.s1.e3'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium carboxymethylcellulose	sodium fluorescein	none	{'e1': {'word': 'sodium carboxymethylcellulose', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d76.s1.e0'}, 'e2': {'word': 'sodium fluorescein', 'word_index': [(25, 26)], 'id': 'DDI-MedLine.d76.s1.e4'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium carboxymethylcellulose	NaFlu	none	{'e1': {'word': 'sodium carboxymethylcellulose', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d76.s1.e0'}, 'e2': {'word': 'NaFlu', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d76.s1.e5'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium carboxymethylcellulose	bacitracin	none	{'e1': {'word': 'sodium carboxymethylcellulose', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d76.s1.e0'}, 'e2': {'word': 'bacitracin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d76.s1.e6'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium carboxymethylcellulose	insulin	none	{'e1': {'word': 'sodium carboxymethylcellulose', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d76.s1.e0'}, 'e2': {'word': 'insulin', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d76.s1.e7'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaCMC	carboxymethylcellulose-cysteine	none	{'e1': {'word': 'NaCMC', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d76.s1.e1'}, 'e2': {'word': 'carboxymethylcellulose-cysteine', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d76.s1.e2'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaCMC	CMC-Cys	none	{'e1': {'word': 'NaCMC', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d76.s1.e1'}, 'e2': {'word': 'CMC-Cys', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d76.s1.e3'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaCMC	sodium fluorescein	none	{'e1': {'word': 'NaCMC', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d76.s1.e1'}, 'e2': {'word': 'sodium fluorescein', 'word_index': [(25, 26)], 'id': 'DDI-MedLine.d76.s1.e4'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaCMC	NaFlu	none	{'e1': {'word': 'NaCMC', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d76.s1.e1'}, 'e2': {'word': 'NaFlu', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d76.s1.e5'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaCMC	bacitracin	none	{'e1': {'word': 'NaCMC', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d76.s1.e1'}, 'e2': {'word': 'bacitracin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d76.s1.e6'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaCMC	insulin	none	{'e1': {'word': 'NaCMC', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d76.s1.e1'}, 'e2': {'word': 'insulin', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d76.s1.e7'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	carboxymethylcellulose-cysteine	CMC-Cys	none	{'e1': {'word': 'carboxymethylcellulose-cysteine', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d76.s1.e2'}, 'e2': {'word': 'CMC-Cys', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d76.s1.e3'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	carboxymethylcellulose-cysteine	sodium fluorescein	none	{'e1': {'word': 'carboxymethylcellulose-cysteine', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d76.s1.e2'}, 'e2': {'word': 'sodium fluorescein', 'word_index': [(25, 26)], 'id': 'DDI-MedLine.d76.s1.e4'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	carboxymethylcellulose-cysteine	NaFlu	none	{'e1': {'word': 'carboxymethylcellulose-cysteine', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d76.s1.e2'}, 'e2': {'word': 'NaFlu', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d76.s1.e5'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	carboxymethylcellulose-cysteine	bacitracin	none	{'e1': {'word': 'carboxymethylcellulose-cysteine', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d76.s1.e2'}, 'e2': {'word': 'bacitracin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d76.s1.e6'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	carboxymethylcellulose-cysteine	insulin	none	{'e1': {'word': 'carboxymethylcellulose-cysteine', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d76.s1.e2'}, 'e2': {'word': 'insulin', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d76.s1.e7'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	CMC-Cys	sodium fluorescein	none	{'e1': {'word': 'CMC-Cys', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d76.s1.e3'}, 'e2': {'word': 'sodium fluorescein', 'word_index': [(25, 26)], 'id': 'DDI-MedLine.d76.s1.e4'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	CMC-Cys	NaFlu	none	{'e1': {'word': 'CMC-Cys', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d76.s1.e3'}, 'e2': {'word': 'NaFlu', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d76.s1.e5'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	CMC-Cys	bacitracin	none	{'e1': {'word': 'CMC-Cys', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d76.s1.e3'}, 'e2': {'word': 'bacitracin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d76.s1.e6'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	CMC-Cys	insulin	none	{'e1': {'word': 'CMC-Cys', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d76.s1.e3'}, 'e2': {'word': 'insulin', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d76.s1.e7'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium fluorescein	NaFlu	none	{'e1': {'word': 'sodium fluorescein', 'word_index': [(25, 26)], 'id': 'DDI-MedLine.d76.s1.e4'}, 'e2': {'word': 'NaFlu', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d76.s1.e5'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium fluorescein	bacitracin	none	{'e1': {'word': 'sodium fluorescein', 'word_index': [(25, 26)], 'id': 'DDI-MedLine.d76.s1.e4'}, 'e2': {'word': 'bacitracin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d76.s1.e6'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	sodium fluorescein	insulin	none	{'e1': {'word': 'sodium fluorescein', 'word_index': [(25, 26)], 'id': 'DDI-MedLine.d76.s1.e4'}, 'e2': {'word': 'insulin', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d76.s1.e7'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaFlu	bacitracin	none	{'e1': {'word': 'NaFlu', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d76.s1.e5'}, 'e2': {'word': 'bacitracin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d76.s1.e6'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	NaFlu	insulin	none	{'e1': {'word': 'NaFlu', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d76.s1.e5'}, 'e2': {'word': 'insulin', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d76.s1.e7'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 	bacitracin	insulin	none	{'e1': {'word': 'bacitracin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d76.s1.e6'}, 'e2': {'word': 'insulin', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d76.s1.e7'}, 'sentence_id': 'DDI-MedLine.d76.s1'}	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose NaCMC and carboxymethylcellulose cysteine CMC Cys conjugates on the intestinal permeation of sodium fluorescein NaFlu and model peptide drugs bacitracin and insulin
Cysteine was covalently linked to carbodiimide activated NaCMC. 	Cysteine	NaCMC	none	{'e1': {'word': 'Cysteine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s2.e0'}, 'e2': {'word': 'NaCMC', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d76.s2.e1'}, 'sentence_id': 'DDI-MedLine.d76.s2'}	Cysteine was covalently linked to carbodiimide activated NaCMC
Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. 	NaCMC	NaFlu	none	{'e1': {'word': 'NaCMC', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d76.s5.e0'}, 'e2': {'word': 'NaFlu', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d76.s5.e1'}, 'sentence_id': 'DDI-MedLine.d76.s5'}	Unmodified NaCMC NUMBER % m v significantly improved the transport ratio R = P app polymer P app control of NaFlu to NUMBER and NUMBER % m v NaCMC conjugated with cysteine further enhanced the permeation
Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. 	NaCMC	NaCMC	none	{'e1': {'word': 'NaCMC', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d76.s5.e0'}, 'e2': {'word': 'NaCMC', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d76.s5.e2'}, 'sentence_id': 'DDI-MedLine.d76.s5'}	Unmodified NaCMC NUMBER % m v significantly improved the transport ratio R = P app polymer P app control of NaFlu to NUMBER and NUMBER % m v NaCMC conjugated with cysteine further enhanced the permeation
Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. 	NaCMC	cysteine	none	{'e1': {'word': 'NaCMC', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d76.s5.e0'}, 'e2': {'word': 'cysteine', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d76.s5.e3'}, 'sentence_id': 'DDI-MedLine.d76.s5'}	Unmodified NaCMC NUMBER % m v significantly improved the transport ratio R = P app polymer P app control of NaFlu to NUMBER and NUMBER % m v NaCMC conjugated with cysteine further enhanced the permeation
Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. 	NaFlu	NaCMC	none	{'e1': {'word': 'NaFlu', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d76.s5.e1'}, 'e2': {'word': 'NaCMC', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d76.s5.e2'}, 'sentence_id': 'DDI-MedLine.d76.s5'}	Unmodified NaCMC NUMBER % m v significantly improved the transport ratio R = P app polymer P app control of NaFlu to NUMBER and NUMBER % m v NaCMC conjugated with cysteine further enhanced the permeation
Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. 	NaFlu	cysteine	none	{'e1': {'word': 'NaFlu', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d76.s5.e1'}, 'e2': {'word': 'cysteine', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d76.s5.e3'}, 'sentence_id': 'DDI-MedLine.d76.s5'}	Unmodified NaCMC NUMBER % m v significantly improved the transport ratio R = P app polymer P app control of NaFlu to NUMBER and NUMBER % m v NaCMC conjugated with cysteine further enhanced the permeation
Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. 	NaCMC	cysteine	none	{'e1': {'word': 'NaCMC', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d76.s5.e2'}, 'e2': {'word': 'cysteine', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d76.s5.e3'}, 'sentence_id': 'DDI-MedLine.d76.s5'}	Unmodified NaCMC NUMBER % m v significantly improved the transport ratio R = P app polymer P app control of NaFlu to NUMBER and NUMBER % m v NaCMC conjugated with cysteine further enhanced the permeation
Decreasing the concentration of CMC-Cys, exhibiting 7.3% (m/m) of immobilised cysteine (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of NaFlu from 1.8 to 1.2. 	CMC-Cys	cysteine	none	{'e1': {'word': 'CMC-Cys', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d76.s7.e0'}, 'e2': {'word': 'cysteine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d76.s7.e1'}, 'sentence_id': 'DDI-MedLine.d76.s7'}	Decreasing the concentration of CMC Cys exhibiting NUMBER % m / m of immobilised cysteine CMC Cys7.3 from NUMBER % m / v to NUMBER % m v decreased the R value of NaFlu from NUMBER to NUMBER
Decreasing the concentration of CMC-Cys, exhibiting 7.3% (m/m) of immobilised cysteine (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of NaFlu from 1.8 to 1.2. 	CMC-Cys	NaFlu	none	{'e1': {'word': 'CMC-Cys', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d76.s7.e0'}, 'e2': {'word': 'NaFlu', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d76.s7.e2'}, 'sentence_id': 'DDI-MedLine.d76.s7'}	Decreasing the concentration of CMC Cys exhibiting NUMBER % m / m of immobilised cysteine CMC Cys7.3 from NUMBER % m / v to NUMBER % m v decreased the R value of NaFlu from NUMBER to NUMBER
Decreasing the concentration of CMC-Cys, exhibiting 7.3% (m/m) of immobilised cysteine (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of NaFlu from 1.8 to 1.2. 	cysteine	NaFlu	none	{'e1': {'word': 'cysteine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d76.s7.e1'}, 'e2': {'word': 'NaFlu', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d76.s7.e2'}, 'sentence_id': 'DDI-MedLine.d76.s7'}	Decreasing the concentration of CMC Cys exhibiting NUMBER % m / m of immobilised cysteine CMC Cys7.3 from NUMBER % m / v to NUMBER % m v decreased the R value of NaFlu from NUMBER to NUMBER
NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. 	NaCMC	cysteine	none	{'e1': {'word': 'NaCMC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s8.e0'}, 'e2': {'word': 'cysteine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d76.s8.e1'}, 'sentence_id': 'DDI-MedLine.d76.s8'}	NaCMC at NUMBER % m v in the presence of free cysteine had no significant effect on the R value of NaFlu compared to NaCMC alone
NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. 	NaCMC	NaFlu	none	{'e1': {'word': 'NaCMC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s8.e0'}, 'e2': {'word': 'NaFlu', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s8.e2'}, 'sentence_id': 'DDI-MedLine.d76.s8'}	NaCMC at NUMBER % m v in the presence of free cysteine had no significant effect on the R value of NaFlu compared to NaCMC alone
NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. 	NaCMC	NaCMC	none	{'e1': {'word': 'NaCMC', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d76.s8.e0'}, 'e2': {'word': 'NaCMC', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d76.s8.e3'}, 'sentence_id': 'DDI-MedLine.d76.s8'}	NaCMC at NUMBER % m v in the presence of free cysteine had no significant effect on the R value of NaFlu compared to NaCMC alone
NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. 	cysteine	NaFlu	none	{'e1': {'word': 'cysteine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d76.s8.e1'}, 'e2': {'word': 'NaFlu', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s8.e2'}, 'sentence_id': 'DDI-MedLine.d76.s8'}	NaCMC at NUMBER % m v in the presence of free cysteine had no significant effect on the R value of NaFlu compared to NaCMC alone
NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. 	cysteine	NaCMC	none	{'e1': {'word': 'cysteine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d76.s8.e1'}, 'e2': {'word': 'NaCMC', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d76.s8.e3'}, 'sentence_id': 'DDI-MedLine.d76.s8'}	NaCMC at NUMBER % m v in the presence of free cysteine had no significant effect on the R value of NaFlu compared to NaCMC alone
NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. 	NaFlu	NaCMC	none	{'e1': {'word': 'NaFlu', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s8.e2'}, 'e2': {'word': 'NaCMC', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d76.s8.e3'}, 'sentence_id': 'DDI-MedLine.d76.s8'}	NaCMC at NUMBER % m v in the presence of free cysteine had no significant effect on the R value of NaFlu compared to NaCMC alone .
Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). 	bacitracin	insulin	none	{'e1': {'word': 'bacitracin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d76.s9.e0'}, 'e2': {'word': 'insulin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d76.s9.e1'}, 'sentence_id': 'DDI-MedLine.d76.s9'}	Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC NUMBER % m / v did not significantly improve the permeation however in the presence of NUMBER % m v CMC Cys NUMBER a significantly improved permeation was observed R = NUMBER
Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). 	bacitracin	NaCMC	none	{'e1': {'word': 'bacitracin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d76.s9.e0'}, 'e2': {'word': 'NaCMC', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d76.s9.e2'}, 'sentence_id': 'DDI-MedLine.d76.s9'}	Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC NUMBER % m / v did not significantly improve the permeation however in the presence of NUMBER % m v CMC Cys NUMBER a significantly improved permeation was observed R = NUMBER
Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). 	bacitracin	CMC-Cys	none	{'e1': {'word': 'bacitracin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d76.s9.e0'}, 'e2': {'word': 'CMC-Cys', 'word_index': [(30, 31)], 'id': 'DDI-MedLine.d76.s9.e3'}, 'sentence_id': 'DDI-MedLine.d76.s9'}	Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC NUMBER % m / v did not significantly improve the permeation however in the presence of NUMBER % m v CMC Cys NUMBER a significantly improved permeation was observed R = NUMBER
Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). 	insulin	NaCMC	none	{'e1': {'word': 'insulin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d76.s9.e1'}, 'e2': {'word': 'NaCMC', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d76.s9.e2'}, 'sentence_id': 'DDI-MedLine.d76.s9'}	Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC NUMBER % m / v did not significantly improve the permeation however in the presence of NUMBER % m v CMC Cys NUMBER a significantly improved permeation was observed R = NUMBER
Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). 	insulin	CMC-Cys	none	{'e1': {'word': 'insulin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d76.s9.e1'}, 'e2': {'word': 'CMC-Cys', 'word_index': [(30, 31)], 'id': 'DDI-MedLine.d76.s9.e3'}, 'sentence_id': 'DDI-MedLine.d76.s9'}	Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC NUMBER % m / v did not significantly improve the permeation however in the presence of NUMBER % m v CMC Cys NUMBER a significantly improved permeation was observed R = NUMBER
Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). 	NaCMC	CMC-Cys	none	{'e1': {'word': 'NaCMC', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d76.s9.e2'}, 'e2': {'word': 'CMC-Cys', 'word_index': [(30, 31)], 'id': 'DDI-MedLine.d76.s9.e3'}, 'sentence_id': 'DDI-MedLine.d76.s9'}	Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC NUMBER % m / v did not significantly improve the permeation however in the presence of NUMBER % m v CMC Cys NUMBER a significantly improved permeation was observed R = NUMBER
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	NaCMC	cysteine	none	{'e1': {'word': 'NaCMC', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d76.s10.e0'}, 'e2': {'word': 'cysteine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d76.s10.e1'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	NaCMC	NaFlu	none	{'e1': {'word': 'NaCMC', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d76.s10.e0'}, 'e2': {'word': 'NaFlu', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d76.s10.e2'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	NaCMC	bacitracin	none	{'e1': {'word': 'NaCMC', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d76.s10.e0'}, 'e2': {'word': 'bacitracin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s10.e3'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	NaCMC	insulin	none	{'e1': {'word': 'NaCMC', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d76.s10.e0'}, 'e2': {'word': 'insulin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d76.s10.e4'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	cysteine	NaFlu	none	{'e1': {'word': 'cysteine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d76.s10.e1'}, 'e2': {'word': 'NaFlu', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d76.s10.e2'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	cysteine	bacitracin	none	{'e1': {'word': 'cysteine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d76.s10.e1'}, 'e2': {'word': 'bacitracin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s10.e3'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	cysteine	insulin	none	{'e1': {'word': 'cysteine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d76.s10.e1'}, 'e2': {'word': 'insulin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d76.s10.e4'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	NaFlu	bacitracin	none	{'e1': {'word': 'NaFlu', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d76.s10.e2'}, 'e2': {'word': 'bacitracin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s10.e3'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	NaFlu	insulin	none	{'e1': {'word': 'NaFlu', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d76.s10.e2'}, 'e2': {'word': 'insulin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d76.s10.e4'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.	bacitracin	insulin	none	{'e1': {'word': 'bacitracin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d76.s10.e3'}, 'e2': {'word': 'insulin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d76.s10.e4'}, 'sentence_id': 'DDI-MedLine.d76.s10'}	Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future
"ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia.
"	ADL 8-2698	morphine	effect	{'e1': {'word': 'ADL 8-2698', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d87.s0.e0'}, 'e2': {'word': 'morphine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d87.s0.e1'}, 'sentence_id': 'DDI-MedLine.d87.s0'}	ADL NUMBER NUMBER a trans NUMBER NUMBER dimethyl NUMBER NUMBER hydroxyphenyl piperidine prevents gastrointestinal effects of intravenous morphine without affecting analgesia
ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia. 	ADL-8-2698	peripherally restricted opioid antagonist	none	{'e1': {'word': 'ADL-8-2698', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d87.s1.e0'}, 'e2': {'word': 'peripherally restricted opioid antagonist', 'word_index': [(6, 9)], 'id': 'DDI-MedLine.d87.s1.e1'}, 'sentence_id': 'DDI-MedLine.d87.s1'}	ADL NUMBER NUMBER is a novel peripherally restricted opioid antagonist that may selectively prevent opioid induced gastrointestinal effects without reversing analgesia
ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia. 	ADL-8-2698	opioid	effect	{'e1': {'word': 'ADL-8-2698', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d87.s1.e0'}, 'e2': {'word': 'opioid', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d87.s1.e2'}, 'sentence_id': 'DDI-MedLine.d87.s1'}	ADL NUMBER NUMBER is a novel peripherally restricted opioid antagonist that may selectively prevent opioid induced gastrointestinal effects without reversing analgesia
ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia. 	peripherally restricted opioid antagonist	opioid	none	{'e1': {'word': 'peripherally restricted opioid antagonist', 'word_index': [(5, 8)], 'id': 'DDI-MedLine.d87.s1.e1'}, 'e2': {'word': 'opioid', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d87.s1.e2'}, 'sentence_id': 'DDI-MedLine.d87.s1'}	ADL NUMBER is a novel peripherally restricted opioid antagonist that may selectively prevent opioid induced gastrointestinal effects without reversing analgesia
Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (0.05 mg x kg(-1)), and oral ADL 8-2698 (4 mg) and intravenous morphine (0.05 mg x kg(-1)) in a double blind, cross-over study. 	morphine	ADL 8-2698	none	{'e1': {'word': 'morphine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d87.s2.e0'}, 'e2': {'word': 'ADL 8-2698', 'word_index': [(30, 32)], 'id': 'DDI-MedLine.d87.s2.e1'}, 'sentence_id': 'DDI-MedLine.d87.s2'}	Gastrointestinal transit time lactulose hydrogen breath test was measured in NUMBER volunteers with oral and intravenous placebo oral placebo and intravenous morphine NUMBER mg x kg - NUMBER and oral ADL NUMBER NUMBER NUMBER mg and intravenous morphine NUMBER mg x kg NUMBER in a double blind cross-over study
Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (0.05 mg x kg(-1)), and oral ADL 8-2698 (4 mg) and intravenous morphine (0.05 mg x kg(-1)) in a double blind, cross-over study. 	morphine	morphine	none	{'e1': {'word': 'morphine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d87.s2.e0'}, 'e2': {'word': 'morphine', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d87.s2.e2'}, 'sentence_id': 'DDI-MedLine.d87.s2'}	Gastrointestinal transit time lactulose hydrogen breath test was measured in NUMBER volunteers with oral and intravenous placebo oral placebo and intravenous morphine NUMBER mg x kg - NUMBER and oral ADL NUMBER NUMBER NUMBER mg and intravenous morphine NUMBER mg x kg - NUMBER in a double blind cross-over study
Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (0.05 mg x kg(-1)), and oral ADL 8-2698 (4 mg) and intravenous morphine (0.05 mg x kg(-1)) in a double blind, cross-over study. 	ADL 8-2698	morphine	none	{'e1': {'word': 'ADL 8-2698', 'word_index': [(30, 32)], 'id': 'DDI-MedLine.d87.s2.e1'}, 'e2': {'word': 'morphine', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d87.s2.e2'}, 'sentence_id': 'DDI-MedLine.d87.s2'}	Gastrointestinal transit time lactulose hydrogen breath test was measured in NUMBER volunteers with oral and intravenous placebo oral placebo and intravenous morphine NUMBER mg x kg - NUMBER and oral ADL NUMBER NUMBER NUMBER mg and intravenous morphine NUMBER mg x kg NUMBER in a double blind cross-over study
Morphine prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005); this was prevented by ADL 8-2698 (P = .004). 	Morphine	ADL 8-2698	effect	{'e1': {'word': 'Morphine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d87.s4.e0'}, 'e2': {'word': 'ADL 8-2698', 'word_index': [(17, 20)], 'id': 'DDI-MedLine.d87.s4.e1'}, 'sentence_id': 'DDI-MedLine.d87.s4'}	Morphine prolonged gastrointestinal transit time from NUMBER to NUMBER minutes P = NUMBER this was prevented by ADL NUMBER - NUMBER P = NUMBER
Postoperatively, 45 patients were randomly assigned in a double-blind fashion to receive ADL 8-2698 (4 mg) or placebo and intravenous morphine (0.15 mg/kg) or to receive oral and intravenous placebo. 	ADL 8-2698	morphine	none	{'e1': {'word': 'ADL 8-2698', 'word_index': [(13, 15)], 'id': 'DDI-MedLine.d87.s5.e0'}, 'e2': {'word': 'morphine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d87.s5.e1'}, 'sentence_id': 'DDI-MedLine.d87.s5'}	Postoperatively NUMBER patients were randomly assigned in a double blind fashion to receive ADL NUMBER NUMBER NUMBER mg or placebo and intravenous morphine NUMBER mg / kg or to receive oral and intravenous placebo
Morphine analgesia and pupil constriction were unaffected by ADL 8-2698 and differed from placebo (P < .002). 	Morphine	ADL 8-2698	none	{'e1': {'word': 'Morphine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d87.s7.e0'}, 'e2': {'word': 'ADL 8-2698', 'word_index': [(8, 10)], 'id': 'DDI-MedLine.d87.s7.e1'}, 'sentence_id': 'DDI-MedLine.d87.s7'}	Morphine analgesia and pupil constriction were unaffected by ADL NUMBER NUMBER and differed from placebo P < NUMBER
We conclude that ADL 8-2698 prevents morphine-induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia.	ADL 8-2698	morphine	effect	{'e1': {'word': 'ADL 8-2698', 'word_index': [(3, 5)], 'id': 'DDI-MedLine.d87.s8.e0'}, 'e2': {'word': 'morphine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d87.s8.e1'}, 'sentence_id': 'DDI-MedLine.d87.s8'}	We conclude that ADL NUMBER NUMBER prevents morphine induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia
Fluvastatin is the first synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor to be approved for clinical use, and has been studied extensively in humans since 1986. 	Fluvastatin	synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor	none	{'e1': {'word': 'Fluvastatin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d119.s1.e0'}, 'e2': {'word': 'synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor', 'word_index': [(4, 13)], 'id': 'DDI-MedLine.d119.s1.e1'}, 'sentence_id': 'DDI-MedLine.d119.s1'}	Fluvastatin is the first synthetic NUMBER hydroxy NUMBER methylglutaryl coenzyme A HMGCoA reductase inhibitor to be approved for clinical use and has been studied extensively in humans since NUMBER
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	HMGCoA reductase inhibitors	lovastatin	none	{'e1': {'word': 'HMGCoA reductase inhibitors', 'word_index': [(9, 11)], 'id': 'DDI-MedLine.d119.s2.e0'}, 'e2': {'word': 'lovastatin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d119.s2.e1'}, 'sentence_id': 'DDI-MedLine.d119.s2'}	It is structurally distinct from the other currently available HMGCoA reductase inhibitors lovastatin simvastatin and pravastatin leading to unique biopharmaceutical properties relative to the other agents of this class
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	HMGCoA reductase inhibitors	simvastatin	none	{'e1': {'word': 'HMGCoA reductase inhibitors', 'word_index': [(9, 11)], 'id': 'DDI-MedLine.d119.s2.e0'}, 'e2': {'word': 'simvastatin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d119.s2.e2'}, 'sentence_id': 'DDI-MedLine.d119.s2'}	It is structurally distinct from the other currently available HMGCoA reductase inhibitors lovastatin simvastatin and pravastatin leading to unique biopharmaceutical properties relative to the other agents of this class
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	HMGCoA reductase inhibitors	pravastatin	none	{'e1': {'word': 'HMGCoA reductase inhibitors', 'word_index': [(9, 11)], 'id': 'DDI-MedLine.d119.s2.e0'}, 'e2': {'word': 'pravastatin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d119.s2.e3'}, 'sentence_id': 'DDI-MedLine.d119.s2'}	It is structurally distinct from the other currently available HMGCoA reductase inhibitors lovastatin simvastatin and pravastatin leading to unique biopharmaceutical properties relative to the other agents of this class
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	lovastatin	simvastatin	none	{'e1': {'word': 'lovastatin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d119.s2.e1'}, 'e2': {'word': 'simvastatin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d119.s2.e2'}, 'sentence_id': 'DDI-MedLine.d119.s2'}	It is structurally distinct from the other currently available HMGCoA reductase inhibitors lovastatin simvastatin and pravastatin leading to unique biopharmaceutical properties relative to the other agents of this class
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	lovastatin	pravastatin	none	{'e1': {'word': 'lovastatin', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d119.s2.e1'}, 'e2': {'word': 'pravastatin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d119.s2.e3'}, 'sentence_id': 'DDI-MedLine.d119.s2'}	It is structurally distinct from the other currently available HMGCoA reductase inhibitors lovastatin simvastatin and pravastatin leading to unique biopharmaceutical properties relative to the other agents of this class
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	simvastatin	pravastatin	none	{'e1': {'word': 'simvastatin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d119.s2.e2'}, 'e2': {'word': 'pravastatin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d119.s2.e3'}, 'sentence_id': 'DDI-MedLine.d119.s2'}	It is structurally distinct from the other currently available HMGCoA reductase inhibitors lovastatin simvastatin and pravastatin leading to unique biopharmaceutical properties relative to the other agents of this class
Cholestyramine, an anionic-binding resin, has a considerable effect in lowering the rate and extent of fluvastatin bioavailability. 	Cholestyramine	fluvastatin	mechanism	{'e1': {'word': 'Cholestyramine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d119.s15.e0'}, 'e2': {'word': 'fluvastatin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d119.s15.e1'}, 'sentence_id': 'DDI-MedLine.d119.s15'}	Cholestyramine an anionic binding resin has a considerable effect in lowering the rate and extent of fluvastatin bioavailability
Although this effect was noted even when cholestyramine was given 4 hours prior to fluvastatin, this regimen did not result in diminished efficacy. 	cholestyramine	fluvastatin	effect	{'e1': {'word': 'cholestyramine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d119.s16.e0'}, 'e2': {'word': 'fluvastatin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d119.s16.e1'}, 'sentence_id': 'DDI-MedLine.d119.s16'}	Although this effect was noted even when cholestyramine was given NUMBER hours prior to fluvastatin this regimen did not result in diminished efficacy
Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of warfarin and fluvastatin. 	warfarin	warfarin	none	{'e1': {'word': 'warfarin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d119.s17.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d119.s17.e1'}, 'sentence_id': 'DDI-MedLine.d119.s17'}	Further no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of warfarin and fluvastatin
Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of warfarin and fluvastatin. 	warfarin	fluvastatin	none	{'e1': {'word': 'warfarin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d119.s17.e0'}, 'e2': {'word': 'fluvastatin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d119.s17.e2'}, 'sentence_id': 'DDI-MedLine.d119.s17'}	Further no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of warfarin and fluvastatin
Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of warfarin and fluvastatin. 	warfarin	fluvastatin	none	{'e1': {'word': 'warfarin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d119.s17.e1'}, 'e2': {'word': 'fluvastatin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d119.s17.e2'}, 'sentence_id': 'DDI-MedLine.d119.s17'}	Further no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of warfarin and fluvastatin
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	niacin	propranolol	none	{'e1': {'word': 'niacin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d119.s18.e0'}, 'e2': {'word': 'propranolol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d119.s18.e1'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	Moreover additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	niacin	fluvastatin	none	{'e1': {'word': 'niacin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d119.s18.e0'}, 'e2': {'word': 'fluvastatin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d119.s18.e2'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	Moreover additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	niacin	digoxin	none	{'e1': {'word': 'niacin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d119.s18.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d119.s18.e3'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	Moreover additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	niacin	digoxin	none	{'e1': {'word': 'niacin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d119.s18.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d119.s18.e4'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	Moreover additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	propranolol	fluvastatin	none	{'e1': {'word': 'propranolol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d119.s18.e1'}, 'e2': {'word': 'fluvastatin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d119.s18.e2'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	Moreover additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	propranolol	digoxin	none	{'e1': {'word': 'propranolol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d119.s18.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d119.s18.e3'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	Moreover additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	propranolol	digoxin	none	{'e1': {'word': 'propranolol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d119.s18.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d119.s18.e4'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	Moreover additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	fluvastatin	digoxin	none	{'e1': {'word': 'fluvastatin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d119.s18.e2'}, 'e2': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d119.s18.e3'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	Moreover additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	fluvastatin	digoxin	none	{'e1': {'word': 'fluvastatin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d119.s18.e2'}, 'e2': {'word': 'digoxin', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d119.s18.e4'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	Moreover additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d119.s18.e3'}, 'e2': {'word': 'digoxin', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d119.s18.e4'}, 'sentence_id': 'DDI-MedLine.d119.s18'}	Moreover additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data
Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats. 	Resveratrol	noradrenaline	none	{'e1': {'word': 'Resveratrol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d95.s4.e0'}, 'e2': {'word': 'noradrenaline', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d95.s4.e1'}, 'sentence_id': 'DDI-MedLine.d95.s4'}	Resveratrol NUMBER - NUMBER micromol / l induced concentration dependent relaxation of mesenteric arteries preconstricted with noradrenaline NUMBER micromol / l or KCl NUMBER mmol / l from both lean and dietary obese rats
Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats. 	Resveratrol	KCl	none	{'e1': {'word': 'Resveratrol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d95.s4.e0'}, 'e2': {'word': 'KCl', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d95.s4.e2'}, 'sentence_id': 'DDI-MedLine.d95.s4'}	Resveratrol NUMBER - NUMBER micromol / l induced concentration dependent relaxation of mesenteric arteries preconstricted with noradrenaline NUMBER micromol / l or KCl NUMBER mmol / l from both lean and dietary obese rats
Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats. 	noradrenaline	KCl	none	{'e1': {'word': 'noradrenaline', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d95.s4.e1'}, 'e2': {'word': 'KCl', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d95.s4.e2'}, 'sentence_id': 'DDI-MedLine.d95.s4'}	Resveratrol NUMBER - NUMBER micromol / l induced concentration dependent relaxation of mesenteric arteries preconstricted with noradrenaline NUMBER micromol / l or KCl NUMBER mmol / l from both lean and dietary obese rats
However, L-NAME (100 and 300 micromol/l) did not alter the effects of reseveratrol on arteries from dietary-obese rats, giving superimposed concentration-responses curves. 	L-NAME	reseveratrol	none	{'e1': {'word': 'L-NAME', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d95.s6.e0'}, 'e2': {'word': 'reseveratrol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d95.s6.e1'}, 'sentence_id': 'DDI-MedLine.d95.s6'}	However L NAME NUMBER and NUMBER micromol / l did not alter the effects of reseveratrol on arteries from dietary obese rats giving superimposed concentration responses curves
Indomethacin was also ineffective in altering resveratrol activity in arteries from both lean and dietary-obese rats. 	Indomethacin	resveratrol	none	{'e1': {'word': 'Indomethacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d95.s7.e0'}, 'e2': {'word': 'resveratrol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d95.s7.e1'}, 'sentence_id': 'DDI-MedLine.d95.s7'}	Indomethacin was also ineffective in altering resveratrol activity in arteries from both lean and dietary obese rats
In noradrenaline-precontracted arteries from dietary-obese rats, responses to resveratrol were not attenuated by endothelial denudation, indicating an action independent of the endothelium. 	noradrenaline	resveratrol	none	{'e1': {'word': 'noradrenaline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d95.s8.e0'}, 'e2': {'word': 'resveratrol', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d95.s8.e1'}, 'sentence_id': 'DDI-MedLine.d95.s8'}	In noradrenaline precontracted arteries from dietary obese rats responses to resveratrol were not attenuated by endothelial denudation indicating an action independent of the endothelium
This study indicates that: (a) the maximal effects of resveratrol on resistance arteries from lean and dietary-obese rats are not effected by endothelial dysfunction, and (b) the effects of resveratrol in lean animals (where endothelial function is not impaired), but not in dietary-obese rats, are mediated via NO.	resveratrol	resveratrol	none	{'e1': {'word': 'resveratrol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d95.s9.e0'}, 'e2': {'word': 'resveratrol', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d95.s9.e1'}, 'sentence_id': 'DDI-MedLine.d95.s9'}	This study indicates that a the maximal effects of resveratrol on resistance arteries from lean and dietary obese rats are not effected by endothelial dysfunction and b the effects of resveratrol in lean animals where endothelial function is not impaired but not in dietary obese rats are mediated via NO
On the basis of the estimated number of regular users of intravenous amphetamine in Ontario, the mortality rate in such users is at least four times as high as in the general population of the same age, and is comparable to that in alcoholics and heroin addicts. 	amphetamine	heroin	none	{'e1': {'word': 'amphetamine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d13.s7.e0'}, 'e2': {'word': 'heroin', 'word_index': [(45, 45)], 'id': 'DDI-MedLine.d13.s7.e1'}, 'sentence_id': 'DDI-MedLine.d13.s7'}	On the basis of the estimated number of regular users of intravenous amphetamine in Ontario the mortality rate in such users is at least NUMBER times as high as in the general population of the same age and is comparable to that in alcoholics and heroin addicts
However, the absolute number of alcohol-related deaths is far greater than the number of deaths in amphetamine or heroin users.	alcohol	amphetamine	none	{'e1': {'word': 'alcohol', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d13.s8.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d13.s8.e1'}, 'sentence_id': 'DDI-MedLine.d13.s8'}	However the absolute number of alcohol related deaths is far greater than the number of deaths in amphetamine or heroin users
However, the absolute number of alcohol-related deaths is far greater than the number of deaths in amphetamine or heroin users.	alcohol	heroin	none	{'e1': {'word': 'alcohol', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d13.s8.e0'}, 'e2': {'word': 'heroin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d13.s8.e2'}, 'sentence_id': 'DDI-MedLine.d13.s8'}	However the absolute number of alcohol related deaths is far greater than the number of deaths in amphetamine or heroin users
However, the absolute number of alcohol-related deaths is far greater than the number of deaths in amphetamine or heroin users.	amphetamine	heroin	none	{'e1': {'word': 'amphetamine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d13.s8.e1'}, 'e2': {'word': 'heroin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d13.s8.e2'}, 'sentence_id': 'DDI-MedLine.d13.s8'}	However the absolute number of alcohol related deaths is far greater than the number of deaths in amphetamine or heroin users
"The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine.
"	phenytoin	quetiapine	none	{'e1': {'word': 'phenytoin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d0.s0.e0'}, 'e2': {'word': 'quetiapine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d0.s0.e1'}, 'sentence_id': 'DDI-MedLine.d0.s0'}	The effects of concomitant phenytoin administration on the steady state pharmacokinetics of quetiapine
Quetiapine fumarate ('Seroquel') is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia. 	Quetiapine fumarate	Seroquel	none	{'e1': {'word': 'Quetiapine fumarate', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d0.s1.e0'}, 'e2': {'word': 'Seroquel', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d0.s1.e1'}, 'sentence_id': 'DDI-MedLine.d0.s1'}	Quetiapine fumarate Seroquel is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia
Quetiapine fumarate ('Seroquel') is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia. 	Quetiapine fumarate	atypical antipsychotic	none	{'e1': {'word': 'Quetiapine fumarate', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d0.s1.e0'}, 'e2': {'word': 'atypical antipsychotic', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d0.s1.e2'}, 'sentence_id': 'DDI-MedLine.d0.s1'}	Quetiapine fumarate Seroquel is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia
Quetiapine fumarate ('Seroquel') is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia. 	Seroquel	atypical antipsychotic	none	{'e1': {'word': 'Seroquel', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d0.s1.e1'}, 'e2': {'word': 'atypical antipsychotic', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d0.s1.e2'}, 'sentence_id': 'DDI-MedLine.d0.s1'}	Quetiapine fumarate Seroquel is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia
This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder. 	phenytoin	quetiapine	mechanism	{'e1': {'word': 'phenytoin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d0.s4.e0'}, 'e2': {'word': 'quetiapine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d0.s4.e1'}, 'sentence_id': 'DDI-MedLine.d0.s4'}	This study demonstrated that the potent cytochrome P450 enzyme inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM NUMBER diagnosed schizophrenia schizoaffective disorder or bipolar disorder
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	caffeine	theophylline	none	{'e1': {'word': 'caffeine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d51.s1.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d51.s1.e1'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	We investigated the effects of adenosine receptor antagonists caffeine theophylline NUMBER phenyltheophylline and NUMBER cyclopentyl NUMBER NUMBER dipropylxanthine DPCPX in a light dark test in mice
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	caffeine	8-phenyltheophylline	none	{'e1': {'word': 'caffeine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d51.s1.e0'}, 'e2': {'word': '8-phenyltheophylline', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d51.s1.e2'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	We investigated the effects of adenosine receptor antagonists caffeine theophylline NUMBER phenyltheophylline and NUMBER cyclopentyl NUMBER NUMBER dipropylxanthine DPCPX in a light dark test in mice
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	caffeine	8-cyclopentyl-1,3-dipropylxanthine	none	{'e1': {'word': 'caffeine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d51.s1.e0'}, 'e2': {'word': '8-cyclopentyl-1,3-dipropylxanthine', 'word_index': [(13, 17)], 'id': 'DDI-MedLine.d51.s1.e3'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	We investigated the effects of adenosine receptor antagonists caffeine theophylline NUMBER phenyltheophylline and NUMBER cyclopentyl NUMBER NUMBER dipropylxanthine DPCPX in a light dark test in mice
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	caffeine	DPCPX	none	{'e1': {'word': 'caffeine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d51.s1.e0'}, 'e2': {'word': 'DPCPX', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d51.s1.e4'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	We investigated the effects of adenosine receptor antagonists caffeine theophylline NUMBER phenyltheophylline and NUMBER cyclopentyl NUMBER NUMBER dipropylxanthine DPCPX in a light dark test in mice
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	theophylline	8-phenyltheophylline	none	{'e1': {'word': 'theophylline', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d51.s1.e1'}, 'e2': {'word': '8-phenyltheophylline', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d51.s1.e2'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	We investigated the effects of adenosine receptor antagonists caffeine theophylline NUMBER phenyltheophylline and NUMBER cyclopentyl NUMBER NUMBER dipropylxanthine DPCPX in a light dark test in mice
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	theophylline	8-cyclopentyl-1,3-dipropylxanthine	none	{'e1': {'word': 'theophylline', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d51.s1.e1'}, 'e2': {'word': '8-cyclopentyl-1,3-dipropylxanthine', 'word_index': [(13, 17)], 'id': 'DDI-MedLine.d51.s1.e3'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	We investigated the effects of adenosine receptor antagonists caffeine theophylline NUMBER phenyltheophylline and NUMBER cyclopentyl NUMBER NUMBER dipropylxanthine DPCPX in a light dark test in mice
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	theophylline	DPCPX	none	{'e1': {'word': 'theophylline', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d51.s1.e1'}, 'e2': {'word': 'DPCPX', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d51.s1.e4'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	We investigated the effects of adenosine receptor antagonists caffeine theophylline NUMBER phenyltheophylline and NUMBER cyclopentyl NUMBER NUMBER dipropylxanthine DPCPX in a light dark test in mice
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	8-phenyltheophylline	8-cyclopentyl-1,3-dipropylxanthine	none	{'e1': {'word': '8-phenyltheophylline', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d51.s1.e2'}, 'e2': {'word': '8-cyclopentyl-1,3-dipropylxanthine', 'word_index': [(13, 17)], 'id': 'DDI-MedLine.d51.s1.e3'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	We investigated the effects of adenosine receptor antagonists caffeine theophylline NUMBER phenyltheophylline and NUMBER cyclopentyl NUMBER NUMBER dipropylxanthine DPCPX in a light dark test in mice
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	8-phenyltheophylline	DPCPX	none	{'e1': {'word': '8-phenyltheophylline', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d51.s1.e2'}, 'e2': {'word': 'DPCPX', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d51.s1.e4'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	We investigated the effects of adenosine receptor antagonists caffeine theophylline NUMBER phenyltheophylline and NUMBER cyclopentyl NUMBER NUMBER dipropylxanthine DPCPX in a light dark test in mice
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 	8-cyclopentyl-1,3-dipropylxanthine	DPCPX	none	{'e1': {'word': '8-cyclopentyl-1,3-dipropylxanthine', 'word_index': [(13, 17)], 'id': 'DDI-MedLine.d51.s1.e3'}, 'e2': {'word': 'DPCPX', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d51.s1.e4'}, 'sentence_id': 'DDI-MedLine.d51.s1'}	We investigated the effects of adenosine receptor antagonists caffeine theophylline NUMBER phenyltheophylline and NUMBER cyclopentyl NUMBER NUMBER dipropylxanthine DPCPX in a light dark test in mice
The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. 	theophylline	CGS 21680	effect	{'e1': {'word': 'theophylline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d51.s3.e0'}, 'e2': {'word': 'CGS 21680', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d51.s3.e1'}, 'sentence_id': 'DDI-MedLine.d51.s3'}	The anxiogenic effects of theophylline were reduced by pretreatment with CGS NUMBER an A2 selective agonist but not by N6 cyclopentyladenosine CPA an A1 selective agonist
The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. 	theophylline	N6-cyclopentyladenosine	none	{'e1': {'word': 'theophylline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d51.s3.e0'}, 'e2': {'word': 'N6-cyclopentyladenosine', 'word_index': [(19, 20)], 'id': 'DDI-MedLine.d51.s3.e2'}, 'sentence_id': 'DDI-MedLine.d51.s3'}	The anxiogenic effects of theophylline were reduced by pretreatment with CGS NUMBER an A2 selective agonist but not by N6 cyclopentyladenosine CPA an A1 selective agonist
The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. 	theophylline	CPA	none	{'e1': {'word': 'theophylline', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d51.s3.e0'}, 'e2': {'word': 'CPA', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d51.s3.e3'}, 'sentence_id': 'DDI-MedLine.d51.s3'}	The anxiogenic effects of theophylline were reduced by pretreatment with CGS NUMBER an A2 selective agonist but not by N6 cyclopentyladenosine CPA an A1 selective agonist
The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. 	CGS 21680	N6-cyclopentyladenosine	none	{'e1': {'word': 'CGS 21680', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d51.s3.e1'}, 'e2': {'word': 'N6-cyclopentyladenosine', 'word_index': [(19, 20)], 'id': 'DDI-MedLine.d51.s3.e2'}, 'sentence_id': 'DDI-MedLine.d51.s3'}	The anxiogenic effects of theophylline were reduced by pretreatment with CGS NUMBER an A2 selective agonist but not by N6 cyclopentyladenosine CPA an A1 selective agonist
The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. 	CGS 21680	CPA	none	{'e1': {'word': 'CGS 21680', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d51.s3.e1'}, 'e2': {'word': 'CPA', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d51.s3.e3'}, 'sentence_id': 'DDI-MedLine.d51.s3'}	The anxiogenic effects of theophylline were reduced by pretreatment with CGS NUMBER an A2 selective agonist but not by N6 cyclopentyladenosine CPA an A1 selective agonist
The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. 	N6-cyclopentyladenosine	CPA	none	{'e1': {'word': 'N6-cyclopentyladenosine', 'word_index': [(19, 20)], 'id': 'DDI-MedLine.d51.s3.e2'}, 'e2': {'word': 'CPA', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d51.s3.e3'}, 'sentence_id': 'DDI-MedLine.d51.s3'}	The anxiogenic effects of theophylline were reduced by pretreatment with CGS NUMBER an A2 selective agonist but not by N6 cyclopentyladenosine CPA an A1 selective agonist
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	theophylline	CGS21680	effect	{'e1': {'word': 'theophylline', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d51.s4.e0'}, 'e2': {'word': 'CGS21680', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d51.s4.e1'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	However the antagonism of the theophylline induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone and DPCPX induced anxiogenic effects were neither reversed by CGS NUMBER nor by CPA
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	theophylline	DPCPX	none	{'e1': {'word': 'theophylline', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d51.s4.e0'}, 'e2': {'word': 'DPCPX', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d51.s4.e2'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	However the antagonism of the theophylline induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone and DPCPX induced anxiogenic effects were neither reversed by CGS NUMBER nor by CPA
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	theophylline	CGS 21680	none	{'e1': {'word': 'theophylline', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d51.s4.e0'}, 'e2': {'word': 'CGS 21680', 'word_index': [(31, 32)], 'id': 'DDI-MedLine.d51.s4.e3'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	However the antagonism of the theophylline induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone and DPCPX induced anxiogenic effects were neither reversed by CGS NUMBER nor by CPA
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	theophylline	CPA	none	{'e1': {'word': 'theophylline', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d51.s4.e0'}, 'e2': {'word': 'CPA', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d51.s4.e4'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	However the antagonism of the theophylline induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone and DPCPX induced anxiogenic effects were neither reversed by CGS NUMBER nor by CPA
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	CGS21680	DPCPX	none	{'e1': {'word': 'CGS21680', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d51.s4.e1'}, 'e2': {'word': 'DPCPX', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d51.s4.e2'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	However the antagonism of the theophylline induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone and DPCPX induced anxiogenic effects were neither reversed by CGS NUMBER nor by CPA
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	CGS21680	CGS 21680	none	{'e1': {'word': 'CGS21680', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d51.s4.e1'}, 'e2': {'word': 'CGS 21680', 'word_index': [(31, 32)], 'id': 'DDI-MedLine.d51.s4.e3'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	However the antagonism of the theophylline induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone and DPCPX induced anxiogenic effects were neither reversed by CGS NUMBER nor by CPA
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	CGS21680	CPA	none	{'e1': {'word': 'CGS21680', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d51.s4.e1'}, 'e2': {'word': 'CPA', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d51.s4.e4'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	However the antagonism of the theophylline induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone and DPCPX induced anxiogenic effects were neither reversed by CGS NUMBER nor by CPA
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	DPCPX	CGS 21680	none	{'e1': {'word': 'DPCPX', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d51.s4.e2'}, 'e2': {'word': 'CGS 21680', 'word_index': [(31, 32)], 'id': 'DDI-MedLine.d51.s4.e3'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	However the antagonism of the theophylline induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone and DPCPX induced anxiogenic effects were neither reversed by CGS NUMBER nor by CPA
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	DPCPX	CPA	none	{'e1': {'word': 'DPCPX', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d51.s4.e2'}, 'e2': {'word': 'CPA', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d51.s4.e4'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	However the antagonism of the theophylline induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone and DPCPX induced anxiogenic effects were neither reversed by CGS NUMBER nor by CPA
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 	CGS 21680	CPA	none	{'e1': {'word': 'CGS 21680', 'word_index': [(31, 32)], 'id': 'DDI-MedLine.d51.s4.e3'}, 'e2': {'word': 'CPA', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d51.s4.e4'}, 'sentence_id': 'DDI-MedLine.d51.s4'}	However the antagonism of the theophylline induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone and DPCPX induced anxiogenic effects were neither reversed by CGS NUMBER nor by CPA
"Interactions of cobalt and iron in absorption and retention.
"	cobalt	iron	mechanism	{'e1': {'word': 'cobalt', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d34.s0.e0'}, 'e2': {'word': 'iron', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d34.s0.e1'}, 'sentence_id': 'DDI-MedLine.d34.s0'}	Interactions of cobalt and iron in absorption and retention
The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. 	cobalt	iron	none	{'e1': {'word': 'cobalt', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d34.s1.e0'}, 'e2': {'word': 'iron', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d34.s1.e1'}, 'sentence_id': 'DDI-MedLine.d34.s1'}	The effects of supplementary oral cobalt and iron as well as the interaction between both at the absorption site fecal and urinary excretion as well as the retention of these trace elements were determined by using NUMBER diets containing either NUMBER or NUMBER micrograms / kg of Co and NUMBER or NUMBER mg / kg of Fe over a period of NUMBER days in a total of NUMBER rats
The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. 	cobalt	Co	none	{'e1': {'word': 'cobalt', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d34.s1.e0'}, 'e2': {'word': 'Co', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d34.s1.e2'}, 'sentence_id': 'DDI-MedLine.d34.s1'}	The effects of supplementary oral cobalt and iron as well as the interaction between both at the absorption site fecal and urinary excretion as well as the retention of these trace elements were determined by using NUMBER diets containing either NUMBER or NUMBER micrograms / kg of Co and NUMBER or NUMBER mg / kg of Fe over a period of NUMBER days in a total of NUMBER rats
The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. 	cobalt	Fe	none	{'e1': {'word': 'cobalt', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d34.s1.e0'}, 'e2': {'word': 'Fe', 'word_index': [(56, 56)], 'id': 'DDI-MedLine.d34.s1.e3'}, 'sentence_id': 'DDI-MedLine.d34.s1'}	The effects of supplementary oral cobalt and iron as well as the interaction between both at the absorption site fecal and urinary excretion as well as the retention of these trace elements were determined by using NUMBER diets containing either NUMBER or NUMBER micrograms / kg of Co and NUMBER or NUMBER mg / kg of Fe over a period of NUMBER days in a total of NUMBER rats
The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. 	iron	Co	none	{'e1': {'word': 'iron', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d34.s1.e1'}, 'e2': {'word': 'Co', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d34.s1.e2'}, 'sentence_id': 'DDI-MedLine.d34.s1'}	The effects of supplementary oral cobalt and iron as well as the interaction between both at the absorption site fecal and urinary excretion as well as the retention of these trace elements were determined by using NUMBER diets containing either NUMBER or NUMBER micrograms / kg of Co and NUMBER or NUMBER mg / kg of Fe over a period of NUMBER days in a total of NUMBER rats
The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. 	iron	Fe	none	{'e1': {'word': 'iron', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d34.s1.e1'}, 'e2': {'word': 'Fe', 'word_index': [(56, 56)], 'id': 'DDI-MedLine.d34.s1.e3'}, 'sentence_id': 'DDI-MedLine.d34.s1'}	The effects of supplementary oral cobalt and iron as well as the interaction between both at the absorption site fecal and urinary excretion as well as the retention of these trace elements were determined by using NUMBER diets containing either NUMBER or NUMBER micrograms / kg of Co and NUMBER or NUMBER mg / kg of Fe over a period of NUMBER days in a total of NUMBER rats
The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. 	Co	Fe	none	{'e1': {'word': 'Co', 'word_index': [(47, 47)], 'id': 'DDI-MedLine.d34.s1.e2'}, 'e2': {'word': 'Fe', 'word_index': [(56, 56)], 'id': 'DDI-MedLine.d34.s1.e3'}, 'sentence_id': 'DDI-MedLine.d34.s1'}	The effects of supplementary oral cobalt and iron as well as the interaction between both at the absorption site fecal and urinary excretion as well as the retention of these trace elements were determined by using NUMBER diets containing either NUMBER or NUMBER micrograms / kg of Co and NUMBER or NUMBER mg / kg of Fe over a period of NUMBER days in a total of NUMBER rats
Cobalt excretion was enhanced by supplementary cobalt; 	Cobalt	cobalt	none	{'e1': {'word': 'Cobalt', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d34.s4.e0'}, 'e2': {'word': 'cobalt', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d34.s4.e1'}, 'sentence_id': 'DDI-MedLine.d34.s4'}	Cobalt excretion was enhanced by supplementary cobalt
Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments. 	iron	cobalt	mechanism	{'e1': {'word': 'iron', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d34.s7.e0'}, 'e2': {'word': 'cobalt', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d34.s7.e1'}, 'sentence_id': 'DDI-MedLine.d34.s7'}	Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments
Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments. 	iron	cobalt	mechanism	{'e1': {'word': 'iron', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d34.s7.e0'}, 'e2': {'word': 'cobalt', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d34.s7.e2'}, 'sentence_id': 'DDI-MedLine.d34.s7'}	Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments
Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments. 	cobalt	cobalt	none	{'e1': {'word': 'cobalt', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d34.s7.e1'}, 'e2': {'word': 'cobalt', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d34.s7.e2'}, 'sentence_id': 'DDI-MedLine.d34.s7'}	Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments
The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt. 	Fe	Fe	none	{'e1': {'word': 'Fe', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d34.s8.e0'}, 'e2': {'word': 'Fe', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d34.s8.e1'}, 'sentence_id': 'DDI-MedLine.d34.s8'}	The lower rate of absorption in the groups receiving NUMBER mg Fe instead of NUMBER mg of Fe per kg diet resulted in a decreased renal excretion of cobalt
The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt. 	Fe	cobalt	mechanism	{'e1': {'word': 'Fe', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d34.s8.e0'}, 'e2': {'word': 'cobalt', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d34.s8.e2'}, 'sentence_id': 'DDI-MedLine.d34.s8'}	The lower rate of absorption in the groups receiving NUMBER mg Fe instead of NUMBER mg of Fe per kg diet resulted in a decreased renal excretion of cobalt
The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt. 	Fe	cobalt	none	{'e1': {'word': 'Fe', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d34.s8.e1'}, 'e2': {'word': 'cobalt', 'word_index': [(28, 28)], 'id': 'DDI-MedLine.d34.s8.e2'}, 'sentence_id': 'DDI-MedLine.d34.s8'}	The lower rate of absorption in the groups receiving NUMBER mg Fe instead of NUMBER mg of Fe per kg diet resulted in a decreased renal excretion of cobalt
Consequently, the effect of iron on the retention of cobalt was lower than on absorption. 	iron	cobalt	mechanism	{'e1': {'word': 'iron', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d34.s9.e0'}, 'e2': {'word': 'cobalt', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d34.s9.e1'}, 'sentence_id': 'DDI-MedLine.d34.s9'}	Consequently the effect of iron on the retention of cobalt was lower than on absorption
Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. 	cobalt	iron	none	{'e1': {'word': 'cobalt', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d34.s11.e0'}, 'e2': {'word': 'iron', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d34.s11.e1'}, 'sentence_id': 'DDI-MedLine.d34.s11'}	Because of the low dietary cobalt concentration as compared to the iron contents of the diets no effect of cobalt on iron absorption and excretion occurred
Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. 	cobalt	cobalt	none	{'e1': {'word': 'cobalt', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d34.s11.e0'}, 'e2': {'word': 'cobalt', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d34.s11.e2'}, 'sentence_id': 'DDI-MedLine.d34.s11'}	Because of the low dietary cobalt concentration as compared to the iron contents of the diets no effect of cobalt on iron absorption and excretion occurred
Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. 	cobalt	iron	none	{'e1': {'word': 'cobalt', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d34.s11.e0'}, 'e2': {'word': 'iron', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d34.s11.e3'}, 'sentence_id': 'DDI-MedLine.d34.s11'}	Because of the low dietary cobalt concentration as compared to the iron contents of the diets no effect of cobalt on iron absorption and excretion occurred
Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. 	iron	cobalt	none	{'e1': {'word': 'iron', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d34.s11.e1'}, 'e2': {'word': 'cobalt', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d34.s11.e2'}, 'sentence_id': 'DDI-MedLine.d34.s11'}	Because of the low dietary cobalt concentration as compared to the iron contents of the diets no effect of cobalt on iron absorption and excretion occurred
Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. 	iron	iron	none	{'e1': {'word': 'iron', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d34.s11.e1'}, 'e2': {'word': 'iron', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d34.s11.e3'}, 'sentence_id': 'DDI-MedLine.d34.s11'}	Because of the low dietary cobalt concentration as compared to the iron contents of the diets no effect of cobalt on iron absorption and excretion occurred
Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. 	cobalt	iron	none	{'e1': {'word': 'cobalt', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d34.s11.e2'}, 'e2': {'word': 'iron', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d34.s11.e3'}, 'sentence_id': 'DDI-MedLine.d34.s11'}	Because of the low dietary cobalt concentration as compared to the iron contents of the diets no effect of cobalt on iron absorption and excretion occurred
Differences in iron balance were only observed between both dietary concentrations, showing a higher absolute but a lower relative absorption as well as retention in the groups fed further Fe.(ABSTRACT TRUNCATED AT 250 WORDS)	iron	Fe	none	{'e1': {'word': 'iron', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d34.s12.e0'}, 'e2': {'word': 'Fe', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d34.s12.e1'}, 'sentence_id': 'DDI-MedLine.d34.s12'}	Differences in iron balance were only observed between both dietary concentrations showing a higher absolute but a lower relative absorption as well as retention in the groups fed further Fe ABSTRACT TRUNCATED AT NUMBER WORDS
By contrast, spermidine (1 mM) and putrescine (1 mM) had no significant effect on the translocation when added alone. 	spermidine	putrescine	none	{'e1': {'word': 'spermidine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d22.s2.e0'}, 'e2': {'word': 'putrescine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d22.s2.e1'}, 'sentence_id': 'DDI-MedLine.d22.s2'}	By contrast spermidine NUMBER mM and putrescine NUMBER mM had no significant effect on the translocation when added alone
Spermine, and to a lesser extent, spermidine, enhanced the translocating action of oleate and increased its effectiveness in transferring the phosphohydrolase from the soluble to the microsomal fraction. 	Spermine	spermidine	none	{'e1': {'word': 'Spermine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d22.s3.e0'}, 'e2': {'word': 'spermidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d22.s3.e1'}, 'sentence_id': 'DDI-MedLine.d22.s3'}	Spermine and to a lesser extent spermidine enhanced the translocating action of oleate and increased its effectiveness in transferring the phosphohydrolase from the soluble to the microsomal fraction
In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.  	progestin-only oral contraceptives	POC	none	{'e1': {'word': 'progestin-only oral contraceptives', 'word_index': [(12, 15)], 'id': 'DDI-MedLine.d80.s1.e0'}, 'e2': {'word': 'POC', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d80.s1.e1'}, 'sentence_id': 'DDI-MedLine.d80.s1'}	In order to provide information for the appropriate package insert labeling of progestin only oral contraceptives POC in the US a comprehensive review was made of norgestrel NUMBER mg and norethindrone NUMBER mg with the clinical differences indicated where applicable
In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.  	progestin-only oral contraceptives	norgestrel	none	{'e1': {'word': 'progestin-only oral contraceptives', 'word_index': [(12, 15)], 'id': 'DDI-MedLine.d80.s1.e0'}, 'e2': {'word': 'norgestrel', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d80.s1.e2'}, 'sentence_id': 'DDI-MedLine.d80.s1'}	In order to provide information for the appropriate package insert labeling of progestin only oral contraceptives POC in the US a comprehensive review was made of norgestrel NUMBER mg and norethindrone NUMBER mg with the clinical differences indicated where applicable
In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.  	progestin-only oral contraceptives	norethindrone	none	{'e1': {'word': 'progestin-only oral contraceptives', 'word_index': [(12, 15)], 'id': 'DDI-MedLine.d80.s1.e0'}, 'e2': {'word': 'norethindrone', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d80.s1.e3'}, 'sentence_id': 'DDI-MedLine.d80.s1'}	In order to provide information for the appropriate package insert labeling of progestin only oral contraceptives POC in the US a comprehensive review was made of norgestrel NUMBER mg and norethindrone NUMBER mg with the clinical differences indicated where applicable
In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.  	POC	norgestrel	none	{'e1': {'word': 'POC', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d80.s1.e1'}, 'e2': {'word': 'norgestrel', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d80.s1.e2'}, 'sentence_id': 'DDI-MedLine.d80.s1'}	In order to provide information for the appropriate package insert labeling of progestin only oral contraceptives POC in the US a comprehensive review was made of norgestrel NUMBER mg and norethindrone NUMBER mg with the clinical differences indicated where applicable
In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.  	POC	norethindrone	none	{'e1': {'word': 'POC', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d80.s1.e1'}, 'e2': {'word': 'norethindrone', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d80.s1.e3'}, 'sentence_id': 'DDI-MedLine.d80.s1'}	In order to provide information for the appropriate package insert labeling of progestin only oral contraceptives POC in the US a comprehensive review was made of norgestrel NUMBER mg and norethindrone NUMBER mg with the clinical differences indicated where applicable
In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.  	norgestrel	norethindrone	none	{'e1': {'word': 'norgestrel', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d80.s1.e2'}, 'e2': {'word': 'norethindrone', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d80.s1.e3'}, 'sentence_id': 'DDI-MedLine.d80.s1'}	In order to provide information for the appropriate package insert labeling of progestin only oral contraceptives POC in the US a comprehensive review was made of norgestrel NUMBER mg and norethindrone NUMBER mg with the clinical differences indicated where applicable
"Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant.
"	budesonide	Survanta	none	{'e1': {'word': 'budesonide', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d18.s0.e0'}, 'e2': {'word': 'Survanta', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d18.s0.e1'}, 'sentence_id': 'DDI-MedLine.d18.s0'}	Note dissolution of aerosol particles of budesonide in Survanta a model lung surfactant
"Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant.
"	budesonide	lung surfactant	none	{'e1': {'word': 'budesonide', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d18.s0.e0'}, 'e2': {'word': 'lung surfactant', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d18.s0.e2'}, 'sentence_id': 'DDI-MedLine.d18.s0'}	Note dissolution of aerosol particles of budesonide in Survanta a model lung surfactant
"Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant.
"	Survanta	lung surfactant	none	{'e1': {'word': 'Survanta', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d18.s0.e1'}, 'e2': {'word': 'lung surfactant', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d18.s0.e2'}, 'sentence_id': 'DDI-MedLine.d18.s0'}	Note dissolution of aerosol particles of budesonide in Survanta a model lung surfactant
The effect of a pulmonary surfactant extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of budesonide was determined. 	pulmonary surfactant	Survanta	none	{'e1': {'word': 'pulmonary surfactant', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d18.s1.e0'}, 'e2': {'word': 'Survanta', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d18.s1.e1'}, 'sentence_id': 'DDI-MedLine.d18.s1'}	The effect of a pulmonary surfactant extract from bovine lung Survanta on the dissolution rate of aerosol particles of budesonide was determined
The effect of a pulmonary surfactant extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of budesonide was determined. 	pulmonary surfactant	budesonide	none	{'e1': {'word': 'pulmonary surfactant', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d18.s1.e0'}, 'e2': {'word': 'budesonide', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d18.s1.e2'}, 'sentence_id': 'DDI-MedLine.d18.s1'}	The effect of a pulmonary surfactant extract from bovine lung Survanta on the dissolution rate of aerosol particles of budesonide was determined
The effect of a pulmonary surfactant extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of budesonide was determined. 	Survanta	budesonide	none	{'e1': {'word': 'Survanta', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d18.s1.e1'}, 'e2': {'word': 'budesonide', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d18.s1.e2'}, 'sentence_id': 'DDI-MedLine.d18.s1'}	The effect of a pulmonary surfactant extract from bovine lung Survanta on the dissolution rate of aerosol particles of budesonide was determined
Aerosol particles of budesonide were generated from an ethanol solution, dried, and collected by a cascade impactor for characterization or by a liquid impinger for dissolution experiments. 	budesonide	ethanol	none	{'e1': {'word': 'budesonide', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d18.s2.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d18.s2.e1'}, 'sentence_id': 'DDI-MedLine.d18.s2'}	Aerosol particles of budesonide were generated from an ethanol solution dried and collected by a cascade impactor for characterization or by a liquid impinger for dissolution experiments
Survanta increased the extent of dissolution of budesonide in proportion to the added concentration, which was also verified by equilibrium solubilization studies. 	Survanta	budesonide	none	{'e1': {'word': 'Survanta', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d18.s6.e0'}, 'e2': {'word': 'budesonide', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d18.s6.e1'}, 'sentence_id': 'DDI-MedLine.d18.s6'}	Survanta increased the extent of dissolution of budesonide in proportion to the added concentration which was also verified by equilibrium solubilization studies
Survanta also increased rate of dissolution, in a manner similar to sodium dodecyl sulfate. 	Survanta	sodium dodecyl sulfate	none	{'e1': {'word': 'Survanta', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d18.s7.e0'}, 'e2': {'word': 'sodium dodecyl sulfate', 'word_index': [(11, 13)], 'id': 'DDI-MedLine.d18.s7.e1'}, 'sentence_id': 'DDI-MedLine.d18.s7'}	Survanta also increased rate of dissolution in a manner similar to sodium dodecyl sulfate
Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase. 	budesonide	budesonide	none	{'e1': {'word': 'budesonide', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d18.s8.e0'}, 'e2': {'word': 'budesonide', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d18.s8.e1'}, 'sentence_id': 'DDI-MedLine.d18.s8'}	Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase
Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase. 	budesonide	Survanta	none	{'e1': {'word': 'budesonide', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d18.s8.e0'}, 'e2': {'word': 'Survanta', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d18.s8.e2'}, 'sentence_id': 'DDI-MedLine.d18.s8'}	Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase
Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase. 	budesonide	Survanta	none	{'e1': {'word': 'budesonide', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d18.s8.e1'}, 'e2': {'word': 'Survanta', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d18.s8.e2'}, 'sentence_id': 'DDI-MedLine.d18.s8'}	Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase
"Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.
"	diltiazem	sirolimus	mechanism	{'e1': {'word': 'diltiazem', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d86.s0.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d86.s0.e1'}, 'sentence_id': 'DDI-MedLine.d86.s0'}	Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. 	sirolimus	macrolide immunosuppressant	none	{'e1': {'word': 'sirolimus', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d86.s1.e0'}, 'e2': {'word': 'macrolide immunosuppressant', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d86.s1.e1'}, 'sentence_id': 'DDI-MedLine.d86.s1'}	AIM AND BACKGROUND The pharmacokinetic interaction between sirolimus a macrolide immunosuppressant metabolized by CYP3A4 and the calcium channel blocker diltiazem was studied in NUMBER healthy subjects
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. 	sirolimus	calcium channel blocker	none	{'e1': {'word': 'sirolimus', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d86.s1.e0'}, 'e2': {'word': 'calcium channel blocker', 'word_index': [(16, 18)], 'id': 'DDI-MedLine.d86.s1.e2'}, 'sentence_id': 'DDI-MedLine.d86.s1'}	AIM AND BACKGROUND The pharmacokinetic interaction between sirolimus a macrolide immunosuppressant metabolized by CYP3A4 and the calcium channel blocker diltiazem was studied in NUMBER healthy subjects
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. 	sirolimus	diltiazem	none	{'e1': {'word': 'sirolimus', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d86.s1.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d86.s1.e3'}, 'sentence_id': 'DDI-MedLine.d86.s1'}	AIM AND BACKGROUND The pharmacokinetic interaction between sirolimus a macrolide immunosuppressant metabolized by CYP3A4 and the calcium channel blocker diltiazem was studied in NUMBER healthy subjects
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. 	macrolide immunosuppressant	calcium channel blocker	none	{'e1': {'word': 'macrolide immunosuppressant', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d86.s1.e1'}, 'e2': {'word': 'calcium channel blocker', 'word_index': [(16, 18)], 'id': 'DDI-MedLine.d86.s1.e2'}, 'sentence_id': 'DDI-MedLine.d86.s1'}	AIM AND BACKGROUND The pharmacokinetic interaction between sirolimus a macrolide immunosuppressant metabolized by CYP3A4 and the calcium channel blocker diltiazem was studied in NUMBER healthy subjects
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. 	macrolide immunosuppressant	diltiazem	none	{'e1': {'word': 'macrolide immunosuppressant', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d86.s1.e1'}, 'e2': {'word': 'diltiazem', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d86.s1.e3'}, 'sentence_id': 'DDI-MedLine.d86.s1'}	AIM AND BACKGROUND The pharmacokinetic interaction between sirolimus a macrolide immunosuppressant metabolized by CYP3A4 and the calcium channel blocker diltiazem was studied in NUMBER healthy subjects
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. 	calcium channel blocker	diltiazem	none	{'e1': {'word': 'calcium channel blocker', 'word_index': [(16, 18)], 'id': 'DDI-MedLine.d86.s1.e2'}, 'e2': {'word': 'diltiazem', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d86.s1.e3'}, 'sentence_id': 'DDI-MedLine.d86.s1'}	AIM AND BACKGROUND The pharmacokinetic interaction between sirolimus a macrolide immunosuppressant metabolized by CYP3A4 and the calcium channel blocker diltiazem was studied in NUMBER healthy subjects
Several clinically important interactions have previously been reported for other immunosuppressive drugs that are metabolized by the same enzyme and for calcium antagonists. 	immunosuppressive drugs	calcium antagonists	none	{'e1': {'word': 'immunosuppressive drugs', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d86.s2.e0'}, 'e2': {'word': 'calcium antagonists', 'word_index': [(21, 22)], 'id': 'DDI-MedLine.d86.s2.e1'}, 'sentence_id': 'DDI-MedLine.d86.s2'}	Several clinically important interactions have previously been reported for other immunosuppressive drugs that are metabolized by the same enzyme and for calcium antagonists
METHODS: Healthy subjects who were 20 to 43 years old participated in an open, three-period, randomized, crossover study of the pharmacokinetics of a single 10-mg oral dose of sirolimus, a single oral 120-mg dose of diltiazem, and the two drugs given together. 	sirolimus	diltiazem	none	{'e1': {'word': 'sirolimus', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d86.s3.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d86.s3.e1'}, 'sentence_id': 'DDI-MedLine.d86.s3'}	METHODS Healthy subjects who were NUMBER to NUMBER years old participated in an open NUMBER period randomized crossover study of the pharmacokinetics of a single NUMBER mg oral dose of sirolimus a single oral NUMBER mg dose of diltiazem and the NUMBER drugs given together
RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. 	sirolimus	diltiazem	mechanism	{'e1': {'word': 'sirolimus', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d86.s5.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(54, 54)], 'id': 'DDI-MedLine.d86.s5.e1'}, 'sentence_id': 'DDI-MedLine.d86.s5'}	RESULTS The geometric mean NUMBER % confidence interval whole blood sirolimus area under the plasma concentration time curve increased NUMBER % NUMBER % - NUMBER % from NUMBER to NUMBER ng x h / mL and maximum concentration increased NUMBER % NUMBER % - NUMBER % from NUMBER to NUMBER ng / mL with diltiazem coadministration whereas the mean elimination half life of sirolimus decreased slightly from NUMBER to NUMBER hours
RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. 	sirolimus	sirolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d86.s5.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(63, 63)], 'id': 'DDI-MedLine.d86.s5.e2'}, 'sentence_id': 'DDI-MedLine.d86.s5'}	RESULTS The geometric mean NUMBER % confidence interval whole blood sirolimus area under the plasma concentration time curve increased NUMBER % NUMBER % - NUMBER % from NUMBER to NUMBER ng x h / mL and maximum concentration increased NUMBER % NUMBER % - NUMBER % from NUMBER to NUMBER ng / mL with diltiazem coadministration whereas the mean elimination half life of sirolimus decreased slightly from NUMBER to NUMBER hours
RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. 	diltiazem	sirolimus	none	{'e1': {'word': 'diltiazem', 'word_index': [(54, 54)], 'id': 'DDI-MedLine.d86.s5.e1'}, 'e2': {'word': 'sirolimus', 'word_index': [(63, 63)], 'id': 'DDI-MedLine.d86.s5.e2'}, 'sentence_id': 'DDI-MedLine.d86.s5'}	RESULTS The geometric mean NUMBER % confidence interval whole blood sirolimus area under the plasma concentration time curve increased NUMBER % NUMBER % - NUMBER % from NUMBER to NUMBER ng x h / mL and maximum concentration increased NUMBER % NUMBER % - NUMBER % from NUMBER to NUMBER ng / mL with diltiazem coadministration whereas the mean elimination half life of sirolimus decreased slightly from NUMBER to NUMBER hours
Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem. 	sirolimus	sirolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d86.s6.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d86.s6.e1'}, 'sentence_id': 'DDI-MedLine.d86.s6'}	Apparent oral clearance and volume of distribution of sirolimus decreased with NUMBER % and NUMBER % respectively when sirolimus was given with diltiazem
Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem. 	sirolimus	diltiazem	none	{'e1': {'word': 'sirolimus', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d86.s6.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d86.s6.e2'}, 'sentence_id': 'DDI-MedLine.d86.s6'}	Apparent oral clearance and volume of distribution of sirolimus decreased with NUMBER % and NUMBER % respectively when sirolimus was given with diltiazem
Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem. 	sirolimus	diltiazem	mechanism	{'e1': {'word': 'sirolimus', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d86.s6.e1'}, 'e2': {'word': 'diltiazem', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d86.s6.e2'}, 'sentence_id': 'DDI-MedLine.d86.s6'}	Apparent oral clearance and volume of distribution of sirolimus decreased with NUMBER % and NUMBER % respectively when sirolimus was given with diltiazem
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	diltiazem	desacetyldiltiazem	none	{'e1': {'word': 'diltiazem', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d86.s7.e0'}, 'e2': {'word': 'desacetyldiltiazem', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d86.s7.e1'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	The plasma maximum concentration and area under the plasma concentration time curve of diltiazem desacetyldiltiazem and desmethyldiltiazem were unchanged after coadministration of sirolimus and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	diltiazem	desmethyldiltiazem	none	{'e1': {'word': 'diltiazem', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d86.s7.e0'}, 'e2': {'word': 'desmethyldiltiazem', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d86.s7.e2'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	The plasma maximum concentration and area under the plasma concentration time curve of diltiazem desacetyldiltiazem and desmethyldiltiazem were unchanged after coadministration of sirolimus and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	diltiazem	sirolimus	none	{'e1': {'word': 'diltiazem', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d86.s7.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d86.s7.e3'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	The plasma maximum concentration and area under the plasma concentration time curve of diltiazem desacetyldiltiazem and desmethyldiltiazem were unchanged after coadministration of sirolimus and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	diltiazem	diltiazem	none	{'e1': {'word': 'diltiazem', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d86.s7.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d86.s7.e4'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	The plasma maximum concentration and area under the plasma concentration time curve of diltiazem desacetyldiltiazem and desmethyldiltiazem were unchanged after coadministration of sirolimus and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	desacetyldiltiazem	desmethyldiltiazem	none	{'e1': {'word': 'desacetyldiltiazem', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d86.s7.e1'}, 'e2': {'word': 'desmethyldiltiazem', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d86.s7.e2'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	The plasma maximum concentration and area under the plasma concentration time curve of diltiazem desacetyldiltiazem and desmethyldiltiazem were unchanged after coadministration of sirolimus and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	desacetyldiltiazem	sirolimus	none	{'e1': {'word': 'desacetyldiltiazem', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d86.s7.e1'}, 'e2': {'word': 'sirolimus', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d86.s7.e3'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	The plasma maximum concentration and area under the plasma concentration time curve of diltiazem desacetyldiltiazem and desmethyldiltiazem were unchanged after coadministration of sirolimus and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	desacetyldiltiazem	diltiazem	none	{'e1': {'word': 'desacetyldiltiazem', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d86.s7.e1'}, 'e2': {'word': 'diltiazem', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d86.s7.e4'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	The plasma maximum concentration and area under the plasma concentration time curve of diltiazem desacetyldiltiazem and desmethyldiltiazem were unchanged after coadministration of sirolimus and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	desmethyldiltiazem	sirolimus	none	{'e1': {'word': 'desmethyldiltiazem', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d86.s7.e2'}, 'e2': {'word': 'sirolimus', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d86.s7.e3'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	The plasma maximum concentration and area under the plasma concentration time curve of diltiazem desacetyldiltiazem and desmethyldiltiazem were unchanged after coadministration of sirolimus and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	desmethyldiltiazem	diltiazem	none	{'e1': {'word': 'desmethyldiltiazem', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d86.s7.e2'}, 'e2': {'word': 'diltiazem', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d86.s7.e4'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	The plasma maximum concentration and area under the plasma concentration time curve of diltiazem desacetyldiltiazem and desmethyldiltiazem were unchanged after coadministration of sirolimus and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	sirolimus	diltiazem	none	{'e1': {'word': 'sirolimus', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d86.s7.e3'}, 'e2': {'word': 'diltiazem', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d86.s7.e4'}, 'sentence_id': 'DDI-MedLine.d86.s7'}	The plasma maximum concentration and area under the plasma concentration time curve of diltiazem desacetyldiltiazem and desmethyldiltiazem were unchanged after coadministration of sirolimus and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen
CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus. 	diltiazem	sirolimus	mechanism	{'e1': {'word': 'diltiazem', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d86.s8.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d86.s8.e1'}, 'sentence_id': 'DDI-MedLine.d86.s8'}	CONCLUSIONS Single dose diltiazem coadministration leads to higher sirolimus exposure presumably by inhibition of the first pass metabolism of sirolimus
CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus. 	diltiazem	sirolimus	none	{'e1': {'word': 'diltiazem', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d86.s8.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d86.s8.e2'}, 'sentence_id': 'DDI-MedLine.d86.s8'}	CONCLUSIONS Single dose diltiazem coadministration leads to higher sirolimus exposure presumably by inhibition of the first pass metabolism of sirolimus
CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus. 	sirolimus	sirolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d86.s8.e1'}, 'e2': {'word': 'sirolimus', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d86.s8.e2'}, 'sentence_id': 'DDI-MedLine.d86.s8'}	CONCLUSIONS Single dose diltiazem coadministration leads to higher sirolimus exposure presumably by inhibition of the first pass metabolism of sirolimus
Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.	sirolimus	diltiazem	advise	{'e1': {'word': 'sirolimus', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d86.s9.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d86.s9.e1'}, 'sentence_id': 'DDI-MedLine.d86.s9'}	Because of the pronounced intersubject variability in the extent of the sirolimus diltiazem interaction whole blood sirolimus concentrations should be monitored closely in patients treated with the NUMBER drugs
Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.	sirolimus	sirolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d86.s9.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d86.s9.e2'}, 'sentence_id': 'DDI-MedLine.d86.s9'}	Because of the pronounced intersubject variability in the extent of the sirolimus diltiazem interaction whole blood sirolimus concentrations should be monitored closely in patients treated with the NUMBER drugs
Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.	diltiazem	sirolimus	none	{'e1': {'word': 'diltiazem', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d86.s9.e1'}, 'e2': {'word': 'sirolimus', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d86.s9.e2'}, 'sentence_id': 'DDI-MedLine.d86.s9'}	Because of the pronounced intersubject variability in the extent of the sirolimus diltiazem interaction whole blood sirolimus concentrations should be monitored closely in patients treated with the NUMBER drugs
Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents. 	antidepressant drugs	hypoglycemic agents	int	{'e1': {'word': 'antidepressant drugs', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d21.s2.e0'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d21.s2.e1'}, 'sentence_id': 'DDI-MedLine.d21.s2'}	Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	Imipramine	moclobemide	none	{'e1': {'word': 'Imipramine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s6.e0'}, 'e2': {'word': 'moclobemide', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d21.s6.e1'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	Imipramine NUMBER mg / kg moclobemide NUMBER mg / kg clonazepam NUMBER mg / kg fluoxetine NUMBER mg / kg sertraline NUMBER mg / kg or vehicle was administered
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	Imipramine	clonazepam	none	{'e1': {'word': 'Imipramine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s6.e0'}, 'e2': {'word': 'clonazepam', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d21.s6.e2'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	Imipramine NUMBER mg / kg moclobemide NUMBER mg / kg clonazepam NUMBER mg / kg fluoxetine NUMBER mg / kg sertraline NUMBER mg / kg or vehicle was administered
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	Imipramine	fluoxetine	none	{'e1': {'word': 'Imipramine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s6.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d21.s6.e3'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	Imipramine NUMBER mg / kg moclobemide NUMBER mg / kg clonazepam NUMBER mg / kg fluoxetine NUMBER mg / kg sertraline NUMBER mg / kg or vehicle was administered
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	Imipramine	sertraline	none	{'e1': {'word': 'Imipramine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s6.e0'}, 'e2': {'word': 'sertraline', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d21.s6.e4'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	Imipramine NUMBER mg / kg moclobemide NUMBER mg / kg clonazepam NUMBER mg / kg fluoxetine NUMBER mg / kg sertraline NUMBER mg / kg or vehicle was administered
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	moclobemide	clonazepam	none	{'e1': {'word': 'moclobemide', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d21.s6.e1'}, 'e2': {'word': 'clonazepam', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d21.s6.e2'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	Imipramine NUMBER mg / kg moclobemide NUMBER mg / kg clonazepam NUMBER mg / kg fluoxetine NUMBER mg / kg sertraline NUMBER mg / kg or vehicle was administered
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	moclobemide	fluoxetine	none	{'e1': {'word': 'moclobemide', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d21.s6.e1'}, 'e2': {'word': 'fluoxetine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d21.s6.e3'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	Imipramine NUMBER mg / kg moclobemide NUMBER mg / kg clonazepam NUMBER mg / kg fluoxetine NUMBER mg / kg sertraline NUMBER mg / kg or vehicle was administered
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	moclobemide	sertraline	none	{'e1': {'word': 'moclobemide', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d21.s6.e1'}, 'e2': {'word': 'sertraline', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d21.s6.e4'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	Imipramine NUMBER mg / kg moclobemide NUMBER mg / kg clonazepam NUMBER mg / kg fluoxetine NUMBER mg / kg sertraline NUMBER mg / kg or vehicle was administered
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	clonazepam	fluoxetine	none	{'e1': {'word': 'clonazepam', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d21.s6.e2'}, 'e2': {'word': 'fluoxetine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d21.s6.e3'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	Imipramine NUMBER mg / kg moclobemide NUMBER mg / kg clonazepam NUMBER mg / kg fluoxetine NUMBER mg / kg sertraline NUMBER mg / kg or vehicle was administered
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	clonazepam	sertraline	none	{'e1': {'word': 'clonazepam', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d21.s6.e2'}, 'e2': {'word': 'sertraline', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d21.s6.e4'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	Imipramine NUMBER mg / kg moclobemide NUMBER mg / kg clonazepam NUMBER mg / kg fluoxetine NUMBER mg / kg sertraline NUMBER mg / kg or vehicle was administered
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	fluoxetine	sertraline	none	{'e1': {'word': 'fluoxetine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d21.s6.e3'}, 'e2': {'word': 'sertraline', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d21.s6.e4'}, 'sentence_id': 'DDI-MedLine.d21.s6'}	Imipramine NUMBER mg / kg moclobemide NUMBER mg / kg clonazepam NUMBER mg / kg fluoxetine NUMBER mg / kg sertraline NUMBER mg / kg or vehicle was administered
An oral glucose overload of 1 ml of a 50% glucose solution was given to rats and blood glucose was determined after 30, 60 and 90 min. 	glucose	glucose	none	{'e1': {'word': 'glucose', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d21.s8.e0'}, 'e2': {'word': 'glucose', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d21.s8.e1'}, 'sentence_id': 'DDI-MedLine.d21.s8'}	An oral glucose overload of NUMBER ml of a NUMBER % glucose solution was given to rats and blood glucose was determined after NUMBER NUMBER and NUMBER min
Imipramine and clonazepam did not change fasting or overload glycemia. 	Imipramine	clonazepam	none	{'e1': {'word': 'Imipramine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s9.e0'}, 'e2': {'word': 'clonazepam', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d21.s9.e1'}, 'sentence_id': 'DDI-MedLine.d21.s9'}	Imipramine and clonazepam did not change fasting or overload glycemia
Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. 	Fluoxetine	moclobemide	none	{'e1': {'word': 'Fluoxetine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s10.e0'}, 'e2': {'word': 'moclobemide', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d21.s10.e1'}, 'sentence_id': 'DDI-MedLine.d21.s10'}	Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload
Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. 	Fluoxetine	glucose	none	{'e1': {'word': 'Fluoxetine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s10.e0'}, 'e2': {'word': 'glucose', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d21.s10.e2'}, 'sentence_id': 'DDI-MedLine.d21.s10'}	Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload
Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. 	moclobemide	glucose	none	{'e1': {'word': 'moclobemide', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d21.s10.e1'}, 'e2': {'word': 'glucose', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d21.s10.e2'}, 'sentence_id': 'DDI-MedLine.d21.s10'}	Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload
Sertraline neutralized the increase of glycemia induced by oral glucose overload. 	Sertraline	glucose	none	{'e1': {'word': 'Sertraline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d21.s11.e0'}, 'e2': {'word': 'glucose', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d21.s11.e1'}, 'sentence_id': 'DDI-MedLine.d21.s11'}	Sertraline neutralized the increase of glycemia induced by oral glucose overload
In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of glucose tolerance 30 min after glucose overload. 	glucose	glucose	none	{'e1': {'word': 'glucose', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d21.s12.e0'}, 'e2': {'word': 'glucose', 'word_index': [(26, 26)], 'id': 'DDI-MedLine.d21.s12.e1'}, 'sentence_id': 'DDI-MedLine.d21.s12'}	In the second experiment non-diabetic and streptozotocin induced diabetic rats were fasted and the same procedures were followed for estimation of glucose tolerance NUMBER min after glucose overload
Again, sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats. 	sertraline	glucose	none	{'e1': {'word': 'sertraline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d21.s13.e0'}, 'e2': {'word': 'glucose', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d21.s13.e1'}, 'sentence_id': 'DDI-MedLine.d21.s13'}	Again sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats
"18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
"	18-Methoxycoronaridine	18-MC	none	{'e1': {'word': '18-Methoxycoronaridine', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d110.s0.e0'}, 'e2': {'word': '18-MC', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d110.s0.e1'}, 'sentence_id': 'DDI-MedLine.d110.s0'}	NUMBER Methoxycoronaridine NUMBER MC and ibogaine comparison of antiaddictive efficacy toxicity and mechanisms of action
"18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
"	18-Methoxycoronaridine	ibogaine	none	{'e1': {'word': '18-Methoxycoronaridine', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d110.s0.e0'}, 'e2': {'word': 'ibogaine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d110.s0.e2'}, 'sentence_id': 'DDI-MedLine.d110.s0'}	NUMBER Methoxycoronaridine NUMBER MC and ibogaine comparison of antiaddictive efficacy toxicity and mechanisms of action
"18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
"	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d110.s0.e1'}, 'e2': {'word': 'ibogaine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d110.s0.e2'}, 'sentence_id': 'DDI-MedLine.d110.s0'}	NUMBER - NUMBER ) and ibogaine : comparison antiaddictive efficacy , toxicity and of action .
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s2.e0'}, 'e2': {'word': '18-MC', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d110.s2.e1'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like ibogaine NUMBER mg / kg NUMBER MC NUMBER mg / kg decreases the intravenous self administration of morphine and cocaine and the oral self administration of ethanol and nicotine in rats
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	ibogaine	morphine	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s2.e0'}, 'e2': {'word': 'morphine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d110.s2.e2'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like ibogaine NUMBER mg / kg NUMBER MC NUMBER mg / kg decreases the intravenous self administration of morphine and cocaine and the oral self administration of ethanol and nicotine in rats
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	ibogaine	cocaine	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s2.e0'}, 'e2': {'word': 'cocaine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d110.s2.e3'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like ibogaine NUMBER mg / kg NUMBER MC NUMBER mg / kg decreases the intravenous self administration of morphine and cocaine and the oral self administration of ethanol and nicotine in rats
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	ibogaine	ethanol	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s2.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d110.s2.e4'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like ibogaine NUMBER mg / kg NUMBER MC NUMBER mg / kg decreases the intravenous self administration of morphine and cocaine and the oral self administration of ethanol and nicotine in rats
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	ibogaine	nicotine	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s2.e0'}, 'e2': {'word': 'nicotine', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d110.s2.e5'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like ibogaine NUMBER mg / kg NUMBER MC NUMBER mg / kg decreases the intravenous self administration of morphine and cocaine and the oral self administration of ethanol and nicotine in rats
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	18-MC	morphine	none	{'e1': {'word': '18-MC', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d110.s2.e1'}, 'e2': {'word': 'morphine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d110.s2.e2'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like ibogaine NUMBER mg / kg NUMBER MC NUMBER mg / kg decreases the intravenous self administration of morphine and cocaine and the oral self administration of ethanol and nicotine in rats
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	18-MC	cocaine	none	{'e1': {'word': '18-MC', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d110.s2.e1'}, 'e2': {'word': 'cocaine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d110.s2.e3'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like ibogaine NUMBER mg / kg NUMBER MC NUMBER mg / kg decreases the intravenous self administration of morphine and cocaine and the oral self administration of ethanol and nicotine in rats
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	18-MC	ethanol	none	{'e1': {'word': '18-MC', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d110.s2.e1'}, 'e2': {'word': 'ethanol', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d110.s2.e4'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like ibogaine NUMBER mg / kg NUMBER MC NUMBER mg / kg decreases the intravenous self administration of morphine and cocaine and the oral self administration of ethanol and nicotine in rats
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	18-MC	nicotine	none	{'e1': {'word': '18-MC', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d110.s2.e1'}, 'e2': {'word': 'nicotine', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d110.s2.e5'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like ibogaine NUMBER mg / kg NUMBER MC NUMBER mg / kg decreases the intravenous self administration of morphine and cocaine and the oral self administration of ethanol and nicotine in rats
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	morphine	cocaine	none	{'e1': {'word': 'morphine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d110.s2.e2'}, 'e2': {'word': 'cocaine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d110.s2.e3'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like ibogaine NUMBER mg / kg NUMBER MC NUMBER mg / kg decreases the intravenous self administration of morphine and cocaine and the oral self administration of ethanol and nicotine in rats
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	morphine	ethanol	none	{'e1': {'word': 'morphine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d110.s2.e2'}, 'e2': {'word': 'ethanol', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d110.s2.e4'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like ibogaine NUMBER mg / kg NUMBER MC NUMBER mg / kg decreases the intravenous self administration of morphine and cocaine and the oral self administration of ethanol and nicotine in rats
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	morphine	nicotine	none	{'e1': {'word': 'morphine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d110.s2.e2'}, 'e2': {'word': 'nicotine', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d110.s2.e5'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like ibogaine NUMBER mg / kg NUMBER MC NUMBER mg / kg decreases the intravenous self administration of morphine and cocaine and the oral self administration of ethanol and nicotine in rats
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	cocaine	ethanol	none	{'e1': {'word': 'cocaine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d110.s2.e3'}, 'e2': {'word': 'ethanol', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d110.s2.e4'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like ibogaine NUMBER mg / kg NUMBER MC NUMBER mg / kg decreases the intravenous self administration of morphine and cocaine and the oral self administration of ethanol and nicotine in rats
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	cocaine	nicotine	none	{'e1': {'word': 'cocaine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d110.s2.e3'}, 'e2': {'word': 'nicotine', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d110.s2.e5'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like ibogaine NUMBER mg / kg NUMBER MC NUMBER mg / kg decreases the intravenous self administration of morphine and cocaine and the oral self administration of ethanol and nicotine in rats
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	ethanol	nicotine	none	{'e1': {'word': 'ethanol', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d110.s2.e4'}, 'e2': {'word': 'nicotine', 'word_index': [(29, 29)], 'id': 'DDI-MedLine.d110.s2.e5'}, 'sentence_id': 'DDI-MedLine.d110.s2'}	Like ibogaine NUMBER mg / kg NUMBER MC NUMBER mg / kg decreases the intravenous self administration of morphine and cocaine and the oral self administration of ethanol and nicotine in rats
unlike ibogaine, 18-MC does not affect responding for a nondrug reinforcer (water). 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s3.e0'}, 'e2': {'word': '18-MC', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d110.s3.e1'}, 'sentence_id': 'DDI-MedLine.d110.s3'}	unlike ibogaine NUMBER MC does not affect responding for a nondrug reinforcer water
Both ibogaine and 18-MC ameliorate opioid withdrawal signs. 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s4.e0'}, 'e2': {'word': '18-MC', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d110.s4.e1'}, 'sentence_id': 'DDI-MedLine.d110.s4'}	Both ibogaine and NUMBER MC ameliorate opioid withdrawal signs
Both ibogaine and 18-MC ameliorate opioid withdrawal signs. 	ibogaine	opioid	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s4.e0'}, 'e2': {'word': 'opioid', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d110.s4.e2'}, 'sentence_id': 'DDI-MedLine.d110.s4'}	Both ibogaine and NUMBER MC ameliorate opioid withdrawal signs
Both ibogaine and 18-MC ameliorate opioid withdrawal signs. 	18-MC	opioid	none	{'e1': {'word': '18-MC', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d110.s4.e1'}, 'e2': {'word': 'opioid', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d110.s4.e2'}, 'sentence_id': 'DDI-MedLine.d110.s4'}	Both ibogaine and NUMBER MC ameliorate opioid withdrawal signs
Both ibogaine and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens. 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s5.e0'}, 'e2': {'word': '18-MC', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d110.s5.e1'}, 'sentence_id': 'DDI-MedLine.d110.s5'}	Both ibogaine and NUMBER MC decrease extracellular levels of dopamine in the nucleus accumbens but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens
Both ibogaine and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens. 	ibogaine	ibogaine	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s5.e0'}, 'e2': {'word': 'ibogaine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d110.s5.e2'}, 'sentence_id': 'DDI-MedLine.d110.s5'}	Both ibogaine and NUMBER MC decrease extracellular levels of dopamine in the nucleus accumbens but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens
Both ibogaine and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens. 	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d110.s5.e1'}, 'e2': {'word': 'ibogaine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d110.s5.e2'}, 'sentence_id': 'DDI-MedLine.d110.s5'}	Both ibogaine and NUMBER MC decrease extracellular levels of dopamine in the nucleus accumbens but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens
Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s6.e0'}, 'e2': {'word': '18-MC', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d110.s6.e1'}, 'sentence_id': 'DDI-MedLine.d110.s6'}	Both ibogaine and NUMBER MC block morphine induced and nicotine induced dopamine release in the nucleus accumbens
Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; 	ibogaine	morphine	effect	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s6.e0'}, 'e2': {'word': 'morphine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d110.s6.e2'}, 'sentence_id': 'DDI-MedLine.d110.s6'}	Both ibogaine and NUMBER MC block morphine induced and nicotine induced dopamine release in the nucleus accumbens
Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; 	ibogaine	nicotine	effect	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s6.e0'}, 'e2': {'word': 'nicotine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d110.s6.e3'}, 'sentence_id': 'DDI-MedLine.d110.s6'}	Both ibogaine and NUMBER MC block morphine induced and nicotine induced dopamine release in the nucleus accumbens
Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; 	18-MC	morphine	effect	{'e1': {'word': '18-MC', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d110.s6.e1'}, 'e2': {'word': 'morphine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d110.s6.e2'}, 'sentence_id': 'DDI-MedLine.d110.s6'}	Both ibogaine and NUMBER MC block morphine induced and nicotine induced dopamine release in the nucleus accumbens
Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; 	18-MC	nicotine	effect	{'e1': {'word': '18-MC', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d110.s6.e1'}, 'e2': {'word': 'nicotine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d110.s6.e3'}, 'sentence_id': 'DDI-MedLine.d110.s6'}	Both ibogaine and NUMBER MC block morphine induced and nicotine induced dopamine release in the nucleus accumbens
Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; 	morphine	nicotine	none	{'e1': {'word': 'morphine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d110.s6.e2'}, 'e2': {'word': 'nicotine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d110.s6.e3'}, 'sentence_id': 'DDI-MedLine.d110.s6'}	Both ibogaine and NUMBER MC block morphine induced and nicotine induced dopamine release in the nucleus accumbens
only ibogaine enhances cocaine-induced increases in accumbal dopamine. 	ibogaine	cocaine	effect	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s7.e0'}, 'e2': {'word': 'cocaine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s7.e1'}, 'sentence_id': 'DDI-MedLine.d110.s7'}	only ibogaine enhances cocaine induced increases in accumbal dopamine
Both ibogaine and 18-MC enhance the locomotor and/or stereotypic effects of stimulants. 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d110.s8.e0'}, 'e2': {'word': '18-MC', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d110.s8.e1'}, 'sentence_id': 'DDI-MedLine.d110.s8'}	Both ibogaine and NUMBER MC enhance the locomotor and or stereotypic effects of stimulants
Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine; 	Ibogaine	18-MC	none	{'e1': {'word': 'Ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s9.e0'}, 'e2': {'word': '18-MC', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d110.s9.e1'}, 'sentence_id': 'DDI-MedLine.d110.s9'}	Ibogaine attenuates but NUMBER MC potentiates the acute locomotor effects of morphine
Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine; 	Ibogaine	morphine	effect	{'e1': {'word': 'Ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s9.e0'}, 'e2': {'word': 'morphine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d110.s9.e2'}, 'sentence_id': 'DDI-MedLine.d110.s9'}	Ibogaine attenuates but NUMBER MC potentiates the acute locomotor effects of morphine
Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine; 	18-MC	morphine	effect	{'e1': {'word': '18-MC', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d110.s9.e1'}, 'e2': {'word': 'morphine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d110.s9.e2'}, 'sentence_id': 'DDI-MedLine.d110.s9'}	Ibogaine attenuates but NUMBER MC potentiates the acute locomotor effects of morphine
both compounds attenuate morphine-induced locomotion in morphine-experienced rats. 	morphine	morphine	none	{'e1': {'word': 'morphine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d110.s10.e0'}, 'e2': {'word': 'morphine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d110.s10.e1'}, 'sentence_id': 'DDI-MedLine.d110.s10'}	both compounds attenuate morphine induced locomotion in morphine experienced rats
Ibogaine, but not 18-MC, decreases heart rate at high doses. 	Ibogaine	18-MC	none	{'e1': {'word': 'Ibogaine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d110.s13.e0'}, 'e2': {'word': '18-MC', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d110.s13.e1'}, 'sentence_id': 'DDI-MedLine.d110.s13'}	Ibogaine but not NUMBER MC decreases heart rate at high doses
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d110.s14.e0'}, 'e2': {'word': 'ibogaine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d110.s14.e1'}, 'sentence_id': 'DDI-MedLine.d110.s14'}	While NUMBER MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors NUMBER MC has much lower affinities than ibogaine for NMDA and sigma NUMBER receptors sodium channels and the NUMBER HT transporter
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	18-MC	18-MC	none	{'e1': {'word': '18-MC', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d110.s14.e0'}, 'e2': {'word': '18-MC', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d110.s14.e2'}, 'sentence_id': 'DDI-MedLine.d110.s14'}	While NUMBER MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors NUMBER MC has much lower affinities than ibogaine for NMDA and sigma NUMBER receptors sodium channels and the NUMBER HT transporter
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d110.s14.e0'}, 'e2': {'word': 'ibogaine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d110.s14.e3'}, 'sentence_id': 'DDI-MedLine.d110.s14'}	While NUMBER MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors NUMBER MC has much lower affinities than ibogaine for NMDA and sigma NUMBER receptors sodium channels and the NUMBER HT transporter
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d110.s14.e1'}, 'e2': {'word': '18-MC', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d110.s14.e2'}, 'sentence_id': 'DDI-MedLine.d110.s14'}	While NUMBER MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors NUMBER MC has much lower affinities than ibogaine for NMDA and sigma NUMBER receptors sodium channels and the NUMBER HT transporter
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	ibogaine	ibogaine	none	{'e1': {'word': 'ibogaine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d110.s14.e1'}, 'e2': {'word': 'ibogaine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d110.s14.e3'}, 'sentence_id': 'DDI-MedLine.d110.s14'}	While NUMBER MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors NUMBER MC has much lower affinities than ibogaine for NMDA and sigma NUMBER receptors sodium channels and the NUMBER HT transporter
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d110.s14.e2'}, 'e2': {'word': 'ibogaine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d110.s14.e3'}, 'sentence_id': 'DDI-MedLine.d110.s14'}	While NUMBER MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors NUMBER MC has much lower affinities than ibogaine for NMDA and sigma NUMBER receptors sodium channels and the NUMBER HT transporter
Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. 	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d110.s15.e0'}, 'e2': {'word': 'ibogaine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d110.s15.e1'}, 'sentence_id': 'DDI-MedLine.d110.s15'}	Both NUMBER MC and ibogaine are sequestered in fat and like ibogaine NUMBER MC probably has an active metabolite
Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. 	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d110.s15.e0'}, 'e2': {'word': 'ibogaine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d110.s15.e2'}, 'sentence_id': 'DDI-MedLine.d110.s15'}	Both NUMBER MC and ibogaine are sequestered in fat and like ibogaine NUMBER MC probably has an active metabolite
Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. 	18-MC	18-MC	none	{'e1': {'word': '18-MC', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d110.s15.e0'}, 'e2': {'word': '18-MC', 'word_index': [(12, 13)], 'id': 'DDI-MedLine.d110.s15.e3'}, 'sentence_id': 'DDI-MedLine.d110.s15'}	Both NUMBER MC and ibogaine are sequestered in fat and like ibogaine NUMBER MC probably has an active metabolite
Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. 	ibogaine	ibogaine	none	{'e1': {'word': 'ibogaine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d110.s15.e1'}, 'e2': {'word': 'ibogaine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d110.s15.e2'}, 'sentence_id': 'DDI-MedLine.d110.s15'}	Both NUMBER MC and ibogaine are sequestered in fat and like ibogaine NUMBER MC probably has an active metabolite
Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d110.s15.e1'}, 'e2': {'word': '18-MC', 'word_index': [(12, 13)], 'id': 'DDI-MedLine.d110.s15.e3'}, 'sentence_id': 'DDI-MedLine.d110.s15'}	Both NUMBER MC and ibogaine are sequestered in fat and like ibogaine NUMBER MC probably has an active metabolite
Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. 	ibogaine	18-MC	none	{'e1': {'word': 'ibogaine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d110.s15.e2'}, 'e2': {'word': '18-MC', 'word_index': [(12, 13)], 'id': 'DDI-MedLine.d110.s15.e3'}, 'sentence_id': 'DDI-MedLine.d110.s15'}	Both NUMBER MC and ibogaine are sequestered in fat and like ibogaine NUMBER MC probably has an active metabolite
The data suggest that 18-MC has a narrower spectrum of actions and will have a substantially greater therapeutic index than ibogaine.	18-MC	ibogaine	none	{'e1': {'word': '18-MC', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d110.s16.e0'}, 'e2': {'word': 'ibogaine', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d110.s16.e1'}, 'sentence_id': 'DDI-MedLine.d110.s16'}	The data suggest that NUMBER MC has a narrower spectrum of actions and will have a substantially greater therapeutic index than ibogaine
"Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline.
"	estradiol	progesterone	none	{'e1': {'word': 'estradiol', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d102.s0.e0'}, 'e2': {'word': 'progesterone', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d102.s0.e1'}, 'sentence_id': 'DDI-MedLine.d102.s0'}	Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline
"Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline.
"	estradiol	noradrenaline	none	{'e1': {'word': 'estradiol', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d102.s0.e0'}, 'e2': {'word': 'noradrenaline', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d102.s0.e2'}, 'sentence_id': 'DDI-MedLine.d102.s0'}	Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline
"Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline.
"	progesterone	noradrenaline	none	{'e1': {'word': 'progesterone', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d102.s0.e1'}, 'e2': {'word': 'noradrenaline', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d102.s0.e2'}, 'sentence_id': 'DDI-MedLine.d102.s0'}	Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline
The aim of this study was to investigate the effects of low and high doses of estradiol, and of progesterone on the response to noradrenaline in rat thoracic aorta. 	estradiol	progesterone	none	{'e1': {'word': 'estradiol', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d102.s1.e0'}, 'e2': {'word': 'progesterone', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d102.s1.e1'}, 'sentence_id': 'DDI-MedLine.d102.s1'}	The aim of this study was to investigate the effects of low and high doses of estradiol and of progesterone on the response to noradrenaline in rat thoracic aorta
The aim of this study was to investigate the effects of low and high doses of estradiol, and of progesterone on the response to noradrenaline in rat thoracic aorta. 	estradiol	noradrenaline	none	{'e1': {'word': 'estradiol', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d102.s1.e0'}, 'e2': {'word': 'noradrenaline', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d102.s1.e2'}, 'sentence_id': 'DDI-MedLine.d102.s1'}	The aim of this study was to investigate the effects of low and high doses of estradiol and of progesterone on the response to noradrenaline in rat thoracic aorta
The aim of this study was to investigate the effects of low and high doses of estradiol, and of progesterone on the response to noradrenaline in rat thoracic aorta. 	progesterone	noradrenaline	none	{'e1': {'word': 'progesterone', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d102.s1.e1'}, 'e2': {'word': 'noradrenaline', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d102.s1.e2'}, 'sentence_id': 'DDI-MedLine.d102.s1'}	The aim of this study was to investigate the effects of low and high doses of estradiol and of progesterone on the response to noradrenaline in rat thoracic aorta
injection of vehicle (corn oil, 0.1 mL/day), estradiol (10 microg/kg/day or 4 mg/kg/day) and/or progesterone (20 mg/kg/day), for eight days. 	estradiol	progesterone	none	{'e1': {'word': 'estradiol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d102.s3.e0'}, 'e2': {'word': 'progesterone', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d102.s3.e1'}, 'sentence_id': 'DDI-MedLine.d102.s3'}	injection of vehicle corn oil NUMBER mL / day estradiol NUMBER microg / kg / day or NUMBER mg / kg / day and or progesterone NUMBER mg / kg / day for NUMBER days
Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively). 	estradiol	noradrenaline	effect	{'e1': {'word': 'estradiol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d102.s5.e0'}, 'e2': {'word': 'noradrenaline', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d102.s5.e1'}, 'sentence_id': 'DDI-MedLine.d102.s5'}	Aortic rings with intact endothelium from the high dose NUMBER mg / kg / day estradiol group were supersensitive to noradrenaline compared to the vehicle or low dose NUMBER microg / kg / day estradiol groups pD2 values = NUMBER + - NUMBER NUMBER + - NUMBER and NUMBER + - NUMBER respectively
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	estradiol	noradrenaline	effect	{'e1': {'word': 'estradiol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d102.s6.e0'}, 'e2': {'word': 'noradrenaline', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d102.s6.e1'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	Endothelium intact aortic rings from high estradiol rats were supersensitive to noradrenaline when compared to vehicle progesterone and progesterone + high estradiol treated rats pD2 values = NUMBER + - NUMBER NUMBER NUMBER and NUMBER + - NUMBER respectively
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	estradiol	progesterone	none	{'e1': {'word': 'estradiol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d102.s6.e0'}, 'e2': {'word': 'progesterone', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d102.s6.e2'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	Endothelium intact aortic rings from high estradiol rats were supersensitive to noradrenaline when compared to vehicle progesterone and progesterone + high estradiol treated rats pD2 values = NUMBER + - NUMBER NUMBER NUMBER and NUMBER + - NUMBER respectively
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	estradiol	progesterone	none	{'e1': {'word': 'estradiol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d102.s6.e0'}, 'e2': {'word': 'progesterone', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d102.s6.e3'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	Endothelium intact aortic rings from high estradiol rats were supersensitive to noradrenaline when compared to vehicle progesterone and progesterone + high estradiol treated rats pD2 values = NUMBER + - NUMBER NUMBER NUMBER and NUMBER + - NUMBER respectively
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	estradiol	estradiol	none	{'e1': {'word': 'estradiol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d102.s6.e0'}, 'e2': {'word': 'estradiol', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d102.s6.e4'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	Endothelium intact aortic rings from high estradiol rats were supersensitive to noradrenaline when compared to vehicle progesterone and progesterone + high estradiol treated rats pD2 values = NUMBER + - NUMBER NUMBER NUMBER and NUMBER + - NUMBER respectively
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	noradrenaline	progesterone	none	{'e1': {'word': 'noradrenaline', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d102.s6.e1'}, 'e2': {'word': 'progesterone', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d102.s6.e2'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	Endothelium intact aortic rings from high estradiol rats were supersensitive to noradrenaline when compared to vehicle progesterone and progesterone + high estradiol treated rats pD2 values = NUMBER + - NUMBER NUMBER NUMBER and NUMBER + - NUMBER respectively
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	noradrenaline	progesterone	none	{'e1': {'word': 'noradrenaline', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d102.s6.e1'}, 'e2': {'word': 'progesterone', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d102.s6.e3'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	Endothelium intact aortic rings from high estradiol rats were supersensitive to noradrenaline when compared to vehicle progesterone and progesterone + high estradiol treated rats pD2 values = NUMBER + - NUMBER NUMBER NUMBER and NUMBER + - NUMBER respectively
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	noradrenaline	estradiol	none	{'e1': {'word': 'noradrenaline', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d102.s6.e1'}, 'e2': {'word': 'estradiol', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d102.s6.e4'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	Endothelium intact aortic rings from high estradiol rats were supersensitive to noradrenaline when compared to vehicle progesterone and progesterone + high estradiol treated rats pD2 values = NUMBER + - NUMBER NUMBER NUMBER and NUMBER + - NUMBER respectively
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	progesterone	progesterone	none	{'e1': {'word': 'progesterone', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d102.s6.e2'}, 'e2': {'word': 'progesterone', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d102.s6.e3'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	Endothelium intact aortic rings from high estradiol rats were supersensitive to noradrenaline when compared to vehicle progesterone and progesterone + high estradiol treated rats pD2 values = NUMBER + - NUMBER NUMBER NUMBER and NUMBER + - NUMBER respectively
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	progesterone	estradiol	none	{'e1': {'word': 'progesterone', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d102.s6.e2'}, 'e2': {'word': 'estradiol', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d102.s6.e4'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	Endothelium intact aortic rings from high estradiol rats were supersensitive to noradrenaline when compared to vehicle progesterone and progesterone + high estradiol treated rats pD2 values = NUMBER + - NUMBER NUMBER NUMBER and NUMBER + - NUMBER respectively
Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 	progesterone	estradiol	none	{'e1': {'word': 'progesterone', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d102.s6.e3'}, 'e2': {'word': 'estradiol', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d102.s6.e4'}, 'sentence_id': 'DDI-MedLine.d102.s6'}	Endothelium intact aortic rings from high estradiol rats were supersensitive to noradrenaline when compared to vehicle progesterone and progesterone + high estradiol treated rats pD2 values = NUMBER + - NUMBER NUMBER -0.13 6.93+/-0.04 NUMBER NUMBER / 0.18 NUMBER respectively NUMBER .
"Rifampin and warfarin: a drug interaction.
"	Rifampin	warfarin	int	{'e1': {'word': 'Rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d116.s0.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d116.s0.e1'}, 'sentence_id': 'DDI-MedLine.d116.s0'}	Rifampin and warfarin a drug interaction
The drug interaction between warfarin and rifampin is not well known. 	warfarin	rifampin	int	{'e1': {'word': 'warfarin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d116.s1.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d116.s1.e1'}, 'sentence_id': 'DDI-MedLine.d116.s1'}	The drug interaction between warfarin and rifampin is not well known
Rifampin has been reported to increase the warfarin requirements in human subjects ingesting these agents simultaneously. 	Rifampin	warfarin	mechanism	{'e1': {'word': 'Rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d116.s2.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d116.s2.e1'}, 'sentence_id': 'DDI-MedLine.d116.s2'}	Rifampin has been reported to increase the warfarin requirements in human subjects ingesting these agents simultaneously
The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. 	rifampin	warfarin	mechanism	{'e1': {'word': 'rifampin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d116.s3.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d116.s3.e1'}, 'sentence_id': 'DDI-MedLine.d116.s3'}	The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin NUMBER mg per day in order to produce a therapeutic effect
The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. 	rifampin	warfarin	none	{'e1': {'word': 'rifampin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d116.s3.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d116.s3.e2'}, 'sentence_id': 'DDI-MedLine.d116.s3'}	The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin NUMBER mg per day in order to produce a therapeutic effect
The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. 	warfarin	warfarin	none	{'e1': {'word': 'warfarin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d116.s3.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d116.s3.e2'}, 'sentence_id': 'DDI-MedLine.d116.s3'}	The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin NUMBER mg per day in order to produce a therapeutic effect
Withdrawal of rifampin decreased the warfarin requirement by 50%. 	rifampin	warfarin	mechanism	{'e1': {'word': 'rifampin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d116.s4.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d116.s4.e1'}, 'sentence_id': 'DDI-MedLine.d116.s4'}	Withdrawal of rifampin decreased the warfarin requirement by NUMBER %
This effect may be mediated by the ability of rifampin to induce microsomal enzymes and, thus, the catabolism of warfarin. 	rifampin	warfarin	mechanism	{'e1': {'word': 'rifampin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d116.s5.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d116.s5.e1'}, 'sentence_id': 'DDI-MedLine.d116.s5'}	This effect may be mediated by the ability of rifampin to induce microsomal enzymes and thus the catabolism of warfarin
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. 	rifampin	warfarin	effect	{'e1': {'word': 'rifampin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d116.s6.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d116.s6.e1'}, 'sentence_id': 'DDI-MedLine.d116.s6'}	The effect of rifampin on the warfarin requirement of our patient appeared to be maximal NUMBER to NUMBER days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. 	rifampin	rifampin	none	{'e1': {'word': 'rifampin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d116.s6.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d116.s6.e2'}, 'sentence_id': 'DDI-MedLine.d116.s6'}	The effect of rifampin on the warfarin requirement of our patient appeared to be maximal NUMBER to NUMBER days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. 	rifampin	rifampin	none	{'e1': {'word': 'rifampin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d116.s6.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d116.s6.e3'}, 'sentence_id': 'DDI-MedLine.d116.s6'}	The effect of rifampin on the warfarin requirement of our patient appeared to be maximal NUMBER to NUMBER days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. 	warfarin	rifampin	none	{'e1': {'word': 'warfarin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d116.s6.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d116.s6.e2'}, 'sentence_id': 'DDI-MedLine.d116.s6'}	The effect of rifampin on the warfarin requirement of our patient appeared to be maximal NUMBER to NUMBER days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. 	warfarin	rifampin	none	{'e1': {'word': 'warfarin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d116.s6.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d116.s6.e3'}, 'sentence_id': 'DDI-MedLine.d116.s6'}	The effect of rifampin on the warfarin requirement of our patient appeared to be maximal NUMBER to NUMBER days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. 	rifampin	rifampin	none	{'e1': {'word': 'rifampin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d116.s6.e2'}, 'e2': {'word': 'rifampin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d116.s6.e3'}, 'sentence_id': 'DDI-MedLine.d116.s6'}	The effect of rifampin on the warfarin requirement of our patient appeared to be maximal NUMBER to NUMBER days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal
"Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.
"	Misonidazole	CCNU	effect	{'e1': {'word': 'Misonidazole', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d85.s0.e0'}, 'e2': {'word': 'CCNU', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d85.s0.e1'}, 'sentence_id': 'DDI-MedLine.d85.s0'}	Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU
Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. 	nitrosourea	CCNU	none	{'e1': {'word': 'nitrosourea', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d85.s1.e0'}, 'e2': {'word': 'CCNU', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d85.s1.e1'}, 'sentence_id': 'DDI-MedLine.d85.s1'}	Because the nitrosourea CCNU is given exclusively by the oral route in man we have carried out studies in mice on the antitumour activity acute toxicity and pharmacokinetics of oral CCNU either alone or in combination with the chemosensitizer misonidazole
Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. 	nitrosourea	CCNU	none	{'e1': {'word': 'nitrosourea', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d85.s1.e0'}, 'e2': {'word': 'CCNU', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d85.s1.e2'}, 'sentence_id': 'DDI-MedLine.d85.s1'}	Because the nitrosourea CCNU is given exclusively by the oral route in man we have carried out studies in mice on the antitumour activity acute toxicity and pharmacokinetics of oral CCNU either alone or in combination with the chemosensitizer misonidazole
Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. 	nitrosourea	misonidazole	none	{'e1': {'word': 'nitrosourea', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d85.s1.e0'}, 'e2': {'word': 'misonidazole', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d85.s1.e3'}, 'sentence_id': 'DDI-MedLine.d85.s1'}	Because the nitrosourea CCNU is given exclusively by the oral route in man we have carried out studies in mice on the antitumour activity acute toxicity and pharmacokinetics of oral CCNU either alone or in combination with the chemosensitizer misonidazole
Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. 	CCNU	CCNU	none	{'e1': {'word': 'CCNU', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d85.s1.e1'}, 'e2': {'word': 'CCNU', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d85.s1.e2'}, 'sentence_id': 'DDI-MedLine.d85.s1'}	Because the nitrosourea CCNU is given exclusively by the oral route in man we have carried out studies in mice on the antitumour activity acute toxicity and pharmacokinetics of oral CCNU either alone or in combination with the chemosensitizer misonidazole
Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. 	CCNU	misonidazole	none	{'e1': {'word': 'CCNU', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d85.s1.e1'}, 'e2': {'word': 'misonidazole', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d85.s1.e3'}, 'sentence_id': 'DDI-MedLine.d85.s1'}	Because the nitrosourea CCNU is given exclusively by the oral route in man we have carried out studies in mice on the antitumour activity acute toxicity and pharmacokinetics of oral CCNU either alone or in combination with the chemosensitizer misonidazole
Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. 	CCNU	misonidazole	none	{'e1': {'word': 'CCNU', 'word_index': [(30, 30)], 'id': 'DDI-MedLine.d85.s1.e2'}, 'e2': {'word': 'misonidazole', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d85.s1.e3'}, 'sentence_id': 'DDI-MedLine.d85.s1'}	Because the nitrosourea CCNU is given exclusively by the oral route in man we have carried out studies in mice on the antitumour activity acute toxicity and pharmacokinetics of oral CCNU either alone or in combination with the chemosensitizer misonidazole
Misonidazole reduced the antitumour activity of oral CCNU by dose modifying factors (DMF) of 0.58-0.71. 	Misonidazole	CCNU	effect	{'e1': {'word': 'Misonidazole', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d85.s7.e0'}, 'e2': {'word': 'CCNU', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d85.s7.e1'}, 'sentence_id': 'DDI-MedLine.d85.s7'}	Misonidazole reduced the antitumour activity of oral CCNU by dose modifying factors DMF of NUMBER - NUMBER
Misonidazole has a complex effect on oral CCNU pharmacokinetics. 	Misonidazole	CCNU	mechanism	{'e1': {'word': 'Misonidazole', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d85.s9.e0'}, 'e2': {'word': 'CCNU', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d85.s9.e1'}, 'sentence_id': 'DDI-MedLine.d85.s9'}	Misonidazole has a complex effect on oral CCNU pharmacokinetics
We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral CCNU cytotoxicity by misonidazole. 	CCNU	misonidazole	mechanism	{'e1': {'word': 'CCNU', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d85.s14.e0'}, 'e2': {'word': 'misonidazole', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d85.s14.e1'}, 'sentence_id': 'DDI-MedLine.d85.s14'}	We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral CCNU cytotoxicity by misonidazole
[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration] The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	radiopertechnetate	sodium perchlorate	none	{'e1': {'word': 'radiopertechnetate', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d134.s0.e0'}, 'e2': {'word': 'sodium perchlorate', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d134.s0.e1'}, 'sentence_id': 'DDI-MedLine.d134.s0'}	Dose time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate in dependence on application mode was studied
[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration] The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	radiopertechnetate	sodium perchlorate	none	{'e1': {'word': 'radiopertechnetate', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d134.s0.e0'}, 'e2': {'word': 'sodium perchlorate', 'word_index': [(22, 23)], 'id': 'DDI-MedLine.d134.s0.e2'}, 'sentence_id': 'DDI-MedLine.d134.s0'}	Dose time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate in dependence on application mode was studied
[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration] The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	radiopertechnetate	radiopertechnetate	none	{'e1': {'word': 'radiopertechnetate', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d134.s0.e0'}, 'e2': {'word': 'radiopertechnetate', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d134.s0.e3'}, 'sentence_id': 'DDI-MedLine.d134.s0'}	Dose time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate in dependence on application mode was studied
[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration] The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	sodium perchlorate	sodium perchlorate	none	{'e1': {'word': 'sodium perchlorate', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d134.s0.e1'}, 'e2': {'word': 'sodium perchlorate', 'word_index': [(22, 23)], 'id': 'DDI-MedLine.d134.s0.e2'}, 'sentence_id': 'DDI-MedLine.d134.s0'}	Dose time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate in dependence on application mode was studied
[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration] The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	sodium perchlorate	radiopertechnetate	none	{'e1': {'word': 'sodium perchlorate', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d134.s0.e1'}, 'e2': {'word': 'radiopertechnetate', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d134.s0.e3'}, 'sentence_id': 'DDI-MedLine.d134.s0'}	Dose time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate in dependence on application mode was studied
[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration] The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	sodium perchlorate	radiopertechnetate	none	{'e1': {'word': 'sodium perchlorate', 'word_index': [(22, 23)], 'id': 'DDI-MedLine.d134.s0.e2'}, 'e2': {'word': 'radiopertechnetate', 'word_index': [(38, 38)], 'id': 'DDI-MedLine.d134.s0.e3'}, 'sentence_id': 'DDI-MedLine.d134.s0'}	Dose time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate in dependence on application mode was studied
An intravenous dose of 50 mg perchlorate was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radiopertechnetate. 	perchlorate	pertechnetate	none	{'e1': {'word': 'perchlorate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d134.s1.e0'}, 'e2': {'word': 'pertechnetate', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d134.s1.e1'}, 'sentence_id': 'DDI-MedLine.d134.s1'}	An intravenous dose of NUMBER mg perchlorate was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous NUMBER mg ClO NUMBER simultaneously or NUMBER mg orally NUMBER min before the injection of radiopertechnetate
An intravenous dose of 50 mg perchlorate was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radiopertechnetate. 	perchlorate	radiopertechnetate	none	{'e1': {'word': 'perchlorate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d134.s1.e0'}, 'e2': {'word': 'radiopertechnetate', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d134.s1.e2'}, 'sentence_id': 'DDI-MedLine.d134.s1'}	An intravenous dose of NUMBER mg perchlorate was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous NUMBER mg ClO NUMBER simultaneously or NUMBER mg orally NUMBER min before the injection of radiopertechnetate
An intravenous dose of 50 mg perchlorate was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radiopertechnetate. 	pertechnetate	radiopertechnetate	none	{'e1': {'word': 'pertechnetate', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d134.s1.e1'}, 'e2': {'word': 'radiopertechnetate', 'word_index': [(37, 37)], 'id': 'DDI-MedLine.d134.s1.e2'}, 'sentence_id': 'DDI-MedLine.d134.s1'}	An intravenous dose of NUMBER mg perchlorate was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous NUMBER mg ClO NUMBER simultaneously or NUMBER mg orally NUMBER min before the injection of radiopertechnetate
An intravenous injection of perchlorate given later also produces a complete and immediately beginning depletion of pertechnetate already accumulated in the thyroid, within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels. 	perchlorate	pertechnetate	mechanism	{'e1': {'word': 'perchlorate', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d134.s2.e0'}, 'e2': {'word': 'pertechnetate', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d134.s2.e1'}, 'sentence_id': 'DDI-MedLine.d134.s2'}	An intravenous injection of perchlorate given later also produces a complete and immediately beginning depletion of pertechnetate already accumulated in the thyroid within a period of NUMBER min after NUMBER m TcO NUMBER injection with a corresponding increase in blood levels
"Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
"	amprenavir	rifabutin	none	{'e1': {'word': 'amprenavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s0.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d3.s0.e1'}, 'sentence_id': 'DDI-MedLine.d3.s0'}	Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males
"Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
"	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s0.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d3.s0.e2'}, 'sentence_id': 'DDI-MedLine.d3.s0'}	Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males
"Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
"	rifabutin	rifampin	none	{'e1': {'word': 'rifabutin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d3.s0.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d3.s0.e2'}, 'sentence_id': 'DDI-MedLine.d3.s0'}	Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males
The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). 	amprenavir	rifabutin	none	{'e1': {'word': 'amprenavir', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d3.s1.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d3.s1.e1'}, 'sentence_id': 'DDI-MedLine.d3.s1'}	The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test ERMBT
The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). 	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d3.s1.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d3.s1.e2'}, 'sentence_id': 'DDI-MedLine.d3.s1'}	The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test ERMBT
The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). 	rifabutin	rifampin	none	{'e1': {'word': 'rifabutin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d3.s1.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d3.s1.e2'}, 'sentence_id': 'DDI-MedLine.d3.s1'}	The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test ERMBT
All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. 	amprenavir	rifabutin	none	{'e1': {'word': 'amprenavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s3.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d3.s3.e1'}, 'sentence_id': 'DDI-MedLine.d3.s3'}	All subjects received amprenavir NUMBER mg twice a day for NUMBER days followed by a NUMBER day washout period followed by either rifabutin NUMBER mg once a day QD cohort NUMBER or rifampin NUMBER mg QD cohort NUMBER for NUMBER days
All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. 	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d3.s3.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d3.s3.e2'}, 'sentence_id': 'DDI-MedLine.d3.s3'}	All subjects received amprenavir NUMBER mg twice a day for NUMBER days followed by a NUMBER day washout period followed by either rifabutin NUMBER mg once a day QD cohort NUMBER or rifampin NUMBER mg QD cohort NUMBER for NUMBER days
All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. 	rifabutin	rifampin	none	{'e1': {'word': 'rifabutin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d3.s3.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(32, 32)], 'id': 'DDI-MedLine.d3.s3.e2'}, 'sentence_id': 'DDI-MedLine.d3.s3'}	All subjects received amprenavir NUMBER mg twice a day for NUMBER days followed by a NUMBER day washout period followed by either rifabutin NUMBER mg once a day QD cohort NUMBER or rifampin NUMBER mg QD cohort NUMBER for NUMBER days
Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. 	amprenavir	rifabutin	none	{'e1': {'word': 'amprenavir', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d3.s4.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d3.s4.e1'}, 'sentence_id': 'DDI-MedLine.d3.s4'}	Cohort NUMBER then received amprenavir plus rifabutin for NUMBER days and cohort NUMBER received amprenavir plus rifampin for NUMBER days
Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. 	amprenavir	amprenavir	none	{'e1': {'word': 'amprenavir', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d3.s4.e0'}, 'e2': {'word': 'amprenavir', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d3.s4.e2'}, 'sentence_id': 'DDI-MedLine.d3.s4'}	Cohort NUMBER then received amprenavir plus rifabutin for NUMBER days and cohort NUMBER received amprenavir plus rifampin for NUMBER days
Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. 	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d3.s4.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d3.s4.e3'}, 'sentence_id': 'DDI-MedLine.d3.s4'}	Cohort NUMBER then received amprenavir plus rifabutin for NUMBER days and cohort NUMBER received amprenavir plus rifampin for NUMBER days
Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. 	rifabutin	amprenavir	none	{'e1': {'word': 'rifabutin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d3.s4.e1'}, 'e2': {'word': 'amprenavir', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d3.s4.e2'}, 'sentence_id': 'DDI-MedLine.d3.s4'}	Cohort NUMBER then received amprenavir plus rifabutin for NUMBER days and cohort NUMBER received amprenavir plus rifampin for NUMBER days
Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. 	rifabutin	rifampin	none	{'e1': {'word': 'rifabutin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d3.s4.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d3.s4.e3'}, 'sentence_id': 'DDI-MedLine.d3.s4'}	Cohort NUMBER then received amprenavir plus rifabutin for NUMBER days and cohort NUMBER received amprenavir plus rifampin for NUMBER days
Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. 	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d3.s4.e2'}, 'e2': {'word': 'rifampin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d3.s4.e3'}, 'sentence_id': 'DDI-MedLine.d3.s4'}	Cohort NUMBER then received amprenavir plus rifabutin for NUMBER days and cohort NUMBER received amprenavir plus rifampin for NUMBER days
Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. 	amprenavir	rifabutin	none	{'e1': {'word': 'amprenavir', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d3.s5.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d3.s5.e1'}, 'sentence_id': 'DDI-MedLine.d3.s5'}	Serial plasma and urine samples for measurement of amprenavir rifabutin and rifampin and their NUMBER O desacetyl metabolites were measured by high performance liquid chromatography
Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. 	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d3.s5.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d3.s5.e2'}, 'sentence_id': 'DDI-MedLine.d3.s5'}	Serial plasma and urine samples for measurement of amprenavir rifabutin and rifampin and their NUMBER O desacetyl metabolites were measured by high performance liquid chromatography
Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. 	amprenavir	25-O-desacetyl metabolites	none	{'e1': {'word': 'amprenavir', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d3.s5.e0'}, 'e2': {'word': '25-O-desacetyl metabolites', 'word_index': [(14, 17)], 'id': 'DDI-MedLine.d3.s5.e3'}, 'sentence_id': 'DDI-MedLine.d3.s5'}	Serial plasma and urine samples for measurement of amprenavir rifabutin and rifampin and their NUMBER O desacetyl metabolites were measured by high performance liquid chromatography
Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. 	rifabutin	rifampin	none	{'e1': {'word': 'rifabutin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d3.s5.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d3.s5.e2'}, 'sentence_id': 'DDI-MedLine.d3.s5'}	Serial plasma and urine samples for measurement of amprenavir rifabutin and rifampin and their NUMBER O desacetyl metabolites were measured by high performance liquid chromatography
Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. 	rifabutin	25-O-desacetyl metabolites	none	{'e1': {'word': 'rifabutin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d3.s5.e1'}, 'e2': {'word': '25-O-desacetyl metabolites', 'word_index': [(14, 17)], 'id': 'DDI-MedLine.d3.s5.e3'}, 'sentence_id': 'DDI-MedLine.d3.s5'}	Serial plasma and urine samples for measurement of amprenavir rifabutin and rifampin and their NUMBER O desacetyl metabolites were measured by high performance liquid chromatography
Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. 	rifampin	25-O-desacetyl metabolites	none	{'e1': {'word': 'rifampin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d3.s5.e2'}, 'e2': {'word': '25-O-desacetyl metabolites', 'word_index': [(14, 17)], 'id': 'DDI-MedLine.d3.s5.e3'}, 'sentence_id': 'DDI-MedLine.d3.s5'}	Serial plasma and urine samples for measurement of amprenavir rifabutin and rifampin and their NUMBER O desacetyl metabolites were measured by high performance liquid chromatography
Rifabutin did not significantly affect amprenavir's pharmacokinetics. 	Rifabutin	amprenavir	none	{'e1': {'word': 'Rifabutin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s6.e0'}, 'e2': {'word': 'amprenavir', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d3.s6.e1'}, 'sentence_id': 'DDI-MedLine.d3.s6'}	Rifabutin did not significantly affect amprenavir 's pharmacokinetics
Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. 	Amprenavir	rifabutin	mechanism	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s7.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d3.s7.e1'}, 'sentence_id': 'DDI-MedLine.d3.s7'}	Amprenavir significantly increased the area under the curve at steady state AUC ss of rifabutin by NUMBER fold and the AUC ss of NUMBER O desacetylrifabutin by 13.3-fold
Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. 	Amprenavir	25-O-desacetylrifabutin	mechanism	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s7.e0'}, 'e2': {'word': '25-O-desacetylrifabutin', 'word_index': [(23, 25)], 'id': 'DDI-MedLine.d3.s7.e2'}, 'sentence_id': 'DDI-MedLine.d3.s7'}	Amprenavir significantly increased the area under the curve at steady state AUC ss of rifabutin by NUMBER fold and the AUC ss of NUMBER O desacetylrifabutin by 13.3-fold
Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. 	rifabutin	25-O-desacetylrifabutin	none	{'e1': {'word': 'rifabutin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d3.s7.e1'}, 'e2': {'word': '25-O-desacetylrifabutin', 'word_index': [(22, 24)], 'id': 'DDI-MedLine.d3.s7.e2'}, 'sentence_id': 'DDI-MedLine.d3.s7'}	Amprenavir significantly increased the area under the curve at steady state AUC ss of rifabutin by NUMBER and the AUC ( ) 25 NUMBER - by 13.3-fold .
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. 	Rifampin	amprenavir	mechanism	{'e1': {'word': 'Rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s8.e0'}, 'e2': {'word': 'amprenavir', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d3.s8.e1'}, 'sentence_id': 'DDI-MedLine.d3.s8'}	Rifampin significantly decreased the AUC ss of amprenavir by NUMBER % but amprenavir had no effect on rifampin pharmacokinetics
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. 	Rifampin	amprenavir	none	{'e1': {'word': 'Rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s8.e0'}, 'e2': {'word': 'amprenavir', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d3.s8.e2'}, 'sentence_id': 'DDI-MedLine.d3.s8'}	Rifampin significantly decreased the AUC ss of amprenavir by NUMBER % but amprenavir had no effect on rifampin pharmacokinetics
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. 	Rifampin	rifampin	none	{'e1': {'word': 'Rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s8.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d3.s8.e3'}, 'sentence_id': 'DDI-MedLine.d3.s8'}	Rifampin significantly decreased the AUC ss of amprenavir by NUMBER % but amprenavir had no effect on rifampin pharmacokinetics
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. 	amprenavir	amprenavir	none	{'e1': {'word': 'amprenavir', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d3.s8.e1'}, 'e2': {'word': 'amprenavir', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d3.s8.e2'}, 'sentence_id': 'DDI-MedLine.d3.s8'}	Rifampin significantly decreased the AUC ss of amprenavir by NUMBER % but amprenavir had no effect on rifampin pharmacokinetics
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. 	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d3.s8.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d3.s8.e3'}, 'sentence_id': 'DDI-MedLine.d3.s8'}	Rifampin significantly decreased the AUC ss of amprenavir by NUMBER % but amprenavir had no effect on rifampin pharmacokinetics
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. 	amprenavir	rifampin	none	{'e1': {'word': 'amprenavir', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d3.s8.e2'}, 'e2': {'word': 'rifampin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d3.s8.e3'}, 'sentence_id': 'DDI-MedLine.d3.s8'}	Rifampin significantly decreased the AUC ss of amprenavir by NUMBER % but amprenavir had no effect on rifampin pharmacokinetics
The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively. 	rifabutin	rifampin	none	{'e1': {'word': 'rifabutin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d3.s10.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d3.s10.e1'}, 'sentence_id': 'DDI-MedLine.d3.s10'}	The results of the ERMBT after NUMBER weeks of rifabutin and rifampin therapy were increased NUMBER and NUMBER % respectively
Amprenavir plus rifampin was well tolerated. 	Amprenavir	rifampin	none	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s11.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d3.s11.e1'}, 'sentence_id': 'DDI-MedLine.d3.s11'}	Amprenavir plus rifampin was well tolerated
Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. 	Amprenavir	rifabutin	effect	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s12.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d3.s12.e1'}, 'sentence_id': 'DDI-MedLine.d3.s12'}	Amprenavir plus rifabutin was poorly tolerated and NUMBER of NUMBER subjects discontinued therapy
Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. 	Rifampin	amprenavir	mechanism	{'e1': {'word': 'Rifampin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s13.e0'}, 'e2': {'word': 'amprenavir', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d3.s13.e1'}, 'sentence_id': 'DDI-MedLine.d3.s13'}	Rifampin markedly increases the metabolic clearance of amprenavir and coadministration is contraindicated
Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. 	Amprenavir	rifabutin	mechanism	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s14.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d3.s14.e1'}, 'sentence_id': 'DDI-MedLine.d3.s14'}	Amprenavir significantly decreases clearance of rifabutin and NUMBER O desacetylrifabutin and the combination is poorly tolerated
Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. 	Amprenavir	25-O-desacetylrifabutin	mechanism	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s14.e0'}, 'e2': {'word': '25-O-desacetylrifabutin', 'word_index': [(7, 9)], 'id': 'DDI-MedLine.d3.s14.e2'}, 'sentence_id': 'DDI-MedLine.d3.s14'}	Amprenavir significantly decreases clearance of rifabutin and NUMBER O desacetylrifabutin and the combination is poorly tolerated
Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. 	rifabutin	25-O-desacetylrifabutin	none	{'e1': {'word': 'rifabutin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d3.s14.e1'}, 'e2': {'word': '25-O-desacetylrifabutin', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d3.s14.e2'}, 'sentence_id': 'DDI-MedLine.d3.s14'}	Amprenavir significantly decreases clearance of rifabutin and NUMBER O-desacetylrifabutin , and combination is poorly tolerated .
Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.	Amprenavir	rifampin	none	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s15.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d3.s15.e1'}, 'sentence_id': 'DDI-MedLine.d3.s15'}	Amprenavir inhibits the ERMBT and rifampin and rifabutin are equipotent inducers of the ERMBT
Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.	Amprenavir	rifabutin	none	{'e1': {'word': 'Amprenavir', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d3.s15.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d3.s15.e2'}, 'sentence_id': 'DDI-MedLine.d3.s15'}	Amprenavir inhibits the ERMBT and rifampin and rifabutin are equipotent inducers of the ERMBT
Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.	rifampin	rifabutin	none	{'e1': {'word': 'rifampin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d3.s15.e1'}, 'e2': {'word': 'rifabutin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d3.s15.e2'}, 'sentence_id': 'DDI-MedLine.d3.s15'}	Amprenavir inhibits the ERMBT and rifampin and rifabutin are equipotent inducers of the ERMBT
"Behavioral responses to repeated cocaine exposure in mice selectively bred for differential sensitivity to pentobarbital.
"	cocaine	pentobarbital	none	{'e1': {'word': 'cocaine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d98.s0.e0'}, 'e2': {'word': 'pentobarbital', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d98.s0.e1'}, 'sentence_id': 'DDI-MedLine.d98.s0'}	Behavioral responses to repeated cocaine exposure in mice selectively bred for differential sensitivity to pentobarbital
Mice from the 20th generation of three lines divergently selected for response to pentobarbital-induced sedation times [long-sedation time (LST), short sedation time (SST), and randomly bred control (RBC)] were used to study cocaine-induced behavioral sensitization. 	pentobarbital	cocaine	none	{'e1': {'word': 'pentobarbital', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d98.s1.e0'}, 'e2': {'word': 'cocaine', 'word_index': [(34, 34)], 'id': 'DDI-MedLine.d98.s1.e1'}, 'sentence_id': 'DDI-MedLine.d98.s1'}	Mice from the 20th generation of NUMBER lines divergently selected for response to pentobarbital induced sedation times long sedation time LST short sedation time SST and randomly bred control RBC were used to study cocaine induced behavioral sensitization
Changes in urinary homocysteine following synthetic steroidal estrogen and progestogen administration to rats.	synthetic steroidal estrogen	synthetic steroidal progestogen	none	{'e1': {'word': 'synthetic steroidal estrogen', 'word_index': [(5, 7)], 'id': 'DDI-MedLine.d66.s0.e0'}, 'e2': {'word': 'synthetic steroidal progestogen', 'word_index': [(8, 9), (12, 12)], 'id': 'DDI-MedLine.d66.s0.e1'}, 'sentence_id': 'DDI-MedLine.d66.s0'}	Changes in urinary homocysteine following synthetic steroidal estrogen synthetic steroidal estrogen and progestogen administration to rats
The present work involved the administration of both ethynyl estradiol and levonorgestrel to groups of rats, followed by determination of the homocysteine excretion rate in urine. 	ethynyl estradiol	levonorgestrel	none	{'e1': {'word': 'ethynyl estradiol', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d66.s1.e0'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d66.s1.e1'}, 'sentence_id': 'DDI-MedLine.d66.s1'}	The present work involved the administration of both ethynyl estradiol and levonorgestrel to groups of rats followed by determination of the homocysteine excretion rate in urine
The results indicate that a statistically significant difference exists between the excreted levels of homocysteine in the urine of both control and levonorgestrel-treated rats and the levels shown by rats treated with ethynyl estradiol. 	levonorgestrel	ethynyl estradiol	none	{'e1': {'word': 'levonorgestrel', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d66.s2.e0'}, 'e2': {'word': 'ethynyl estradiol', 'word_index': [(33, 34)], 'id': 'DDI-MedLine.d66.s2.e1'}, 'sentence_id': 'DDI-MedLine.d66.s2'}	The results indicate that a statistically significant difference exists between the excreted levels of homocysteine in the urine of both control and levonorgestrel treated rats and the levels shown by rats treated with ethynyl estradiol
"Therapeutic drug monitoring can avoid iatrogenic alterations caused by 99mTc-methylene diphosphonate (MDP)-gentamicin interaction.
"	99mTc-methylene diphosphonate	gentamicin	effect	{'e1': {'word': '99mTc-methylene diphosphonate', 'word_index': [(9, 12)], 'id': 'DDI-MedLine.d89.s0.e0'}, 'e2': {'word': 'gentamicin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d89.s0.e1'}, 'sentence_id': 'DDI-MedLine.d89.s0'}	Therapeutic drug monitoring can avoid iatrogenic alterations caused by NUMBER mTc methylene diphosphonate MDP gentamicin interaction
Gentamicin is an aminoglycoside antibiotic used to treat a wide variety of infections caused by gram-negative organisms, but it is potentially toxic to the kidneys. 	Gentamicin	aminoglycoside antibiotic	none	{'e1': {'word': 'Gentamicin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d89.s1.e0'}, 'e2': {'word': 'aminoglycoside antibiotic', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d89.s1.e1'}, 'sentence_id': 'DDI-MedLine.d89.s1'}	Gentamicin is an aminoglycoside antibiotic used to treat a wide variety of infections caused by gram negative organisms but it is potentially toxic to the kidneys
Due to its nephrotoxicity, gentamicin may cause abnormal renal uptake to be seen on 99mTc-MDP bone scintigraphy. 	gentamicin	99mTc-MDP	mechanism	{'e1': {'word': 'gentamicin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d89.s2.e0'}, 'e2': {'word': '99mTc-MDP', 'word_index': [(14, 16)], 'id': 'DDI-MedLine.d89.s2.e1'}, 'sentence_id': 'DDI-MedLine.d89.s2'}	Due to its nephrotoxicity gentamicin may cause abnormal renal uptake to be seen on NUMBER mTc MDP bone scintigraphy
Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing 99mTc-MDP as the radiopharmaceutical was carried out in 22 patients. 	gentamicin	99mTc-MDP	none	{'e1': {'word': 'gentamicin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d89.s7.e0'}, 'e2': {'word': '99mTc-MDP', 'word_index': [(11, 13)], 'id': 'DDI-MedLine.d89.s7.e1'}, 'sentence_id': 'DDI-MedLine.d89.s7'}	Therapeutic drug monitoring TDM of gentamicin therapy and bone scintigraphy employing NUMBER mTc MDP as the radiopharmaceutical was carried out in NUMBER patients
Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing 99mTc-MDP as the radiopharmaceutical was carried out in 22 patients. 	gentamicin	radiopharmaceutical	none	{'e1': {'word': 'gentamicin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d89.s7.e0'}, 'e2': {'word': 'radiopharmaceutical', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d89.s7.e2'}, 'sentence_id': 'DDI-MedLine.d89.s7'}	Therapeutic drug monitoring TDM of gentamicin therapy and bone scintigraphy employing NUMBER mTc MDP as the radiopharmaceutical was carried out in NUMBER patients
Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing 99mTc-MDP as the radiopharmaceutical was carried out in 22 patients. 	99mTc-MDP	radiopharmaceutical	none	{'e1': {'word': '99mTc-MDP', 'word_index': [(11, 13)], 'id': 'DDI-MedLine.d89.s7.e1'}, 'e2': {'word': 'radiopharmaceutical', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d89.s7.e2'}, 'sentence_id': 'DDI-MedLine.d89.s7'}	Therapeutic drug monitoring TDM of gentamicin therapy and bone scintigraphy employing NUMBER mTc MDP as the radiopharmaceutical was carried out in NUMBER patients
The data presented here demonstrate that with serial pharmacokinetic dosing of gentamicin, the iatrogenic alteration caused by gentamicin therapy can be avoided.	gentamicin	gentamicin	none	{'e1': {'word': 'gentamicin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d89.s8.e0'}, 'e2': {'word': 'gentamicin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d89.s8.e1'}, 'sentence_id': 'DDI-MedLine.d89.s8'}	The data presented here demonstrate that with serial pharmacokinetic dosing of gentamicin the iatrogenic alteration caused by gentamicin therapy can be avoided
Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.	Dexamethasone	retinyl acetate	none	{'e1': {'word': 'Dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s0.e0'}, 'e2': {'word': 'retinyl acetate', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d12.s0.e1'}, 'sentence_id': 'DDI-MedLine.d12.s0'}	Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF or insulin induced proliferation of prostatic epithelium
Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.	Dexamethasone	EGF	effect	{'e1': {'word': 'Dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s0.e0'}, 'e2': {'word': 'EGF', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d12.s0.e2'}, 'sentence_id': 'DDI-MedLine.d12.s0'}	Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF or insulin induced proliferation of prostatic epithelium
Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.	Dexamethasone	insulin	effect	{'e1': {'word': 'Dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s0.e0'}, 'e2': {'word': 'insulin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d12.s0.e3'}, 'sentence_id': 'DDI-MedLine.d12.s0'}	Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF or insulin induced proliferation of prostatic epithelium
Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.	retinyl acetate	EGF	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d12.s0.e1'}, 'e2': {'word': 'EGF', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d12.s0.e2'}, 'sentence_id': 'DDI-MedLine.d12.s0'}	Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF or insulin induced proliferation of prostatic epithelium
Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.	retinyl acetate	insulin	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d12.s0.e1'}, 'e2': {'word': 'insulin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d12.s0.e3'}, 'sentence_id': 'DDI-MedLine.d12.s0'}	Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF or insulin induced proliferation of prostatic epithelium
Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.	EGF	insulin	none	{'e1': {'word': 'EGF', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d12.s0.e2'}, 'e2': {'word': 'insulin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d12.s0.e3'}, 'sentence_id': 'DDI-MedLine.d12.s0'}	Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF or insulin induced proliferation of prostatic epithelium
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml), EGF (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml). 	transferrin	EGF	none	{'e1': {'word': 'transferrin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d12.s1.e0'}, 'e2': {'word': 'EGF', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d12.s1.e1'}, 'sentence_id': 'DDI-MedLine.d12.s1'}	Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin NUMBER microgram / ml EGF NUMBER ng / ml and insulin NUMBER micrograms / ml or NUMBER IU / ml
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml), EGF (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml). 	transferrin	insulin	none	{'e1': {'word': 'transferrin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d12.s1.e0'}, 'e2': {'word': 'insulin', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d12.s1.e2'}, 'sentence_id': 'DDI-MedLine.d12.s1'}	Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin NUMBER microgram / ml EGF NUMBER ng / ml and insulin NUMBER micrograms / ml or NUMBER IU / ml
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml), EGF (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml). 	EGF	insulin	none	{'e1': {'word': 'EGF', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d12.s1.e1'}, 'e2': {'word': 'insulin', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d12.s1.e2'}, 'sentence_id': 'DDI-MedLine.d12.s1'}	Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin NUMBER microgram / ml EGF NUMBER ng / ml and insulin NUMBER micrograms / ml or NUMBER IU / ml
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	dexamethasone	retinyl acetate	none	{'e1': {'word': 'dexamethasone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d12.s2.e0'}, 'e2': {'word': 'retinyl acetate', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d12.s2.e1'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone they modify the mitogenic effect of EGF and insulin
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	dexamethasone	transferrin	none	{'e1': {'word': 'dexamethasone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d12.s2.e0'}, 'e2': {'word': 'transferrin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d12.s2.e2'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone they modify the mitogenic effect of EGF and insulin
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	dexamethasone	EGF	effect	{'e1': {'word': 'dexamethasone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d12.s2.e0'}, 'e2': {'word': 'EGF', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d12.s2.e3'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone they modify the mitogenic effect of EGF and insulin
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	dexamethasone	insulin	effect	{'e1': {'word': 'dexamethasone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d12.s2.e0'}, 'e2': {'word': 'insulin', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d12.s2.e4'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone they modify the mitogenic effect of EGF and insulin
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	retinyl acetate	transferrin	none	{'e1': {'word': 'retinyl acetate', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d12.s2.e1'}, 'e2': {'word': 'transferrin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d12.s2.e2'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone they modify the mitogenic effect of EGF and insulin
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	retinyl acetate	EGF	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d12.s2.e1'}, 'e2': {'word': 'EGF', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d12.s2.e3'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone they modify the mitogenic effect of EGF and insulin
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	retinyl acetate	insulin	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d12.s2.e1'}, 'e2': {'word': 'insulin', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d12.s2.e4'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone they modify the mitogenic effect of EGF and insulin
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	transferrin	EGF	none	{'e1': {'word': 'transferrin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d12.s2.e2'}, 'e2': {'word': 'EGF', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d12.s2.e3'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone they modify the mitogenic effect of EGF and insulin
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	transferrin	insulin	none	{'e1': {'word': 'transferrin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d12.s2.e2'}, 'e2': {'word': 'insulin', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d12.s2.e4'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone they modify the mitogenic effect of EGF and insulin
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 	EGF	insulin	none	{'e1': {'word': 'EGF', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d12.s2.e3'}, 'e2': {'word': 'insulin', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d12.s2.e4'}, 'sentence_id': 'DDI-MedLine.d12.s2'}	Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone they modify the mitogenic effect of EGF and insulin
Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF. 	Dexamethasone	retinyl acetate	none	{'e1': {'word': 'Dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s3.e0'}, 'e2': {'word': 'retinyl acetate', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d12.s3.e1'}, 'sentence_id': 'DDI-MedLine.d12.s3'}	Dexamethasone at NUMBER - NUMBER M or retinyl acetate at about NUMBER X NUMBER NUMBER M inhibits proliferation stimulated by EGF
Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF. 	Dexamethasone	EGF	effect	{'e1': {'word': 'Dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s3.e0'}, 'e2': {'word': 'EGF', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d12.s3.e2'}, 'sentence_id': 'DDI-MedLine.d12.s3'}	Dexamethasone at NUMBER - NUMBER M or retinyl acetate at about NUMBER X NUMBER NUMBER M inhibits proliferation stimulated by EGF
Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF. 	retinyl acetate	EGF	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d12.s3.e1'}, 'e2': {'word': 'EGF', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d12.s3.e2'}, 'sentence_id': 'DDI-MedLine.d12.s3'}	Dexamethasone at NUMBER - NUMBER M or retinyl acetate at about NUMBER X NUMBER NUMBER M inhibits proliferation stimulated by EGF
Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF. 	dexamethasone	retinyl acetate	none	{'e1': {'word': 'dexamethasone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d12.s4.e0'}, 'e2': {'word': 'retinyl acetate', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d12.s4.e1'}, 'sentence_id': 'DDI-MedLine.d12.s4'}	Higher concentrations of dexamethasone NUMBER NUMBER NUMBER NUMBER M or retinyl acetate NUMBER X NUMBER NUMBER NUMBER NUMBER M enhance the mitogenic activity of EGF
Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF. 	dexamethasone	EGF	effect	{'e1': {'word': 'dexamethasone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d12.s4.e0'}, 'e2': {'word': 'EGF', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d12.s4.e2'}, 'sentence_id': 'DDI-MedLine.d12.s4'}	Higher concentrations of dexamethasone NUMBER NUMBER NUMBER NUMBER M or retinyl acetate NUMBER X NUMBER NUMBER NUMBER NUMBER M enhance the mitogenic activity of EGF
Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF. 	retinyl acetate	EGF	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d12.s4.e1'}, 'e2': {'word': 'EGF', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d12.s4.e2'}, 'sentence_id': 'DDI-MedLine.d12.s4'}	Higher concentrations of dexamethasone NUMBER - NUMBER NUMBER NUMBER M or retinyl acetate NUMBER X NUMBER NUMBER NUMBER NUMBER M enhance the mitogenic activity of EGF
Dexamethasone had a similar effect in the presence of insulin. 	Dexamethasone	insulin	none	{'e1': {'word': 'Dexamethasone', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d12.s5.e0'}, 'e2': {'word': 'insulin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d12.s5.e1'}, 'sentence_id': 'DDI-MedLine.d12.s5'}	Dexamethasone had a similar effect in the presence of insulin
However, retinyl acetate stimulated, but did not significantly inhibit, proliferation in the presence of insulin. 	retinyl acetate	insulin	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d12.s6.e0'}, 'e2': {'word': 'insulin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d12.s6.e1'}, 'sentence_id': 'DDI-MedLine.d12.s6'}	However retinyl acetate stimulated but did not significantly inhibit proliferation in the presence of insulin
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	dexamethasone	retinyl acetate	none	{'e1': {'word': 'dexamethasone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d12.s7.e0'}, 'e2': {'word': 'retinyl acetate', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d12.s7.e1'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both dexamethasone and retinyl acetate and possibly other glucocorticoids and retinoids may regulate the proliferation of prostate epithelium by a dose dependent modification of the activity of insulin and EGF
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	dexamethasone	glucocorticoids	none	{'e1': {'word': 'dexamethasone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d12.s7.e0'}, 'e2': {'word': 'glucocorticoids', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d12.s7.e2'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both dexamethasone and retinyl acetate and possibly other glucocorticoids and retinoids may regulate the proliferation of prostate epithelium by a dose dependent modification of the activity of insulin and EGF
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	dexamethasone	retinoids	none	{'e1': {'word': 'dexamethasone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d12.s7.e0'}, 'e2': {'word': 'retinoids', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d12.s7.e3'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both dexamethasone and retinyl acetate and possibly other glucocorticoids and retinoids may regulate the proliferation of prostate epithelium by a dose dependent modification of the activity of insulin and EGF
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	dexamethasone	insulin	effect	{'e1': {'word': 'dexamethasone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d12.s7.e0'}, 'e2': {'word': 'insulin', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d12.s7.e4'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both dexamethasone and retinyl acetate and possibly other glucocorticoids and retinoids may regulate the proliferation of prostate epithelium by a dose dependent modification of the activity of insulin and EGF
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	dexamethasone	EGF	effect	{'e1': {'word': 'dexamethasone', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d12.s7.e0'}, 'e2': {'word': 'EGF', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d12.s7.e5'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both dexamethasone and retinyl acetate and possibly other glucocorticoids and retinoids may regulate the proliferation of prostate epithelium by a dose dependent modification of the activity of insulin and EGF
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	retinyl acetate	glucocorticoids	none	{'e1': {'word': 'retinyl acetate', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d12.s7.e1'}, 'e2': {'word': 'glucocorticoids', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d12.s7.e2'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both dexamethasone and retinyl acetate and possibly other glucocorticoids and retinoids may regulate the proliferation of prostate epithelium by a dose dependent modification of the activity of insulin and EGF
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	retinyl acetate	retinoids	none	{'e1': {'word': 'retinyl acetate', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d12.s7.e1'}, 'e2': {'word': 'retinoids', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d12.s7.e3'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both dexamethasone and retinyl acetate and possibly other glucocorticoids and retinoids may regulate the proliferation of prostate epithelium by a dose dependent modification of the activity of insulin and EGF
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	retinyl acetate	insulin	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d12.s7.e1'}, 'e2': {'word': 'insulin', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d12.s7.e4'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both dexamethasone and retinyl acetate and possibly other glucocorticoids and retinoids may regulate the proliferation of prostate epithelium by a dose dependent modification of the activity of insulin and EGF
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	retinyl acetate	EGF	effect	{'e1': {'word': 'retinyl acetate', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d12.s7.e1'}, 'e2': {'word': 'EGF', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d12.s7.e5'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both dexamethasone and retinyl acetate and possibly other glucocorticoids and retinoids may regulate the proliferation of prostate epithelium by a dose dependent modification of the activity of insulin and EGF
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	glucocorticoids	retinoids	none	{'e1': {'word': 'glucocorticoids', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d12.s7.e2'}, 'e2': {'word': 'retinoids', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d12.s7.e3'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both dexamethasone and retinyl acetate and possibly other glucocorticoids and retinoids may regulate the proliferation of prostate epithelium by a dose dependent modification of the activity of insulin and EGF
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	glucocorticoids	insulin	effect	{'e1': {'word': 'glucocorticoids', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d12.s7.e2'}, 'e2': {'word': 'insulin', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d12.s7.e4'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both dexamethasone and retinyl acetate and possibly other glucocorticoids and retinoids may regulate the proliferation of prostate epithelium by a dose dependent modification of the activity of insulin and EGF
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	glucocorticoids	EGF	effect	{'e1': {'word': 'glucocorticoids', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d12.s7.e2'}, 'e2': {'word': 'EGF', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d12.s7.e5'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both dexamethasone and retinyl acetate and possibly other glucocorticoids and retinoids may regulate the proliferation of prostate epithelium by a dose dependent modification of the activity of insulin and EGF
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	retinoids	insulin	effect	{'e1': {'word': 'retinoids', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d12.s7.e3'}, 'e2': {'word': 'insulin', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d12.s7.e4'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both dexamethasone and retinyl acetate and possibly other glucocorticoids and retinoids may regulate the proliferation of prostate epithelium by a dose dependent modification of the activity of insulin and EGF
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	retinoids	EGF	effect	{'e1': {'word': 'retinoids', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d12.s7.e3'}, 'e2': {'word': 'EGF', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d12.s7.e5'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both dexamethasone and retinyl acetate and possibly other glucocorticoids and retinoids may regulate the proliferation of prostate epithelium by a dose dependent modification of the activity of insulin and EGF
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	insulin	EGF	none	{'e1': {'word': 'insulin', 'word_index': [(31, 31)], 'id': 'DDI-MedLine.d12.s7.e4'}, 'e2': {'word': 'EGF', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d12.s7.e5'}, 'sentence_id': 'DDI-MedLine.d12.s7'}	These results suggest that both dexamethasone and retinyl acetate and possibly other glucocorticoids and retinoids may regulate the proliferation of prostate epithelium by a dose dependent modification of the activity of insulin and EGF
Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat.	acetaminophen	caffeine	effect	{'e1': {'word': 'acetaminophen', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d55.s0.e0'}, 'e2': {'word': 'caffeine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d55.s0.e1'}, 'sentence_id': 'DDI-MedLine.d55.s0'}	Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat
Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. 	caffeine	acetaminophen	none	{'e1': {'word': 'caffeine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d55.s1.e0'}, 'e2': {'word': 'acetaminophen', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d55.s1.e1'}, 'sentence_id': 'DDI-MedLine.d55.s1'}	Since caffeine is frequently co-administered with acetaminophen it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen
Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. 	caffeine	caffeine	none	{'e1': {'word': 'caffeine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d55.s1.e0'}, 'e2': {'word': 'caffeine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d55.s1.e2'}, 'sentence_id': 'DDI-MedLine.d55.s1'}	Since caffeine is frequently co-administered with acetaminophen it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen
Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. 	caffeine	acetaminophen	none	{'e1': {'word': 'caffeine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d55.s1.e0'}, 'e2': {'word': 'acetaminophen', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d55.s1.e3'}, 'sentence_id': 'DDI-MedLine.d55.s1'}	Since caffeine is frequently co-administered with acetaminophen it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen
Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. 	acetaminophen	caffeine	none	{'e1': {'word': 'acetaminophen', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d55.s1.e1'}, 'e2': {'word': 'caffeine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d55.s1.e2'}, 'sentence_id': 'DDI-MedLine.d55.s1'}	Since caffeine is frequently co-administered with acetaminophen it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen
Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. 	acetaminophen	acetaminophen	none	{'e1': {'word': 'acetaminophen', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d55.s1.e1'}, 'e2': {'word': 'acetaminophen', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d55.s1.e3'}, 'sentence_id': 'DDI-MedLine.d55.s1'}	Since caffeine is frequently co-administered with acetaminophen it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen
Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. 	caffeine	acetaminophen	none	{'e1': {'word': 'caffeine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d55.s1.e2'}, 'e2': {'word': 'acetaminophen', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d55.s1.e3'}, 'sentence_id': 'DDI-MedLine.d55.s1'}	Since caffeine is frequently co-administered with acetaminophen it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen
Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.	acetaminophen	caffeine	effect	{'e1': {'word': 'acetaminophen', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d55.s4.e0'}, 'e2': {'word': 'caffeine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d55.s4.e1'}, 'sentence_id': 'DDI-MedLine.d55.s4'}	Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine
Failure of neomycin to modify ACTH induced hypertension in sheep.	neomycin	ACTH	none	{'e1': {'word': 'neomycin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d2.s0.e0'}, 'e2': {'word': 'ACTH', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d2.s0.e1'}, 'sentence_id': 'DDI-MedLine.d2.s0'}	Failure of neomycin to modify ACTH induced hypertension in sheep
Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension. 	neomycin	adrenocortical steroid	none	{'e1': {'word': 'neomycin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d2.s1.e0'}, 'e2': {'word': 'adrenocortical steroid', 'word_index': [(12, 13)], 'id': 'DDI-MedLine.d2.s1.e1'}, 'sentence_id': 'DDI-MedLine.d2.s1'}	Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension including ACTH hypertension
Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension. 	neomycin	ACTH	effect	{'e1': {'word': 'neomycin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d2.s1.e0'}, 'e2': {'word': 'ACTH', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d2.s1.e2'}, 'sentence_id': 'DDI-MedLine.d2.s1'}	Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension including ACTH hypertension
Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension. 	adrenocortical steroid	ACTH	none	{'e1': {'word': 'adrenocortical steroid', 'word_index': [(12, 13)], 'id': 'DDI-MedLine.d2.s1.e1'}, 'e2': {'word': 'ACTH', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d2.s1.e2'}, 'sentence_id': 'DDI-MedLine.d2.s1'}	Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension including ACTH hypertension
The effects of oral neomycin on ACTH induced hypertension were examined in conscious sheep. 	neomycin	ACTH	none	{'e1': {'word': 'neomycin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d2.s2.e0'}, 'e2': {'word': 'ACTH', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d2.s2.e1'}, 'sentence_id': 'DDI-MedLine.d2.s2'}	The effects of oral neomycin on ACTH induced hypertension were examined in conscious sheep
Neomycin has no effect on the blood pressure or metabolic responses to ACTH in sheep.	Neomycin	ACTH	none	{'e1': {'word': 'Neomycin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d2.s3.e0'}, 'e2': {'word': 'ACTH', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d2.s3.e1'}, 'sentence_id': 'DDI-MedLine.d2.s3'}	Neomycin has no effect on the blood pressure or metabolic responses to ACTH in sheep
For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved. 	calcium-entry blocking agents	verapamil	none	{'e1': {'word': 'calcium-entry blocking agents', 'word_index': [(2, 5)], 'id': 'DDI-MedLine.d9.s3.e0'}, 'e2': {'word': 'verapamil', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d9.s3.e1'}, 'sentence_id': 'DDI-MedLine.d9.s3'}	For the calcium entry blocking agents now available in the United States verapamil nifedipine and diltiazem these data appeared well after clinical patterns of use evolved
For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved. 	calcium-entry blocking agents	nifedipine	none	{'e1': {'word': 'calcium-entry blocking agents', 'word_index': [(2, 5)], 'id': 'DDI-MedLine.d9.s3.e0'}, 'e2': {'word': 'nifedipine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d9.s3.e2'}, 'sentence_id': 'DDI-MedLine.d9.s3'}	For the calcium entry blocking agents now available in the United States verapamil nifedipine and diltiazem these data appeared well after clinical patterns of use evolved
For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved. 	calcium-entry blocking agents	diltiazem	none	{'e1': {'word': 'calcium-entry blocking agents', 'word_index': [(2, 5)], 'id': 'DDI-MedLine.d9.s3.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d9.s3.e3'}, 'sentence_id': 'DDI-MedLine.d9.s3'}	For the calcium entry blocking agents now available in the United States verapamil nifedipine and diltiazem these data appeared well after clinical patterns of use evolved
For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved. 	verapamil	nifedipine	none	{'e1': {'word': 'verapamil', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d9.s3.e1'}, 'e2': {'word': 'nifedipine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d9.s3.e2'}, 'sentence_id': 'DDI-MedLine.d9.s3'}	For the calcium entry blocking agents now available in the United States verapamil nifedipine and diltiazem these data appeared well after clinical patterns of use evolved
For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved. 	verapamil	diltiazem	none	{'e1': {'word': 'verapamil', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d9.s3.e1'}, 'e2': {'word': 'diltiazem', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d9.s3.e3'}, 'sentence_id': 'DDI-MedLine.d9.s3'}	For the calcium entry blocking agents now available in the United States verapamil nifedipine and diltiazem these data appeared well after clinical patterns of use evolved
For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved. 	nifedipine	diltiazem	none	{'e1': {'word': 'nifedipine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d9.s3.e2'}, 'e2': {'word': 'diltiazem', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d9.s3.e3'}, 'sentence_id': 'DDI-MedLine.d9.s3'}	For the calcium entry blocking agents now available in the United States verapamil nifedipine and diltiazem these data appeared well after clinical patterns of use evolved
by the nonlinear kinetic characteristics for verapamil and diltiazem (and probably for nifedipine, as well) and the derivative implications for decreased dosing frequency requirements; 	verapamil	diltiazem	none	{'e1': {'word': 'verapamil', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d9.s5.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d9.s5.e1'}, 'sentence_id': 'DDI-MedLine.d9.s5'}	by the nonlinear kinetic characteristics for verapamil and diltiazem and probably for nifedipine as well and the derivative implications for decreased dosing frequency requirements
by the nonlinear kinetic characteristics for verapamil and diltiazem (and probably for nifedipine, as well) and the derivative implications for decreased dosing frequency requirements; 	verapamil	nifedipine	none	{'e1': {'word': 'verapamil', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d9.s5.e0'}, 'e2': {'word': 'nifedipine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d9.s5.e2'}, 'sentence_id': 'DDI-MedLine.d9.s5'}	by the nonlinear kinetic characteristics for verapamil and diltiazem and probably for nifedipine as well and the derivative implications for decreased dosing frequency requirements
by the nonlinear kinetic characteristics for verapamil and diltiazem (and probably for nifedipine, as well) and the derivative implications for decreased dosing frequency requirements; 	diltiazem	nifedipine	none	{'e1': {'word': 'diltiazem', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d9.s5.e1'}, 'e2': {'word': 'nifedipine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d9.s5.e2'}, 'sentence_id': 'DDI-MedLine.d9.s5'}	by the nonlinear kinetic characteristics for verapamil and diltiazem and probably for nifedipine as well and the derivative implications for decreased dosing frequency requirements
"The effects of chlordiazepoxide, amphetamine and cocaine on bar-press behavior in normal and genetically nervous dogs.
"	chlordiazepoxide	amphetamine	none	{'e1': {'word': 'chlordiazepoxide', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d88.s0.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d88.s0.e1'}, 'sentence_id': 'DDI-MedLine.d88.s0'}	The effects of chlordiazepoxide amphetamine and cocaine on bar press behavior in normal and genetically nervous dogs
"The effects of chlordiazepoxide, amphetamine and cocaine on bar-press behavior in normal and genetically nervous dogs.
"	chlordiazepoxide	cocaine	none	{'e1': {'word': 'chlordiazepoxide', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d88.s0.e0'}, 'e2': {'word': 'cocaine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d88.s0.e2'}, 'sentence_id': 'DDI-MedLine.d88.s0'}	The effects of chlordiazepoxide amphetamine and cocaine on bar press behavior in normal and genetically nervous dogs
"The effects of chlordiazepoxide, amphetamine and cocaine on bar-press behavior in normal and genetically nervous dogs.
"	amphetamine	cocaine	none	{'e1': {'word': 'amphetamine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d88.s0.e1'}, 'e2': {'word': 'cocaine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d88.s0.e2'}, 'sentence_id': 'DDI-MedLine.d88.s0'}	The effects of chlordiazepoxide amphetamine and cocaine on bar press behavior in normal and genetically nervous dogs
"Studies on two strains of pointer dogs have demonstrated that administration of a benzodiazepine (chlordiazepoxide) facilitates acquisition of goal-directed behavior in ""genetically nervous"""	benzodiazepine	chlordiazepoxide	none	{'e1': {'word': 'benzodiazepine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d88.s1.e0'}, 'e2': {'word': 'chlordiazepoxide', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d88.s1.e1'}, 'sentence_id': 'DDI-MedLine.d88.s1'}	Studies on NUMBER strains of pointer dogs have demonstrated that administration of a benzodiazepine chlordiazepoxide facilitates acquisition of goal directed behavior in genetically nervous
The concomitant administration of either cocaine or amphetamine, compounds which inhibit neuronal reuptake of norepinephrine, disrupts the behavioral response of the genetically nervous E-strain subjects to a far greater extent than the stable A-strain subjects. 	cocaine	amphetamine	none	{'e1': {'word': 'cocaine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d88.s4.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d88.s4.e1'}, 'sentence_id': 'DDI-MedLine.d88.s4'}	The concomitant administration of either cocaine or amphetamine compounds which inhibit neuronal reuptake of norepinephrine disrupts the behavioral response of the genetically nervous E strain subjects to a far greater extent than the stable A strain subjects
"Interaction of clindamycin and gentamicin in vitro.
"	clindamycin	gentamicin	int	{'e1': {'word': 'clindamycin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d49.s0.e0'}, 'e2': {'word': 'gentamicin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d49.s0.e1'}, 'sentence_id': 'DDI-MedLine.d49.s0'}	Interaction of clindamycin and gentamicin in vitro
The minimal inhibitory concentrations of clindamycin and gentamicin alone and in combinations were determined by a microdilution method for 163 aerobic, facultative, and anaerobic clinical isolates. 	clindamycin	gentamicin	none	{'e1': {'word': 'clindamycin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d49.s1.e0'}, 'e2': {'word': 'gentamicin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d49.s1.e1'}, 'sentence_id': 'DDI-MedLine.d49.s1'}	The minimal inhibitory concentrations of clindamycin and gentamicin alone and in combinations were determined by a microdilution method for NUMBER aerobic facultative and anaerobic clinical isolates
Gentamicin did not interfere with the activity of clindamycin within the range of concentrations tested (0.1 to 100 mug/ml); 	Gentamicin	clindamycin	none	{'e1': {'word': 'Gentamicin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d49.s3.e0'}, 'e2': {'word': 'clindamycin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d49.s3.e1'}, 'sentence_id': 'DDI-MedLine.d49.s3'}	Gentamicin did not interfere with the activity of clindamycin within the range of concentrations tested NUMBER to NUMBER mug / ml
Combinations of clindamycin and gentamicin were indifferent for 29 strains and synergistic for 33 strains. 	clindamycin	gentamicin	effect	{'e1': {'word': 'clindamycin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d49.s6.e0'}, 'e2': {'word': 'gentamicin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d49.s6.e1'}, 'sentence_id': 'DDI-MedLine.d49.s6'}	Combinations of clindamycin and gentamicin were indifferent for NUMBER strains and synergistic for NUMBER strains
All 20 strains of enterococcus, three strains of Clostridium, three strains of Escherichia coli, and one strain of Proteus rettgeri were resistant to both clindamycin (minimal inhibitory concentration greater than 3.1 mug/ml) and gentamicin (minimal inhibitory concentration greater than 6.2 mug/ml). 	clindamycin	gentamicin	none	{'e1': {'word': 'clindamycin', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d49.s7.e0'}, 'e2': {'word': 'gentamicin', 'word_index': [(35, 35)], 'id': 'DDI-MedLine.d49.s7.e1'}, 'sentence_id': 'DDI-MedLine.d49.s7'}	All NUMBER strains of enterococcus NUMBER strains of Clostridium NUMBER strains of Escherichia coli and NUMBER strain of Proteus rettgeri were resistant to both clindamycin minimal inhibitory concentration greater than NUMBER mug / ml and gentamicin minimal inhibitory concentration greater than NUMBER mug / ml
Combinations of clindamycin and gentamicin were indifferent for 16 and synergistic for 11 of the resistant strains. 	clindamycin	gentamicin	effect	{'e1': {'word': 'clindamycin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d49.s8.e0'}, 'e2': {'word': 'gentamicin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d49.s8.e1'}, 'sentence_id': 'DDI-MedLine.d49.s8'}	Combinations of clindamycin and gentamicin were indifferent for NUMBER and synergistic for NUMBER of the resistant strains
"Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
"	neurotensin	enkephalins	effect	{'e1': {'word': 'neurotensin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d131.s0.e0'}, 'e2': {'word': 'enkephalins', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d131.s0.e1'}, 'sentence_id': 'DDI-MedLine.d131.s0'}	Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin
"Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
"	neurotensin	tuftsin	effect	{'e1': {'word': 'neurotensin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d131.s0.e0'}, 'e2': {'word': 'tuftsin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d131.s0.e2'}, 'sentence_id': 'DDI-MedLine.d131.s0'}	Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin
"Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
"	enkephalins	tuftsin	none	{'e1': {'word': 'enkephalins', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d131.s0.e1'}, 'e2': {'word': 'tuftsin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d131.s0.e2'}, 'sentence_id': 'DDI-MedLine.d131.s0'}	Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	neurotensin	enkephalins	none	{'e1': {'word': 'neurotensin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d131.s1.e0'}, 'e2': {'word': 'enkephalins', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d131.s1.e1'}, 'sentence_id': 'DDI-MedLine.d131.s1'}	The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D Ala2 metenkephalinamide or tuftsin on the antinonciceptive effect of these peptides in mice after intracisternal injection
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	neurotensin	D-Ala2-metenkephalinamide	none	{'e1': {'word': 'neurotensin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d131.s1.e0'}, 'e2': {'word': 'D-Ala2-metenkephalinamide', 'word_index': [(19, 21)], 'id': 'DDI-MedLine.d131.s1.e2'}, 'sentence_id': 'DDI-MedLine.d131.s1'}	The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D Ala2 metenkephalinamide or tuftsin on the antinonciceptive effect of these peptides in mice after intracisternal injection
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	neurotensin	tuftsin	none	{'e1': {'word': 'neurotensin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d131.s1.e0'}, 'e2': {'word': 'tuftsin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d131.s1.e3'}, 'sentence_id': 'DDI-MedLine.d131.s1'}	The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D Ala2 metenkephalinamide or tuftsin on the antinonciceptive effect of these peptides in mice after intracisternal injection
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	enkephalins	D-Ala2-metenkephalinamide	none	{'e1': {'word': 'enkephalins', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d131.s1.e1'}, 'e2': {'word': 'D-Ala2-metenkephalinamide', 'word_index': [(19, 21)], 'id': 'DDI-MedLine.d131.s1.e2'}, 'sentence_id': 'DDI-MedLine.d131.s1'}	The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D Ala2 metenkephalinamide or tuftsin on the antinonciceptive effect of these peptides in mice after intracisternal injection
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	enkephalins	tuftsin	none	{'e1': {'word': 'enkephalins', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d131.s1.e1'}, 'e2': {'word': 'tuftsin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d131.s1.e3'}, 'sentence_id': 'DDI-MedLine.d131.s1'}	The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D Ala2 metenkephalinamide or tuftsin on the antinonciceptive effect of these peptides in mice after intracisternal injection
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	D-Ala2-metenkephalinamide	tuftsin	none	{'e1': {'word': 'D-Ala2-metenkephalinamide', 'word_index': [(19, 21)], 'id': 'DDI-MedLine.d131.s1.e2'}, 'e2': {'word': 'tuftsin', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d131.s1.e3'}, 'sentence_id': 'DDI-MedLine.d131.s1'}	The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D Ala2 metenkephalinamide or tuftsin on the antinonciceptive effect of these peptides in mice after intracisternal injection
It was shown that neurotensin antagonized evidently the antinociceptive effect of enkephalins and their analogue. 	neurotensin	enkephalins	effect	{'e1': {'word': 'neurotensin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d131.s3.e0'}, 'e2': {'word': 'enkephalins', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d131.s3.e1'}, 'sentence_id': 'DDI-MedLine.d131.s3'}	It was shown that neurotensin antagonized evidently the antinociceptive effect of enkephalins and their analogue
On the contrary, neurotensin and tuftsin were agonists in induction of analgesia. 	neurotensin	tuftsin	effect	{'e1': {'word': 'neurotensin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d131.s4.e0'}, 'e2': {'word': 'tuftsin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d131.s4.e1'}, 'sentence_id': 'DDI-MedLine.d131.s4'}	On the contrary neurotensin and tuftsin were agonists in induction of analgesia
It is concluded that neurotensin modulates in an opposite way the function of the enkephalinergic neurons and the central action of tuftsin.	neurotensin	tuftsin	effect	{'e1': {'word': 'neurotensin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d131.s5.e0'}, 'e2': {'word': 'tuftsin', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d131.s5.e1'}, 'sentence_id': 'DDI-MedLine.d131.s5'}	It is concluded that neurotensin modulates in an opposite way the function of the enkephalinergic neurons and the central action of tuftsin
"Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.
"	rofecoxib	digoxin	none	{'e1': {'word': 'rofecoxib', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d109.s0.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d109.s0.e1'}, 'sentence_id': 'DDI-MedLine.d109.s0'}	Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers
The authors examined the effect of the cyclooxygenase-2 (COX-2) inhibitor, rofecoxib, at steady state on the pharmacokinetics of digoxin following a single dose in healthy subjects. 	rofecoxib	digoxin	none	{'e1': {'word': 'rofecoxib', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d109.s1.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d109.s1.e1'}, 'sentence_id': 'DDI-MedLine.d109.s1'}	The authors examined the effect of the cyclooxygenase NUMBER COX NUMBER inhibitor rofecoxib at steady state on the pharmacokinetics of digoxin following a single dose in healthy subjects
Samples for plasma and urine immunoreactive digoxin concentrations were collected through 120 hours following the digoxin dose. 	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d109.s5.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d109.s5.e1'}, 'sentence_id': 'DDI-MedLine.d109.s5'}	Samples for plasma and urine immunoreactive digoxin concentrations were collected through NUMBER hours following the digoxin dose
For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 	digoxin	rofecoxib	none	{'e1': {'word': 'digoxin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d109.s7.e0'}, 'e2': {'word': 'rofecoxib', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d109.s7.e1'}, 'sentence_id': 'DDI-MedLine.d109.s7'}	For digoxin AUC NUMBER infinity AUC NUMBER - NUMBER and Cmax the geometric mean ratios NUMBER % confidence interval for rofecoxib + digoxin placebo + digoxin were NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER and NUMBER NUMBER NUMBER respectively
For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d109.s7.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d109.s7.e2'}, 'sentence_id': 'DDI-MedLine.d109.s7'}	For digoxin AUC NUMBER infinity AUC NUMBER - NUMBER and Cmax the geometric mean ratios NUMBER % confidence interval for rofecoxib + digoxin placebo + digoxin were NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER and NUMBER NUMBER NUMBER respectively
For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d109.s7.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d109.s7.e3'}, 'sentence_id': 'DDI-MedLine.d109.s7'}	For digoxin AUC NUMBER infinity AUC NUMBER - NUMBER and Cmax the geometric mean ratios NUMBER % confidence interval for rofecoxib + digoxin placebo + digoxin were NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER and NUMBER NUMBER NUMBER respectively
For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 	rofecoxib	digoxin	none	{'e1': {'word': 'rofecoxib', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d109.s7.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d109.s7.e2'}, 'sentence_id': 'DDI-MedLine.d109.s7'}	For digoxin AUC NUMBER infinity AUC NUMBER - NUMBER and Cmax the geometric mean ratios NUMBER % confidence interval for rofecoxib + digoxin placebo + digoxin were NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER and NUMBER NUMBER NUMBER respectively
For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 	rofecoxib	digoxin	none	{'e1': {'word': 'rofecoxib', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d109.s7.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d109.s7.e3'}, 'sentence_id': 'DDI-MedLine.d109.s7'}	For digoxin AUC NUMBER infinity AUC NUMBER - NUMBER and Cmax the geometric mean ratios NUMBER % confidence interval for rofecoxib + digoxin placebo + digoxin were NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER and NUMBER NUMBER NUMBER respectively
For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d109.s7.e2'}, 'e2': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-MedLine.d109.s7.e3'}, 'sentence_id': 'DDI-MedLine.d109.s7'}	For digoxin AUC NUMBER infinity AUC NUMBER - NUMBER and Cmax the geometric mean ratios NUMBER % confidence interval for rofecoxib + digoxin placebo + digoxin were NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER and NUMBER NUMBER NUMBER respectively
The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively. 	rofecoxib	digoxin	none	{'e1': {'word': 'rofecoxib', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d109.s9.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d109.s9.e1'}, 'sentence_id': 'DDI-MedLine.d109.s9'}	The harmonic mean elimination half life was NUMBER and NUMBER hours for rofecoxib + digoxin and placebo + digoxin treatments respectively
The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively. 	rofecoxib	digoxin	none	{'e1': {'word': 'rofecoxib', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d109.s9.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d109.s9.e2'}, 'sentence_id': 'DDI-MedLine.d109.s9'}	The harmonic mean elimination half life was NUMBER and NUMBER hours for rofecoxib + digoxin and placebo + digoxin treatments respectively
The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively. 	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d109.s9.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d109.s9.e2'}, 'sentence_id': 'DDI-MedLine.d109.s9'}	The harmonic mean elimination half life was NUMBER and NUMBER hours for rofecoxib + digoxin and placebo + digoxin treatments respectively
The mean (SD) cumulative urinary excretion of immunoreactive digoxin after concurrent treatment with rofecoxib or placebo was 228.2 (+/- 30.8) and 235.1 (+/- 39.1) micrograms/120 hours, respectively. 	digoxin	rofecoxib	none	{'e1': {'word': 'digoxin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d109.s11.e0'}, 'e2': {'word': 'rofecoxib', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d109.s11.e1'}, 'sentence_id': 'DDI-MedLine.d109.s11'}	The mean SD cumulative urinary excretion of immunoreactive digoxin after concurrent treatment with rofecoxib or placebo was NUMBER + - NUMBER and NUMBER + - NUMBER micrograms / NUMBER hours respectively
Rofecoxib did not influence the plasma pharmacokinetics or renal elimination of a single oral dose of digoxin.	Rofecoxib	digoxin	none	{'e1': {'word': 'Rofecoxib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d109.s13.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d109.s13.e1'}, 'sentence_id': 'DDI-MedLine.d109.s13'}	Rofecoxib did not influence the plasma pharmacokinetics or renal elimination of a single oral dose of digoxin
Many people use both alcohol and nicotine (i.e., cigarettes and other tobacco products). 	alcohol	nicotine	none	{'e1': {'word': 'alcohol', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d122.s1.e0'}, 'e2': {'word': 'nicotine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d122.s1.e1'}, 'sentence_id': 'DDI-MedLine.d122.s1'}	Many people use both alcohol and nicotine i.e. cigarettes and other tobacco products
The initiation of alcohol or nicotine use may be precipitated by similar personality characteristics in the user, such as impulsivity and sensation seeking. 	alcohol	nicotine	none	{'e1': {'word': 'alcohol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d122.s3.e0'}, 'e2': {'word': 'nicotine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d122.s3.e1'}, 'sentence_id': 'DDI-MedLine.d122.s3'}	The initiation of alcohol or nicotine use may be precipitated by similar personality characteristics in the user such as impulsivity and sensation seeking
Moreover, the mechanisms underlying the development of dependence may be similar for alcohol and nicotine. 	alcohol	nicotine	none	{'e1': {'word': 'alcohol', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d122.s4.e0'}, 'e2': {'word': 'nicotine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d122.s4.e1'}, 'sentence_id': 'DDI-MedLine.d122.s4'}	Moreover the mechanisms underlying the development of dependence may be similar for alcohol and nicotine
"Clinical implications of warfarin interactions with five sedatives.
"	warfarin	sedatives	int	{'e1': {'word': 'warfarin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s0.e0'}, 'e2': {'word': 'sedatives', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d106.s0.e1'}, 'sentence_id': 'DDI-MedLine.d106.s0'}	Clinical implications of warfarin interactions with NUMBER sedatives
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	anticoagulant	phenobarbital	none	{'e1': {'word': 'anticoagulant', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d106.s1.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d106.s1.e1'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity uniformity and time course of anticoagulant interference by phenobarbital secobarbital glutethimide chloral hydrate and methaqualone were systematically investigated in NUMBER patients receiving coumarin therapy
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	anticoagulant	secobarbital	none	{'e1': {'word': 'anticoagulant', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d106.s1.e0'}, 'e2': {'word': 'secobarbital', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d106.s1.e2'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity uniformity and time course of anticoagulant interference by phenobarbital secobarbital glutethimide chloral hydrate and methaqualone were systematically investigated in NUMBER patients receiving coumarin therapy
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	anticoagulant	glutethimide	none	{'e1': {'word': 'anticoagulant', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d106.s1.e0'}, 'e2': {'word': 'glutethimide', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d106.s1.e3'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity uniformity and time course of anticoagulant interference by phenobarbital secobarbital glutethimide chloral hydrate and methaqualone were systematically investigated in NUMBER patients receiving coumarin therapy
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	anticoagulant	chloral hydrate	none	{'e1': {'word': 'anticoagulant', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d106.s1.e0'}, 'e2': {'word': 'chloral hydrate', 'word_index': [(13, 14)], 'id': 'DDI-MedLine.d106.s1.e4'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity uniformity and time course of anticoagulant interference by phenobarbital secobarbital glutethimide chloral hydrate and methaqualone were systematically investigated in NUMBER patients receiving coumarin therapy
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	anticoagulant	methaqualone	none	{'e1': {'word': 'anticoagulant', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d106.s1.e0'}, 'e2': {'word': 'methaqualone', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d106.s1.e5'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity uniformity and time course of anticoagulant interference by phenobarbital secobarbital glutethimide chloral hydrate and methaqualone were systematically investigated in NUMBER patients receiving coumarin therapy
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	anticoagulant	coumarin	none	{'e1': {'word': 'anticoagulant', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d106.s1.e0'}, 'e2': {'word': 'coumarin', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d106.s1.e6'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity uniformity and time course of anticoagulant interference by phenobarbital secobarbital glutethimide chloral hydrate and methaqualone were systematically investigated in NUMBER patients receiving coumarin therapy
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	phenobarbital	secobarbital	none	{'e1': {'word': 'phenobarbital', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d106.s1.e1'}, 'e2': {'word': 'secobarbital', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d106.s1.e2'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity uniformity and time course of anticoagulant interference by phenobarbital secobarbital glutethimide chloral hydrate and methaqualone were systematically investigated in NUMBER patients receiving coumarin therapy
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	phenobarbital	glutethimide	none	{'e1': {'word': 'phenobarbital', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d106.s1.e1'}, 'e2': {'word': 'glutethimide', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d106.s1.e3'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity uniformity and time course of anticoagulant interference by phenobarbital secobarbital glutethimide chloral hydrate and methaqualone were systematically investigated in NUMBER patients receiving coumarin therapy
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	phenobarbital	chloral hydrate	none	{'e1': {'word': 'phenobarbital', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d106.s1.e1'}, 'e2': {'word': 'chloral hydrate', 'word_index': [(13, 14)], 'id': 'DDI-MedLine.d106.s1.e4'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity uniformity and time course of anticoagulant interference by phenobarbital secobarbital glutethimide chloral hydrate and methaqualone were systematically investigated in NUMBER patients receiving coumarin therapy
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	phenobarbital	methaqualone	none	{'e1': {'word': 'phenobarbital', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d106.s1.e1'}, 'e2': {'word': 'methaqualone', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d106.s1.e5'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity uniformity and time course of anticoagulant interference by phenobarbital secobarbital glutethimide chloral hydrate and methaqualone were systematically investigated in NUMBER patients receiving coumarin therapy
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	phenobarbital	coumarin	none	{'e1': {'word': 'phenobarbital', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d106.s1.e1'}, 'e2': {'word': 'coumarin', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d106.s1.e6'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity uniformity and time course of anticoagulant interference by phenobarbital secobarbital glutethimide chloral hydrate and methaqualone were systematically investigated in NUMBER patients receiving coumarin therapy
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	secobarbital	glutethimide	none	{'e1': {'word': 'secobarbital', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d106.s1.e2'}, 'e2': {'word': 'glutethimide', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d106.s1.e3'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity uniformity and time course of anticoagulant interference by phenobarbital secobarbital glutethimide chloral hydrate and methaqualone were systematically investigated in NUMBER patients receiving coumarin therapy
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	secobarbital	chloral hydrate	none	{'e1': {'word': 'secobarbital', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d106.s1.e2'}, 'e2': {'word': 'chloral hydrate', 'word_index': [(13, 14)], 'id': 'DDI-MedLine.d106.s1.e4'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity uniformity and time course of anticoagulant interference by phenobarbital secobarbital glutethimide chloral hydrate and methaqualone were systematically investigated in NUMBER patients receiving coumarin therapy
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	secobarbital	methaqualone	none	{'e1': {'word': 'secobarbital', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d106.s1.e2'}, 'e2': {'word': 'methaqualone', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d106.s1.e5'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity uniformity and time course of anticoagulant interference by phenobarbital secobarbital glutethimide chloral hydrate and methaqualone were systematically investigated in NUMBER patients receiving coumarin therapy
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	secobarbital	coumarin	none	{'e1': {'word': 'secobarbital', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d106.s1.e2'}, 'e2': {'word': 'coumarin', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d106.s1.e6'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity uniformity and time course of anticoagulant interference by phenobarbital secobarbital glutethimide chloral hydrate and methaqualone were systematically investigated in NUMBER patients receiving coumarin therapy
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	glutethimide	chloral hydrate	none	{'e1': {'word': 'glutethimide', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d106.s1.e3'}, 'e2': {'word': 'chloral hydrate', 'word_index': [(13, 14)], 'id': 'DDI-MedLine.d106.s1.e4'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity uniformity and time course of anticoagulant interference by phenobarbital secobarbital glutethimide chloral hydrate and methaqualone were systematically investigated in NUMBER patients receiving coumarin therapy
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	glutethimide	methaqualone	none	{'e1': {'word': 'glutethimide', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d106.s1.e3'}, 'e2': {'word': 'methaqualone', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d106.s1.e5'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity uniformity and time course of anticoagulant interference by phenobarbital secobarbital glutethimide chloral hydrate and methaqualone were systematically investigated in NUMBER patients receiving coumarin therapy
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	glutethimide	coumarin	none	{'e1': {'word': 'glutethimide', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d106.s1.e3'}, 'e2': {'word': 'coumarin', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d106.s1.e6'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity uniformity and time course of anticoagulant interference by phenobarbital secobarbital glutethimide chloral hydrate and methaqualone were systematically investigated in NUMBER patients receiving coumarin therapy
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	chloral hydrate	methaqualone	none	{'e1': {'word': 'chloral hydrate', 'word_index': [(13, 14)], 'id': 'DDI-MedLine.d106.s1.e4'}, 'e2': {'word': 'methaqualone', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d106.s1.e5'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity uniformity and time course of anticoagulant interference by phenobarbital secobarbital glutethimide chloral hydrate and methaqualone were systematically investigated in NUMBER patients receiving coumarin therapy
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	chloral hydrate	coumarin	none	{'e1': {'word': 'chloral hydrate', 'word_index': [(13, 14)], 'id': 'DDI-MedLine.d106.s1.e4'}, 'e2': {'word': 'coumarin', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d106.s1.e6'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity uniformity and time course of anticoagulant interference by phenobarbital secobarbital glutethimide chloral hydrate and methaqualone were systematically investigated in NUMBER patients receiving coumarin therapy
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 	methaqualone	coumarin	none	{'e1': {'word': 'methaqualone', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d106.s1.e5'}, 'e2': {'word': 'coumarin', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d106.s1.e6'}, 'sentence_id': 'DDI-MedLine.d106.s1'}	The intensity uniformity and time course of anticoagulant interference by phenobarbital secobarbital glutethimide chloral hydrate and methaqualone were systematically investigated in NUMBER patients receiving coumarin therapy
Anticoagulant inhibition was observed during the administration of phenobarbital, secobarbital and glutethimide; 	phenobarbital	secobarbital	none	{'e1': {'word': 'phenobarbital', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d106.s4.e0'}, 'e2': {'word': 'secobarbital', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d106.s4.e1'}, 'sentence_id': 'DDI-MedLine.d106.s4'}	Anticoagulant inhibition was observed during the administration of phenobarbital secobarbital and glutethimide
Anticoagulant inhibition was observed during the administration of phenobarbital, secobarbital and glutethimide; 	phenobarbital	glutethimide	none	{'e1': {'word': 'phenobarbital', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d106.s4.e0'}, 'e2': {'word': 'glutethimide', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d106.s4.e2'}, 'sentence_id': 'DDI-MedLine.d106.s4'}	Anticoagulant inhibition was observed during the administration of phenobarbital secobarbital and glutethimide
Anticoagulant inhibition was observed during the administration of phenobarbital, secobarbital and glutethimide; 	secobarbital	glutethimide	none	{'e1': {'word': 'secobarbital', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d106.s4.e1'}, 'e2': {'word': 'glutethimide', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d106.s4.e2'}, 'sentence_id': 'DDI-MedLine.d106.s4'}	Anticoagulant inhibition was observed during the administration of phenobarbital secobarbital and glutethimide
there was no significant change in prothrombin test results during the trials of chloral hydrate and methaqualone. 	chloral hydrate	methaqualone	none	{'e1': {'word': 'chloral hydrate', 'word_index': [(13, 14)], 'id': 'DDI-MedLine.d106.s5.e0'}, 'e2': {'word': 'methaqualone', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d106.s5.e1'}, 'sentence_id': 'DDI-MedLine.d106.s5'}	there was no significant change in prothrombin test results during the trials of chloral hydrate and methaqualone
Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs. 	Barbiturates	glutethimide	none	{'e1': {'word': 'Barbiturates', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s6.e0'}, 'e2': {'word': 'glutethimide', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d106.s6.e1'}, 'sentence_id': 'DDI-MedLine.d106.s6'}	Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs
Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs. 	Barbiturates	coumarin drugs	advise	{'e1': {'word': 'Barbiturates', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d106.s6.e0'}, 'e2': {'word': 'coumarin drugs', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d106.s6.e2'}, 'sentence_id': 'DDI-MedLine.d106.s6'}	Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs
Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs. 	glutethimide	coumarin drugs	advise	{'e1': {'word': 'glutethimide', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d106.s6.e1'}, 'e2': {'word': 'coumarin drugs', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d106.s6.e2'}, 'sentence_id': 'DDI-MedLine.d106.s6'}	Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs
Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant. 	Chloral hydrate	methaqualone	none	{'e1': {'word': 'Chloral hydrate', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d106.s8.e0'}, 'e2': {'word': 'methaqualone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s8.e1'}, 'sentence_id': 'DDI-MedLine.d106.s8'}	Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents but the effect is not clinically significant
Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant. 	Chloral hydrate	anticoagulant agents	int	{'e1': {'word': 'Chloral hydrate', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d106.s8.e0'}, 'e2': {'word': 'anticoagulant agents', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d106.s8.e2'}, 'sentence_id': 'DDI-MedLine.d106.s8'}	Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents but the effect is not clinically significant
Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant. 	methaqualone	anticoagulant agents	int	{'e1': {'word': 'methaqualone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d106.s8.e1'}, 'e2': {'word': 'anticoagulant agents', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d106.s8.e2'}, 'sentence_id': 'DDI-MedLine.d106.s8'}	Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents but the effect is not clinically significant
It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.	chloral hydrate	methaqualone	none	{'e1': {'word': 'chloral hydrate', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d106.s9.e0'}, 'e2': {'word': 'methaqualone', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d106.s9.e1'}, 'sentence_id': 'DDI-MedLine.d106.s9'}	It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy
It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.	chloral hydrate	anticoagulant	none	{'e1': {'word': 'chloral hydrate', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d106.s9.e0'}, 'e2': {'word': 'anticoagulant', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d106.s9.e2'}, 'sentence_id': 'DDI-MedLine.d106.s9'}	It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy
It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.	methaqualone	anticoagulant	none	{'e1': {'word': 'methaqualone', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d106.s9.e1'}, 'e2': {'word': 'anticoagulant', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d106.s9.e2'}, 'sentence_id': 'DDI-MedLine.d106.s9'}	It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy
"Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
"	everolimus	cyclosporine	none	{'e1': {'word': 'everolimus', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d140.s0.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d140.s0.e1'}, 'sentence_id': 'DDI-MedLine.d140.s0'}	Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year pharmacokinetics exposure response relationships and influence on cyclosporine
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation. 	everolimus	cyclosporine	none	{'e1': {'word': 'everolimus', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d140.s1.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d140.s1.e1'}, 'sentence_id': 'DDI-MedLine.d140.s1'}	OBJECTIVE Our objective was to characterize the steady state pharmacokinetics of everolimus and cyclosporine INN ciclosporin when coadministered in de novo kidney allograft recipients during the first year after transplantation
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation. 	everolimus	ciclosporin	none	{'e1': {'word': 'everolimus', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d140.s1.e0'}, 'e2': {'word': 'ciclosporin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d140.s1.e2'}, 'sentence_id': 'DDI-MedLine.d140.s1'}	OBJECTIVE Our objective was to characterize the steady state pharmacokinetics of everolimus and cyclosporine INN ciclosporin when coadministered in de novo kidney allograft recipients during the first year after transplantation
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation. 	cyclosporine	ciclosporin	none	{'e1': {'word': 'cyclosporine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d140.s1.e1'}, 'e2': {'word': 'ciclosporin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d140.s1.e2'}, 'sentence_id': 'DDI-MedLine.d140.s1'}	OBJECTIVE Our objective was to characterize the steady state pharmacokinetics of everolimus and cyclosporine INN ciclosporin when coadministered in de novo kidney allograft recipients during the first year after transplantation
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone. 	everolimus	cyclosporine	none	{'e1': {'word': 'everolimus', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d140.s2.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d140.s2.e1'}, 'sentence_id': 'DDI-MedLine.d140.s2'}	METHOD This study was a multicenter randomized double blind study of NUMBER patients who were randomly assigned NUMBER : NUMBER : NUMBER to receive everolimus tablets at doses of NUMBER mg NUMBER mg or NUMBER mg twice daily with cyclosporine and prednisone
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone. 	everolimus	prednisone	none	{'e1': {'word': 'everolimus', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d140.s2.e0'}, 'e2': {'word': 'prednisone', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d140.s2.e2'}, 'sentence_id': 'DDI-MedLine.d140.s2'}	METHOD This study was a multicenter randomized double blind study of NUMBER patients who were randomly assigned NUMBER : NUMBER : NUMBER to receive everolimus tablets at doses of NUMBER mg NUMBER mg or NUMBER mg twice daily with cyclosporine and prednisone
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone. 	cyclosporine	prednisone	none	{'e1': {'word': 'cyclosporine', 'word_index': [(39, 39)], 'id': 'DDI-MedLine.d140.s2.e1'}, 'e2': {'word': 'prednisone', 'word_index': [(41, 41)], 'id': 'DDI-MedLine.d140.s2.e2'}, 'sentence_id': 'DDI-MedLine.d140.s2'}	METHOD This study was a multicenter randomized double blind study of NUMBER patients who were randomly assigned NUMBER : NUMBER : NUMBER to receive everolimus tablets at doses of NUMBER mg NUMBER mg or NUMBER mg twice daily with cyclosporine and prednisone
Blood sampling for the pharmacokinetics of everolimus and cyclosporine was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12. 	everolimus	cyclosporine	none	{'e1': {'word': 'everolimus', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d140.s3.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d140.s3.e1'}, 'sentence_id': 'DDI-MedLine.d140.s3'}	Blood sampling for the pharmacokinetics of everolimus and cyclosporine was performed on day NUMBER on weeks NUMBER NUMBER NUMBER and NUMBER and on months NUMBER NUMBER NUMBER NUMBER and NUMBER
Potential differences in cyclosporine dosing and pharmacokinetics at different levels of everolimus exposure were assessed in the context of ANOVA. 	cyclosporine	everolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d140.s6.e0'}, 'e2': {'word': 'everolimus', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d140.s6.e1'}, 'sentence_id': 'DDI-MedLine.d140.s6'}	Potential differences in cyclosporine dosing and pharmacokinetics at different levels of everolimus exposure were assessed in the context of ANOVA
Cyclosporine doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered everolimus dose level (P = .13, .82, and .76, respectively). 	Cyclosporine	everolimus	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d140.s13.e0'}, 'e2': {'word': 'everolimus', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d140.s13.e1'}, 'sentence_id': 'DDI-MedLine.d140.s13'}	Cyclosporine doses trough concentrations and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered everolimus dose level P = NUMBER NUMBER and NUMBER respectively
For a 4-fold range of everolimus doses there were no differential effects on cyclosporine dosing or pharmacokinetics.	everolimus	cyclosporine	none	{'e1': {'word': 'everolimus', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d140.s15.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d140.s15.e1'}, 'sentence_id': 'DDI-MedLine.d140.s15'}	For a 4-fold range of everolimus doses there were no differential effects on cyclosporine dosing or pharmacokinetics
